



RESOURCE AND PATIENT MANAGEMENT SYSTEM

# **Clinical Reporting System**

(BGP)

## **CRS Clinical Performance Measure Logic Manual for FY 2016 Clinical Measures**

Version 16.0  
November 2015

Office of Information Technology (OIT)  
Division of Information Resource Management

# Table of Contents

<b>1.0</b>	<b>Introduction.....</b>	<b>1</b>
<b>2.0</b>	<b>Performance Measure Logic.....</b>	<b>2</b>
2.1	Performance Measure Logic Basics .....	2
2.1.1	CRS Denominator Definitions.....	2
2.1.2	Performance Measure Logic Example.....	11
2.1.3	Age Ranges.....	12
2.1.4	Standard Health Care Codes.....	13
2.2	Diabetes Related Measure Topics.....	14
2.2.1	Diabetes Prevalence .....	14
2.2.2	Diabetes Comprehensive Care.....	17
2.2.3	Diabetes: Glycemic Control .....	22
2.2.4	Diabetes: Blood Pressure Control .....	28
2.2.5	Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes .....	32
2.2.6	Diabetes: Nephropathy Assessment .....	39
2.2.7	Diabetic Retinopathy .....	43
2.2.8	RAS Antagonist Use in Diabetic Patients .....	48
2.2.9	Diabetes: Access to Dental Services.....	54
2.3	Dental Measure Topics.....	57
2.3.1	Access to Dental Services.....	57
2.3.2	Dental Sealants .....	60
2.3.3	Topical Fluoride .....	64
2.4	Immunization Measure Topics.....	66
2.4.1	Influenza .....	66
2.4.2	Adult Immunizations .....	72
2.4.3	Childhood Immunizations .....	79
2.4.4	Adolescent Immunizations.....	90
2.5	Childhood Diseases Group.....	95
2.5.1	Appropriate Treatment for Children with Upper Respiratory Infection.....	95
2.5.2	Appropriate Testing for Children with Pharyngitis.....	98
2.6	Cancer Related Measure Topics .....	101
2.6.1	Cancer Screening: Pap Smear Rates.....	101
2.6.2	Cancer Screening: Mammogram Rates .....	105
2.6.3	Colorectal Cancer Screening.....	109
2.6.4	Comprehensive Cancer Screening.....	114
2.6.5	Tobacco Use and Exposure Assessment.....	120
2.6.6	Tobacco Cessation.....	128
2.7	Behavioral Health Related Performance Measure Topics .....	135
2.7.1	Alcohol Screening (FAS Prevention) .....	135

2.7.2	Screening, Brief Intervention, and Referral to Treatment (SBIRT).....	140
2.7.3	Intimate Partner (Domestic) Violence Screening .....	145
2.7.4	Depression Screening .....	148
2.7.5	Antidepressant Medication Management .....	154
2.8	Cardiovascular Disease Related Measure Topics .....	157
2.8.1	Obesity Assessment.....	158
2.8.2	Childhood Weight Control.....	163
2.8.3	Weight Assessment and Counseling for Nutrition and Physical Activity .....	166
2.8.4	Nutrition and Exercise Education for At Risk Patients .....	170
2.8.5	Physical Activity Assessment .....	174
2.8.6	Comprehensive Health Screening.....	177
2.8.7	Cardiovascular Disease and Blood Pressure Control.....	184
2.8.8	Controlling High Blood Pressure.....	188
2.8.9	Controlling High Blood Pressure (Million Hearts).....	191
2.8.10	Comprehensive CVD-Related Assessment.....	195
2.8.11	Appropriate Medication Therapy after a Heart Attack.....	204
2.8.12	Persistence of Appropriate Medication Therapy after a Heart Attack.....	215
2.8.13	Appropriate Medication Therapy in High Risk Patients.....	227
2.8.14	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge.....	239
2.8.15	Heart Failure and Evaluation of LVS Function.....	241
2.9	STD-Related Measure Topics .....	244
2.9.1	HIV Screening .....	244
2.9.2	HIV Quality of Care.....	250
2.9.3	Hepatitis C Screening.....	252
2.9.4	Chlamydia Screening .....	255
2.9.5	Sexually Transmitted Infection Screening .....	258
2.10	Other Clinical Measures Topics.....	262
2.10.1	Osteoporosis Management.....	262
2.10.2	Osteoporosis Screening in Women .....	266
2.10.3	Rheumatoid Arthritis Medication Monitoring .....	268
2.10.4	Osteoarthritis Medication Monitoring .....	273
2.10.5	Asthma .....	277
2.10.6	Asthma Assessments .....	280
2.10.7	Asthma Quality of Care .....	285
2.10.8	Medication Therapy for Persons with Asthma .....	289
2.10.9	Chronic Kidney Disease Assessment.....	295
2.10.10	Proportion of Days Covered by Medication Therapy .....	298
2.10.11	Primary Medication Non-adherence .....	305
2.10.12	Medications Education .....	309
2.10.13	Medication Therapy Management Services .....	311

---

2.10.14 Self Management (Confidence).....	313
2.10.15 Public Health Nursing.....	314
2.10.16 Breastfeeding Rates.....	318
2.10.17 Use of High-Risk Medications in the Elderly.....	321
2.10.18 Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly.....	326
2.10.19 Functional Status Assessment in Elders.....	328
2.10.20 Fall Risk Assessment in Elders.....	330
2.10.21 Palliative Care.....	333
2.10.22 Annual Wellness Visit.....	335
2.10.23 Optometry.....	337
2.10.24 Goal Setting.....	339
<b>Contact Information.....</b>	<b>342</b>

## Preface

The Government Performance and Results Act (GPRA) requires federal agencies to report annually on how the agency measured up against the performance targets set in its annual Plan. The Indian Health Service (IHS) GPRA report includes measures for clinical prevention and treatment, quality of care, infrastructure, and administrative efficiency functions.

The IHS Clinical Reporting System (CRS) is a Resource and Patient Management System (RPMS) software application designed for national reporting as well as Area Office and local monitoring of clinical GPRA and developmental measures. CRS was first released for Fiscal Year (FY) 2002 performance measures (as GPRA+) and is based on a design by the Aberdeen Area (GPRA2000).

This manual contains the FY 2016 clinical performance measure definitions and logic for the CRS 2016 Version 16.0 software. CRS is the reporting tool used by the IHS Office of Planning and Evaluation to collect and report clinical performance results annually to the Department of Health and Human Services and to Congress.

Each year, an updated version of CRS software is released to reflect changes in the logic descriptions of the different denominators and numerators. Additional performance measures may also be added. Local facilities can run reports as often as they want to and can also use CRS to transmit data to their Area. The Area Office can use CRS to produce an aggregated Area report for either annual GPRA or Area Director Performance reports.

CRS produces reports on demand from local RPMS databases for both GPRA and developmental clinical measures that are based on RPMS data, thus eliminating the need for manual chart audits for evaluating and reporting clinical measures.

To produce reports with comparable data across every facility, the GPRA measures definitions was “translated” into programming code with the assistance of clinical subject matter experts. CRS uses predefined taxonomies to find data items in the RPMS Patient Care Component (PCC) to determine if a patient meets the performance measure criteria. Taxonomies contain groups of codes (e.g., diagnoses or procedures) or site-specific terms. Each performance measure has one or more defined denominators and numerators.

Administrative and clinical users can produce reports for selected measures at any time to:

- Identify potential data issues in their RPMS, i.e., missing or incorrect data.

- Monitor their site's performance against past national performance and upcoming agency goals.
- Identify specific areas where the facility is not meeting the measure in order to initiate business process or other changes.
- Quickly measure impact of process changes on performance measures.
- Identify areas meeting or exceeding measures to provide lessons learned.

Users of the RPMS CRS include:

- Area Office and site quality improvement staff
- Compliance Officers
- GPRA coordinators
- Clinical staff, such as physicians, nurses, nurse practitioners, and other providers
- Area Office directors
- Any staff involved with quality assurance initiatives
- Staff who run various CRS reports

## 1.0 Introduction

This manual provides information on the performance measure logic used by the Clinical Reporting System (CRS) Version 16.0 Selected Measures (Local) Report (Fiscal Year [FY] 2016 Clinical Performance Measures). For information on system setup, available reports and steps for running the reports, and performing Area Office functions, refer to the CRS Version 16.0 User Manual.

## 2.0 Performance Measure Logic

This section provides the following information for each performance measure topic:

- For Government Performance and Results Act (GPRA) measures, the measure description is provided as stated in the Indian Health Service (IHS) Annual Performance Report to Congress
- Definitions of all denominators and numerators for each performance measure topic
- Detailed description of the logic for the denominator and numerator, including specific codes, fields, taxonomies, and/or values searched
- Key changes to logic from the previous year, if any
- Description of which patients and information are contained on the patient list
- Performance measure source and past IHS performance, if any, and IHS or Healthy People (HP) 2020 targets for the performance measure
- Report examples
- Patient list examples

**Note:** All report examples and patient list examples used in this section were produced from “scrubbed” demonstration databases and do not represent individual patient data.

### 2.1 Performance Measure Logic Basics

#### 2.1.1 CRS Denominator Definitions

Each performance measure topic has one or more define denominators and numerators. The denominator is the total population that is being reviewed for a specific measure. For the National GPRA/GPRAMA Report, only one denominator for each topic is reported. These denominators are pre-defined, based on the Active Clinical Population definition. For the Selected Measures reports for local use (CRS Version 16.0 User Manual, Section 5.11), multiple denominators may be reported to provide a complete picture of clinical performance. There are also additional options available to further refine denominator definitions.



### 2.1.1.1 Denominator Definitions for National GPRA Reporting

The Active Clinical population is the denominator definition used as the basis for *most* GPRA measures. This denominator was developed in FY 2003 specifically for clinical performance measures because it is more representative of the active clinical population.

Prior to FY 2003, the GPRA User Population denominator definition was used for national reporting, similar to the agency's IHS User Population definition.

The *Active Clinical* population for the National GPRA/GPRAMA Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the Resource and Patient Management System (RPMS) Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two visits to medical clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology

Clinic Code	Clinic Description
07	ENT
08	Family Planning
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology - Hepatology
B9	Oncology - Hematology
C3	Colposcopy

- Patient must be alive on the last day of the report period.
- Patient must be American Indian/Alaska Native (AI/AN) (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the Purchased and Referred Care (PRC) catchment area specified in the community taxonomy specified by the user.

The *Active Clinical Plus Behavioral Health Population* for National GPRA/GPRAMA Reports is defined as follows:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the Patient Care Component [PCC] Management Reports, Other section) will be automatically excluded from the denominator.

- Patient must have *two* visits to *medical* clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
14	Mental Health
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology

Clinic Code	Clinic Description
43	Alcohol & Substance Abuse
48	Medical Social Services
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology – Hepatology
B9	Oncology – Hematology
C3	Colposcopy
C4	Behavioral Health
C9	Telebehavioral Health

- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the PRC catchment area specified in the community taxonomy that is specified by the user.

The *GPRA User Population* for the National GPRA/GPRAMA Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have been seen at least once in the 3 years prior to the end of the time period, regardless of the clinic type.
- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the PRC catchment area specified in the community taxonomy specified by the user.

**Note:** The GPRA User Population definition is similar, but not identical, to the definition used by IHS headquarters (HQ) for annual user population statistics. GPRA “visits” are not required to be workload reportable as defined by IHS HQ.

### 2.1.1.2 Denominator Definitions for Selected Measures Reports

In addition to the National GPRA/GPRAMA Report, CRS provides Selected Measures reports intended for local facility use for specific public health and/or performance improvement initiatives (CRS Version 16.0 User Manual, Section 5.11). Multiple denominators and numerators will be reported for each measure (e.g., *both* Active Clinical and GPRA User Population). Users have additional options to define the denominators as explained below.

The Active Clinical Population for Selected Measures (Local) Reports is defined as follows:

- Patients with name “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two visits to medical clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women’s Health
80	Urgent Care
89	Evening

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology - Hepatology
B9	Oncology - Hematology
C3	Colposcopy

- Patient must be alive on the last day of the Report period.
- User defines population type: AI/AN patients only, non AI/AN, or both. This data item is entered and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

The *Active Clinical Plus Behavioral Health Population* for Selected Measures (Local) Reports is defined as follows:

- Patients with the name of “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have *two* visits to *medical* clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
14	Mental Health
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk

Clinic Code	Clinic Description
27	General Preventive
31	Hypertension
38	Rheumatology
43	Alcohol & Substance Abuse
48	Medical Social Services
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology – Hepatology
B9	Oncology – Hematology
C3	Colposcopy

- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both. This data item is typed and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patients (patient panel); or all patients, regardless of community of residence.

The *User Population* for Selected Measures (Local) reports is defined as follows:

- Patients with the name of “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be excluded from the denominator automatically.
- Patient must have been seen at least once in the 3 years prior to the end of the time period, regardless of the clinic type.
- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.



## 2.1.2 Performance Measure Logic Example

**Cancer Screening: Mammogram Rates:** During GPRA Year 2016, achieve the target rate of 55.9% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last 2 years.

For CRS, the GPRA measure definition is defined as:

- Denominator (total number of patients evaluated): Active Clinical female patients ages 52 through 64, excluding those with documented history of bilateral mastectomy. (The clinical owner of the measure has determined based on current medical guidelines that “eligible” women are defined as ages 52 through 64.)
- Numerator (those from the denominator who meet the criteria for the measure): patients with documented mammogram in past 2 years.

For the programmer, the Mammogram measure is described in terms of the following logic:

1. Begin with the Active Clinical population definition.
  - Exclude any patients with the name of “DEMO, PATIENT.”
  - Exclude any patient records that are included in the RPMS Demo/Test Patient Search Template.
  - Exclude any patients with a date of death in the Patient Registration file.
  - Exclude any patients who do *not* have value 01 (AI/AN) in the Beneficiary field in Patient Registration file.
  - Exclude any patients whose Community of Residence is not included in the site’s defined GPRA Community Taxonomy for this report.
  - For the remaining patients, search Visit files for the 3 years prior to the selected report end date; exclude any patient records whose visits do not meet the “two medical clinics” definition.
2. From these patients, identify the subset that are female and at least age 52 on the first day of the current report period and less than age 65 on the last day of the report period.

3. Exclude patients with documented bilateral mastectomy by searching the V Procedure file for Procedure Codes ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HTV0ZZ or V CPT for CPT Codes 19300.50-19307.50 OR 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, 19240, w/modifier of 50 or 09950 any time before the end of the report period; *or* who have two separate occurrences for either CPT Codes 19300-19307, or old codes 19180, 19200, 19220, 19240 or Procedure Codes ICD-9: 85.41, 85.43, 85.45, 85.47; ICD-10: 07T50ZZ, 07T60ZZ, 07T70ZZ, 07T80ZZ, 07T90ZZ, 0HTT0ZZ, 0HTU0ZZ, 0KTH0ZZ, 0KTJ0ZZ on either two different dates of service or on the same date of service if the codes include both a right side modifier (RT) and left side modifier (LT).
4. For these patients (the denominator), check for a mammogram in the past 2 years in the following order:
  - a. Check V Radiology or V CPT for the following CPT Codes: 77052 through 77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206; G0204, G0202
  - b. Check the Purpose of Visit file (V POV) for a diagnosis of ICD-9: V76.11 Screening Mammogram for High Risk Patient; V76.12 Other Screening Mammogram; 793.80 Abnormal Mammogram, Unspecified; 793.81 Mammographic Microcalcification; 793.89 Other Abnormal Findings On Radiological Exam of Breast or ICD-10: R92.0, R92.1, R92.8, Z12.31.
  - c. Check V Procedures for a procedure of ICD-9: 87.36 Xerography of Breast, 87.37 Other Mammography or ICD-10: BH00ZZZ, BH01ZZZ, BH02ZZZ.
  - d. Check the Women's Health Tracking package for documentation of a procedure called Mammogram Screening, Mammogram Dx Bilat, or Mammogram Dx Unilat and where the result does *not* have "ERROR/DISREGARD".

If a visit with any of the specified codes is found, the patient is considered to have met the measure, and the program checks the next patient.

### 2.1.3 Age Ranges

Unless otherwise noted, for the purposes of CRS reports, the age of a patient is calculated at the beginning of the report period. For example, for a report period of July 1, 2015 through June 30, 2016, Jane Doe is defined as age 74 if her birth date is June 10, 1941, even though she becomes age 75 during the report period.

## 2.1.4 Standard Health Care Codes

### 2.1.4.1 Current Procedural Terminology Codes

One of several code sets used by the healthcare industry to standardize data, and allow for comparison and analysis. Current Procedural Terminology (CPT) was developed and is updated annually by the American Medical Association, and is widely used in producing bills for services rendered to patients. CPTs include codes for diagnostic and therapeutic procedures, and specify information that differentiates the codes based on cost. CPT codes are the most widely accepted nomenclature in the United States for reporting physician procedures and services for federal and private insurance third-party reimbursement. CRS searches for CPT and other codes as specified in the logic definition to determine if a patient meets a denominator or numerator definition.

### 2.1.4.2 International Classification of Disease Codes

One of several code sets used by the healthcare industry to standardize data. The International Classification of Disease (ICD) is an international diagnostic coding scheme. In addition to diseases, ICD also includes several families of terms for medical-specialty diagnoses, health status, disablements, procedure, and reasons for contact with healthcare providers. IHS currently uses ICD, Ninth Revision (ICD-9) for coding, but will be switching to ICD-10 in 2015. CRS searches for ICD and other codes as specified in the logic definition, to determine if a patient meets a denominator or numerator definition.

### 2.1.4.3 Logical Observation Identifiers Names and Codes

Logical Observation Identifiers Names and Codes (LOINC®). A standard coding system originally initiated for laboratory values, the system is being extended to include non-laboratory observations (electrocardiograms, vital signs, etc.). Standard code sets are used to define individual tests and mitigate variations in local terminologies for laboratory and other healthcare procedures, for example, Glucose or Glucose Test. IHS began integrating LOINC values into RPMS in several pilot sites in 2002.

Refer to the CRS Version 16.0 Technical Guide for a list of specific LOINC codes included in each LOINC taxonomy.

## 2.2 Diabetes Related Measure Topics

### 2.2.1 Diabetes Prevalence

#### Denominators

All *User Population patients*. Broken down by gender and age groups (less than (<) 15, 15 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, greater than (>) 64 years).

#### Numerators

Anyone diagnosed with Diabetes *at any time* before the end of the Report Period.

Anyone diagnosed with Diabetes *during* the Report Period.

#### Logic Description

Age is calculated at the beginning of the Report Period.

*Diabetes definition:* At least one POV diagnosis of ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\*.

#### Key Logic Changes from CRS Version 15.1

None.

#### Patient List Description

List of diabetic patients with most recent diagnosis.

#### Measure Source

HP 2010 5–2, 5–3

#### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2015 Performance	14.4%
IHS FY 2014 Performance	14.0%
IHS FY 2013 Performance	13.9%
IHS FY 2012 Performance	13.4%
IHS FY 2011 Performance	12.8%

Performance	Percent
IHS FY 2010 Performance	12.0%
IHS FY 2009 Performance	12.0%
IHS FY 2008 Performance	12.0%
IHS FY 2007 Performance	11.0%
IHS FY 2006 Performance	11.0%
IHS FY 2005 Performance	11.0%
IHS FY 2004 Performance	10.0%

DU November 25, 2016 Page 1

\*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2016 to Dec 31, 2016

Previous Year Period: Jan 01, 2015 to Dec 31, 2015

Baseline Period: Jan 01, 2010 to Dec 31, 2010

-----

Diabetes Prevalence

Denominator(s):

- All User Population patients. Broken down by gender and by age groups: < 15, 15-19, 20-24, 25-34, 35-44, 45-54, 55-64, > 64.

Numerator(s):

- Anyone diagnosed with Diabetes at any time before the end of the Report Period.
- Anyone diagnosed with Diabetes during the Report Period.

Logic:

Age is calculated at the beginning of the Report Period. Diabetes diagnosis is defined as at least one POV diagnosis ICD-9: 250.00-250.93 or ICD-10: E10.\*-E13.\*.

Performance Measure Description:

Continue tracking (i.e., data collection and analyses) Area age-specific diabetes prevalence rates to identify trends in the age-specific prevalence of diabetes (as a surrogate marker for diabetes incidence) for the AI/AN population.

Past Performance and/or Target:

IHS Performance: FY 2015 - 14.4%, FY 2014 - 14.0%, FY 2013 - 13.9%, FY 2012 - 13.4%, FY 2011 - 12.8%, FY 2010 - 12%, FY 2009 - 12%, FY 2008 - 12%, FY 2007 - 11%, FY 2006 - 11%, FY 2005 - 11%, FY 2004 - 10%

Source:

HP 2010 5-2, 5-3

Diabetes Prevalence

REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
---------------	---	----------------	---	--------------------	-------------	---	-----------------

# User Pop	2,896		2,456			2,346		
# w/ any DM DX	265	9.2	243	9.9	-0.7	197	8.4	+0.8
# w/ DM DX w/in past year	173	6.0	146	5.9	+0.0	100	4.3	+1.7
# Male User Pop	1,368		1,152			1,109		
# w/ any DM DX	114	8.3	104	9.0	-0.7	72	6.5	+1.8
# w/DM DX w/in past year	82	6.0	78	6.8	-0.8	48	4.3	+1.7
# Female User Pop	1,528		1,304			1,237		
# w/ any DM DX	151	9.9	139	10.7	-0.8	125	10.1	-0.2
# w/ DM DX w/in past year	91	6.0	68	5.2	+0.7	52	4.2	+1.8

Figure 2-1: Sample Summary Report, Diabetes Prevalence Topic

DU	November 25, 2016							Page 2
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Diabetes Prevalence (con't)								
TOTAL USER POPULATION								
Age Distribution								
	<15	15-19	20-24	25-34	35-44	45-54	55-64	>64 yrs
CURRENT REPORT PERIOD								
Total # User Pop	730	239	261	403	389	390	262	222
# w/ DM DX ever	1	3	7	37	57	67	50	43
% w/ DM DX ever	0.1	1.3	2.7	9.2	14.7	17.2	19.1	19.4
# w/DM DX in past yr	0	2	3	14	42	49	34	29
% w/DM DX in past yr	0.0	0.8	1.1	3.5	10.8	12.6	13.0	13.1
PREVIOUS YEAR PERIOD								
Total # User Pop	711	227	243	352	316	277	181	149
# w/ DM DX ever	3	4	9	31	54	57	45	40
% w/ DM DX ever	0.4	1.8	3.7	8.8	17.1	20.6	24.9	26.8
# w/DM DX in past yr	1	3	3	9	33	37	31	29
% w/DM DX in past yr	0.1	1.3	1.2	2.6	10.4	13.4	17.1	19.5
CHANGE FROM PREV YR %								
w/ DM DX ever	-0.3	-0.5	-1.0	+0.4	-2.4	-3.4	-5.8	-7.5
w/DM DX in past yr	-0.1	-0.5	-0.1	+0.9	+0.4	-0.8	-4.1	-6.4
BASELINE REPORT PERIOD								
Total # User Pop	787	208	217	329	293	228	141	143
# w/ DM DX ever	2	4	12	20	38	46	31	44
% w/ DM DX ever	0.3	1.9	5.5	6.1	13.0	20.2	22.0	30.8

# w/DM DX in past yr	2	1	3	7	18	21	20	28
% w/DM DX in past yr	0.3	0.5	1.4	2.1	6.1	9.2	14.2	19.6
CHANGE FROM BASE YR %								
w/ DM DX ever	-0.1	-0.7	-2.8	+3.1	+1.7	-3.0	-2.9	-11.4
w/DM DX in past yr	-0.3	+0.4	-0.2	+1.3	+4.7	+3.4	-1.2	-6.5

Figure 2-2: Sample Age Breakdown Page, Diabetes Prevalence Topic

DU	November 25, 2016				Page 1			
*** IHS 2016 Clinical Performance Measure Patient List ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Entire Patient List								
-----								
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic								
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;								
HR=High Risk Patient								
Diabetes Prevalence: List of diabetic patients with most recent diagnosis								
PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB			
DENOMINATOR		NUMERATOR						
-----								
PATIENT1,DEBORAH	000001	COMMUNITY #1	F	20	01/06/96			
UP		02/01/16	POV	250.00				
PATIENT2,TARA	000002	COMMUNITY #1	F	21	03/15/95			
UP		05/24/15	POV	E11.21				
PATIENT3,BOBBIE	000003	COMMUNITY #1	F	28	10/01/88			
UP		03/30/15	POV	250.00				
PATIENT4,WINONA	000004	COMMUNITY #1	F	37	05/03/79			
UP		04/30/16	POV	250.00				
PATIENT5,NADINE	000005	COMMUNITY #1	F	44	07/07/72			
UP		03/19/15	POV	250.00				
PATIENT6,RUTH	000006	COMMUNITY #1	F	44	11/03/72			
UP		03/19/16	POV	E10.10				

Figure 2-3: Sample Patient List, Diabetes Prevalence, Patients with Diabetes Diagnosis

## 2.2.2 Diabetes Comprehensive Care

### Denominators

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two diabetes mellitus- (DM-) related visits ever.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two diabetes mellitus- (DM-) related visits ever, without a documented history of bilateral blindness.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two diabetes mellitus- (DM-) related visits ever, without a documented history of bilateral foot amputation or two separate unilateral foot amputations.

## Numerators

Patients with hemoglobin A1c documented during the Report Period, regardless of result

Patients with blood pressure (BP) documented during the Report Period

Patients with controlled BP, defined as less than (<) 140/90, i.e., the mean systolic value is less than (<) 140 and the mean diastolic value is less than (<) 90

Patients with nephropathy assessment, defined as an estimated GFR with result and a urine albumin-to-creatinine ratio (UACR) during the Report Period *or* with the evidence of diagnosis and/or treatment of end-stage renal disease (ESRD) at any time before the end of the Report Period

Patients receiving a qualified retinal evaluation during the Report Period

**Note:** This numerator does *not* include refusals.

Patients with diabetic foot exam during the Report Period

**Note:** This numerator does *not* include refusals.

Patients with comprehensive diabetes care (Documented A1c *and* Blood Pressure *and* Nephropathy Assessment *and* Retinal Exam *and* Diabetic Foot Exam).

## Logic Description

*Diabetes definition:* First Purpose of Visit (POV) ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the POV file prior to the Report Period.

*A1c definition:* Searches for most recent A1c test with a result during the Report Period. If none found, CRS searches for the most recent A1c test without a result. A1c defined as: CPT 83036, 83037, 3044F through 3046F, 3047F (old code); LOINC taxonomy; or site-populated taxonomy DM AUDIT HGB A1C TAX.



*BP documented definition:* Having a minimum of 2 BPs documented during the Report Period.

Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of last 2 BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) BPs and dividing by 3 (or 2).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

*Controlled BP definition:* CRS uses a mean, as described above. If the mean systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

BP documented and Controlled BP: If CRS is not able to calculate a mean BP from BP measurements, it will search for the most recent of any of the following CPT codes documented during the Report Period: BP Documented: 0001F, 2000F, G9273, G9274 or POV ICD-9: V81.1; *or* Systolic 3074F, 3075F, or 3077F *with* Diastolic: 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combinations represent BP less than (<) 140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F *and* 3078F or 3079F; *or* G9273. All other combinations *will not* be included in the Controlled BP numerator.

*Nephropathy assessment definition:* (1) Estimated GFR with result during the report period, defined as any of the following: (A) Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or (B) LOINC taxonomy, *and* (2) Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period, defined as any of the following: (A) CPT 82043 WITH 82570; (B) LOINC taxonomy; or (C) site-populated taxonomy BGP QUANT UACR TESTS.

<p><b>Note:</b> Be sure to check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values.</p>
--

(3) ESRD diagnosis/treatment defined as any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

*Qualified retinal evaluation definition:* (1) diabetic retinal exam or (2) other eye exam. The following methods are qualifying for this measure: (1) dilated retinal evaluation by an optometrist or ophthalmologist, or (2) seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist, or (3) any photographic method formally validated to seven standard fields (ETDRS).

- *Diabetic Retinal Exam:* Any of the following during the Report Period: (1) Exam Code 03 Diabetic Eye Exam (dilated retinal examination or formally validated\* ETDRS photographic equivalent), (2) CPT 2022F Dilated retinal eye exam; 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist; 2026F Eye imaging formally validated\* to match the diagnosis from seven standard field stereoscopic photos; S0620 Routine ophthalmological examination including refraction; new patient; S0621 Routine ophthalmological examination including refraction; established patient; S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.
- *Other Eye Exam:* (1) Non-DNKA (did not keep appointment) visits to ophthalmology, optometry or formally validated\* teleophthalmology retinal evaluation clinics or (2) non-DNKA visits to an optometrist or ophthalmologist. Searches for the following codes in the following order: Clinic Codes A2 (Diabetic Retinopathy)\*\*, 17, 18; Provider Code 24, 79, 08; CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014.

\*Validation study properly powered and controlled against the ETDRS gold standard.

\*\*Validated photographic (teleophthalmology) retinal surveillance.

Bilateral blindness defined as: 1) Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 369.01, 369.03, 369.04; ICD-10: H54.0 through H54.12.

*Diabetic foot exam definition:* (1) Exam Code 28 Diabetic Foot Exam, Complete; (2) non-DNKA visit with a podiatrist (Provider Codes 33, 84 or 25), (3) non-DNKA visit to Podiatry Clinic or Diabetic Foot Clinic (Clinic Codes 65 and B7), or (4) CPT 2028F, G9226.

*Bilateral foot amputation definition:* CPT 27290.50 through 27295.50, 27590.50 through 27592.50, 27598.50, 27880.50 through 27882.50 (50 modifier indicates bilateral), G9224; 2) Procedure ICD-10: 0Y640ZZ.

*Unilateral foot amputation definition:* Must have two separate occurrences on two different dates of service: (1) CPT 27290 through 27295, 27590 through 27592, 27598, 27880 through 27882; (2) Procedure ICD-9: 84.10, 84.13 through 84.19; ICD-10: 0Y620ZZ, 0Y630ZZ, 0Y670ZZ, 0Y680ZZ, 0Y6C0Z\*, 0Y6D0Z\*, 0Y6F0ZZ, 0Y6G0ZZ, 0Y6H0Z\*, 0Y6J0Z\*, 0Y6M0Z0, 0Y6N0Z0, or (3) POV ICD-9: V49.7\*.

**Key Logic Changes from CRS Version 15.1**

1. Removed LDL measure and logic from topic.
2. Added LOINC codes 77254-1 and 77253-3 to BGP QUANT UACR LOINC taxonomy.
3. Removed LOINC code 48643-1 from BGP ESTIMATED GFR LOINC taxonomy.

**Patient List Description**

List of diabetic patients with documented tests, if any.

**Measure Source**

Foot Exam: HP 2020 D-9

**Measure Past Performance and Long-Term Targets**

Target	Percent
HP 2020 goal for foot exam	74.8%

DU	November 25, 2016						Page 9	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Diabetes Comprehensive Care								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Diabetic Pts	144		97			87		
# w/Comp Diabetes Care	10	6.9	1	1.0	+5.9	0	0.0	+6.9

# w/Alc done								
w/ or w/o result	92	63.9	70	72.2	-8.3	52	59.8	+4.1
# w/ BPs documented	120	83.3	78	80.4	+2.9	74	85.1	-1.7
# w/Controlled BP								
<140/90	28	19.4	20	20.6	-1.2	13	14.9	+4.5
# w/ est GFR & UACR								
or w/ESRD	53	36.8	11	11.3	+25.5	6	6.9	+29.9
Active Diabetic Pts w/o								
Hx of Bilateral								
Blindness	141		97			87		
# w/Retinal Evaluation								
-No Refusals	53	37.6	38	39.2	-1.6	44	50.6	-13.0
Active Diabetic Pts w/o								
Hx of Bilateral								
Amputation	137		97			87		
# w/Diabetic Foot Exam								
-No Refusals	20	14.6	18	18.6	-4.0	16	18.4	-3.8

Figure 2-4: Sample Summary Report, Diabetes Comprehensive Care Topic

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Diabetes Comprehensive Care: List of diabetic patients with documented tests, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH AD	000001	COMMUNITY #1 Alc: 02/28/16	F	45	05/23/71
PATIENT2,TARA AD	000002	COMMUNITY #1 BP: <140/90: BPs: 118/61; ESRD: 03/03/16	F	51	09/10/65
PATIENT3,BARBIE AD	000003	COMMUNITY #1 Alc: 04/09/16 6.5; BPs: 148/86 UNC; GFR: 04/09/16 & UACR: 03/31/16 QUANT UACR; EYE: 03/30/16 C1 18; FOOT EXAM: 01/07/16 C1 65	F	52	02/12/64
PATIENT4,DONALD AD	000004	COMMUNITY #1 BILATERAL BLINDNESS	M	25	08/01/91

Figure 2-5: Sample Patient List, Diabetes Comprehensive Care

## 2.2.3 Diabetes: Glycemic Control

### GPRAMA Measure Description, Good Glycemic Control

During GPRA Year 2016, achieve the target rate of 49.5% for the proportion of patients with diagnosed diabetes who have good glycemic control (defined as A1c less than (<) 8).

## Denominators

All *User Population patients* diagnosed with diabetes prior to the report period.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRAMA Denominator)

*Active Adult Diabetic patients*, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever; (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

## Numerators

Number of patients with a Hemoglobin A1c documented during the Report Period, regardless of result.

*Poor Control*: Total of Poor and Very Poor Control: Patients with A1c greater than (>) 9.5.

*Very Poor Control*: Patients with A1c greater than or equal to (=>) 12.

*Poor Control*: Patients with A1c greater than (>) 9.5 and less than (<) 12.

*Fair Control*: Patients with A1c greater than or equal to (=>) 8 and less than or equal to (<=) 9.5.

Patients with A1c greater than or equal to (=>) 7 and less than (<) 8.

*Good Control*: Patients with A1c less than (<) 8. (GPRAMA Numerator)

Patients with A1c less than (<) 7.

*Without Result*: Patients with A1c documented but no value.

## Logic Description

*Diabetes definition*: First Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

*Hemoglobin A1c definition:* Searches for most recent A1c test with a result during the Report Period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If both tests have a result, the last test done on the visit will be used. If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result. Without result is defined as A1c documented but with no value.

CRS uses the following definitions:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX
Hemoglobin A1c	83036, 83037, 3044F-3046F, 3047F (old code) <b>Note:</b> CPT 3044F represents A1c less than (<) 7 and will be included in the A1c less than (<) 7 and A1c less than (<) 8 numerators.	Yes	DM AUDIT HGB A1C TAX

In the CPT Codes column, specific LOINC codes used CRS are located in the *CRS Technical Manual*.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of diabetic patients with most recent A1c value, if any.

### Measure Source

HEDIS; HP 2020 D-11, D-5

**Measure Past Performance and Long-Term Targets**  
**Hemoglobin A1c Documented**

<b>Performance</b>	<b>Percent</b>
IHS FY 2015 Performance	84.7%
IHS FY 2014 Performance	85.7%
IHS FY 2013 Performance	85.2%
IHS FY 2012 Performance	84.9%
IHS FY 2011 Performance	83.0%
IHS FY 2010 Performance	82.0%
IHS FY 2009 Performance	80.0%
IHS FY 2008 Performance	79.0%
IHS FY 2007 Performance	79.0%
IHS FY 2006 Performance	79.0%
IHS FY 2005 Performance	78.0%
IHS FY 2004 Performance	77.0%
IHS FY 2003 Performance	75.0%
IHS FY 2002 Performance	73.0%
<i>HP 2020 Goal</i>	71.1%

**Good Glycemic Control (A1c less than (<) 8)**

<b>Performance</b>	<b>Percent</b>
IHS FY 2015 Performance	47.4%
IHS FY 2014 Performance	48.6%
IHS FY 2013 Performance	48.3%

**Poor Glycemic Control (A1c greater than (>) 9.5)**

<b>Performance</b>	<b>Percent</b>
IHS FY 2015 Performance	20.9%
IHS FY 2014 Performance	20.7%
IHS FY 2013 Performance	20.7%
IHS FY 2012 Performance	19.8%
IHS FY 2011 Performance	19.1%
IHS FY 2010 Performance	18.0%
IHS FY 2009 Performance	18.0%
IHS FY 2008 Performance	17.0%
IHS FY 2007 Performance	16.0%

Performance	Percent
IHS FY 2006 Performance	16.0%
IHS FY 2005 Performance	15.0%
IHS FY 2004 Performance	17.0%
IHS FY 2003 Performance	17.0%
IHS FY 2002 Performance	18.0%

### Ideal Glycemic Control (A1c less than (<) 7)

Performance	Percent
IHS FY 2012 Performance	33.2%
IHS FY 2011 Performance	31.9%
IHS FY 2010 Performance	32.0%
IHS FY 2009 Performance	31.0%
IHS FY 2008 Performance	32.0%
IHS FY 2007 Performance	31.0%
IHS FY 2006 Performance	31.0%
IHS FY 2005 Performance	30.0%
IHS FY 2004 Performance	27.0%
IHS FY 2003 Performance	28.0%
IHS FY 2002 Performance	25.0%
<i>HP 2020 Goal</i>	<i>58.9%</i>

DU		November 25, 2016				Page 11			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Diabetes: Glycemic Control									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
User Pop w/ DM DX prior to report end date	233		203			180			
# w/A1c done w/ or w/o result	97	41.6	72	35.5	+6.2	53	29.4	+12.2	
# w/A1c =>12	4	1.7	2	1.0	+0.7	3	1.7	+0.1	
# w/A1c >9.5 and <12	15	6.4	4	2.0	+4.5	8	4.4	+2.0	
# w/A1c =>8 and =<9.5	11	4.7	18	8.9	-4.1	10	5.6	-0.8	
# w/A1c=>7									



and <8	15	6.4	15	7.4	-1.0	7	3.9	+2.5
# w/Alc <8	53	22.7	48	23.6	-0.9	30	16.7	+6.1
# w/Alc <7	38	16.3	33	16.3	+0.1	23	12.8	+3.5
# w/Alc w/o Result	14	6.0	0	0.0	+6.0	2	1.1	+4.9
Active Diabetic Pts (GPRAMA)	147		99			87		
# w/Alc done w/ or w/o result	94	63.9	70	70.7	-6.8	52	59.8	+4.2
# w/Alc > 9.5	19	12.9	6	6.1	+6.9	11	12.6	+0.3
# w/Alc =>12	4	2.7	2	2.0	+0.7	3	3.4	-0.7
# w/Alc >9.5 and < 12	15	10.2	4	4.0	+6.2	8	9.2	+1.0
# w/Alc =>8 and =<9.5	11	7.5	18	18.2	-10.7	10	11.5	-4.0
# w/Alc=>7 and <8	15	10.2	15	15.2	-4.9	7	8.0	+2.2
# w/Alc <8 (GPRAMA)	50	34.0	46	46.5	-12.5	29	33.3	+0.7
# w/Alc <7	35	23.8	31	31.3	-7.5	22	25.3	-1.5
# w/Alc w/o Result	14	9.5	0	0.0	+9.5	2	2.3	+7.2
Active Adult Diabetic Patients	104		76			63		
# w/Alc done w/ or w/o result	73	70.2	61	80.3	-10.1	46	73.0	-2.8
# w/Alc =>12	3	2.9	1	1.3	+1.6	3	4.8	-1.9
# w/Alc >9.5 and <12	13	12.5	3	3.9	+8.6	7	11.1	+1.4
# w/Alc =>8 and =<9.5	10	9.6	17	22.4	-12.8	8	12.7	-3.1
# w/Alc =>7 and <8	12	11.5	12	15.8	-4.3	6	9.5	+2.0
# w/Alc <8	41	39.4	40	52.6	-13.2	28	44.4	-5.0
# w/Alc <7	29	27.9	28	36.8	-9.0	22	34.9	-7.0
# w/Alc w/o Result	6	5.8	0	0.0	+5.8	0	0.0	+5.8

Figure 2-6: Sample Report, Diabetes: Glycemic Control Topic

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Diabetes: Glycemic Control: List of diabetic patients with most recent Alc value, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH	000001	COMMUNITY #1	F	45	11/11/71
UP,AD,AAD		03/28/16 Alc:		6.6	
PATIENT2,TARA	000002	COMMUNITY #1	F	51	02/10/65
UP,AD,AAD		02/20/16 Alc:		12.4	

PATIENT3 ,BOBBIE UP ,AD ,AAD	000003	COMMUNITY #1	F	52	05/06/64
		04/09/16	A1c:	6.5	
PATIENT4 ,WINONA UP	000004	COMMUNITY #1	F	53	07/21/63
PATIENT5 ,NADINE UP ,AD ,AAD	000005	COMMUNITY #1	F	61	08/12/55
		02/01/16	A1c:	6.5	
PATIENT6 ,RUTH UP	000006	COMMUNITY #1	F	64	06/30/52

Figure 2-7: Sample Patient List, Diabetes: Glycemic Control

## 2.2.4 Diabetes: Blood Pressure Control

### **GPRC Measure Description**

During GPRC Year 2016, achieve the target rate of 65.0% for the proportion of patients with diagnosed diabetes who have achieved blood pressure control (defined as less than (<)140/90).

### **Denominators**

*All User Population patients* diagnosed with diabetes prior to the Report Period.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRC Denominator)

*Active Adult Diabetic patients*, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM-related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

### **Numerators**

Patients with BP documented during the report period.

Patients with controlled BP, defined as less than (<) 140/90, i.e., the mean systolic value is less than 140 and the mean diastolic value is less than 90 (GPRC Numerator).

Patients with BP that is not controlled.

### **Logic Description**

*Diabetes definition*: First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

*BP documented definition:* CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of the last 2 BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F-3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

*Controlled BP definition:* CRS uses a mean, as described above where BP is less than (<)140/90. If the mean systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

*BP documented and Controlled BP:* If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented during the Report Period: BP Documented: CPT 0001F, 2000F, G9273, G9274 or ICD-9: POV V81.1; *or* Systolic: CPT 3074F, 3075F or 3077F *with* Diastolic: CPT 3078F, 3079F, or 3080F. The systolic and diastolic values do *not* have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combinations represent BP less than (<)140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F *and* 3078F or 3079F; *or* G9273. All other combinations will *not* be included in the Controlled BP numerator.

CRS uses the following definition:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX

In the LOINC Codes column, specific LOINC codes by CRS are location in the *CRS Technical Manual*.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of diabetic patients with BP value, if any.

### Measure Source

HP 2020 D-7

### Measure Past Performance and Long-Term Targets

#### Controlled BP

Performance	Percent
IHS FY 2015 Performance	62.5%
IHS FY 2014 Performance	63.8%
IHS FY 2013 Performance	64.6%
<i>Former definition of BP less than (&lt;) 130/80:</i>	
IHS FY 2012 Performance	38.9%
IHS FY 2011 Performance	37.8%
IHS FY 2010 Performance	38.0%
IHS FY 2009 Performance	37.0%
IHS FY 2008 Performance	38.0%
IHS FY 2007 Performance	39.0%
IHS FY 2006 Performance	37.0%
IHS FY 2005 Performance	37.0%
IHS FY 2004 Performance	35.0%
IHS FY 2003 Performance	37.0%
IHS FY 2002 Performance	36.1%
<i>HP 2020 Goal</i>	<i>57.0%</i>

#### BP Assessed

Performance	Percent
IHS FY 2015 Performance	86.7%
IHS FY 2014 Performance	87.5%

Performance	Percent
IHS FY 2013 Performance	87.5%
IHS FY 2012 Performance	88.5%
IHS FY 2011 Performance	87.9%
IHS FY 2010 Performance	89.0%
IHS FY 2009 Performance	88.0%
IHS FY 2008 Performance	89.0%
IHS FY 2005 Performance	89.0%

DU	November 25, 2016						Page 13	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Diabetes: Blood Pressure Control								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
User Pop w/ DM DX prior to report period	229		202			180		
# w/ BPs Documented	132	57.6	88	43.6	+14.1	84	46.7	+11.0
# w/controlled BP < 140/90	32	14.0	24	11.9	+2.1	18	10.0	+4.0
# w/Not controlled BP	100	43.7	64	31.7	+12.0	66	36.7	+7.0
Active Diabetic Pts (GPRA)	144		97			87		
# w/ BPs Documented	120	83.3	78	80.4	+2.9	74	85.1	-1.7
# w/Controlled BP < 140/90 (GPRA)	28	19.4	20	20.6	-1.2	13	14.9	+4.5
# w/Not controlled BP	92	63.9	58	59.8	+4.1	61	70.1	-6.2
Active Adult Diabetic Patients	102		75			63		
# w/ BPs Documented	82	80.4	61	81.3	-0.9	56	88.9	-8.5
# w/Controlled BP < 140/90	20	19.6	14	18.7	+0.9	8	12.7	+6.9
# w/Not controlled BP	62	60.8	47	62.7	-1.9	48	76.2	-15.4

Figure 2-8: Sample Report, Diabetes: Blood Pressure Control Topic

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Diabetes: Blood Pressure Control: List of diabetic patients with BP value, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH UP,AD,AAD	000001	COMMUNITY #1 133/82 CON	F	45	11/11/71
PATIENT2,TARA UP,AD,AAD	000002	COMMUNITY #1 3074F/3080F UNC	F	51	02/10/65
PATIENT3,BOBBIE UP,AD,AAD	000003	COMMUNITY #1 138/66 CON	F	52	05/06/64
PATIENT4,WINONA UP	000004	COMMUNITY #1	F	53	07/21/63
PATIENT5,NADINE UP,AD,AAD	000005	COMMUNITY #1 159/86 UNC	F	61	08/12/55
PATIENT6,RUTH UP	000006	COMMUNITY #1 139/74 CON	F	64	06/30/52

Figure 2-9: Sample Patient List, Diabetes: Blood Pressure Control

## 2.2.5 Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes

### GPRM Measure Description

During GPRM Year 2016, establish a baseline for the proportion of patients with diagnosed diabetes and cardiovascular disease who are on statin therapy.

### Denominators

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, ages 40 through 75 or age 21 and older with documented CVD or an LDL greater than or equal to ( $\geq$ ) 190, broken down by age groups. (GPRM Denominator)

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least 2 visits during the Report Period, and 2 DM-related visits ever, ages 40 through 75.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least 2 visits during the Report Period, and 2 DM-related visits ever, age 21 and older.

All *User Population patients* diagnosed with diabetes prior to the Report Period, ages 40 through 75 or age 21 and older with documented CVD or an LDL greater than or equal to ( $\geq$ ) 190.

## Numerators

Patients who are statin therapy users during the Report Period or who receive an order (prescription) to receive statin therapy at any point during the Report Period. (GPRA Numerator)

Patients with any of the listed denominator exclusions.

- a. Patients with documented allergy, intolerance, or other adverse effect to statin medication.

## Logic Description

Age is calculated at the beginning of the Report Period.

## Denominator Logic

*Diabetes definition:* First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Cardiovascular Disease (CVD) diagnosis defined as any of the following:

Subject Defined	ICD and Other Codes
Coronary Heart Disease (CHD)	<b>POV:</b> ICD-9: 410.0-413.*, 414.0-414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9, Z95.5
Acute Myocardial Infarction (AMI)	<b>POV:</b> ICD-9: 410.0*-410.9*, 412; ICD-10: I21.*, I22.*
Ischemic Vascular Disease (IVD)	<b>POV:</b> ICD-9: 411.*, 413.*, 414.0*, 414.2, 414.8, 414.9, 429.2, 433.*-434.*, 440.1, 440.2*, 440.4, 444.*, 445.*; ICD-10: I20.*, I24.*, I25.1*, I25.5-I25.812, I65.*, I66.*, I70.1, I70.201-I70.299, I70.92, I74.*, I75.*
Ischemic Stroke or Transient Ischemic Attack (TIA)	<b>POV:</b> ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9; ICD-10: G45.0-G45.2, G45.8, G45.9, G46.0-G46.2, I63.*
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1 <b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33530, 33533-33536, 33572, 35500, 35600, S2205-S2209 <b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	<b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61 <b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290

Subject Defined	ICD and Other Codes
	<b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05 (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**

CRS uses the following to define the tests:

Subject Defined	LOINC Codes	Taxonomy
LDL Done	Yes	DM AUDIT LDL CHOLESTEROL TAX
LDL greater than or equal to ( $\geq$ ) 190		Tests in above taxonomy with LDL greater than or equal to ( $\geq$ ) 190
LDL less than ( $<$ ) 70		Tests in above taxonomy with LDL less than ( $<$ ) 70

In the LOINC Codes column, specific LOINC codes used by CRS are located in the *CRS Technical Manual*.

#### *Denominator Exclusions*

Patients meeting any of the following conditions will be excluded from the denominator.

1. Patients with documented allergy, intolerance, or other adverse effect to statin medication.
2. Patients who have an active diagnosis of pregnancy or who are breastfeeding.
3. Patients who are receiving palliative care.
4. Patients with end-stage renal disease (ESRD).
5. Patients with diabetes whose most recent LDL result is less than ( $<$ ) 70 and who have never had an LDL result greater than or equal to ( $\geq$ ) 190 and who are not taking statin therapy.

CRS uses the following codes to define contraindications to statins.



<b>Contraindication to Statins (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Pregnancy		See below for definition
Breastfeeding		See below for definition
Acute Alcoholic Hepatitis		<b>POV:</b> ICD-9: 571.1; ICD-10: K70.10, K70.11 during the Report Period
NMI Refusal		<b>Refusal:</b> NMI refusal for any statin at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documentated allergies to statins.

### **Adverse Drug Reaction/Allergy to Statins**

<b>ICD and Other Codes</b>
<b>Site-Populated Lab Taxonomy or LOINC Taxonomy:</b> DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period
<b>Site-Populated Lab Taxonomy or LOINC Taxonomy:</b> BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period
<b>POV:</b> Myopathy/Myalgia, defined as any of the following during the Report Period: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1
<b>Any of the following occurring anytime ever:</b> <b>POV:</b> ICD-9: 995.0-995.3 AND E942.9 <b>Entry in ART (Patient Allergies File):</b> "statin" or "statins" <b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "Statin" or "Statins"

Subject Defined	ICD and CPT Codes
<b>Pregnancy</b>	<p>At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with:</p> <p><b>POV or Problem List:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36</p> <p><b>Procedure:</b> ICD-9: 72.*, 73.*, 74.*</p> <p><b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828</p> <p>Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion (defined below) occurring after the second pregnancy-related visit.</p>
<b>Abortion</b>	<p><b>CPT:</b> 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267</p> <p><b>POV:</b> ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2</p> <p><b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z</p>
<b>Miscarriage</b>	<p><b>CPT:</b> 59812, 59820, 59821, 59830</p> <p><b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9</p>

<b>Breastfeeding</b>	<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
----------------------	---

*Palliative care visit definition:* POV ICD-9: V66.7; ICD-10: Z51.5.

*ESRD diagnosis/treatment definition:* Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

## Numerator Logic

*Statin therapy user definition:* CPT 4013F

*Statin medication codes* defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altacor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

## Key Logic Changes from CRS Version 15.1

1. New topic.

## Patient List Description

List of diabetic patients with statin therapy or exclusion, if any.

## Measure Source

HHS Statin Therapy eMeasure

## Measure Past Performance and Long-Term Targets:

Performance	Percent
N/A	N/A

DU		November 25, 2016				Page 15			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %	
Active Diabetic Pts 40-75 or 21+ w/ CVD or LDL >=190 (GPRA)	272		284			285			
# w/Statin Rx (GPRA)	90	33.1	97	34.2	-1.1	117	41.1	-8.0	
Active Diabetic Pts 21-39 w/ CVD or LDL>=190	8		7			4			
# w/ statin Rx	2	25.0	3	42.9	-17.9	4	100.0	-75.0	
Active Diabetic Pts 40-75 w/ CVD or LDL >=190	77		80			71			
# w/ statin Rx	36	46.8	39	48.8	-2.0	38	53.5	-6.8	
Active Diabetic Pts 76+ w/ CVD or LDL >=190	14		10			12			
# w/ statin Rx	6	42.9	3	30.0	+12.9	3	25.0	+17.9	
Active Diabetic Pts 40-75	250		267			269			
# w/ statin Rx	82	32.8	91	34.1	-1.3	110	40.9	-8.1	
Active Diabetic Pts 40-75 or 21+ w/CVD or LDL>=190, incl exclusions	337		349			333			
# w/ exclusions	65	19.3	65	18.6	+0.7	48	14.4	+4.9	
A. # w/ allergy/ADR w/ % of Total	18	27.7	37	56.9	-29.2	24	50.0	-22.3	
User Pop w/ DM DX 40-75 or 21+ w/ CVD or LDL >=190	385		361			344			
# w/ statin Rx	93	24.2	99	27.4	-3.3	121	35.2	-11.0	

Figure 2-10: Sample Report, Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes: List of diabetic patients with statin therapy or exclusion, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH UP,AD (CHD)	000001	COMMUNITY #1 Statin: 02/27/13	F	35	11/11/80
PATIENT2,TARA UP	000002	COMMUNITY #1	F	51	02/10/64
PATIENT3,BOBBIE UP,AD (CHD)	000003	COMMUNITY #1 Exclusion: 02/02/02	F	52	05/06/63
PATIENT4,WINONA UP,AD	000004	COMMUNITY #1 Statin: 01/08/13	F	53	07/21/62
PATIENT5,NADINE UP,AD	000005	COMMUNITY #1	F	61	08/12/54
PATIENT6,RUTH UP (CHD)	000006	COMMUNITY #1 Exclusion: 02/15/00	F	64	06/30/51

Figure 2-11: Sample Patient List, Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes

## 2.2.6 Diabetes: Nephropathy Assessment

### GPRA Measure Description

During GPRA Year 2016, achieve the target rate of 61.1% for the proportion of patients with diagnosed diabetes who are assessed for nephropathy.

### Denominators

*All User Population patients* diagnosed with diabetes prior to the Report Period.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever (GPRA Denominator).

*Active Adult Diabetic patients*, defined by meeting the following criteria: (1) who are aged 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

## Numerator

Patients with nephropathy assessment, defined as an estimated GFR with result and a urine albumin-to-creatinine ratio (UACR) during the Report Period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the Report Period (GPRA Numerator).k

## Logic Description

*Diabetes definition:* First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Nephropathy assessment definition:*

- Estimated GFR with result during the Report Period and Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period, *or*
- ESRD diagnosis/treatment defined as any diagnosis ever.

CRS uses the following to define the tests/diagnoses:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic Denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX
Estimated GFR		Yes	BGP GPRA ESTIMATED GFR TAX
Urine Albumin-to-Creatinine Ratio (UACR)	<b>CPT:</b> 82043 WITH 82570	Yes	BGP QUANT UACR TESTS <b>Note:</b> Be sure to check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
End Stage Renal Disease	<b>CPT:</b> 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339 <b>POV:</b> ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56*; ICD-10: N18.6, Z48.22, Z49. *, Z91.15, Z94.0, Z99.2 <b>Procedure:</b> ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6*		

In the LOINC Codes column, specific LOINC codes used by CRS are located in the *CRS Technical Manual*.

### Key Logic Changes from CRS Version 15.1

1. Added LOINC codes 77254-1 and 77253-3 to BGP QUANT UACR LOINC taxonomy.
2. Removed LOINC code 48643-1 from BGP ESTIMATED GFR LOINC taxonomy.

### Patient List Description

List of diabetic patients with nephropathy assessment, if any.

### Measure Source

HP 2010 5–11

**Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2015 Performance	62.0%
IHS FY 2014 Performance	60.0%
IHS FY 2013 Performance	68.2%
IHS FY 2012 Performance	66.7%
IHS FY 2011 Performance	56.5%
IHS FY 2010 Performance	55.0%
IHS FY 2009 Performance	50.0%
IHS FY 2008 Performance	50.0%
IHS FY 2007 Performance (new baseline established; revised standards of care resulted in revised measure definition)	40.0%
IHS FY 2006 Performance (measure definition was different from current definition)	55.0%
IHS FY 2005 Performance (measure definition was different from current definition)	47.0%
IHS FY 2004 Performance (measure definition was different from current definition)	42.0%
IHS FY 2003 Performance (measure definition was different from current definition)	37.5%
IHS FY 2002 Performance (measure definition was different from current definition)	35.0%

DU		November 25, 2016				Page 17			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Diabetes: Nephropathy Assessment									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	%
User Pop w/ DM DX prior to Report Period	229		202			180			
# w/ est GFR & quant UP assmt or w/ESRD	55	24.0	16	7.9	+16.1	8	4.4	+19.6	
Active Diabetic Pts (GPRA)	144		97			87			
# w/ est GFR &									



quant UP assmt or w/ESRD (GPRA)	53	36.8	11	11.3	+25.5	6	6.9	+29.9
Active Adult Diabetic Patients	102		75			63		
# w/ est GFR & quant UP assmt or w/ESRD	41	40.2	6	8.0	+32.2	4	6.3	+33.8

Figure 2-12: Sample Report, Diabetes: Nephropathy Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Diabetes: Nephropathy Assessment: List of diabetic patients with nephropathy assessment, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH UP,AD,AAD	000001	COMMUNITY #1	F	45	11/11/71
PATIENT2,TARA UP,AD,AAD	000002	COMMUNITY #1 GFR: 08/06/16 & UACR: 08/06/16	F	51	02/10/65
PATIENT3,BOBBIE UP,AD,AAD	000003	COMMUNITY #1 GFR: 09/09/16 & QUANT UP: 03/31/16	F	52	05/06/64
PATIENT4,WINONA UP	000004	COMMUNITY #1	F	53	07/21/63
PATIENT5,NADINE UP,AD,AAD	000005	COMMUNITY #1 ESRD: 03/03/16	F	61	08/12/55
PATIENT6,RUTH UP	000006	COMMUNITY #1	F	64	06/30/52
PATIENT7,DANIELLE UP	000007	COMMUNITY #1 ESRD: 11/01/15	F	79	03/22/37

Figure 2-13: Sample Patient List, Diabetes: Nephropathy Assessment

## 2.2.7 Diabetic Retinopathy

### GPRA Measure Description

During GPRA Year 2016, achieve the target rate of 61.6% for the proportion of patients with diagnosed diabetes who receive an annual retinal examination.

### Denominators

All *User Population patients* diagnosed with diabetes prior to the Report Period, without a documented history of bilateral blindness.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, without a documented history of bilateral blindness. (GPRA Denominator)

*Active Adult Diabetic patients*, defined by meeting the following criteria: (1) who are 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5, without a documented history of bilateral blindness.

## Numerators

Patients receiving a qualified retinal evaluation during the Report Period.

**Note:** This numerator does not include refusals. (GPRA Numerator)

- a. Patients receiving diabetic retinal exam during the Report Period
- b. Patients receiving other eye exams during the Report Period
- c. Patients with a JVN visit during the Report Period.
- d. Patients with an Ophthalmology visit during the Report Period.
- e. Patients with an Optometry visit during the Report Period.

## Logic Description

*Diabetes definition:* First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

*Serum creatinine definition (used with Active Adult Diabetic denominator):* Site-populated taxonomy DM AUDIT CREATININE TAX; or LOINC taxonomy (NOTE: CPT codes are not included since they do not store the result, which is used in this topic.).

*Qualified retinal evaluation definition:* (1) Diabetic retinal exam or (2) other eye exam, as shown below. The following methods are qualifying for this measure:

- Dilated retinal evaluation by an optometrist or ophthalmologist
- Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist
- Any photographic method validated to sevenk standard fields (ETDRS).

CRS searches in the following order for:

***Diabetic Retinal Exam (any of the following during the report period)***

Exam	CPT Codes	Other Codes
Diabetic Retinal Exam	2022F, 2024F, 2026F, S0620, S0621, S3000	<b>Exam:</b> 03 (dilated retinal examination or formally validated* photographic equivalent)

***Other Eye Exam (any of the following during the report period)***

Exam	CPT Codes	Other Codes
Non-Did Not Keep Appointment (DNKA) visit to ophthalmology or optometry or formally validated* tele-ophthalmology retinal evaluation clinics		<b>Clinic codes:</b> A2 (Diabetic Retinopathy)**, 17, 18
Non-DNKA visit to an optometrist or ophthalmologist	67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014	<b>Provider Codes:</b> 24, 79, 08

\*Validation study properly powered and controlled against the ETDRS gold standard.

\*\*Validated photographic (teleophthalmology) retinal surveillance.

***JVN visit (any of the following during the report period)***

Subject Defined	Other Codes
JVN	<b>Clinic code:</b> A2

***Ophthalmology visit (any of the following during the report period)***

Subject Defined	Other Codes
Ophthalmology	<b>Clinic code:</b> A2 <b>Provider Code:</b> 79

**Optometry visit (any of the following during the report period)**

Subject Defined	Other Codes
Optometry	<b>Clinic code:</b> 18 <b>Provider Code:</b> 08, 24

**Bilateral Blindness Exclusion**

Subject Defined	Other Codes
Bilateral blindness	<b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 369.01, 369.03, 369.04; ICD-10: H54.0 through H54.12

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of diabetic patients with qualified retinal evaluation, if any.

**Measure Source**

HP 2020 D-10

**Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2015 Performance	61.3% (National rate)
IHS FY 2014 Performance	59.9% (National rate)
IHS FY 2013 Performance	57.6% (National rate)
IHS FY 2012 Performance	55.7% (National rate)
IHS FY 2011 Performance	54.8% (National rate)
IHS FY 2010 Performance	53.0% (National rate)
IHS FY 2009 Performance	51.0% (National rate)
IHS FY 2008 Performance	50.0% (National rate)
IHS FY 2007 Performance	49.0% (National rate)
IHS FY 2006 Performance	49.0% (National Rate) 52.0% (Designated Sites Rate)
IHS FY 2005 Performance	50.0% (National Rate) 50.0% (Designated Sites Rate)

Performance	Percent
IHS FY 2004 Performance	47.0% (National Rate) 55.0% (Designated Sites Rate)
IHS FY 2003 Performance	49.0%
IHS FY 2002 Performance	49.0%
<i>HP 2020 Goal</i>	<i>58.7%</i>

DU November 25, 2016 Page 19  
 \*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*  
 DEMO INDIAN HOSPITAL  
 Report Period: Jan 01, 2016 to Dec 31, 2016  
 Previous Year Period: Jan 01, 2015 to Dec 31, 2015  
 Baseline Period: Jan 01, 2010 to Dec 31, 2010

---

Diabetic Retinopathy

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop w/ DM DX prior to report period w/o Hx of Bilateral Blindness	227		200			180		
# w/Retinal Evaluation -No Refusals	64	28.2	46	23.0	+5.2	54	30.0	-1.8
A. # w/ DM Retinal exam	7	3.1	6	3.0	+0.1	6	3.3	-0.2
B. # w/Other Eye Exams	57	25.1	40	20.0	+5.1	48	26.7	-1.6
Active Diabetic Pts w/o Hx of Bilateral Blindness (GPRA)	141		97			87		
# w/Retinal Evaluation -No Refusals (GPRA)	53	37.6	38	39.2	-1.6	44	50.6	-13.0
A. # w/ DM Retinal exam	7	5.0	6	6.2	-1.2	6	6.9	-1.9
B. # w/Other Eye Exams	46	32.6	32	33.0	-0.4	38	43.7	-11.1
C. # w/JVN visit	1	0.7	0	0.0	+0.7	0	0.0	+0.7
D. # w/Ophthalmology visit	22	15.6	6	6.2	+9.4	22	25.3	-9.7
E. # w/ Optometry visit	33	23.4	36	37.1	-13.7	31	35.6	-12.2
Active Adult Diabetic Patients w/o Hx of Bilateral Blindness	99		75			63		
# w/Retinal Evaluation -No Refusals	38	38.4	31	41.3	-2.9	39	61.9	-23.5
A. # w/ DM Retinal exam	6	6.1	4	5.3	+0.7	6	9.5	-3.5
B. # w/Other Eye Exams	32	32.3	27	36.0	-3.7	33	52.4	-20.1

Figure 2-14: Sample Report, Diabetic Retinopathy

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Diabetic Retinopathy: List of diabetic patients with qualified retinal evaluation, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH UP,AD,AAD	000001	COMMUNITY #1 Eval: 01/07/16	F	45	11/11/71
PATIENT2,TARA UP,AD,AAD	000002	COMMUNITY #1	F	51	02/10/65
PATIENT3,BOBBIE UP,AD,AAD	000003	COMMUNITY #1 Eval: 05/29/16	F	52	05/06/64
PATIENT4,WINONA UP	000004	COMMUNITY #1	F	53	07/21/63
PATIENT5,NADINE UP,AD,AAD	000005	COMMUNITY #1 Eval: 02/06/16	F	61	08/12/55
PATIENT6,RUTH UP	000006	COMMUNITY #1	F	64	06/30/52
PATIENT7,JONELLE UP,AD,AAD	000007	COMMUNITY #1 03/29/16 Diab Eye Ex	F	69	10/27/47

Figure 2-15: Sample Patient List, Diabetic Retinopathy

## 2.2.8 RAS Antagonist Use in Diabetic Patients

### Denominator

*Active Diabetic patients* with HTN, defined as all Active Clinical patients diagnosed with diabetes and hypertension prior to the Report Period, AND at least two visits during the Report Period, AND two DM-related visits ever, and no documented history of ESRD.

### Numerators

Patients receiving a RAS Antagonist medication during the Report Period.

Patients with contraindication/previous adverse reaction to RAS Antagonist therapy.

### Logic Description

*Diabetes definition:* First Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

*Hypertension definition:* Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 401.\*; ICD-10: I10 prior to the Report Period, and at least one hypertension POV during the Report Period.

*ESRD diagnosis/treatment definition:* Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

### **RAS Antagonist Numerator Logic**

*Renin Angiotensin System (RAS) Antagonist medication codes* defined with medication taxonomy BGP PQA RASA MEDS.

ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Lisinopril-hydrochlorothiazide, Moexipril-hydrochlorothiazide, Quinapril-hydrochlorothiazide, Trandolopril-verapamil).

ARB medications are: Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan).

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Irbesartan-hydrochlorothiazide, Losartan-hydrochlorothiazide, Olmesartan-amlodipine-hydrochlorothiazide, Olmesartan-hydrochlorothiazide, Telmisartan-amlodipine, Telmisartan-hydrochlorothiazide, Valsartan-hydrochlorothiazide).

Direct Renin Inhibitor medications are: Direct Renin Inhibitors (Aliskiren).

Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-hydrochlorothiazide, Aliskiren-hydrochlorothiazide, Aliskiren-valsartan).

CRS uses the following codes to define contraindications to ACE inhibitors/ARBs.

<b>Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
<p>Pregnancy - At least two visits during the Report Period where the primary provider is not a CHR (Provider code 53) with any of the following codes. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion (defined below) occurring after the second pregnancy POV.</p>	<p><b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828</p>	<p><b>POV or Problem List:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0 through V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01 through V89.09; ICD-10: O00.*, O01.*, O03.1, O03.31 through O03.33, O03.6, O03.81 through O03.83, O04.6, O04.81 through O04.83, Z33.2 to abortion definition. (3) Added ICD-10 POV code O03.9 to miscarriage definition. (4) Added ICD-10 POV codes O09.00 through O10.02, O10.111 through O10.12, O10.211 through O10.22, O10.311 through O10.32, O10.411 through O10.42, O10.911 through O10.92, O11.1 through O15.1, O15.9 through O24.02, O24.111 through O24.12, O24.311 through O24.32, O24.41*, O24.811 through O24.82, O24.911 through O24.92, O25.10 through O25.2, O26.00 through O26.62, O26.711 through O26.72, O26.811 through O26.93, O29.011 through O30.93, O31.* through O48.*, O60.0*, O61.* through O66.*, O68, O69.*, O71.00 through O71.1, O71.89, O71.9, O74.0 through O75.81, O75.89, O75.9, O76 through O77.*, O88.011 through O88.02, O88.111 through O88.12, O88.211 through O88.22, O88.311 through O88.32, O88.811 through O88.82, O90.3, O91.011 through O91.019, O91.111 through O91.119, O91.211 through O91.219,</p>



<b>Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Pregnancy		O92.011 through O92.019, O92.20, O92.29, O98.011 through O98.02, O98.111 through O98.12, O98.211 through O98.22, O98.311 through O98.32, O98.411 through O98.42, O98.511 through O98.52, O98.611 through O98.62, O98.711 through O98.72, O98.811 through O98.82, O98.911 through O98.92, O99.011 through O99.02, O99.111 through O99.12, O99.210 through O99.214, O99.280 through O99.284, O99.310 through O99.314, O99.320 through O99.324, O99.330 through O99.334, O99.340 through O99.344, O99.350 through O99.354, O99.411 through O99.42, O99.511 through O99.52, O99.611 through O99.62, O99.711 through O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840 through O99.844, O99.89, O9A.111 through O9A.12, O9A.211 through O9A.22, O9A.311 through O9A.32, O9A.411 through O9A.42, O9A.511 through O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36 <b>Procedure:</b> ICD-9: 72.*, 73.*, 74.*
Pregnancy	<b>Abortion:</b> Any of the following: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267	<b>Abortion:</b> Any of the following POVs: ICD-9: 635*, 636*, or 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 <b>Procedures:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z
Pregnancy	<b>Miscarriage:</b> Any of the following: 59812, 59820, 59821, 59830	<b>Miscarriage:</b> Any of the following POVs: ICD-9: 630, 631, 632, 633*, or 634*; ICD-10: O03.9

<b>Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		<b>Refusal:</b> NMI (not medically indicated) refusal for any RAS Antagonist at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documentated allergies to RAS Antagonists.

#### **Adverse Drug Reaction/Allergy to RAS Antagonists**

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
<b>Entry in ART (Patient Allergies File):</b> “ace inhibitor”, “ACEI”, “Angiotensin Receptor Blocker” or “ARB”
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3 or V14.8; ICD-10: Z88.8:</b> “ace i*”, “ACEI”, “Angiotensin Receptor Blocker” or “ARB”

#### **Key Logic Changes from CRS Version 15.1**

1. Removed POV codes 674.\*3, 675.\*3, 676.\*3 from pregnancy definition.
2. Added POV codes V24.\*, V27.\* to pregnancy definition.
3. Added Procedure codes 72.\*, 73.\*, 74.\* to pregnancy definition.
4. Added CPT codes 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 to pregnancy definition.

5. Added SNOMED codes to Patient Education for breastfeeding.
6. Updated BGP PQA RASA MEDS medication taxonomy.

**Patient List Description**

List of diabetic patients with hypertension, with RAS Antagonist medication, contraindication, or ADR, if any.

**Measure Source**

PQA (Pharmacy Quality Alliance)

**Measure Past Performance and Long-Term Targets**

None

DU		November 25, 2016				Page 24			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
RAS Antagonist Use in Diabetic Patients									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Diabetic Pts w/ HTN	79		57			54			
# w/RAS Antagonist Rx	55	69.6	48	84.2	-14.6	48	88.9	-19.3	
# w/contra/ADR	14	17.7	2	3.5	+14.2	2	3.7	+14.0	

Figure 2-16: Sample Report, ACEI/ARB Use in Diabetic Patients

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

ACEI/ARB Use in Diabetic Patients: List of diabetic patients with hypertension, with RAS Antagonist medication, contraindication, or ADR, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH	000001	COMMUNITY #1	F	20	01/30/96
AD		ACEI/ARB Contra			pregnant
PATIENT2,TARA	000002	COMMUNITY #1	F	44	05/27/72
AD		06/05/16			
PATIENT3,BOBBIE	000003	COMMUNITY #1	F	45	09/10/71

AD	01/29/16					
PATIENT4 ,WINONA	000004	COMMUNITY #1	F	57	07/02/59	
AD		ACEI/ARB Allergy:		05/05/14	ADR POV 995.2 + E942.6	
PATIENT5 ,NADINE	000005	COMMUNITY #1	F	57	09/04/59	
AD						
PATIENT6 ,RUTH	000006	COMMUNITY #1	F	61	04/12/55	
AD		09/22/16				
PATIENT7 ,JONELLE	000007	COMMUNITY #1	M	25	08/12/91	
AD		06/01/16	ACEI/ARB Contra	POV 425.1		

Figure 2-17: Sample Patient List: ACEI/ARB Use in Diabetic Patients

## 2.2.9 Diabetes: Access to Dental Services

### Denominator

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two DM-related visits ever.

### Numerators

Patients with documented dental visit during the Report Period.

**Note:** This numerator does *not* include refusals.

### Logic Description

*Diabetes definition:* First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Dental visit definition:* For non-PRC dental visits, searches for Dental ADA codes 0000, 0190, or 0191; CPT codes D0190 or D0191; Exam 30; or POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21. For PRC dental visits, searches for any visit with an ADA code. PRC visit defined as Type code of C in Visit file.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of diabetic patients with documented dental visit, if any.

### Measure Source

HP 2020 D-8

**Measure Past Performance and Long-Term Targets:**

Past Performance	Percent
IHS FY 2005 Performance	39.0%
IHS FY 2004 Performance	37.0%
IHS FY 2003 Performance	36.0%
IHS FY 2002 Performance	36.0%
HP 2020 Goal	61.2%

**Performance Improvement Tip**

If your facility’s dental services are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the “on” position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

```

DU                               November 25, 2016                               Page 26
*** IHS 2016 Selected Measures with Community Specified Report ***
                                DEMO INDIAN HOSPITAL
                                Report Period: Jan 01, 2016 to Dec 31, 2016
                                Previous Year Period: Jan 01, 2015 to Dec 31, 2015
                                Baseline Period: Jan 01, 2010 to Dec 31, 2010
-----
Diabetes: Access to Dental Services

                                REPORT    %    PREV YR    %    CHG from    BASE    %    CHG from
                                PERIOD    PERIOD    PERIOD    PERIOD    PREV YR %    PERIOD    BASE %

Active Diabetic Pts            144                97                87

# w/dental visit in
past yr-No Refusals            17  11.8            20  20.6            -8.8            18  20.7            -8.9
    
```

Figure 2-18: Sample Report, Diabetes and Dental Access

```

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Diabetes: Access to Dental Services: List of diabetic patients and documented
dental visit, if any.

PATIENT NAME                HRN    COMMUNITY    SEX AGE    DOB
DENOMINATOR                NUMERATOR
-----
PATIENT1,DEBORAH            000001    COMMUNITY #1    F  45    11/11/71
AD                          03/03/16    ADA 0000
PATIENT2,TARA                000002    COMMUNITY #1    F  51    02/10/65
AD
PATIENT3,BOBBIE             000003    COMMUNITY #1    F  52    05/06/64
AD                          01/06/16    ADA 0190
PATIENT4,NADINE             000004    COMMUNITY #1    F  61    08/12/55
AD
    
```

PATIENT5, SHERRY	000005	COMMUNITY #1	F	68	03/18/48
AD					
PATIENT6, JONELLE	000006	COMMUNITY #1	F	69	09/22/47
AD		03/29/16 ADA 0000			

Figure 2-19: Sample Patient List, Diabetes and Dental Access

## 2.3 Dental Measure Topics

### 2.3.1 Access to Dental Services

#### **GPRA Measure Description**

During GPRA Year 2016, achieve the target rate of 29.3% for the proportion of patients who receive dental services.

#### **Denominators**

All patients in the *User Population*. Broken down by age groups (0 through 5, 6 through 21, 22 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)74). (GPRA Denominator)

#### **Numerators**

Patients with documented dental visit during the Report Period.

**Note:** This numerator does *not* include refusals. (GPRA Numerator)

#### **Logic Description**

*Dental visit definition:* For non-PRC dental visits, searches for Dental ADA codes 0000, 0190, or 0191; CPT codes D0190 or D0191; Exam 30; or POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21. For PRC dental visits, searches for any visit with an ADA code. PRC visit defined as Type code of C in Visit file.

#### **Key Logic Changes from CRS Version 15.1**

None.

#### **Patient List Description**

List of patients with documented dental visit and date.

#### **Measure Source**

HP 2020 OH-7

#### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2015 Performance	29.2%

Performance	Percent
IHS FY 2014 Performance	28.8%
IHS FY 2013 Performance	28.3%
IHS FY 2012 Performance	28.8%
IHS FY 2011 Performance	26.9%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	25.0%
IHS FY 2008 Performance	25.0%
IHS FY 2007 Performance	25.0%
IHS FY 2006 Performance	23.0%
IHS FY 2005 Performance	24.0%
IHS FY 2004 Performance	24.0%
IHS FY 2003 Performance	25.0%
IHS FY 2002 Performance	24.9%
<i>HP 2020 Goal</i>	<i>49.0%</i>

**Performance Improvement Tip**

If your facility’s dental services are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the “on” position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

```

DU                               November 25, 2016                               Page 28
*** IHS 2016 Selected Measures with Community Specified Report ***
                                DEMO INDIAN HOSPITAL
                                Report Period: Jan 01, 2016 to Dec 31, 2016
                                Previous Year Period: Jan 01, 2015 to Dec 31, 2015
                                Baseline Period: Jan 01, 2010 to Dec 31, 2010
-----
Access to Dental Services

                                REPORT    %    PREV YR    %    CHG from    BASE    %    CHG from
                                PERIOD    PERIOD    PERIOD    PERIOD    PREV YR    %    PERIOD    BASE    %

# User Pop
(GPRA)                            2,896                2,456                2,346

# w/dental visit in
past yr-No Refusals
(GPRA)                            252    8.7        201    8.2        +0.5        207    8.8        -0.1
    
```

Figure 2-20: Sample Report, Access to Dental Services

```

DU                               November 25, 2016                               Page 29
*** IHS 2016 Selected Measures with Community Specified Report ***
                                DEMO INDIAN HOSPITAL
                                Report Period: Jan 01, 2016 to Dec 31, 2016
                                Previous Year Period: Jan 01, 2015 to Dec 31, 2015
    
```



Baseline Period: Jan 01, 2010 to Dec 31, 2010							
-----							
Access to Dental Services (con't)							
	TOTAL USER POPULATION						
	Age Distribution						
	0-5	6-21	22-34	35-44	45-54	55-74	>74 yrs
CURRENT REPORT PERIOD							
Total # User Pop	355	759	577	407	397	411	81
# w/dental visit in past yr-No Refusals (GPRA)	25	71	63	35	32	25	1
% w/dental visit in past yr-No Refusals (GPRA)	7.0	9.4	10.9	8.6	8.1	6.1	1.2
PREVIOUS YEAR PERIOD							
Total # User Pop	361	704	517	332	284	292	56
# w/dental visit in past yr-No Refusals (GPRA)	19	59	46	24	24	25	4
% w/dental visit in past yr-No Refusals (GPRA)	5.3	8.4	8.9	7.2	8.5	8.6	7.1
CHANGE FROM PREV YR %							
w/dental visit in past yr-No Refusals (GPRA)	+1.8	+1.0	+2.0	+1.4	-0.4	-2.5	-5.9
BASELINE REPORT PERIOD							
Total # User Pop	363	728	455	293	228	236	52
# w/dental visit in past yr-No Refusals (GPRA)	17	70	39	31	27	20	3
% w/dental visit in past yr-No Refusals (GPRA)	4.7	9.6	8.6	10.6	11.8	8.5	5.8
CHANGE FROM BASE YR %							
w/dental visit in past yr-No Refusals (GPRA)	+2.4	-0.3	+2.3	-2.0	-3.8	-2.4	-4.5

Figure 2-21: Sample Age Breakdown Report, Access to Dental Services

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;

HR=High Risk Patient

Access to Dental Service: List of patients with documented dental visit and date.  
(con't)

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT10, JOHN UP	000010	COMMUNITY #1 01/03/16 ADA 0190	M	17	01/10/99
PATIENT11, HOWARD UP	000011	COMMUNITY #1 01/24/16 ADA 0000	M	25	03/16/91
PATIENT12, JAMES UP	000012	COMMUNITY #1 02/19/16 ADA 0000	M	31	05/10/85
PATIENT13, STEVEN UP	000013	COMMUNITY #1 01/24/16 ADA 0000	M	32	02/18/84
PATIENT14, EDWARD UP	000014	COMMUNITY #1 06/10/16 ADA 0000	M	32	09/29/84
PATIENT15, DAVID UP	000015	COMMUNITY #1 04/10/16 ADA 0190	M	33	07/19/83

Figure 2-22: Sample Patient List, Access to Dental Services

## 2.3.2 Dental Sealants

### GPRA Measure Description

During GPRA Year 2016, achieve the target rate of 14.8% for the proportion of patients with at least one or more intact dental sealants.

### Denominator

User Population patients ages 2 through 15. Broken down by age groups: 2 through 5, 3 through 5, 6 through 9, 10 through 12, 13 through 15, and 5 through 19 (GPRA Denominator)

No denominator. This measure is a total count only, not a percentage.

### Numerators

Patients with at least one or more intact dental sealants (GPRA Numerator)

For patients meeting the *User Population* definition, the total number of dental sealants during the report period.

**Note:** This numerator does not include refusals.

- a. Dental sealants in patients 2 through 15 years.
- b. Dental sealants in patients greater than (>) 15 yrs.

Age breakouts are based on Healthy People 2020 age groups for dental sealants.

## Logic Description

Age of the patient is calculated at the beginning of the report period.

*Sealants definition:* Dental ADA Code 1351, 1352, 1353 or CPT Code D1351, D1352, D1353 documented during the Report Period or Dental ADA code 0007 documented during the past 3 years from the end of the Report Period, as long as the 007 code is not documented on the same visits as 1351, 1352, 1353, D1351, D1352, or D1353. If both ADA and CPT codes are found on the same visit, only the ADA will be counted.

For the count measure, only two sealants per tooth and only one repair (ADA code 1353 or CPT D1353) per tooth will be counted during the Report Period. Each tooth is identified by the data element Operative Site in RPMS.

### Key Logic Changes from CRS Version 15.1

1. Added new age breakdown of 2 through 5.
2. Added ADA code 1353 and CPT code D1353 to Dental Sealant definition.
3. Updated logic for the count measure to only count one dental sealant repair per tooth.

### Patient List Description

List of patients with intact dental sealants.

### Measure Source

HP 2020 OH-2

### Measure Past Performance and Long-Term Targets:

Performance	Percent
IHS FY 2015 Performance	16.3%
IHS FY 2014 Performance	14.6%
IHS FY 2013 Performance	13.9%

Performance	# of Sealants
IHS FY 2012 Performance	295,734
IHS FY 2011 Performance	276,893
IHS FY 2010 Performance	275,459
IHS FY 2009 Performance	257,067
IHS FY 2008 Performance	241,207
IHS FY 2007 Performance	245,449

Performance	# of Sealants
IHS FY 2006 Performance	246,645
IHS FY 2005 Performance	249,882
IHS FY 2004 Performance	230,295 287,158
IHS FY 2003 Performance	232,182
IHS FY 2002 Performance	227,945
IHS FY 2001 Performance	212,612

For the IHS FY 2004 Performance, # of Sealants, please note this was reported by the National Patient Information Reporting System (NPIRS).

### Performance Improvement Tip

If your facility's dental visits are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the "on" position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

DU		November 25, 2016				Page 30			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Dental Sealants									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
User Pop Pts 2-15 (GPRA)	621		629			670			
# w/intact dental sealants (GPRA)	19	3.1	11	1.7	+1.3	14	2.1	+1.0	
Total User Population, Ages 3-5yrs	152		143			141			
# w/intact dental sealants (GPRA)	2	1.3	1	0.7	+0.6	0	0.0	+1.3	
Total User Population, Ages 6-9yrs	181		173			194			
# w/intact dental sealants (GPRA)	8	4.4	5	2.9	+1.5	7	3.6	+0.8	
Total User Population,									

Ages 10-12yrs	120		121			125		
# w/intact dental sealants (GPRA)	2	1.7	2	1.7	+0.0	3	2.4	-0.7
Total User Population, Ages 13-15yrs	126		131			149		
# w/intact dental sealants (GPRA)	5	4.0	3	2.3	+1.7	4	2.7	+1.3
Total User Population, Ages 5-19yrs	719		727			753		
# w/intact dental sealants (GPRA)	34	4.7	41	5.6	-0.9	43	5.7	-1.0
Total # of Sealants Documented	56		61		-5	81		-25
A. # Dental Sealants documented pts 2-15 yrs	52		40		+12	80		-28
B. # Dental Sealants documented pts >15 yrs	4		21		-17	1		+3

Figure 2-23: Sample Report, Dental Sealants

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Dental Sealants: List of patients with intact dental sealants.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT20,GEORGE UP	000020	COMMUNITY #1	M	5	03/02/11
		4 sealants:			03/28/16 ADA 1351 (1); 03/28/16 ADA 1351 (1); 03/28/16 ADA 1351 (1); 03/28/16 ADA 1351 (1)
PATIENT21,CODY UP	000021	COMMUNITY #1	M	7	10/02/09
		1 sealants:			03/03/16 ADA 1351
PATIENT50,DAWN UP	000050	COMMUNITY #2	F	4	08/06/12
		3 sealants:			04/15/16 ADA 1351 (1); 05/19/16 ADA 1351 (1); 05/19/16 ADA 1351 (1)
PATIENT51,JOY UP	000051	COMMUNITY #2	F	6	06/08/10
		2 sealants:			03/17/16 ADA 1351 (2)
PATIENT52,DONALD UP	000052	COMMUNITY #2	M	8	05/25/08
		1 sealants:			02/02/16 CPT D1351 (1)

Figure 2-24: Sample Patient List, Dental Sealants

### 2.3.3 Topical Fluoride

#### **GPRA Measure Description**

During GPRA Year 2016, achieve the target rate of 28.3% for the proportion of patients who received one or more topical fluoride applications.

#### **Denominator**

User Population patients ages 1-15 (GPRA Denominator).

No denominator. This measure is a total count only, not a percentage.

#### **Numerators**

Patients who received one or more topical fluoride applications during the report period (GPRA Numerator).

For patients meeting the *User Population* definition, the total number of patients with at least one topical fluoride treatment during the Report Period.

**Note:** This numerator does *not* include refusals. (GPRA Numerator)

- a. Topical fluoride treatment in patients 1 through 15 yrs.

For patients meeting the *User Population* definition, the total number of appropriate topical fluoride applications based on a maximum of four per patient per year.

#### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

*Topical fluoride application definition:* (1) Dental ADA Codes 1201 (old code), 1203 (old code), 1204 (old code), 1205 (old code), 1206, 1208 or 5986; (2) CPT Codes D1201 (old code), D1203 (old code), D1204 (old code), D1205 (old code), D1206, D1208, D5986, or 99188; 3) POV ICD-9: V07.31.

For the count measure, a maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

#### **Key Logic Changes from CRS Version 15.1**

1. Added CPT code 99188 to topical fluoride definition.

## Patient List Description

List of patients who received at least one topical fluoride application during Report Period.

## Measure Source

Not Available

## Measure Past Performance and Long-Term Targets:

Performance	Percent
IHS FY 2015 Performance	29.4%
IHS FY 2014 Performance	27.9%
IHS FY 2013 Performance	26.7%

Performance	Number of Patients
IHS FY 2012 Performance	169,083
IHS FY 2011 Performance	161,461
IHS FY 2010 Performance	145,181
IHS FY 2009 Performance	136,794
IHS FY 2008 Performance	120,754
IHS FY 2007 Performance	107,934
IHS FY 2006 Performance	95,439
IHS FY 2005 Performance	85,318
IHS FY 2005 Performance	113,324

For the IHS FY 2005 Performance, Number of Patients (113,324) is the number of applications.

## Performance Improvement Tip

If your facility's dental visits are paid for with PRC funds, ensure the final payment for each purchase order is posted and the PRC to PCC link is set to the "on" position. Having the PRC to PCC link on will enable the PRC data to be passed from PRC/MIS to PCC, where CRS can find it and include it in your CRS reporting.

DU	November 25, 2016	Page 33
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		
Baseline Period: Jan 01, 2010 to Dec 31, 2010		
-----		

Topical Fluoride	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
User Pop Pts 1-15 (GPRA)	684		679			734		
# w/topical fluoride application (GPRA)	24	3.5	5	0.7	+2.8	2	0.3	+3.2
Total # of patients w/At Least 1 Topical Fluoride App -No Refusals	47		26		+21	15		+32
A: # Topical Fluoride App, pts 1-15 yrs	25		5		+20	2		+23
Total # of Topical Fluoride Applications	52		26		+26	15		+37

Figure 2-25: Sample Report, Topical Fluoride

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Topical Fluoride: List of patients who received or refused at least one topical fluoride application during Report period.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT20,GEORGE UP	000020	COMMUNITY #1 1 topical fluoride:	M	5	03/02/11 06/18/16 CPT D5986
PATIENT21,RYAN UP	000021	COMMUNITY #1 1 topical fluoride:	M	8	05/25/08 03/03/16 ADA 1201
PATIENT22,MICHAEL UP	000022	COMMUNITY #1 1 topical fluoride:	M	9	06/22/07 03/03/16 CPT D1203
PATIENT23,MARTY UP	000023	COMMUNITY #1 2 topical fluoride:	M	15	11/23/01 01/07/16 ADA 1204; 08/27/16 ADA 1204

Figure 2-26: Sample Patient List, Topical Fluoride

## 2.4 Immunization Measure Topics

### 2.4.1 Influenza

#### GPRA Measure Description

Children: During GPRA Year 2016, establish a baseline for the proportion of patients age 6 months to 17 years who receive an influenza immunization.



Adults: During GPRA Year 2016, establish a baseline for the proportion of patients age 18 years and older who receive an influenza immunization.

### Denominators

All *Active Clinical patients*. Broken down by age groups.

- a. Active Clinical patients *ages 6 months through 17 years*. (GPRA Denominator)
- b. Active Clinical patients *ages 18 and older*. (GPRA Denominator)
- c. Active Clinical patients *ages 18 through 49*.
- d. Active Clinical patients *ages 18 through 49 and considered high risk for influenza*.
- e. Active Clinical patients *ages 50 through 64*.
- f. Active Clinical patients *ages 65 and older*.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two DM-related visits ever.

All *User Population patients*. Broken down by age groups.

- a. User Population patients *ages 6 months through 17 years*.
- b. User Population patients *ages 18 and older*.
- c. User Population patients *ages 18 through 49*.
- d. User Population patients *ages 18 through 49 and considered high risk for influenza*.
- e. User Population patients *ages 50 through 64*.
- f. User Population patients *ages 65 and older*.

### Numerators

Patients with influenza vaccine documented during the report period or with a contraindication documented at any time before the end of the report period.

**Note:** The only refusals included in this numerator are not medically indicated (NMI) refusals. (GPRA Numerator)

- a. Patients with a contraindication or a documented NMI refusal.

### Logic Description

Age of the patient is calculated at the beginning of the report period.

*Diabetes:* First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Influenza definition:* Any of the following documented during the Report Period unless otherwise noted.

1. **Influenza immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Influenza vaccine	90630, 90654-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)	<b>Immunization (CVX) Codes:</b> 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 166 <b>POV:</b> ICD-9: V04.8 (old code), V04.81 NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, V06.6 NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142

2. **Contraindication:** Any of the following documented at any time before the end of the Report Period, defined as: (A) Contraindication in the Immunization Package of "Egg Allergy" or "Anaphylaxis" or (B) PCC NMI Refusal.
3. **High Risk for Influenza:** Persons considered high risk for influenza are defined as those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following:

High Risk Category	ICD-9 Codes	ICD-10 Codes
HIV Infection	042, 042.0 through 044.9 (old codes), 079.53, V08	B20, B52.0, B97.35, Z21
Diabetes	250.00 through 250.93	E08.2*, E09.2*, E10.* through E13.*
Rheumatic Heart Disease	393. through 398.99	I05.* through I09.*
Hypertensive Heart Disease	402.00 through 402.91	I11.*
Hypertensive Heart/Renal Disease	404.00 through 404.93	I13.*
Ischemic Heart Disease	410.00 through 414.9	I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9
Pulmonary Heart Disease	415.0 through 416.9	I26.* through I27.*
Other Endocardial Heart Disease	424.0 through 424.9	I34.* through I39

High Risk Category	ICD-9 Codes	ICD-10 Codes
Cardiomyopathy	425.0 through 425.9	I42.* , I43
Congestive Heart Failure	428.0 through 428.9, 429.2	I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9
Chronic Bronchitis	491.0 through 491.9	J41.* , J42
Emphysema	492.0 through 492.8	J43.*
Asthma	493.00 through 493.91	J45.21 through J45.902
Bronchiectasis, CLD, COPD	494.0 through 496.	J44.* , J47.*
Pneumoconioses	500 through 505	J60 through J64, J66.8 through J67.6, J67.8 through J67.9
Chronic Liver Disease	571.0 through 571.9	K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
Nephrotic Syndrome	581.0 through 581.9	N02.* , N04.* , N08
Renal Failure	585.6, 585.9	N18.6 through N19
Transplant	996.80 through 996.89	T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
Kidney Transplant	V42.0 through V42.89	
Chemotherapy	V58.1	Z51.11, Z51.12
Chemotherapy follow-up	V67.2	Z08

### Key Logic Changes from CRS Version 15.1

1. Changed GPRA measure from 65 and older to both 6 months through 17 years and 18 years and older.

### Patient List Description

List of patients with Influenza code, if any.

### Measure Source

HP 2020 IID-12.7

### Measure Past Performance and Long-Term Targets for Patients => 65 Vaccine Rate:

Performance	Percent
IHS FY 2015 Performance	65.4%
IHS FY 2014 Performance	68.1%
IHS FY 2013 Performance	68.0%
IHS FY 2012 Performance	65.0%
IHS FY 2011 Performance	62.0%
IHS FY 2010 Performance	62.0%
IHS FY 2009 Performance	59.0%
IHS FY 2008 Performance	62.0%
IHS FY 2007 Performance	59.0%
IHS FY 2006 Performance	58.0%
IHS FY 2005 Performance	59.0%
IHS FY 2004 Performance	54.0%
IHS FY 2003 Performance	51.0%
IHS FY 2002 Performance	51.4%
<i>HP 2020 Goal</i>	<i>90.0%</i>

### Performance Improvement Tips

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write “Refused” in Influenza Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU	November 25, 2016				Page 35			
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Influenza								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
Active Clinical Pts	1,554		1,209			1,101		
Total # w/Flu vaccine/ contra/NMI Refusal	194	12.5	115	9.5	+3.0	49	4.5	+8.0
A. # w/ Contraind/ NMI Ref w/ % of Total IZ	12	6.2	2	1.7	+4.4	0	0.0	+6.2
Active Clinical Pts <18	442		416			435		
Total # w/Flu vaccine/								

contra/NMI Refusal	54	12.2	21	5.0	+7.2	6	1.4	+10.8
A. # w/ Contraind/ NMI Ref								
w/ % of Total IZ	3	5.6	0	0.0	+5.6	0	0.0	+5.6
Active Clinical Pts								
18-49	752		572			486		
Total # w/Flu vaccine/								
contra/NMI Refusal	48	6.4	33	5.8	+0.6	14	2.9	+3.5
A. # w/ Contraind/ NMI Ref								
w/ % of Total IZ	3	6.3	2	6.1	+0.2	0	0.0	+6.3
Active Clinical Pts								
18-49 high risk	166		109			69		
Total # w/Flu vaccine/								
contra/NMI Refusal	25	15.1	25	22.9	-7.9	7	10.1	+4.9
A. # w/ Contraind/ NMI Ref								
w/ % of Total IZ	3	12.0	1	4.0	+8.0	0	0.0	+12.0
Active Clinical Patients								
ages 50-64	244		157			115		
Total # w/Flu								
vaccine/contra/								
NMI Refusal	59	24.2	37	23.6	+0.6	14	12.2	+12.0
A. # w/ Contraind/ NMI								
Ref w/ % of								
Total IZ	5	8.5	0	0.0	+8.5	0	0.0	+8.5

Figure 2-27: Sample Report, Adult Immunizations: Influenza

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Influenza: List of patients with Influenza code, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH AD	000001	COMMUNITY #1 01/28/16 Imm 88	F	15	06/22/01
PATIENT2,CRYSTAL UP,AC	000002	COMMUNITY #1	F	24	08/11/92
PATIENT3,DEMETRIA UP,AC, HR	000003	COMMUNITY #1 02/25/16 Imm 140	F	35	03/20/81
PATIENT4,JADE UP	000004	COMMUNITY #1	F	50	06/09/66
PATIENT5,MARIE UP,AC,AD,HR	000005	COMMUNITY #1 01/21/16 NMI Refusal	F	65	12/12/51

Figure 2-28: Sample Patient List, Adult Immunization: Influenza

## 2.4.2 Adult Immunizations

### GPRA Measure Description

During GPRA Year 2016, achieve the target rate of 87.3% for the proportion of adult patients age 65 years and older who receive a pneumococcal immunization.

#### Denominators

*Active Clinical patients ages 19 through 59.*

*Active Clinical patients ages 60 through 64.*

*Active Clinical patients ages 65 or older. (GPRA Denominator)*

*Active Clinical patients ages 18 through 64 and considered high risk for pneumococcal.*

*Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.*

*Active Clinical patients ages 18 and older.*

*All User Population patients 19 through 59.*

*All User Population patients 60 through 64.*

*All User Population patients ages 65 or older.*

*User Population patients ages 18 through 64 and considered high risk for pneumococcal.*

*User Population patients ages 18 and older.*

#### Numerators

Patients who have received 1 dose of Tdap/Td in the past 10 years, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received 1 dose of Tdap ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients with influenza vaccine documented during the Report Period or with a contraindication documented at any time before the end of the Report Period.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received 1 dose of Zoster ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients with Pneumococcal vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of pneumococcal vaccine after the age of 65 or a dose of pneumococcal vaccine in the past 5 years. (GPRA Numerator)

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period), including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever), including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever), including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever), including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever, 1 up-to-date pneumococcal vaccine), including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever, 1 up-to-date pneumococcal vaccine), including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

- a. Patients with a contraindication or a documented NMI refusal.

Patients with Pneumococcal vaccine or contraindication documented at any time before the end of the Report Period.

**Note:** The only refusals included in this numerator are NMI refusals.

## Logic Description

Age of the patient is calculated at the beginning of the Report period.

*Diabetes definition:* First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.



*Pneumococcal Immunization definition:* Any of the following documented any time before the end of the Report Period unless otherwise noted.

1. **Pneumococcal immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Pneumococcal Vaccine	90669, 90670, 90732, G0009, G8115 (old code), G9279	<b>Immunization (CVX) Codes:</b> 33, 100, 109, 133, 152 <b>POV:</b> ICD-9: V06.6; V03.82

2. **Pneumococcal Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.
3. **High Risk for Pneumococcal:** Persons considered high risk for pneumococcal are defined as those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following:

High Risk Category	ICD-9 Codes	ICD-10 Codes
HIV Infection	042, 042.0 through 044.9 (old codes), 079.53, V08	B20, B52.0, B97.35, Z21
Diabetes	250.00 through 250.93	E08.2*, E09.2*, E10.* through E13.*
Chronic alcoholism	303.90, 303.91	F10.20, F10.220 through F10.29
Congestive Heart Failure	428.0 through 428.9, 429.2	I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9
Emphysema	492.0 through 492.8	J43.*
Asthma	493.00 through 493.91	J45.21 through J45.902
Bronchiectasis, CLD, COPD	494.0 through 496.	J44.*, J47.*
Pneumoconioses	500 through 505	J60 through J64, J66.8 through J67.6, J67.8 through J67.9
Chronic Liver Disease	571.0 through 571.9	K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
Nephrotic Syndrome	581.0 through 581.9	N02.*, N04.*, N08
Renal Failure	585.6, 585.9	N18.6 through N19
Injury to spleen	865.00 through 865.19	

High Risk Category	ICD-9 Codes	ICD-10 Codes
Transplant	996.80 through 996.89	T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
Kidney Transplant	V42.0 through V42.89	
Chemotherapy	V58.1	Z51.11, Z51.12
Chemotherapy follow-up	V67.2	Z08

*Tdap/Td Immunization definition:* Any of the following documented during the applicable time frame.

1. **Tdap/Td immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Tdap Vaccine	90715	<b>Immunization (CVX) Codes:</b> 115
Td Vaccine	90714, 90718	<b>Immunization (CVX) Codes:</b> 9, 113, 138, 139 <b>POV:</b> ICD-9: V06.5

2. **Tdap/Td Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.

*Influenza definition:* Any of the following documented during the Report Period unless otherwise noted.

1. **Influenza immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Influenza vaccine	90630, 90654-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)	<b>Immunization (CVX) Codes:</b> 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 166 <b>POV:</b> ICD-9: V04.8 (old code), V04.81 NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, V06.6 NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142

2. **Contraindication:** Any of the following documented at any time before the end of the Report Period, defined as: (A) Contraindication in the Immunization Package of "Egg Allergy" or "Anaphylaxis" or (B) PCC NMI Refusal.

*Zoster definition:* Any of the following documented any time before the end of the Report Period unless otherwise noted.

1. **Zoster immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Zoster Vaccine	90736	<b>Immunization (CVX) Codes:</b> 121

2. **Zoster Contraindication:** (A) Contraindication in the Immunization Package of "Immune Deficiency" or "Anaphylaxis" or (B) PCC NMI Refusal.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients greater than or equal to (=>)18 yrs or DM DX with IZ or contraindication, if any.

### Measure Source

HP 2020 IID-13.1

### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2015 Performance	84.9%
IHS FY 2014 Performance	85.7%
IHS FY 2013 Performance	89.2%
IHS FY 2012 Performance	88.5%
IHS FY 2011 Performance	85.5%
IHS FY 2010 Performance	84.0%
IHS FY 2009 Performance	82.0%
IHS FY 2008 Performance	82.0%
IHS FY 2007 Performance	79.0%
IHS FY 2006 Performance	74.0%
IHS FY 2005 Performance	69.0%
IHS FY 2004 Performance	69.0%
IHS FY 2003 Performance	65.0%
IHS FY 2002 Performance	64.0%

Performance	Percent
HP 2020 Goal for % of patients greater than or equal to (=>) 65	90.0%

**Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write “Refused” in Pneumo Vax Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU	November 25, 2016						Page 41	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Adult Immunizations								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts 65 & older (GPRA)	128		74			65		
Total # w/Pneumococcal/ contra/NMI Refusal (GPRA)	49	38.3	39	52.7	-14.4	29	44.6	-6.3
A. # w/ Contraind/ NMI Ref w/ % of Total IZ	5	9.6	3	6.7	+2.9	0	0.0	+9.6
Total # w/Pneumococcal ever/ contra/NMI Refusal	52	40.6	45	60.8	-20.2	37	56.9	-16.3
Active Clinical Pts 18-64 high risk	233		169			105		
Total # w/Pneumococcal/ contra/NMI Refusal	55	23.6	47	27.8	-4.2	39	37.1	-13.5
A. # w/ Contra/ NMI Ref w/ % of Total IZ	0	0.0	0	0.0	+0.0	0	0.0	+0.0
Active Diabetic Pts	148		99			87		
Total # w/Pneumococcal/ contra/NMI Refusal	56	37.8	49	49.5	-11.7	46	52.9	-15.0
A. # w/ Contraind/ NMI Ref w/ % of Total IZ	0	0.0	0	0.0	+0.0	0	0.0	+0.0

Figure 2-29: Sample Report, Adult Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic

PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
HR=High Risk Patient

Adult Immunizations: List of patients =>18 yrs or DM DX with IZ or contraindication,  
if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DEBORAH UP,AC,HR	000001	COMMUNITY #1	F	18	02/25/98
					TDAP/TD: 12/22/14 Imm 9 (past 10 yrs)
PATIENT2,TARA UP,AC	000002	COMMUNITY #1	F	27	11/23/89
					TDAP: 03/03/15 Imm 115 (ever); TDAP/TD: 03/03/16
PATIENT3,BOBBIE UP,AC	000003	COMMUNITY #1	F	41	06/11/75
PATIENT4,NADINE UP,AC,HR,AD	000004	COMMUNITY #1	F	55	08/12/61
					Pneumo: 03/27/13 Imm 33 (ever) (up-to-date); TDAP/TD: 03/27/13 Imm 9 (past 10 yrs)
PATIENT5,SHERRY UP,AC,HR	000005	COMMUNITY #1	F	68	09/02/48
					Pneumo: 02/03/16 CPT 90669

Figure 2-30: Sample Patient List, Adult Immunizations

### 2.4.3 Childhood Immunizations

#### GPRAMA Measure Description

During GPRA Year 2016, achieve the target rate of 76.8% for the proportion of American Indian/Alaska Native children ages 19 through 35 months who have received the recommended immunizations.

#### Denominators

*Active Clinical patients* ages 19 through 35 months at end of Report Period.

*User Population patients* ages 19 through 35 months at end of Report Period.

*User Population patients active in the Immunization Package* who are 19 through 35 months at end of Report Period. (GPRAMA Denominator)

**Note:** Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

## Numerators

Patients who have received the 4:3:1:3\*:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 or 4 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals. (GPRAMA Numerator)

Patients who have received 4 doses of DTaP ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of Polio ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of MMR ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 3 or 4 doses of HiB ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of Hepatitis B vaccine ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Varicella ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 4 doses of Pneumococcal conjugate vaccine ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Hepatitis A vaccine ever, including contraindications and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 2 or 3 doses of Rotavirus vaccine ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 2 doses of Influenza vaccine ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

For each of the above numerators, the following sub-numerators are included:

- a. Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal

### **Logic Description**

*Age definition:* Age of the patient is calculated at the beginning of the Report Period. Therefore the age range will be adjusted to 7 through 23 months, which makes the patient between the ages of 19 through 35 months at the end of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

*Active Immunization Package Patients denominator definition:* Same as User Pop definition except includes only patients flagged as active in the Immunization Package.

**Note:** Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

Dosage and types of immunization definitions:

- 4 doses of DTaP: (1) 4 DTaP/DTP/Tdap; (2) 1 DTaP/DTP/Tdap and 3 DT/td; (3) 1 DTaP/DTP/Tdap and 3 each of Diphtheria and Tetanus; (4) 4 DT and 4 Acellular Pertussis; (5) 4 Td and 4 Acellular Pertussis; or (6) 4 each of Diphtheria, Tetanus, and Acellular Pertussis.
- 3 doses of Polio: (1) v OPV; (2) 3 IPV; or (3) combination of OPV and IPV totaling 3 doses.
- One dose of MMR: (1) MMR; (2) 1 M/R and 1 Mumps; (3) 1 R/M and 1 Measles; or (4) 1 each of Measles, Mumps, and Rubella.
- 3 doses of Hep B
- 3 or 4 doses of HIB, depending on the vaccine administered
- 1 dose of Varicella
- 4 doses of Pneumococcal
- 1 dose of Hepatitis A
- 2 or 3 doses of Rotavirus, depending on the vaccine administered
- 2 doses of Influenza

NMI refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

**Note:** NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations that allow a different number of doses (e.g. 2 or 3 Rotavirus): To count toward the numerator with the smaller number of doses, all of the patient's vaccinations must be part of the smaller dose series. For example, for a patient to count toward the Rotavirus numerator with only 2 doses, all 2 doses must be included in the 2-dose series codes listed in the Rotavirus definition. A patient with a mix of 2-dose and 3-dose series codes will need 3 doses to count toward the numerator. An exception to this is for the HIB vaccine: if the first 2 doses are CVX code 49, then the patient only needs 3 doses (even if the third dose is included in the 4-dose series).



- Each immunization must be refused and documented separately. For example, if a patient has an NMI refusal for Rubella only, then there must be an immunization, contraindication, or separate NMI refusal for the Measles and Mumps immunizations.
- For immunizations where required number of doses is greater than (>) 1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than (>)1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.
- Evidence of disease will be checked for at any time in the child's life (prior to the end of the Report Period.)
- To be counted in sub-numerator A, a patient must meet the numerator definition *and* have a REF refusal in PCC or a Parent or Patient Refusal in the IZ program for any of the immunizations in the numerator. For example, if a patient refused Rubella only but had immunizations for Measles and Mumps, the patient would be included in sub-numerator A.

NMI refusals are defined as PCC Refusal type NMI for any of the following IZ codes:

Immunization	Immunization Codes for Refusals	CPT Codes for Refusals
DTaP	20, 50, 102, 106, 107, 110, 120, 130, 132, 146	90696, 90698, 90700, 90721, 90723
DTP	1, 22, 102	90701, 90711 (old code), 90720
Tdap	115	90715
DT (Diphtheria & Tetanus)	28	90702
Td (Tetanus & Diphtheria)	9, 113, 138, 139	90714, 90718
Tetanus	35, 112	90703
Acellular Pertussis	11	
OPV	2, 89	90712
IPV	10, 89, 110, 120, 130, 132, 146	90696, 90698, 90711 (old code), 90713, 90723
MMR	3, 94	90707, 90710; M/R: 90708
M/R (Measles/ Rubella)	4	
R/M (Rubella/ Mumps)	38	90709 (old code)
Measles	5	90705
Mumps	7	90704
Rubella	6	90706

Immunization	Immunization Codes for Refusals	CPT Codes for Refusals
HiB	17, 22, 46-49, 50, 51, 102, 120, 132, 146	90645-90648, 90698, 90720-90721, 90737 (old code), 90748
Hepatitis B	8, 42-45, 51, 102, 104, 110, 132, 146	90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code)
Varicella	21, 94	90710, 90716
Pneumococcal	33, 100, 109, 133, 152	90669, 90670, 90732, G0009, G8115 (old code), G9279
Hepatitis A	1, 52, 83, 84, 85, 104	90632-90634, 90636, 90730 (old code)
Rotavirus	74, 116, 119, 122	90680
Influenza	15, 16, 88, 111, 135, 140, 141, 149, 150, 151, 153, 155, 158, 166	90630, 90654-90658, 90659 (old code), 90660-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)

Childhood immunizations are defined in the following ways:

Immunization	CPT Codes	ICD and Other Codes <b>NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes</b>
DTaP	90696, 90698, 90700, 90721, 90723	<b>Immunization (CVX) Codes:</b> 20, 50, 102, 106, 107, 110, 120, 130, 132, 146 <b>POV:</b> ICD-9: V06.1 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
DTP	90701, 90711 (old code), 90720	<b>Immunization (CVX) Codes:</b> 1, 22, 102 <b>POV:</b> ICD-9: V06.1, V06.2, V06.3 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
Tdap	90715	<b>Immunization (CVX) Codes:</b> 115 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
DT (Diphtheria & Tetanus)	90702	<b>Immunization (CVX) Codes:</b> 28 <b>POV:</b> ICD-9: V06.5 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
Td (Tetanus & Diphtheria)	90714, 90718	<b>Immunization (CVX) Codes:</b> 9, 113, 138, 139 <b>POV:</b> ICD-9: V06.5 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."

<b>Immunization</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b> <b>NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes</b>
Diphtheria	90719	<b>POV:</b> ICD-9: V03.5 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
Tetanus	90703	<b>Immunization (CVX) Codes:</b> 35, 112 <b>POV:</b> ICD-9: V03.7 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
Acellular Pertussis		<b>Immunization (CVX) Codes:</b> 11 <b>POV:</b> ICD-9: V03.6 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
OPV	90712	<b>Immunization (CVX) Codes:</b> 2, 89 <b>Contraindications:</b> Immunization Package contraindication of "Immune Deficiency."
IPV	90696, 90698, 90711 (old code), 90713, 90723	<b>Immunization (CVX) Codes:</b> 10, 89, 110, 120, 130, 132, 146 <b>POV:</b> ICD-9: V04.0, V06.3 <b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 730.70-730.79; ICD-10: M89.6* <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis" or "Neomycin Allergy."
MMR	90707, 90710	<b>Immunization (CVX) Codes:</b> 3, 94 <b>POV:</b> ICD-9: V06.4 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," or "Neomycin Allergy."
M/R (Measles/ Rubella)	90708	<b>Immunization (CVX) Codes:</b> 4 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
R/M (Rubella/ Mumps)	90709 (old code)	<b>Immunization (CVX) Codes:</b> 38 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
Measles	90705	<b>Immunization (CVX) Codes:</b> 5 <b>POV:</b> ICD-9: V04.2 <b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 055*; ICD-10: B05.* <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
Mumps	90704	<b>Immunization (CVX) Codes:</b> 7 <b>POV:</b> ICD-9: V04.6 <b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 072*; ICD-10: B26.* <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"

<b>Immunization</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b> <b>NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes</b>
Rubella	90706	<b>Immunization (CVX) Codes:</b> 6 <b>POV:</b> ICD-9: V04.3 <b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 056*, 771.0; ICD-10: B06.* <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
HiB – 3-dose series	90647, 90748	<b>Immunization (CVX) Codes:</b> 49, 51 <b>POV:</b> ICD-9: V03.81 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
HiB – 4-dose series	90645, 90646, 90648, 90698, 90720-90721, 90737 (old code)	<b>Immunization (CVX) Codes:</b> 17, 22, 46-48, 50, 102, 120, 132, 146 <b>POV:</b> ICD-9: V03.81 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
Hepatitis B	90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021, (old code) Q3023 (old code)	<b>Immunization (CVX) Codes:</b> 8, 42-45, 51, 102, 104, 110, 132, 146 <b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: V02.61, 070.2*, 070.3*; ICD-10: B16.*, B19.1*, Z22.51 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
Varicella	90710, 90716	<b>Immunization (CVX) Codes:</b> 21, 94 <b>POV:</b> ICD-9: V05.4 <b>Evidence of Disease:</b> 1) POV or PCC Problem List (active or inactive) ICD-9: 052*, 053*; ICD-10: B01.* through B02.* or 2) Immunization Package contraindication of "Hx of Chicken Pox" or "Immune." <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," or "Neomycin Allergy."
Pneumococcal	90669, 90670, 90732, G0009, G8115 (old code), G9279	<b>Immunization (CVX) Codes:</b> 33, 100, 109, 133, 152 <b>POV:</b> ICD-9: V06.6; V03.82 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
Hepatitis A	90632-90634, 90636, 90730 (old code)	<b>Immunization (CVX) Codes:</b> 31, 52, 83, 84, 85, 104 <b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 070.0, 070.1; ICD-10: B15.* <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis"
Rotavirus – 2-dose series	90681	<b>Immunization (CVX) Codes:</b> 119 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"
Rotavirus – 3-dose series	90680	<b>Immunization (CVX) Codes:</b> 74, 116, 122 <b>POV:</b> ICD-9: V05.8 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"

<b>Immunization</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b> <b>NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes</b>
Influenza	90630, 90654-90658, 90659 (old code), 90660-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)	<b>Immunization (CVX) Codes:</b> 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 166 <b>POV:</b> ICD-9: V04.8 (old code), V04.81, V06.6 <b>Contraindications:</b> Immunization Package contraindication of "Egg Allergy" or "Anaphylaxis"

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients 19 through 35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP.

**Notes:** Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7 through 23 months.

The order of the display for the immunizations is: 4 Dtap/Dtp;3 IPV/OPV;MMR;3 or 4 HIB;3 HEP;Vari;4 PNEUMO. A blank value in the Numerator column means the patient didn't meet the requirements for any of the immunizations. Another example is "MMR; vari;4 PNEUMO," which means the patient did not have 4 Dtap/Dtp, 3 IPV/OPV, 3 or 4 HIB and 3 Hep B immunizations.

### Measure Source

CDC; HP 2020 IID-7, IID-8; HEDIS

### Measure Past Performance and Long-Term Targets:

<b>Performance</b>	<b>Percent</b>
IHS FY 2015 GPRAMA Performance Active Immunization Package 4:3:1:3*:3:1:4 (rate for children age 19 through 35 months)	73.3%

<b>Performance</b>	<b>Percent</b>
IHS FY 2014 GPRAMA Performance Active Immunization Package 4:3:1:3*:3:1:4 (rate for children age 19 through 35 months)	75.4%
IHS FY 2013 GPRA Performance Active Immunization Package 4:3:1:3*:3:1:4 (rate for children age 19 through 35 months)	74.8%
IHS FY 2012 GPRA Performance Active Immunization Package 4:3:1:3:3:1:4 (rate for children age 19 through 35 months)	76.8%
IHS FY 2011 GPRA Performance Active Immunization Package 4:3:1:3:3:1:4 (rate for children age 19 through 35 months)	75.9%
IHS FY 2010 GPRA Performance Active Immunization Package 4:3:1:3:3:1 (rate for children age 19 through 35 months)	79.0%
IHS FY 2009 GPRA Performance Active Immunization Package 4:3:1:3:3 (rate for children age 19 through 35 months)	79.0%
IHS FY 2008 GPRA Performance Active Immunization Package 4:3:1:3:3 (rate for children age 19 through 35 months)	78.0%
<i>IHS FY 2008 Non-GPRA Performance Active Clinical 4:3:1:3:3 (rate for children age 19 through 35 months)</i>	68.0%
IHS FY 2007 GPRA Performance Active Immunization Package 4:3:1:3:3(rate for children age 19 through 35 months)	78.0%
IHS FY 2006 Performance (rate for children age 19 through 35 months)	80.0%
IHS FY 2005 Performance (rate for children age 19 through 35 months)	75.0%
IHS FY 2004 Performance(baseline rate for children age 19 through 35 months)	72.0%
IHS FY 2004 Performance(rate for children age 3 through 27 months)	81.0%
IHS FY 2003 Performance(rate for children age 3 through 27 months)	80.0%
IHS FY 2002 Performance(rate for children age 3 through 27 months)	80.0%
<i>HP 2020 goal for % of children age 19 through 35 months with 4:3:1:3:3:4 vaccines</i>	80.0%
<i>HP 2020 goal for % of children age 19 through 35 months with each individual vaccine</i>	90.0%

For the IHS FY 2006 Performance (rate for children 19 through 35 months), the Percent (80.0) please consider: All 2002 through 2006 rates reported on this table were reported by the Immunization Program from the quarterly immunization reports. Effective in 2007, CRS reports the rate and not the Immunization Program. The CRS rate is reported using the CRS Active Immunization Package denominator.

### Performance Improvement Tips

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write “Refused” in appropriate vaccine order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU		November 25, 2016				Page 51			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Childhood Immunizations									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts									
19-35 months	63		41			55			
# w/ 4313*314 combo or w/Dx/Contraind/ NMI Refusal	5	7.9	0	0.0	+7.9	0	0.0	+7.9	
A. # w/ Dx/Contraind/NMI Ref w/ % of Total 4313*314	1	20.0	0	0.0	+20.0	0	0.0	+20.0	
# w/ 4 doses DTaP or w/ Contraind/ NMI Refusal	25	39.7	3	7.3	+32.4	9	16.4	+23.3	
A. # w/ Contraind/NMI Ref w/ % of Total DTaP	7	28.0	0	0.0	+28.0	0	0.0	+28.0	
# w/ 3 doses Polio or w/ Dx/ Contraind/ NMI Refusal	32	50.8	12	29.3	+21.5	12	21.8	+29.0	
A. # w/ Dx/Contraind/NMI Ref w/ % of Total Polio	7	21.9	0	0.0	+21.9	0	0.0	+21.9	
# w/ 1 dose MMR or w/ Dx/Contraind/ NMI Refusal	29	46.0	12	29.3	+16.8	19	34.5	+11.5	
A. # w/Dx/Contraind/NMI Ref w/ % of Total MMR	6	20.7	0	0.0	+20.7	1	5.3	+15.4	
# w/ 3-4 doses HIB or w/Contraind NMI Refusal	26	41.3	10	24.4	+16.9	17	30.9	+10.4	

A. # w/ Contraind/NMI Ref w/ % of Total HIB	4	15.4	0	0.0	+15.4	0	0.0	+15.4
# w/ 3 doses Hep B or w/ Dx/Contraind/ NMI Refusal	31	49.2	11	26.8	+22.4	14	25.5	+23.8
A. # w/ Dx/Contraind/NMI Ref w/ % of Total HEP B	5	16.1	0	0.0	+16.1	0	0.0	+16.1

Figure 2-31: Sample Report, Childhood Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Childhood Immunizations: List of patients 19-35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP. NOTE: Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7-23 months.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,ANDREA UP,AC,IMM Vari; 2 Influenza	000001	COMMUNITY #1 4 DTaP/DTP; 3 Polio; MMR; 3 3-Dose Hib; 3 Hep B;	F	0	01/01/16
PATIENT2,HEATHER UP,AC,IMM	000002	COMMUNITY #1 NMI DTaP/DTP; NMI Polio; 2 Hep A; 2 Influenza	F	1	06/12/15
PATIENT3,TONYA UP	000003	COMMUNITY #1	F	1	10/03/15
PATIENT4,JAMES UP,AC,IMM	000004	COMMUNITY #1 3 Polio; MMR; 3 Hep B; Vari; NMI Rota	M	0	05/05/16
PATIENT5,SCOTT UP,AC,IMM	000005	COMMUNITY #1 4 4-Dose Hib; 2 Hep A; 3 Rota; 2 Influenza	M	0	12/13/16

Figure 2-32: Sample Patient List, Childhood Immunizations

## 2.4.4 Adolescent Immunizations

### Denominators

*Active Clinical patients* age 13. Broken down by gender where noted.

*Active Clinical patients* ages 13 through 17. Broken down by gender where noted.

### Numerators

Patients who have received the 1:1:3 combination (i.e., 1 Td/Tdap, 1 meningococcal, 3 HPV), including contraindications.



**Notes:** The only refusals included in this numerator are NMI refusals.

This numerator is broken down by gender.

Patient who have received the 1:1 combination (i.e., 1 Td/Tdap, 1 meningococcal), including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Tdap/Td ever, including contraindications.

- a. Patients with (1) a contraindication or (2) a documented NMI refusal.
- b. Patients who have received 1 dose of Tdap ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of meningococcal ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of HPV ever, including contraindications.

**Notes:** The only refusals included in this numerator are NMI refusals.

This numerator is broken down by gender.

For each of the above numerators, the following sub-numerators are included:

- a. Patients with (1) a contraindication or (2) a documented NMI refusal.

### **Logic Description**

*Age definition:* Age of the patient is calculated at the beginning of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within ten days of each other will be considered as the same immunization.

*Dosage and types of immunization definitions:*

- 1 dose of Td or Tdap

- 1 dose of Meningococcal
- 3 doses of HPV

Not Medically Indicated (NMI) refusals and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

**Note:** NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations where required number of doses is greater than (>)1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for HPV, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than (>)1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HPV, the patient will be included in the numerator.

Adolescent immunizations are defined in the following ways:

Immunization	CPT Codes	ICD and Other Codes
Tdap	90715	<b>Immunization code:</b> 115 <b>NMI Refusals:</b> Immunization code 115 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
Td	90714, 90718	<b>Immunization codes:</b> 9, 113, 138, 139 <b>POV:</b> ICD-9: V06.5 <b>NMI Refusals:</b> Immunization codes 9, 113, 138, 139 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
Meningococcal	90733, 90734	<b>Immunization codes:</b> 32, 108, 114, 136, 147 <b>NMI Refusals:</b> Immunization codes 32, 108, 114, 136, 147 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."
HPV	90649, 90650, 90651	<b>Immunization codes:</b> 62, 118, 137, 165 <b>NMI Refusals:</b> Immunization codes 62, 118, 137, 165 <b>Contraindications:</b> Immunization Package contraindication of "Anaphylaxis."

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients 13 through 17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 HPV, no IZ will be listed for HPV.

**Note:** An absent value in the Numerator column means the patient did not meet the requirements for any of the immunizations. An example for a female patient age 13 with a value of “;3 HPV” which means the patient did not have 1 Td/Tdap and 1 Meningococcal immunizations.

### Measure Source

HEDIS, HP 2020 IID-11

### Measure Past Performance and Long-Term Targets:

Target	Percent
HP 2020 goal for each individual IZ: Tdap, Meningococcal, HPV	80.0%
HP 2020 goal for each individual IZ: varicella	90.0%

### Performance Improvement Tips

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write “Refused” in appropriate vaccine Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU	November 25, 2016				Page 66		
*** IHS 2016 Selected Measures with Community Specified Report ***							
DEMO INDIAN HOSPITAL							
Report Period: Jan 01, 2016 to Dec 31, 2016							
Previous Year Period: Jan 01, 2015 to Dec 31, 2015							
Baseline Period: Jan 01, 2010 to Dec 31, 2010							
-----							
Adolescent Immunizations							
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	% CHG from BASE %
Active Clinical patients age 13	20		17			28	
# w/1:1:3 Combo or w/Dx/Contraind/							

NMI Refusal	2	10.0	0	0.0	+10.0	0	0.0	+10.0
A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total 1:1:3	1	50.0	0	0.0	+50.0	0	0.0	+50.0
Male Active Clinical Pts age 13	8		12			15		
# w/1:1:3 Combo or w/ Dx/Contraind/ NMI Refusal	1	12.5	0	0.0	+12.5	0	0.0	+12.5
A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total 1:1:3	1	100.0	0	0.0	+100.0	0	0.0	+100.0
Female Active Clinical Pts age 13	12		6			13		
# w/1:1:3 Combo or w/ Dx/Contraind/ NMI Refusal	1	8.3	0	0.0	+8.3	0	0.0	+8.3
A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total 1:1:3	0	0.0	0	0.0	+0.0	0	0.0	+0.0

Figure 2-33: Sample Report, Adolescent Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Adolescent Immunizations: List of patients 13-17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 Hep B, no IZ will be listed for Hep B.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,LINDA AC	000001	COMMUNITY #3	F	13	01/31/03
PATIENT2,SHERRY AC	000002	COMMUNITY #3 NMI Tdap	F	13	04/11/03
PATIENT22,JESSICA AC	000022	COMMUNITY #4 Tdap; 3 HPV	F	13	06/24/03
PATIENT23,SAMANTHA AC	000023	COMMUNITY #4 Td; NMI Meningococcal	F	13	07/12/03
PATIENT24,NINA AC	000024	COMMUNITY #4 Contra HPV	F	13	07/19/03
PATIENT25,RHONDA AC	000025	COMMUNITY #4 Td; 3 HPV	F	13	12/12/03

Figure 2-34: Sample Patient List, Adolescent Immunizations

## 2.5 Childhood Diseases Group

### 2.5.1 Appropriate Treatment for Children with Upper Respiratory Infection

#### Denominators

*Active Clinical patients* who were ages 3 months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the report period through the first 6 months of the report period.

*User Population patients* who were ages 3 months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the report period through the first 6 months of the report period.

#### Numerator

Patients who were *not* prescribed an antibiotic on or within 3 days after diagnosis. In this measure, appropriate treatment is *not* to receive an antibiotic.

#### Logic Description

Age is calculated as follows: Children 3 months as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

1. Patient's diagnosis of an upper respiratory infection (URI) must have occurred at an outpatient visit. Upper Respiratory Infection defined as POV ICD-9: 460 or 465.\*; ICD-10: J00. Outpatient visit defined as Service Category A, S, or O.
2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with URI diagnosis.
3. Patient's visit must only have a diagnosis of URI. If any other diagnosis exists, the visit will be excluded.
4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the URI visit date.
5. The patient did not have an active prescription for antibiotics as of the URI visit date. "Active" prescription defined as:

Rx Days Supply greater than or equal to ( $\geq$ ) (URI Visit Date–Prescription Date)

If multiple visits exist that meet the above criteria, the first visit will be used.

*Antibiotic medications* defined with medication taxonomy BGP HEDIS

ANTIBIOTIC MEDS or Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04029, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0K829, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U329, 3E0V329, 3E0W329, 3E0Y329. (Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil, Cefazolin, Cefdinir, Cefditoren, Cefixime, Cefpodoxime, Cefprozil, Ceftributen, Ceftriaxone, Cefuroxime, Cephalexin, Ciprofloxacin, Clarithromycin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate, Erythromycin-sulfisoxazole, Levofloxacin, Minocycline, Moxifloxacin, Ofloxacin, Penicillin VK, Penicillin G, Sulfisoxazole, Tetracycline, Trimethoprim.) Medications must not have a comment of RETURNED TO STOCK.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients 3 months to 18 years of age with upper respiratory infection, with antibiotic prescription, if any.

### Measure Source

HEDIS

### Measure Past Performance and Long-Term Targets

None

DU	November 25, 2016	Page 72
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		
Baseline Period: Jan 01, 2010 to Dec 31, 2010		
-----		
Appropriate Treatment for Children with Upper Respiratory Infection (con't)		

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical 3 months-18 yrs w/Upper Respiratory Infection	38		36			30		
# w/o Antibiotic Rx	37	97.4	35	97.2	+0.1	27	90.0	+7.4
User Pop 3 months-18 yrs w/Upper Respiratory Infection	43		38			35		
# w/o Antibiotic Rx	42	97.7	37	97.4	+0.3	32	91.4	+6.2

Figure 2-35: Sample Report, Appropriate Treatment for Children with Upper Respiratory Infection

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Appropriate Treatment for Children with Upper Respiratory Infection: List of patients 3 months to 18 years with upper respiratory infection, with antibiotic prescription, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,PAMELA UP,AC	000001	COMMUNITY #3 MEETS MEASURE	F	3	02/15/13
PATIENT2,ALICIA UP,AC	000002	COMMUNITY #3 MEETS MEASURE	F	7	06/18/09
PATIENT3,JAMES UP,AC	000003	COMMUNITY #3 MEETS MEASURE	M	0	03/14/16
PATIENT4,HENRY UP,AC	000004	COMMUNITY #3 MEETS MEASURE	M	12	11/21/04
PATIENT25,HEATHER UP,AC	000025	COMMUNITY #4 MEETS MEASURE	F	7	12/06/09
PATIENT26,DYLAN UP,AC	000026	COMMUNITY #4 MEETS MEASURE	M	3	03/02/13
PATIENT27,CODY UP,AC	000027	COMMUNITY #4 MEETS MEASURE	M	4	04/12/12
PATIENT28,KAREN UP,AC	000028	COMMUNITY #5 antibiotic injection: 01/06/16 DOES NOT MEET MEASURE	F	0	09/22/16

Figure 2-36: Sample Patient List, Appropriate Treatment for Children with Upper Respiratory Infection

## 2.5.2 Appropriate Testing for Children with Pharyngitis

### Denominators

*Active Clinical patients* who were ages 2 through 18 years who were diagnosed with *pharyngitis* and prescribed an antibiotic during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

*User Population patients* who were ages 2 through 18 years who were diagnosed with *pharyngitis* and prescribed an antibiotic during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

### Numerator

Patients who received a Group A strep test.

### Logic Description

Age is calculated as follows: Children two years as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

1. Patient's diagnosis of pharyngitis must have occurred at an outpatient visit. Pharyngitis defined as POV ICD-9: 462, 463, 034.0; ICD-10: J02.0, J03.\*. Outpatient visit defined as Service Category A, S, or O.
2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with pharyngitis diagnosis.
3. Patient's visit must only have a diagnosis of pharyngitis. If any other diagnosis exists, the visit will be excluded.
4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the pharyngitis visit date.
5. The patient did not have an active prescription for antibiotics as of the pharyngitis visit date. "Active" prescription defined as:
6. Rx Days Supply greater than or equal to ( $\geq$ )(URI Visit Date - Prescription Date)
7. The patient filled a prescription for antibiotics on or within 3 days after the pharyngitis visit.

If multiple visits exist that meet the above criteria, the first visit will be used.



*Antibiotic medications* defined with medication taxonomy BGP HEDIS ANTIBIOTIC MEDS or Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04029, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0K829, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U329, 3E0V329, 3E0W329, 3E0Y329. (Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil, Cefazolin, Cefdinir, Cefixime, Cefditoren, Cefitibuten, Cefpodoxime, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Ciprofloxacin, Clarithromycin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate, Erythromycin-sulfisoxazole, Levofloxacin, Minocycline, Moxifloxacin, Ofloxacin, Penicillin VK, Penicillin G, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazole.) Medications must not have a comment of RETURNED TO STOCK.

To be included in the numerator, a patient must have received a Group A Streptococcus test within the 7-day period beginning 3 days prior through 3 days after the Pharyngitis visit date.

*Group A Streptococcus* test defined as: CPT 87430 (by enzyme immunoassay), 87650-87652 (by nucleic acid), 87880 (by direct optical observation), 87081 (by throat culture), 3210F (Group A Strep Test); site-populated taxonomy BGP GROUP A STREP TESTS; and LOINC taxonomy.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients 2 through 18 years of age with pharyngitis and a Group A Strep test, if any.

### Measure Source

HEDIS

### Measure Past Performance and Long-Term Targets

None

DU

November 25, 2016

Page 75

\*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*

DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Appropriate Testing for Children with Pharyngitis (con't)									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical 2-18 yrs w/ Pharyngitis and Antibiotic Rx	10		5			8			
# w/Group A Strep Test	9	90.0	3	60.0	+30.0	2	25.0	+65.0	
User Pop 2-18 yrs w/ Pharyngitis and Antibiotic Rx	11		7			10			
# w/Group A Strep Test	9	81.8	4	57.1	+24.7	2	20.0	+61.8	

Figure 2-37: Sample Report, Appropriate Testing for Children with Pharyngitis

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Appropriate Testing for Children with Pharyngitis: List of patients 2-18 years with pharyngitis and a Group A Strep test, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, MICHAEL UP, AC	000001	COMMUNITY #1 03/19/16 RAPID ANTIGEN (STREP A)	M	9	05/23/07
PATIENT2, JOSEPH UP, AC	000002	COMMUNITY #1 05/01/16 RAPID ANTIGEN (STREP A)	M	12	02/16/04
PATIENT3, LESTER UP	000003	COMMUNITY #1	M	13	02/19/03
PATIENT24, MONICA UP, AC	000024	COMMUNITY #2 01/23/16 RAPID ANTIGEN (STREP A)	F	5	07/04/11
PATIENT25, MICHAEL JAMES UP, AC	000025	COMMUNITY #2 03/12/16 RAPID ANTIGEN (STREP A)	M	7	09/09/09

Figure 2-38: Sample Patient List, Appropriate Testing for Children with Pharyngitis

## 2.6 Cancer Related Measure Topics

### 2.6.1 Cancer Screening: Pap Smear Rates

#### **GPRA Measure Description**

During GPRA Year 2016, achieve the target rate of 55.6% for the proportion of female patients ages 24 through 64 without a documented history of hysterectomy who have had a Pap screen within the previous 3 years, or if the patient is over 30, had a Pap screen in the past 3 years or a Pap screen and HPV DNA within the previous 5 years.

#### **Denominators**

*Female Active Clinical patients ages 24 through 64 without documented history of Hysterectomy. (GPRA Denominator)*

*Female Active Clinical patients ages 24 through 29 without documented history of Hysterectomy.*

*Female Active Clinical patients ages 30 through 64 without documented history of Hysterectomy.*

*Female User Population patients ages 24 through 64 without documented history of Hysterectomy.*

*Female User Population patients ages 24 through 29 without documented history of Hysterectomy.*

*Female User Population patients ages 30 through 64 without documented history of Hysterectomy.*

#### **Numerators**

Patients with a Pap smear documented in the past 3 years, or if patient is 30 to 64 years of age, either a Pap Smear documented in the past 3 years or a Pap Smear and an HPV DNA documented in the past 5 years. (GPRA Numerator)

**Note:** This numerator does *not* include refusals.

Patients with a Pap Smear documented in the past 3 years.

Patients with a Pap Smear documented 3-5 years ago and an HPV DNA documented in the past 5 years

## Logic Description

Age of the patient is calculated at the beginning of the report period. Patients must be at least 24 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Hysterectomy	51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200-58294, 58548, 58550-58554, 58570-58573, 58951, 58953-58954, 58956, 59135	<b>Procedure:</b> ICD-9: 68.4-68.9; ICD-10: 0UT9*ZZ <b>Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):</b> ICD-9: 618.5, 752.43, V88.01, V88.03; ICD-10: N99.3, Z12.72, Z90.710-Z90.712, Q51.5 <b>Women's Health:</b> Procedure called Hysterectomy.		
Pap Smear	88141-88154, 88160-88167, 88174-88175, G0123, G0124, G0141, G0143- G0145, G0147, G0148, P3000, P3001, Q0091	<b>Lab:</b> PAP SMEAR <b>POV:</b> ICD-9: V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, 795.0*; ICD-10: R87.61*, R87.810, R87.820, Z01.42, Z12.4 <b>Women's Health:</b> Procedure called Pap Smear and where the result does NOT have "ERROR/DISREGARD"	Yes	BGP PAP SMEAR TAX

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
HPV DNA <b>Note:</b> CRS will only search for a documented HPV DNA if the patient had a Pap Smear 3 to 5 years ago.	87620-87622 (old codes), 87623-87625	<b>Lab:</b> HPV <b>POV:</b> ICD-9: V73.81, 079.4, 796.75, 795.05, 795.15, 796.79, 795.09, 795.19; ICD-10: B97.7, R85.618, R85.81, R85.82, R87.628, R87.810, R87.811, R87.820, R87.821, Z11.51 <b>Women's Health:</b> Procedure called HPV Screen and where the result does NOT have "ERROR/DISREGARD"; Procedure called Pap Smear and where the HPV field equals Yes	Yes	BGP HPV TAX

### Key Logic Changes from CRS Version 15.1

1. Removed LOINC code 6138-2 from BPG HPV LOINC CODES taxonomy.
2. Added codes 74763-4, 74777-4, 75406-9, 75664-3, 75694-0, 75695-7, 75696-5, 77375-4, 77377-0, 77379-6, 77380-4, 77394-5, 77395-2, 77396-0, 77399-4, 77400-0 to BPG HPV LOINC CODES taxonomy.

### Patient List Description

List of women 24 through 64 with documented Pap Smear and HPV, if any.

### Measure Source

HP 2020 C-15

### Measure Past Performance and Long-Term Targets:

Performance	Percent
IHS FY 2015 Performance	54.9%
IHS FY 2014 Performance	54.6%
IHS FY 2013 Performance	61.7%
IHS FY 2012 Performance	57.1%
IHS FY 2011 Performance	58.1%
IHS FY 2010 Performance	59.0%
IHS FY 2009 Performance	59.0%
IHS FY 2008 Performance	59.0%
IHS FY 2007 Performance	59.0%

Performance	Percent
IHS FY 2006 Performance	59.0%
IHS FY 2005 Performance	60.0%
IHS FY 2004 Performance	58.0%
IHS FY 2003 Performance	61.0%
IHS FY 2002 Performance	62.0%
<i>HP 2020 Goal</i>	<i>93.0%</i>

**Performance Improvement Tips**

- Providers should ask about and record off-site tests (date received and location) on PCC forms. Data entry mnemonic: HPAP
- Providers should document refusals; write “Refused” in Pap Order box on PCC form. Data entry mnemonic: REF (Lab Test Value, Date Refused).

DU	November 25, 2016						Page 77		
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Cancer Screening: Pap Smear Rates (con't)									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %	
Female Active Clinical									
24-64 years									
(GPRA)	465		328			271			
# w/Pap Smear recorded									
w/in 3 years - No Refusals									
(GPRA)	159	34.2	140	42.7	-8.5	113	41.7	-7.5	
A. # aged 24-29 w/Pap									
Smear recorded w/in									
3 years-No Refusals									
	49	10.5	48	14.6	-4.1	40	14.8	-4.2	
B. # aged 30-64 w/Pap									
Smear recorded w/in									
3 years-No Refusals									
	109	23.4	92	28.0	-4.6	73	26.9	-3.5	
C. # aged 30-64 w/Pap									
Smear and HPV									
	1	0.2	0	0.0	+0.2	0	0.0	+0.2	
Female User Pop									
24-64 yrs									
	751		656			547			
# w/Pap Smear recorded w/in									
3 years - No Refusals									
	171	22.8	159	24.2	-1.5	128	23.4	-0.6	
A. # aged 24-29 w/Pap Smear									
recorded w/in 3 years									
-No Refusals									
	55	7.3	60	9.1	-1.8	45	8.2	-0.9	
B. # aged 30-64 w/Pap Smear									
recorded w/in 3 years									
-No Refusals									
	115	15.3	99	15.1	+0.2	83	15.2	+0.1	

C. # aged 30-64 w/Pap Smear and HPV	1	0.1	0	0.0	+0.1	0	0.0	+0.1
-------------------------------------	---	-----	---	-----	------	---	-----	------

Figure 2-39: Sample Report, Cancer Screening: Pap Smear Rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Cancer Screening: Pap Smear Rates: List of women 25-64 with documented Pap smear, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,EVELYN UP	000001	COMMUNITY #1 05/05/14 POV 795.06	F	21	11/19/95
PATIENT2,MICHELLE UP,AC	000002	COMMUNITY #1 05/31/16 Lab	F	22	01/10/94
PATIENT3,KAITLYN UP,AC	000003	COMMUNITY #1 05/08/14 CPT 88150	F	22	03/01/94
PATIENT4,BRITNEY UP,AC	000004	COMMUNITY #1 01/10/16 POV V72.32	F	22	09/22/94
PATIENT5,KATY UP,AC	000005	COMMUNITY #1 PAP: 07/01/12 PROC 91.46; HPV: 01/10/13 POV 079.4	F	31	05/07/85

Figure 2-40: Sample Patient List, Cancer Screening: Pap Smear rates

## 2.6.2 Cancer Screening: Mammogram Rates

### GPRM Measure Description

During GPRM Year 2016, achieve the target rate of 55.9% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last 2 years.

### Denominators

*Female Active Clinical patients* ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies. (GPRM Denominator)

*Female User Population patients* ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

### Numerators

All patients who had a Mammogram documented in the past 2 years.

**Note:** This numerator does *not* include refusals. (GPRM Numerator)

Patients with documented mammogram refusal in the past year

### Logic Description

Age of the patient is calculated at the beginning of the Report Period. For all denominators, patients must be at least the minimum age as of the beginning of the Report Period. For the 52 through 64 denominators, the patients must be less than 65 years of age as of the end of the Report Period.

Subject Defined	CPT Codes	ICD and Other Codes
Bilateral Mastectomy	19300.50-19307.50 or old code 19180, 19200, 19220 <b>OR</b> 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral) <b>OR</b> 19240, with modifier of 50 or 09950	<b>Procedure:</b> ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HTV0ZZ
Unilateral Mastectomy	Must have 2 separate occurrences on either 2 different dates of service or on the same date of service if the codes include both a right side modifier (RT) and left side modifier (LT). 19300-19307, or old codes 19180, 19200, 19220, 19240	<b>Procedure:</b> Must have 2 separate occurrences on 2 different dates of service. ICD-9: 85.41, 85.43, 85.45, 85.47; ICD-10: 07T50ZZ, 07T60ZZ, 07T70ZZ, 07T80ZZ, 07T90ZZ, 0HTT0ZZ, 0HTU0ZZ, 0KTH0ZZ, 0KTJ0ZZ
Mammogram	<b>Rad or CPT:</b> 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	<b>POV:</b> ICD-9: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast; ICD-10: R92.0, R92.1, R92.8, Z12.31 <b>Procedure:</b> ICD-9: 87.36-87.37; ICD-10: BH00ZZZ, BH01ZZZ, BH02ZZZ <b>Women's Health:</b> Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD"
Refusal (in past year)	<b>Rad Mammogram for CPT:</b> 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of women 52 through 64 with mammogram/refusal, if any.



**Measure Source**

HP 2020 C-17

**Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2015 Performance	54.5%
IHS FY 2014 Performance	54.2%
IHS FY 2013 Performance	53.8%
IHS FY 2012 Performance	51.9%
IHS FY 2011 Performance	49.8%
IHS FY 2010 Performance	48.0%
IHS FY 2009 Performance	45.0%
IHS FY 2008 Performance	45.0%
IHS FY 2007 Performance	43.0%
IHS FY 2006 Performance	41.0%
IHS FY 2005 Performance	41.0%
IHS FY 2004 Performance	40.0%
IHS FY 2003 Performance	40.0%
IHS FY 2002 Performance	42.0%
<i>HP 2020 Goal</i>	<i>81.1%</i>

**Performance Improvement Tips**

- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.
- Providers should document refusals; write “Refused” in Mammogram Order box on PCC form. Data entry mnemonic: REF (Mammogram, Procedure (CPT) Code, Date Refused).

DU	November 25, 2016	Page 79						
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Cancer Screening: Mammogram Rates (con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Female Active Clinical 52-64 (GPRA)	97		60			47		
# w/Mammogram recorded w/in 2 years-No Refusals								

(GPRA)	31	32.0	22	36.7	-4.7	22	46.8	-14.8
# w/ Mammogram Refusal	7	7.2	0	0.0	+7.2	0	0.0	+7.2
# Female Active Clinical 42+ (GPRA Dev.)	293		188			163		
# w/Mammogram recorded w/in 2 years-No Refusals (GPRA Dev.)	63	21.5	62	33.0	-11.5	54	33.1	-11.6
# w/ Mammogram Refusal	9	3.1	0	0.0	+3.1	0	0.0	+3.1
# Female User Pop 52-64	175		122			102		
# w/Mammogram recorded w/in 2 years-No Refusals	34	19.4	26	21.3	-1.9	23	22.5	-3.1
# w/ Mammogram Refusal	7	4.0	0	0.0	+4.0	0	0.0	+4.0
# Female User Pop 42+	513		380			333		
# w/Mammogram recorded w/in 2 years-No Refusals	67	13.1	69	18.2	-5.1	58	17.4	-4.4
# w/ Mammogram Refusal	9	1.8	0	0.0	+1.8	0	0.0	+1.8

Figure 2-41: Sample Report, Cancer Screening: Mammogram rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Cancer Screening: Mammogram Rates: List of women 42+ with mammogram/refusal, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, CARLA UP, AC	000001	COMMUNITY #1 10/01/15 CPT 77052	F	42	02/20/74
PATIENT2, CRYSTAL UP	000002	COMMUNITY #1	F	43	06/30/73
PATIENT3, ALEXA UP, AC	000003	COMMUNITY #1 04/24/15 CPT 76090	F	45	03/09/71
PATIENT4, HANNAH UP	000004	COMMUNITY #1	F	45	05/10/71
PATIENT5, MARTHA UP	000005	COMMUNITY #1	F	47	12/01/69
PATIENT6, TARA UP, AC	000006	COMMUNITY #1 01/15/16 Refused CPT G0206	F	48	10/22/68
PATIENT7, CAROL LYNN UP, AC	000007	COMMUNITY #2 03/05/16 RAD 76092	F	44	08/08/72
PATIENT8, MARY ANN	000008	COMMUNITY #2	F	52	06/22/64

UP, AC					
PATIENT9, BARBARA	000009	COMMUNITY #2	F	52	09/14/64
UP, AC		04/22/16	CPT	77057	

Figure 2-42: Sample Patient List, Cancer Screening: Mammogram rates

## 2.6.3 Colorectal Cancer Screening

### **GPRA Measure Description**

During GPRA Year 2016, achieve the target rate of 38.7% for the proportion of clinically appropriate patients ages 50-75 who have received colorectal screening.

### **Denominators**

All *Active Clinical patients* ages 50 through 75 without a documented diagnosis of colorectal cancer or total colectomy. Broken down by gender. (GPRA Denominator)

All *User Population patients* ages 50 through 75 without any documented diagnosis of colorectal cancer or total colectomy.

### **Numerators**

Patients who have had any CRC screening, defined as any of the following: (1) Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the Report period; (2) flexible sigmoidoscopy in the past 5 years; or (3) colonoscopy in the past 10 years.

**Note:** This numerator does *not* include refusals. (GPRA Numerator)

Patients with documented CRC screening refusal in the past year.

Patients with FOBT or FIT during the Report Period.

Patients with a flexible sigmoidoscopy in the past 5 years or a colonoscopy in the past 10 years.

### **Logic Description**

Age is calculated at the beginning of the Report Period.

#### *Denominator Exclusions*

Any diagnosis ever of one of the following:

1. **Colorectal Cancer:** POV ICD-9: 153.\*, 154.0, 154.1, 197.5, V10.05; ICD-10: C18.\*, C19, C20, C78.5, Z85.030, Z85.038; CPT G0213–G0215 (old codes), G0231 (old code).
2. **Total Colectomy:** CPT 44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210 through 44212; Procedure ICD-9: 45.8\*; ICD-10: 0DTE\*ZZ.

*Colorectal cancer screening definition:* The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

***Colorectal Cancer Screening (CRS looks for the most recent of any of the following during timeframes specified in numerator section above)***

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Fecal Occult Blood lab test (FOBT) or Fecal Immuno-chemical Test (FIT)	82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)		Yes	BGP GPRA FOB TESTS
Flexible Sigmoidoscopy	45330-45345, G0104	<b>Procedure:</b> ICD-9: 45.24; ICD-10: 0DJD8ZZ		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Colonoscopy	44388 through 44394, 44397, 45355, 45378 through 45387, 45391, 45392, G0105, G0121, G9252, G9253	<b>Procedure:</b> ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5K8ZZ, 0D5L4ZZ, 0D5L8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5N4ZZ, 0D5N8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E8ZX, 0D9F3ZX, 0D9F4ZX, 0D9F7ZX, 0D9F8ZX, 0D9G3ZX, 0D9G4ZX, 0D9G7ZX, 0D9G8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9K3ZX, 0D9K4ZX, 0D9K7ZX, 0D9K8ZX, 0D9L3ZX, 0D9L4ZX, 0D9L7ZX, 0D9L8ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9N3ZX, 0D9N4ZX, 0D9N7ZX, 0D9N8ZX, 0DBE3ZX, 0DBE4ZX, 0DBE7ZX, 0DBE8ZX, 0DBE8ZZ, 0DBF3ZX, 0DBF4ZX, 0DBF7ZX, 0DBF8ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG4ZX, 0DBG7ZX, 0DBG8ZX, 0DBG8ZZ, 0DBH3ZX, 0DBH4ZX, 0DBH7ZX, 0DBH8ZX, 0DBH8ZZ, 0DBK3ZX, 0DBK4ZX, 0DBK7ZX, 0DBK8ZX, 0DBK8ZZ, 0DBL3ZX, 0DBL4ZX, 0DBL7ZX, 0DBL8ZX, 0DBL8ZZ, 0DBM3ZX, 0DBM4ZX, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBN3ZX, 0DBN4ZX, 0DBN7ZX, 0DBN8ZX, 0DBN8ZZ, 0DJD8ZZ		

**Refusal definition: Any of the following in the past year:**

Subject Defined	CPT Codes	ICD and Other Codes	Taxonomy
Refusals	<b>FOBT or FIT:</b> 82270, 82274, 89205 (old code), G0107 (old code), G0328, or G0394 (old code) <b>Flexible Sigmoidoscopy:</b> 45330-45345, G0104 <b>Colonoscopy:</b> 44388 through 44394, 44397, 45355, 45378 through 45387, 45391, 45392, G0105, G0121, G9252, G9253	<b>Flexible Sigmoidoscopy Procedure:</b> ICD-9: 45.24, 45.42; ICD-10: 0DJD8ZZ  <b>Colonoscopy Procedure:</b> ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5K8ZZ, 0D5L4ZZ, 0D5L8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5N4ZZ, 0D5N8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E8ZX, 0D9F3ZX, 0D9F4ZX, 0D9F7ZX, 0D9F8ZX, 0D9G3ZX, 0D9G4ZX, 0D9G7ZX, 0D9G8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9K3ZX, 0D9K4ZX, 0D9K7ZX, 0D9K8ZX, 0D9L3ZX, 0D9L4ZX, 0D9L7ZX, 0D9L8ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9N3ZX, 0D9N4ZX, 0D9N7ZX, 0D9N8ZX, 0DBE3ZX, 0DBE4ZX, 0DBE7ZX, 0DBE8ZX, 0DBE8ZZ, 0DBF3ZX, 0DBF4ZX, 0DBF7ZX, 0DBF8ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG4ZX, 0DBG7ZX, 0DBG8ZX, 0DBG8ZZ, 0DBH3ZX, 0DBH4ZX, 0DBH7ZX, 0DBH8ZX, 0DBH8ZZ, 0DBK3ZX, 0DBK4ZX, 0DBK7ZX, 0DBK8ZX, 0DBK8ZZ, 0DBL3ZX, 0DBL4ZX, 0DBL7ZX, 0DBL8ZX, 0DBL8ZZ, 0DBM3ZX, 0DBM4ZX, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBN3ZX, 0DBN4ZX, 0DBN7ZX, 0DBN8ZX, 0DBN8ZZ, 0DJD8ZZ	V Lab Fecal Occult Blood Test

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of patients 50 through 75 with CRC screening or refusal, if any.

**Measure Source**

HEDIS, HP 2020 C-16

**Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2015 Performance	38.6%
IHS FY 2014 Performance	37.5%
IHS FY 2013 Performance	35.0%
<i>Former definition of CRC:</i>	
IHS FY 2012 Performance	46.1%
IHS FY 2011 Performance	41.7%
IHS FY 2010 Performance	37.0%
IHS FY 2009 Performance	33.0%
IHS FY 2008 Performance	29.0%
IHS FY 2007 Performance	26.0%
IHS FY 2006 Performance	22.0%
<i>HP 2020 Goal</i>	<i>70.5%</i>

**Performance Improvement Tip**

Providers should ask about and record off-site historical tests (test type, date received and location) on PCC forms. Data entry mnemonics: HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG (sigmoidoscopy). Providers should also enter as a refusal if the patient refuses the colorectal cancer screening. Refusals may be entered with the data entry mnemonic of REF (refusal).

DU	November 25, 2016						Page 82	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Colorectal Cancer Screening (con't)								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %
AC Pts 50-75 w/o colorectal cancer or total colectomy (GPRA)	317		201			157		
# w/CRC Screening								
-No Refusals (GPRA)	49	15.5	40	19.9	-4.4	19	12.1	+3.4
# w/ CRC Screening Refusal	8	2.5	0	0.0	+2.5	0	0.0	+2.5

# w/FOBT/FIT during Report period	12	3.8	11	5.5	-1.7	0	0.0	+3.8
# w/Flex Sig or Colonoscopy	40	12.6	31	15.4	-2.8	19	12.1	+0.5
Male Active Clinical 50-75	157		97			72		
# w/CRC Screening -No Refusals	23	14.6	18	18.6	-3.9	9	12.5	+2.1
# w/ CRC Screening Refusal	4	2.5	0	0.0	+2.5	0	0.0	+2.5
# w/FOBT/FIT during Report period	7	4.5	3	3.1	+1.4	0	0.0	+4.5
# w/Flex Sig or Colonoscopy	18	11.5	15	15.5	-4.0	9	12.5	-1.0

Figure 2-43: Sample Report, Colorectal Cancer Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Colorectal Cancer Screening: List of patients 51-80 with CRC screening or refusal, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, DANIELLE UP	000001	COMMUNITY #1 FOB: 08/19/16 CPT G0107	F	51	03/03/65
PATIENT2, MARIE UP, AC	000002	COMMUNITY #1 COLO: 02/12/14 Refused CPT	F	51	05/10/65
PATIENT3, MARY ANN UP, AC	000003	COMMUNITY #1	F	52	05/22/64
PATIENT4, BOBBIE UP, AC	000004	COMMUNITY #1	F	52	07/18/64
PATIENT5, WINONA UP, AC	000005	COMMUNITY #1	F	53	08/05/63
PATIENT6, DARLENE UP, AC 45.24	000006	COMMUNITY #1 SIG: 04/07/12	F	54	08/04/62
PATIENT7, JOYCE UP, AC	000007	COMMUNITY #1 COLO: 07/07/14 POV V76.51	F	57	06/27/59

Figure 2-44: Sample Patient List, Colorectal Cancer Screening

## 2.6.4 Comprehensive Cancer Screening

### GPRA Measure Description

Increase the proportion of patients ages 24 through 75 who received a comprehensive cancer screening.



## Denominators

*Active Clinical patients* ages 24 through 75 who are eligible for cervical cancer, breast cancer, and/or colorectal cancer screening. (GPRA Developmental Denominator)

- a. *Active Clinical female patients* ages 24 through 75.
- b. *Active Clinical male patients* ages 50 through 75.

## Numerators

Patients who have had all screenings for which they are eligible.

**Note:** This numerator does *not* include refusals. (GPRA Developmental Numerator)

- a. Female patients with cervical cancer, breast cancer, and/or colorectal cancer screening.
- b. Male patients with colorectal cancer screening.

## Logic Description

Age is calculated at the beginning of the Report Period.

*Cervical Cancer Screening definition:* To be eligible for this screening, patients must be female Active Clinical ages 24 through 64 and not have a documented history of hysterectomy. Patients must be at least 24 years of age at the beginning of the Report Period and less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Pap Smear documented in the past 3 years, or if the patient is 30 to 64 years of age, either a Pap Smear documented in the past 3 years or a Pap Smear and an HPV DNA documented in the past 5 years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Hysterectomy	51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200-58294, 58548, 58550-58554, 58570-58573, 58951, 58953-58954, 58956, 59135	<b>Procedure:</b> ICD-9: 68.4-68.9; ICD-10: 0UT9*ZZ <b>Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):</b> ICD-9: 618.5, 752.43, V88.01, V88.03; ICD-10: N99.3, Z12.72, Z90.710-Z90.712, Q51.5 <b>Women's Health:</b> Procedure called Hysterectomy.		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Pap Smear	88141-88154, 88160-88167, 88174-88175, G0123, G0124, G0141, G0143- G0145, G0147, G0148, P3000, P3001, Q0091	<b>Lab:</b> PAP SMEAR <b>POV:</b> ICD-9: V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, 795.0*; ICD-10: R87.61*, R87.810, R87.820, Z01.42, Z12.4 <b>Women's Health:</b> Procedure called Pap Smear and where the result does NOT have "ERROR/DISREGARD"	Yes	BGP PAP SMEAR TAX
HPV DNA <b>Note:</b> CRS will only search for a documented HPV DNA if the patient had a Pap Smear 3 to 5 years ago.	87620-87622	<b>Lab:</b> HPV <b>POV:</b> ICD-9: V73.81, 079.4, 796.75, 795.05, 795.15, 796.79, 795.09, 795.19; ICD-10: B97.7, R85.618, R85.81, R85.82, R87.628, R87.810, R87.811, R87.820, R87.821, Z11.51 <b>Women's Health:</b> Procedure called HPV Screen and where the result does NOT have "ERROR/DISREGARD"; Procedure called Pap Smear and where the HPV field equals Yes	Yes	BGP HPV TAX

*Breast Cancer Screening definition:* To be eligible for this screening, patients must be female Active Clinical ages 52 through 64 and not have a documented history ever of bilateral mastectomy or two separate unilateral mastectomies. Patients must be at least age 52 as of the beginning of the Report Period and must be less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Mammogram documented in the past 2 years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes
Bilateral Mastectomy	19300.50-19307.50 or old code 19180, 19200, 19220 <b>OR</b> 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral) <b>OR</b> 19240, with modifier of 50 or 09950	<b>Procedure: ICD-9:</b> 85.42, 85.44, 85.46, 85.48; ICD-10: 0HTV0ZZ

Subject Defined	CPT Codes	ICD and Other Codes
Unilateral Mastectomy	Must have 2 separate occurrences on either 2 different dates of service or on the same date of service if the codes include both a right side modifier (RT) and left side modifier (LT). 19300-19307, or old codes 19180, 19200, 19220, 19240	<b>Procedure:</b> Must have 2 separate occurrences on 2 different dates of service. ICD-9: 85.41, 85.43, 85.45, 85.47; ICD-10: 07T50ZZ, 07T60ZZ, 07T70ZZ, 07T80ZZ, 07T90ZZ, 0HTT0ZZ, 0HTU0ZZ, 0KTH0ZZ, 0KTJ0ZZ
Mammogram	<b>Rad or CPT:</b> 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	<b>POV:</b> ICD-9: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast; ICD-10: R92.0, R92.1, R92.8, Z12.31 <b>Procedure:</b> ICD-9: 87.36-87.37; ICD-10: BH00ZZZ, BH01ZZZ <b>Women's Health:</b> Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD".

*Colorectal cancer screening definition:* To be eligible for this screening, patients must be Active Clinical ages 50 through 75 and not have a documented history ever of colorectal cancer or total colectomy. To be counted as having the screening, patients must have had any of the following: (1) FOBT or FIT during the Report Period; (2) flexible sigmoidoscopy or double contrast barium enema in the past 5 years; or (3) colonoscopy in the past 10 years.

The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Colorectal Cancer	G0213 through G0215, G0231	<b>POV:</b> ICD-9: 153.*, 154.0, 154.1, 197.5, V10.05; ICD-10: C18.*, C19, C20, C78.5, Z85.030, Z85.038		
Total Colectomy	44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210-44212	<b>Procedure:</b> ICD-9: 45.8*; ICD-10: 0DTE*ZZ		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Fecal Occult Blood lab test (FOBT) or Fecal Immuno-chemical Test (FIT)	82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)		Yes	BGP GPRA FOB TESTS
Flexible Sigmoidoscopy	45330 through 45345, G0104	<b>Procedure:</b> ICD-9: 45.24; ICD-10: 0DJD8ZZ		
Colonoscopy	44388 through 44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121, G9252, G9253	<b>Procedure:</b> ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5K8ZZ, 0D5L4ZZ, 0D5L8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5N4ZZ, 0D5N8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E8ZX, 0D9F3ZX, 0D9F4ZX, 0D9F7ZX, 0D9F8ZX, 0D9G3ZX, 0D9G4ZX, 0D9G7ZX, 0D9G8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9K3ZX, 0D9K4ZX, 0D9K7ZX, 0D9K8ZX, 0D9L3ZX, 0D9L4ZX, 0D9L7ZX, 0D9L8ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9N3ZX, 0D9N4ZX, 0D9N7ZX, 0D9N8ZX, 0DBE3ZX, 0DBE4ZX, 0DBE7ZX, 0DBE8ZX, 0DBE8ZZ, 0DBF3ZX, 0DBF4ZX, 0DBF7ZX, 0DBF8ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG4ZX, 0DBG7ZX, 0DBG8ZX, 0DBG8ZZ, 0DBH3ZX, 0DBH4ZX, 0DBH7ZX, 0DBH8ZX, 0DBH8ZZ, 0DBK3ZX, 0DBK4ZX, 0DBK7ZX, 0DBK8ZX, 0DBK8ZZ, 0DBL3ZX, 0DBL4ZX, 0DBL7ZX, 0DBL8ZX, 0DBL8ZZ, 0DBM3ZX, 0DBM4ZX, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBN3ZX, 0DBN4ZX, 0DBN7ZX, 0DBN8ZX, 0DBN8ZZ, 0DJD8ZZ		

### Key Logic Changes from CRS Version 15.1

1. Removed LOINC code 6138-2 from BPG HPV LOINC CODES taxonomy.
2. Added codes 74763-4, 74777-4, 75406-9, 75664-3, 75694-0, 75695-7, 75696-5, 77375-4, 77377-0, 77379-6, 77380-4, 77394-5, 77395-2, 77396-0, 77399-4, 77400-0 to BPG HPV LOINC CODES taxonomy.

**Patient List Description**

List of patients 25 through 75 with comprehensive cancer screening, if any.

**Measure Source**

Not Available

**Measure Past Performance and Long-Term Targets**

None

**Performance Improvement Tip**

- Providers should ask about and record off-site Pap tests (date received and location) on PCC forms. Data entry mnemonic: HPAP
- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.
- Providers should ask about and record off-site historical colorectal cancer tests (test type, date received and location) on PCC forms. Data entry mnemonics: HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG (sigmoidoscopy).

DU	November 25, 2016						Page 87		
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Comprehensive Cancer Screening									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical 24-75 (GPRA Dev.)	721		509			424			
# w/ Comprehensive Cancer Screening-No Refusals (GPRA Dev.)	226	31.3	195	38.3	-7.0	153	36.1	-4.7	
A. Female 24-75	570		416			359			
A. # Female w/all Screens	199	34.9	177	42.5	-7.6	144	40.1	-5.2	
B. Male 50-75	151		93			65			
B. # Male w/CRC									

Screen	27	17.9	18	19.4	-1.5	9	13.8	+4.0
--------	----	------	----	------	------	---	------	------

Figure 2-45: Sample Report, Comprehensive Cancer Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Comprehensive Cancer Screening: List of patients 21-80 with comprehensive cancer screening, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, DANIELLE AC, PAP	000001	COMMUNITY #1 PAP: 05/05/15	F	21	06/05/95
PATIENT2, MARIE AC, PAP	000002	COMMUNITY #1	F	51	11/20/65
PATIENT3, MARY ANN AC, PAP, MAM, CRCS	000003	COMMUNITY #1 PAP: 06/12/16 Lab; MAM: 07/06/15	F	52	08/15/64
03/16/11 Proc 45.22					
PATIENT4, BOBBIE AC, CRCS	000004	COMMUNITY #1 CRCS: 07/20/16	F	53	04/04/63
PATIENT5, WINONA AC, MAM	000005	COMMUNITY #1 MAM: 10/01/15	F	57	01/18/59
PATIENT6, HARRY AC, CRCS	000006	COMMUNITY #1 CRCS: 04/07/12	M	56	05/09/60
PATIENT7, LARRY AC, CRCS	000007	COMMUNITY #1	M	57	06/17/59
PATIENT8, BARRY AC, CRCS	000008	COMMUNITY #1 CRCS: 02/18/16	M	63	10/22/53

Figure 2-46: Sample Patient List, Comprehensive Cancer Screening

## 2.6.5 Tobacco Use and Exposure Assessment

### Denominators

*Active Clinical patients* ages 5 and older. Broken down by gender and age groups (5 through 13, 14 through 17, 18 through 24, 25 through 44, 45 through 64, and 65 and older), based on HP 2010 age groups.

*All pregnant female User Population patients* with no documented miscarriage or abortion.

*All User Population patients* ages 5 and older. Broken down by gender.

### Numerators

Patients who have been screened for tobacco use during the Report Period.

Patients identified as current tobacco users during the Report Period, both smokers and smokeless users.

- a. Patients identified as current smokers during the Report Period.
- b. Patients identified as current smokeless tobacco users during the Report Period.

Patients identified as exposed to environmental tobacco smoke (ETS) (second-hand smoke) during the Report Period.

### **Logic Description**

Ages are calculated at beginning of Report Period.

For screening, an additional eight months is included for patients who were pregnant during the Report Period but who had their tobacco assessment prior to that.

CRS uses the following codes to define the denominators and numerators:

Subject Defined	CPT Codes	ICD and Other Codes
<p>Pregnancy (At least two visits during the past 20 months, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.) An additional 8 months is included for patients who were pregnant during the Report period but who had their tobacco assessment prior to that.</p>	<p><b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828</p>	<p><b>POV:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36</p> <p><b>Procedure:</b> ICD-9: 72.*, 73.*, 74.*</p>
<p>Miscarriage (after second pregnancy POV in past 20 months)</p>	<p>59812, 59820, 59821, 59830</p>	<p><b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9</p>



Subject Defined	CPT Codes	ICD and Other Codes
Abortion (after second pregnancy POV in past 20 months)	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267	<b>POV:</b> ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 <b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0**, 3E1K78Z, 3E1K88Z
Screened for Tobacco Use (time frame for pregnant patients is past 20 months)	D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8453 (old code), G8455- G8457 (old codes), G8402 (old code), G9275, G9276, 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non- User), 1000F (Tobacco Use Assessed)	<b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z72.0, Z87.891 <b>Patient Education codes:</b> Containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, or SNOMED codes 160603005, 160604004, 160605003, 160606002, 160619003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005 <b>Dental code:</b> 1320
Tobacco Users (time frame for pregnant patients is past 20 months)	99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276	<b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2*0, F17.2*3, F17.2*8, F17.2*9, O99.33*, Z72.0 <b>Dental code:</b> 1320
Current Smokers (time frame for pregnant patients is past 20 months)	99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), G8455 (old code), G8402 (old code), G8453 (old code)	<b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.200, F17.203-F17.210, F17.213-F17.290, F17.293-F17.299, O99.33* <b>Dental code:</b> 1320
Current Smokeless (time frame for pregnant patients is past 20 months)	1035F (Current Smokeless Tobacco User), G8456 (old code)	<b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD- 10: F17.220, F17.223-F17.229

For numerator definitions, all existing national Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS–CHEWING/DIP), and TOBACCO (EXPOSURE) Health Factors are listed below with the numerator to which they apply.

Health Factor	Numerator
Ceremonial	Screened (does NOT count as Smoker)
Cessation-Smokeless	Screened; Tobacco Users; Smokeless User
Cessation-Smoker	Screened; Tobacco Users; Smoker
Current Smokeless	Screened; Tobacco Users; Smokeless User
Current Smoker	Screened; Tobacco Users; Smoker
Current Smoker, status unknown	Screened; Tobacco Users; Smoker
Current smoker, every day	Screened; Tobacco Users; Smoker
Current smoker, some day	Screened; Tobacco Users; Smoker
Heavy Tobacco Smoker	Screened; Tobacco Users; Smoker
Light Tobacco Smoker	Screened; Tobacco Users; Smoker
Non-Tobacco User	Screened
Previous Smokeless	Screened
Previous (Former) Smokeless	Screened
Previous Smoker	Screened
Previous (Former) Smoker	Screened
Smoke Free Home	Screened
Smoker In Home	Screened; ETS
Current Smoker & Smokeless	Screened; Tobacco Users; Smoker; Smokeless User
Exposure To Environmental Tobacco Smoke	Screened; ETS

### Key Logic Changes from CRS Version 15.1

1. Removed POV codes 674.\*3, 675.\*3, 676.\*3 from pregnancy definition.
2. Added POV codes V24.\*, V27.\* to pregnancy definition.
3. Added Procedure codes 72.\*, 73.\*, 74.\* to pregnancy definition.
4. Added CPT codes 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 to pregnancy definition.
5. Added SNOMED codes to Patient Education for Tobacco Screening.

### Patient List Description

List of patients 5 and older with documented tobacco screening, if any.

**Measure Source**

HP 2020 TU-1.1 Cigarette smoking 18 and older; TU-1.2 Smokeless tobacco use 18 and older; TU-11 Exposure to ETS-nonsmokers 3 and older

**Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2015 Performance (Screening)	67.5%
IHS FY 2014 Performance (Screening)	67.3%
IHS FY 2013 Performance (Screening)	66.6%
IHS FY 2012 Performance (Screening)	64.3%
IHS FY 2011 Performance (Screening)	62.0%
IHS FY 2010 Performance (Screening)	60.0%
IHS FY 2009 Performance (Screening)	57.0%
IHS FY 2008 Performance (Screening)	54.0%
IHS FY 2005 Performance (Screening)	34.0%
IHS FY 2004 Performance (Screening)	27.0%

Performance	Percent
IHS FY 2015 Performance (Tobacco Users)	27.4%
IHS FY 2014 Performance (Tobacco Users)	28.1%
IHS FY 2013 Performance (Tobacco Users)	28.6%
IHS FY 2012 Performance (Tobacco Users)	30.7%
IHS FY 2011 Performance (Tobacco Users)	31.6%
IHS FY 2010 Performance (Tobacco Users)	27.0%
IHS FY 2009 Performance (Tobacco Users)	26.0%
IHS FY 2008 Performance (Tobacco Users)	29.0%
<i>HP 2020 Goals: TU-1.1 (Cigarette smoking 18 and older): 12%; TU-1.2 (Smokeless tobacco use 18 and older): 0.3%; TU-11 (Exposure to ETS-non smokers 18 and older): 68%</i>	

DU	November 25, 2016	Page 90
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		
Baseline Period: Jan 01, 2010 to Dec 31, 2010		
-----		
Tobacco Use and Exposure Assessment (con't)		
REPORT	%	PREV YR % CHG from BASE % CHG from

	PERIOD		PERIOD		PREV YR % PERIOD		BASE %	
%	PREV YR	% CHG from	BASE	% CHG from	PREV YR % PERIOD	BASE %		
		PERIOD	PERIOD	PERIOD				
# Active Clinical Pts => 5		1,357		1,031			911	
# w/Tobacco Screening		624	46.0	426	41.3	+4.7	328	36.0 +10.0
# Tobacco Users w/ % of Total Screened		294	47.1	165	38.7	+8.4	130	39.6 +7.5
A. # Smokers w/ % of Total Tobacco Users		277	94.2	164	99.4	-5.2	130	100.0 -5.8
B. # Smokeless Tobacco Users w/ % of Total Tobacco Users		29	9.9	5	3.0	+6.8	3	2.3 +7.6
# exposed to ETS/ smoker in home w/ % of Total Screened		4	0.6	2	0.5	+0.2	1	0.3 +0.3
# Male Active Clinical ages => 5		570		430			374	
# w/Tobacco Screening		230	40.4	152	35.3	+5.0	128	34.2 +6.1
# Tobacco Users w/ % of Total Screened		136	59.1	69	45.4	+13.7	59	46.1 +13.0
A. # Smokers w/ % of Total Tobacco Users		124	91.2	69	100.0	-8.8	59	100.0 -8.8
B. # Smokeless Tobacco Users w/ % of Total Tobacco Users		22	16.2	2	2.9	+13.3	3	5.1 +11.1
# exposed to ETS/ smoker in home w/ % of Total Screened		1	0.4	0	0.0	+0.4	1	0.8 -0.3
# Female Active Clinical ages => 5		787		601			537	
# w/Tobacco Screening		394	50.1	274	45.6	+4.5	200	37.2 +12.8
# Tobacco Users w/ % of Total Screened		158	40.1	96	35.0	+5.1	71	35.5 +4.6
A. # Smokers w/ % of Total Tobacco Users		153	96.8	95	99.0	-2.1	71	100.0 -3.2
B. # Smokeless Tobacco Users w/ % of Total Tobacco Users		7	4.4	3	3.1	+1.3	0	0.0 +4.4
# exposed to ETS/ smoker in home w/ % of Total Screened		3	0.8	2	0.7	+0.0	0	0.0 +0.8

Figure 2-47: Sample Report, Tobacco Use Assessment Tobacco Use and Exposure Assessment

DEMO INDIAN HOSPITAL						
Report Period: Jan 01, 2016 to Dec 31, 2016						
Previous Year Period: Jan 01, 2015 to Dec 31, 2015						
Baseline Period: Jan 01, 2010 to Dec 31, 2010						
-----						
Tobacco Use and Exposure Assessment (con't)						
	TOTAL ACTIVE CLINICAL POPULATION					
	Age Distribution					
	5-13	14-17	18-24	25-44	45-64	65 and older
CURRENT REPORT PERIOD						
# Active Clinical	171	74	177	448	371	116
# w/Tobacco Screening	10	19	102	243	199	51
% w/Tobacco Screening	5.8	25.7	57.6	54.2	53.6	44.0
# Tobacco Users	3	8	46	118	104	15
% Tobacco Users w/ % of Total Screened	30.0	42.1	45.1	48.6	52.3	29.4
# Smokers	2	8	43	108	102	14
% Smokers w/ % of Total Tobacco Users	66.7	100.0	93.5	91.5	98.1	93.3
# Smokeless	1	0	3	15	8	2
% Smokeless w/ % of Total Tobacco Users	33.3	0.0	6.5	12.7	7.7	13.3
# ETS/Smk Home	0	0	0	3	1	0
% ETS/Smk Home w/ % of Total Screened	0.0	0.0	0.0	1.2	0.5	0.0
PREVIOUS YEAR PERIOD						
# Active Clinical	176	62	168	323	238	64
# w/Tobacco Screening	11	14	87	147	128	39
% w/Tobacco Screening	6.3	22.6	51.8	45.5	53.8	60.9
# Tobacco Users	0	5	41	60	50	9
% Tobacco Users w/ % of Total Screened	0.0	35.7	47.1	40.8	39.1	23.1
# Smokers	0	5	40	60	50	9
% Smokers w/ % of Total Tobacco Users	0.0	100.0	97.6	100.0	100.0	100.0
# Smokeless	0	0	1	3	1	0
% Smokeless w/ % of Total Tobacco Users	0.0	0.0	2.4	5.0	2.0	0.0
# ETS/Smk Home	0	0	0	2	0	0
% ETS/Smk Home w/ % of Total Screened	0.0	0.0	0.0	1.4	0.0	0.0
CHANGE FROM PREV YR %						
# w/Tobacco Screening	-0.4	+3.1	+5.8	+8.7	-0.1	-17.0
Tobacco Users	+30.0	+6.4	-2.0	+7.7	+13.2	+6.3
Smokers	+66.7	+0.0	-4.1	-8.5	-1.9	-6.7
Smokeless	+33.3	+0.0	+4.1	+7.7	+5.7	+13.3

ETS	+0.0	+0.0	+0.0	-0.1	+0.5	+0.0
-----	------	------	------	------	------	------

Figure 2-48: Sample Age Breakdown Report, Tobacco Use Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Tobacco Use and Exposure Assessment: List of patients 5 and older with documented tobacco screening, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,CHESTER UP,AC	000001	COMMUNITY #1 01/10/16 SCREEN	M	7	06/05/09
PATIENT2,JUAN UP	000002	COMMUNITY #1	M	19	07/07/97
PATIENT3,BEN UP	000003	COMMUNITY #1	M	22	05/18/94
PATIENT4,MARY UP,AC,PREG	000004	COMMUNITY #2 04/10/16 SCREEN,	F	35	03/31/81 04/10/16 USER, 04/10/16 SMOKELESS
PATIENT5,HARRY B UP	000005	COMMUNITY #2 03/15/16 SCREEN	M	13	09/02/03
PATIENT6,EMERSON UP,AC	000006	COMMUNITY #2 05/21/16 SCREEN,	M	15	11/19/01 05/21/16 USER, 05/21/16 SMOKER, 05/21/12 ETS
PATIENT7,EUGENE JAY UP	000007	COMMUNITY #3	M	29	05/18/87
PATIENT8,ROGER UP,AC	000008	COMMUNITY #3 01/21/16 SCREEN,	M	31	08/04/85 01/21/16 USER, 01/21/16 SMOKER
PATIENT9,ANDREW UP	000009	COMMUNITY #3	M	42	09/15/74

Figure 2-49: Sample Patient List, Tobacco Use Assessment

## 2.6.6 Tobacco Cessation

### GPRA Measure Description

During GPRA Year 2016, achieve the target rate of 49.1% for the proportion of tobacco-using patients who receive tobacco cessation intervention or quit tobacco use.

### Denominators

*Active Clinical patients* identified as current tobacco users or tobacco users in cessation. Broken down by gender and age groups. (GPRA Denominator)

*User Population patients* identified as current tobacco users or tobacco users in cessation.

## Numerators

Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid anytime during the Report Period.

**Note:** This numerator does *not* include refusals.

Patients identified as having quit their tobacco use anytime during the Report Period.

Patients who received tobacco cessation counseling, received a prescription for a tobacco cessation aid, or quit their tobacco use anytime during the Report Period.  
(GPRA Numerator)

**Note:** This numerator does *not* include refusals.

## Logic Description

Age is calculated at the beginning of the Report Period.

## Denominator Logic

Current Tobacco Users or Tobacco Users in Cessation:

CRS will search first for all health factors in the Tobacco, TOBACCO (SMOKING) and TOBACCO (SMOKELESS – CHEWING/DIP) categories documented during the Report Period.

If health factor(s) are found and at least one of them is one of the health factors listed below, the patient is counted as a current tobacco user or tobacco user in cessation. The patient is not counted as receiving cessation counseling.

Tobacco User Health Factors (TUHF):

- Cessation-Smoker
- Cessation-Smokeless
- Current Smoker
- Current Smokeless
- Current Smoker and Smokeless
- Current Smoker, status unknown
- Current Smoker, every day
- Current Smoker, some day
- Heavy Tobacco Smoker

- Light Tobacco Smoker

If a health factor is found and it is NOT a TUHF, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a tobacco user.

If no TUHF was found, CRS will then search for any of the following codes documented during the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2\*0, F17.2\*3, F17.2\*8, F17.2\*9, O99.33\*, Z72.0.
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276.

If any of these codes are found, the patient will be considered a tobacco user.

If no TUHF or other tobacco user-defining code listed above was found during the specified timeframe, CRS will then search for the most recent health factor documented during an EXPANDED timeframe of any time prior to the report period. For example, a patient with the most recent health factor being documented 5 years prior to the report period.

**Note:** If multiple health factors were documented on the same date and if any of them are TUHFs, all of the health factors will be considered as TUHFs.

If a health factor is found during the expanded timeframe, and is a TUHF, the patient will be considered a potential tobacco user.

If a health factor is found during the expanded timeframe and it is not one of the TUHFs, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a potential tobacco user.

If no health factor was found, CRS will then search for any of the following codes documented through the beginning of the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2\*0, F17.2\*3, F17.2\*8, F17.2\*9, O99.33\*, Z72.0.



- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276.

If any of these codes are found, the patient will be considered a potential tobacco user. If one of these codes is not found, the patient is considered a non-tobacco user and will not be included in the denominator.

If the patient is considered a potential tobacco user, CRS will then search for diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2\*1, Z87.891 with a date occurring after the health factor date and through the beginning of the report period. If one of these diagnoses is found, the patient will be considered as having quit their tobacco use and will not be included in the denominator. If a diagnosis is not found, the patient is included as a current tobacco user and will be included in the denominator.

## Numerator Logic

### Tobacco Cessation Counseling

Any of the following documented anytime during the Report Period:

- Patient education codes containing "TO-", "-TO", "-SHS", 305.1, 305.1\* (old codes), 649.00-649.04, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402, G8453, or SNOMED codes 160603005, 160604004, 160605003, 160606002, 160619003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005
- Clinic code 94 (tobacco cessation clinic)
- Dental code 1320
- CPT code D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 or G8453

### Prescription for Tobacco Cessation Aid

Any of the following documented anytime during the Report Period:

- Prescription for medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy that does not have a comment of RETURNED TO STOCK.

- Prescription for any medication with name containing “NICOTINE PATCH”, “NICOTINE POLACRILEX”, “NICOTINE INHALER”, or “NICOTINE NASAL SPRAY” that does not have a comment of RETURNED TO STOCK.
- CPT 4001F

### Quit Tobacco Use

Any of the following documented anytime during the Report Period through the end of the Report Period AND after the date of the code found indicating the patient was a current tobacco user.

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2\*1, Z87.891
- Health Factor (looks at the last documented health factor): Previous Smoker, Previous Smokeless, Previous (former) smoker, Previous (former) smokeless

### Key Logic Changes from CRS Version 15.1

1. Added SNOMED codes to Patient Education for Tobacco Cessation Counseling.

### Patient List Description

List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use.

### Measure Source

Smoking Cessation Attempts: HP 2020 TU-4

Smoking Cessation Counseling: HP 2020 TU-10

### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2015 Performance	52.1%
IHS FY 2014 Performance	48.2%
IHS FY 2013 Performance	45.7%
IHS FY 2012 Performance	36.4%
<i>Former definition:</i>	
IHS FY 2012 Performance	35.2%
IHS FY 2011 Performance	29.4%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	24.0%

Performance	Percent
IHS FY 2008 Performance	21.0%
IHS FY 2007 Performance	16.0%
IHS FY 2006 Performance	12.0%
<i>HP 2020 goal for increasing smoking cessation attempts for adult smokers</i>	80.0%

DU November 25, 2016 Page 101  
 \*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*  
 DEMO INDIAN HOSPITAL  
 Report Period: Jan 01, 2016 to Dec 31, 2016  
 Previous Year Period: Jan 01, 2015 to Dec 31, 2015  
 Baseline Period: Jan 01, 2010 to Dec 31, 2010

---

Tobacco Cessation (con't)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Tobacco Users/In Cessation (GPRA)	499		308			230		
# w/tobacco cessation counseling or RX for cessation aid								
-No Refusals	120	24.0	72	23.4	+0.7	69	30.0	-6.0
# who quit	12	2.4	2	0.6	+1.8	1	0.4	+2.0
# w/tobacco cessation counseling, Rx for cessation aid, or quit-No Refusals (GPRA)	131	26.3	73	23.7	+2.6	70	30.4	-4.2
Male Active Clinical Tobacco Users/In Cessation	227		147			115		
# w/tobacco cessation counseling, or RX for cessation aid-								
No Refusals	64	28.2	35	23.8	+4.4	40	34.8	-6.6
# who quit	5	2.2	2	1.4	+0.8	1	0.9	+1.3
# w/tobacco cessation counseling, Rx or cessation aid, or quit-								
No Refusals	69	30.4	36	24.5	+5.9	41	35.7	-5.3
Female Active Clinical Tobacco Users/In Cessation	272		161			115		
# w/tobacco cessation counseling, or RX for cessation aid-								
No Refusals	56	20.6	37	23.0	-2.4	29	25.2	-4.6
# who quit	7	2.6	0	0.0	+2.6	0	0.0	+2.6
# w/tobacco cessation counseling, Rx for cessation aid, or quit-								
No Refusals	62	22.8	37	23.0	-0.2	29	25.2	-2.4

Figure 2-50: Sample Report, Tobacco Cessation

Tobacco Cessation (con't)			
ACTIVE CLINICAL TOBACCO USERS			
	Age Distribution		
	<12	12-17	=>18
CURRENT REPORT PERIOD			
AC Tob Users/in Cess	3	19	477
# w/tobacco cessation counseling or RX for cessation aid- No Refusals	1	3	116
% w/ tobacco cessation counseling or Rx for cessation aid- No Refusals	33.3	15.8	24.3
# who quit	0	1	11
% who quit	0.0	5.3	2.3
# w/tobacco cessation counseling, Rx for cessation aid or quit- No Refusals	1	4	126
% w/ tobacco cessation counseling, Rx for cessation aid or quit- No Refusals	33.3	21.1	26.4
PREVIOUS YEAR PERIOD			
AC Tob Users/in Cess	1	10	297
# w/tobacco cessation counseling or RX for cessation aid- No Refusals	0	2	70
% w/ tobacco cessation counseling or Rx for cessation aid- No Refusals	0.0	20.0	23.6
# who quit	0	0	2
% who quit	0.0	0.0	0.7
# w/tobacco cessation counseling, Rx for cessation aid or quit- No Refusals	0	2	71
% w/ tobacco cessation counseling, Rx for cessation aid or quit- No Refusals	0.0	20.0	23.9
CHANGE FROM PREV YR %			
w/tobacco cessation counseling or RX for cessation aid- No Refusals	+33.3	-4.2	+0.7
# who quit	+0.0	+5.3	+1.6
# w/tobacco cessation counseling, Rx for cessation aid or quit- No Refusals	+33.3	+1.1	+2.5

Figure 2-51: Sample Age Breakdown Report, Tobacco Cessation

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic

PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
HR=High Risk Patient

Tobacco Cessation: List of tobacco users with tobacco cessation intervention,  
if any, or who have quit tobacco use.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, BRITNEY UP, AC	000001	COMMUNITY #1 COUNSEL/RX: 06/10/16 CPT G0375	F	22	08/04/94
PATIENT2, LORETTA UP, AC	000002	COMMUNITY #1 COUNSEL/RX: 01/13/16 305.1-DP	F	22	09/19/94
PATIENT3, HALEY UP, AC	000003	COMMUNITY #1 COUNSEL/RX: 02/19/16 TO-LA	F	25	04/01/91
PATIENT4, ANGEL UP, AC	000004	COMMUNITY #1 COUNSEL/RX: 03/05/16 CPT 4000F	F	30	06/15/86
PATIENT5, JOYCE UP, AC	000005	COMMUNITY #1 QUIT: PREVIOUS (FORMER) SMOKER 05/31/16	F	31	05/22/85
PATIENT6, ESTHER UP, AC TRANSDERMAL PATCH	000006	COMMUNITY #1 COUNSEL/RX: 03/05/16 CESSATION MED - NICOTINE 14MG	F	32	09/23/84
PATIENT7, SARAH UP, AC	000007	COMMUNITY #1	F	33	06/15/83
PATIENT8, PAULA UP, AC	000008	COMMUNITY #1 COUNSEL/RX: 03/17/16 TO-QT	F	34	07/04/82

Figure 2-52: Sample Patient List Tobacco Cessation

## 2.7 Behavioral Health Related Performance Measure Topics

### 2.7.1 Alcohol Screening (FAS Prevention)

#### **GPRA Measure Description**

During GPRA Year 2016, establish a baseline for the proportion of female patients ages 14 to 46 who receive screening for alcohol use.

#### **Denominators**

*Female Active Clinical patients ages 14 to 46. (GPRA Denominator)*

*Female Active Clinical patients ages 14 to 46 screened for alcohol use during the Report Period.*

**Note:** This denominator does *not* include patients with a screening refusal or an alcohol-related diagnosis, procedure, or patient education.

*Female User Population patients ages 14 to 46.*

## Numerators

Patients screened for alcohol use, had an alcohol-related diagnosis or procedure, or received alcohol-related patient education during the report period.

**Note:** This numerator does *not* include refusals. (GPRA Numerator)

- a. Patients with alcohol screening during the report period.
- b. Patients with alcohol-related diagnosis or procedure during the report period
- c. Patients with alcohol-related patient education during the report period.

Patients who were screened positive for alcohol use.

## Logic Description

Ages are calculated at beginning of Report Period.

*Alcohol screening definition:* Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

Subject Defined	ICD and Other Codes
Alcohol Screening	<b>Exam Code:</b> 35 <b>CPT code:</b> 99408, 99409, G0396, G0397, H0049, H0050, 3016F <b>Any CAGE Health Factor</b> <b>POV:</b> ICD-9: V11.3 (history of alcoholism), V79.1 (screening for alcoholism) <b>BHS Problem Code:</b> 29.1 (Screening for Alcoholism) <b>Measurement in PCC or BHS:</b> AUDT, AUDC, or CRFT
Alcohol-related Diagnosis	<b>POV, Current PCC or BHS Problem List:</b> ICD-9: 303.*, 305.0*, 291.*, 357.5*; ICD-10: F10.1*, F10.20, F10.220-F10.29, F10.920-F10.982, F10.99, G62.1 <b>BHS POV or Problem Codes:</b> 10, 12.1, 14.2, 17.1, 18.1, 20.1, 22.1, 27, 29
Alcohol-related Procedure	<b>Procedure:</b> ICD-9: 94.46, 94.53, 94.61-94.63, 94.67-94.69

Subject Defined	ICD and Other Codes
Alcohol-related Education	<b>Patient Education codes:</b> "AOD-" or "-AOD", "CD-" or "-CD" (old codes), or containing V11.3, V79.1, 303.*, 305.0*, 291.* 357.5*, 99408, 99409, G0396, G0397, H0049, H0050, 3016F, or SNOMED codes 15167005, 18653004, 191471000, 191475009, 191476005, 191477001, 191478006, 191480000, 191802004, 191804003, 191805002, 191811004, 191812006, 191813001, 19303008, 281004, 284591009, 288281000119100, 29212009, 30491001, 34938008, 41083005, 42344001, 53936005, 61144001, 66590003, 7052005, 7200002, 73097000, 78524005, 79578000, 8635005
Positive Screen for Alcohol Use	<b>Exam Code:</b> 35 Alcohol Screening result of "Positive" <b>Health Factor:</b> CAGE result of 1/4, 2/4, 3/4 or 4/4 <b>CPT:</b> G0396, G0397, 99408, 99409 <b>Measurement Result in PCC:</b> AUDT result of greater than or equal to (=>) 8, AUDC result of greater than or equal to (=>) 4 for men and greater than or equal to (=>)3 for women, CRFT result of 2-6

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

### Recommended Brief Screening Tool

Single Alcohol Screening Question (SASQ) (below).

*For Women:*

When was the last time you had more than four drinks in one day?

*For Men:*

When was the last time you had more than five drinks in one day?

Any time in the past 3 months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

### Alcohol Health Factors

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

1. Have you ever felt the need to **C**ut down on your drinking?
2. Have people **A**nnoyed you by criticizing your drinking?
3. Have you ever felt bad or **G**uilty about your drinking?

4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?
5. Based on how many YES answers are received, document Health Factor:
  - HF-CAGE 0/4 (all “No” answers)
  - HF-CAGE 1/4
  - HF-CAGE 2/4
  - HF-CAGE 3/4
  - HF-CAGE 4/4

Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: # of drinks daily

### Key Logic Changes from CRS Version 15.1

1. Changed age range (including GPRA measure) to 14-46.
2. Added measure for those screened with a positive result.
3. Added SNOMED codes to Patient Education for alcohol-related patient education.

### Patient List Description

List of female patients with documented alcohol screening and result, if any.

### Measure Source

HP 2010 16–17a

### Measure Past Performance and Long-term Targets

Performance	Percent
IHS FY 2015 Performance	66.6%
IHS FY 2014 Performance	66.0%
IHS FY 2013 Performance	65.7%
IHS FY 2012 Performance	63.8%
IHS FY 2011 Performance	57.8%
IHS FY 2010 Performance	55.0%
IHS FY 2009 Performance	52.0%
IHS FY 2008 Performance	47.0%
IHS FY 2007 Performance	41.0%



Performance	Percent
IHS FY 2006 Performance	28.0%
IHS FY 2005 Performance	11.0%
IHS FY 2004 Performance	7.0%

DU November 25, 2016 Page 114

\*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2016 to Dec 31, 2016

Previous Year Period: Jan 01, 2015 to Dec 31, 2015

Baseline Period: Jan 01, 2010 to Dec 31, 2010

---

Alcohol Screening (FAS Prevention)

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Female Active Clinical ages 15-44 (GPRA)	434		348			304		
# w/ alcohol screening/Dx/Proc/Pt Ed								
-No Refusals (GPRA)	50	11.5	2	0.6	+10.9	1	0.3	+11.2
A. w/alcohol screening	43	9.9	1	0.3	+9.6	0	0.0	+9.9
B. # w/alcohol related Dx or procedure	3	0.7	1	0.3	+0.4	1	0.3	+0.4
C. # w/alcohol related patient education	10	2.3	0	0.0	+2.3	0	0.0	+2.3
Female User Population ages 15-44	725		636			588		
# w/ alcohol screening/Dx/Proc/Pt Ed								
-No Refusals	54	7.4	2	0.3	+7.1	2	0.3	+7.1
A. # w/alcohol screening	46	6.3	1	0.2	+6.2	0	0.0	+6.3
B. # w/alcohol related Dx or procedure	4	0.6	1	0.2	+0.4	2	0.3	+0.2
C. # w/alcohol related patient education	11	1.5	0	0.0	+1.5	0	0.0	+1.5

Figure 2-53: Sample Report, Alcohol Screening (FAS Prevention)

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Alcohol Screening (FAS Prevention): List of female patients with documented alcohol screening, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,CHRISTINE S UP	000001	COMMUNITY #1	F	15	05/25/01
PATIENT2,RITA A UP,AC POV V11.3	000002	COMMUNITY #1 SCREEN: 03/06/16	F	15	07/21/01
PATIENT3,DIANE L UP	000003	COMMUNITY #1	F	15	07/30/01
PATIENT4,ALICIA UP,AC	000004	COMMUNITY #1	F	15	10/22/01
PATIENT5,MELISSA UP,AC	000005	COMMUNITY #1 PT ED: 02/13/16 99408-P	F	16	03/11/00
PATIENT6,LISA MARIE UP,AC	000006	COMMUNITY #1 SCREEN: 10/13/16 HF CAGE 1/4	F	16	05/22/00
PATIENT7,RUTH NELLIE UP	000007	COMMUNITY #1	F	16	07/18/00
PATIENT8,ALISHA DAWN UP,AC	000008	COMMUNITY #1 SCREEN: 03/03/16 CPT 3016F	F	16	09/09/00

Figure 2-54: Sample Patient List, Alcohol Screening (FAS Prevention)

## 2.7.2 Screening, Brief Intervention, and Referral to Treatment (SBIRT)

### Denominators

*Active Clinical Plus BH patients ages 9 through 75.* Broken down by gender and age groups (9 through 12, 13 through 18, 19 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, and 65 through 75).

*Active Clinical Plus BH patients age 9 through 75 years screened positive for risky or harmful alcohol use during the Report Period.* Broken down by gender and age groups (9 through 12, 13 through 18, 19 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, and 65 through 75). (GPRA Developmental Denominator)

### Numerators

Patients screened in Ambulatory Care for risky or harmful alcohol use.

- a. Patients screened positive for risky or harmful alcohol use.
- b. Patients provided a brief negotiated interview (BNI) or Brief Intervention (BI) in Ambulatory care within 7 days of screen.

Patients provided a brief negotiated interview (BNI) or Brief Intervention (BI) in Ambulatory Care within 7 days of screen. (GPRA Developmental Numerator)

- a. Patients who received a BNI/BI on same day as screen.
- b. Patients who received a BNI/BI 1-3 days after screen.
- c. Patients who received a BNI/BI 4-7 days after screen.
- d. Patients who were referred treatment within 7 days of screen.

### Logic Description

Age of the patient is calculated as of the beginning of the Report Period.

Ambulatory Care definition: Service Category A (Ambulatory).

CRS uses the following codes:

Subject Defined	ICD and Other Codes
Screening for Risky or Harmful Alcohol Use	<p><i>Any conducted during an Ambulatory Care visit.</i></p> <p><b>Exam Code:</b> 35</p> <p><b>Any Alcohol Health Factor (i.e., CAGE)</b></p> <p><b>POV:</b> V79.1 Screening for Alcoholism</p> <p><b>CPT:</b> G0396, G0397, H0049, H0050, 99408 (old code), 99409 (old code), 3016F</p> <p><b>Measurement in PCC:</b> AUDT, AUDC, or CRFT</p>
Positive Screen for Hazardous Alcohol Use	<p><i>Any of the following for the screening conducted during an Ambulatory Care visit:</i></p> <p><b>Exam Code:</b> 35 Alcohol Screening result of "Positive"</p> <p><b>Health Factor:</b> CAGE result of 1/4, 2/4, 3/4 or 4/4</p> <p><b>CPT:</b> G0396, G0397, 99408, 99409</p> <p><b>Measurement Result in PCC:</b> AUDT result of greater than or equal to (=&gt;) 8, AUDC result of greater than or equal to (=&gt;) 4 for men and greater than or equal to (=&gt;)3 for women, CRFT result of 2-6</p>
Brief Negotiated Interview/Brief Intervention (BNI/BI)	<p><i>Any of the following documented at the Ambulatory Care visit or within 7 days of the Ambulatory Care visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:</i></p> <p><b>CPT:</b> G0396, G0397, H0050, 99408 (old code), 99409 (old code), 96150-96155</p> <p><b>Patient Education Code:</b> AOD-BNI or containing G0396, G0397, H0050, 99408, 99409, 96150-96155</p>
Referral to treatment	<p><b>Patient Education Code:</b> AOD-TX</p>

### Recommended Brief Screening Tool

SASQ (below).

*For Women:*

When was the last time you had more than four drinks in one day?

*For Men:*

When was the last time you had more than five drinks in one day?

Any time in the past 3 months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

### **Alcohol Health Factors**

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

1. Have you ever felt the need to **C**ut down on your drinking?
2. Have people **A**nnoyed you by criticizing your drinking?
3. Have you ever felt bad or **G**uilty about your drinking?
4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?

Based on how many YES answers are received, document Health Factor:

- HF-CAGE 0/4 (all No answers)
- HF-CAGE 1/4
- HF-CAGE 2/4
- HF-CAGE 3/4
- HF-CAGE 4/4

Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: number of drinks daily

### **Key Logic Changes from CRS Version 15.1**

New topic.

### **Patient List Description**

List of patients with screening for risky or harmful alcohol use, results of screen, BNI/BI, and referral, if any.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016						Page 117		
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Screening, Brief Intervention, and Referral to Treatment (SBIRT)									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
AC+BH Pts 9-75	1,651		1,719			1,685			
# w/ screening for alcohol use	289	17.5	954	55.5	-38.0	968	57.4	-39.9	
A. # w/ positive screen	83	5.0	219	12.7	-7.7	221	13.1	-8.1	
B. # w/ BNI/BI in 7 days of screen	10	0.6	3	0.2	+0.4	5	0.3	+0.3	
Male AC+BH Pts 9-75	741		794			796			
# w/ screening for alcohol use	122	16.5	392	49.4	-32.9	393	49.4	-32.9	
A. # w/ positive screen	45	6.1	133	16.8	-10.7	137	17.2	-11.1	
B. # w/ BNI/BI in 7 days of screen	6	0.8	2	0.3	+0.6	3	0.4	+0.4	
Female AC+BH Pts 9-75	910		925			889			
# w/ screening for alcohol use	167	18.4	562	60.8	-42.4	575	64.7	-46.3	
A. # w/ positive screen	38	4.2	86	9.3	-5.1	84	9.4	-5.3	
B. # w/ BNI/BI in 7 days of screen	4	0.4	1	0.1	+0.3	2	0.2	+0.2	

Figure 2-55: Sample Report, Screening, Brief Intervention, and Referral to Treatment (SBIRT)

DU	November 25, 2016						Page 95		
*** IHS 2016 Selected Measures with Community Specified Report ***									

DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Screening, Brief Intervention, and Referral to Treatment (SBIRT) (con't)								
AC+BH Pts 9-75								
Age Distribution								
	9-12	13-18	19-24	25-34	35-44	45-54	55-64	65-75
CURRENT REPORT PERIOD								
AC+BH Pts 9-75	174	205	232	319	210	224	191	96
# w/ screening for alcohol use	2	37	46	65	29	55	34	21
% w/ screening for alcohol use	1.1	18.0	19.8	20.4	13.8	24.6	17.8	21.9
A. # w/ positive screen	1	9	15	22	11	18	5	2
% A. w/ positive screen	0.6	4.4	6.5	6.9	5.2	8.0	2.6	2.1
B. # w/ BNI/BI in 7 days of screen	1	3	5	1	0	0	0	0
% B. w/ BNI/BI in 7 days of screen	0.6	1.5	2.2	0.3	0.0	0.0	0.0	0.0
PREVIOUS REPORT PERIOD								
AC+BH Pts 9-75	173	231	254	325	213	249	181	93
# w/ screening for alcohol use	15	116	120	205	142	159	128	69
% w/ screening for alcohol use	8.7	50.2	47.2	63.1	66.7	63.9	70.7	74.2
A. # w/ positive screen	2	14	35	59	41	44	19	5
% A. w/ positive screen	1.2	6.1	13.8	18.2	19.2	17.7	10.5	5.4
B. # w/ BNI/BI in 7 days of screen	0	2	0	1	0	0	0	0
% B. w/ BNI/BI in 7 days of screen	0.0	0.9	0.0	0.3	0.0	0.0	0.0	0.0
CHANGE FROM PREVIOUS YR %								
# w/ screening for alcohol use	-7.5	-32.2	-27.4	-42.7	-52.9	-39.3	-52.9	-52.3
A. # w/ positive screen	-0.6	-1.7	-7.3	-11.3	-14.0	-9.6	-7.9	-3.3
B. # w/ BNI/BI in 7 days of screen	+0.6	+0.6	+2.2	+0.0	+0.0	+0.0	+0.0	+0.0

Figure 2-56: Sample Age Breakdown Report, Screening, Brief Intervention, and Referral to Treatment (SBIRT)

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

SBIRT: List of patients with screening for risky or harmful alcohol use, results of screen, BNI/BI, and referral, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,DARLENE S AC+BH	000001	COMMUNITY #1	F	33	04/04/82
SCREEN: 03/01/13 CPT G0396 result=Pos; BNI: 03/01/13 Yes [0]; REFERRAL: No					
PATIENT2,RITA A AC+BH	000002	COMMUNITY #1	F	33	10/22/82
PATIENT3,DIANE L AC+BH	000003	COMMUNITY #1	F	15	06/02/00
PATIENT4,ALICIA AC+BH	000004	COMMUNITY #1	F	18	08/13/97
SCREEN: 02/27/13 HF CAGE 1/4 result=Pos; BNI: No; REFERRAL: No					
PATIENT5,MELISSA AC+BH	000005	COMMUNITY #1	F	16	03/01/99
SCREEN: 07/01/13 Meas AUDC result=Pos; BNI: No; REFERRAL: 07/06/13 Yes					
PATIENT6,LISA MARIE AC+BH	000006	COMMUNITY #1	F	20	06/02/95
SCREEN: 02/06/13 Ex 35; BNI: No;					

Figure 2-57: Sample Patient List, Screening, Brief Intervention, and Referral to Treatment (SBIRT)

## 2.7.3 Intimate Partner (Domestic) Violence Screening

### GPRA Measure Description

During GPRA Year 2016, establish a baseline for the proportion of female patients ages 14 to 46 who receive screening for domestic violence.

#### Denominators

*Female Active Clinical patients ages 13 and older.*

*Female Active Clinical patients ages 14 through 46. (GPRA Denominator)*

*Female User Population patients ages 13 and older.*

*Female User Population patients ages 14 through 46.*

#### Numerators

Patients screened for intimate partner (domestic) violence at any time during the Report Period.

**Note:** This numerator does *not* include refusals. (GPRA Numerator)

- a. Patients with documented IPV/DV exam
- b. Patients with IPV/DV related diagnosis
- c. Patients provided with education or counseling about IPV/DV

### Logic Description

Age of the patient is calculated at the beginning of the report period. CRS uses the following codes to define numerators.

Subject Defined	CPT Codes	ICD and Other Codes
IPV/DV Screening		<b>Exam:</b> Code 34 <b>BHS Exam:</b> IPV/DV
IPV/DV Diagnosis		<b>POV or current PCC or BHS Problem List:</b> <b>ICD-9:</b> 995.80-995.83, 995.85, V15.41, V15.42, V15.49; <b>ICD-10:</b> T74.11XA, T74.21XA, T74.31XA, T74.91XA, T76.11XA, T76.21XA, T76.31XA, T76.91XA, Z91.410 <b>BHS POV:</b> 43.*, 44.*
IPV/DV Education		<b>Patient education codes:</b> Containing "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, V15.49, or SNOMED 3027571011, 3027627017, 371772001, 406138006, 412732008, 429746005, 431027007, 432527004
IPV/DV Counseling		<b>POV:</b> <b>ICD-9:</b> V61.11; <b>ICD-10:</b> Z69.11

### Key Logic Changes from CRS Version 15.1

1. Changed age range (including GPRA measure) to 14-46.
2. Added SNOMED codes to Patient Education for IPV/DV patient education.

### Patient List Description

List of female patients 13 and older with documented IPV/DV screening, if any.

### Measure Source

HP 2010 15–34

### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2015 Performance	63.6%
IHS FY 2014 Performance	63.5%
IHS FY 2013 Performance	62.4%
IHS FY 2012 Performance	61.5%



Performance	Percent
IHS FY 2011 Performance	55.3%
IHS FY 2010 Performance	53.0%
IHS FY 2009 Performance	48.0%
IHS FY 2008 Performance	42.0%
IHS FY 2007 Performance	36.0%
IHS FY 2006 Performance	28.0%
IHS FY 2005 Performance	13.0%
IHS FY 2004 Performance	4.0%

DU	November 25, 2016						Page 128	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Intimate Partner (Domestic) Violence Screening (con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# Female Active Clinical ages 13 and older	712		519			460		
# w/IPV/DV Screening								
-No Refusals	13	1.8	1	0.2	+1.6	0	0.0	+1.8
A. # w/documented IPV/DV exam	8	1.1	0	0.0	+1.1	0	0.0	+1.1
B. # w/ IPV/DV related diagnosis	4	0.6	0	0.0	+0.6	0	0.0	+0.6
C. # provided DV education	4	0.6	1	0.2	+0.4	0	0.0	+0.6
# Female Active Clinical ages 15-40 (GPRA)	380		311			267		
# w/IPV/DV screening -No Refusals (GPRA)	11	2.9	1	0.3	+2.6	0	0.0	+2.9
A. # w/ documented IPV/DV exam	6	1.6	0	0.0	+1.6	0	0.0	+1.6
B. # w/ IPV/DV related diagnosis	3	0.8	0	0.0	+0.8	0	0.0	+0.8
C. # provided DV education	4	1.1	1	0.3	+0.7	0	0.0	+1.1
# Female User Pop 13 and older	1,218		1,005			917		

# w/IPV/DV Screening								
-No Refusals	13	1.1	1	0.1	+1.0	1	0.1	+1.0
A. # w/ documented								
IPV/DV exam	8	0.7	0	0.0	+0.7	0	0.0	+0.7
B. # w/ IPV/DV related								
diagnosis	4	0.3	0	0.0	+0.3	1	0.1	+0.2
C. # provided DV								
education	4	0.3	1	0.1	+0.2	0	0.0	+0.3

Figure 2-58: Sample Report, Intimate Partner (Domestic) Violence Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Intimate Partner (Domestic) Violence Screening: List of female patients  
 13 and older with documented IPV/DV screening, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, ELVIRA UP	000001	COMMUNITY #1 EXAM: 03/18/16	F	13 Ex 34	08/03/03
PATIENT2, SHARON KAY UP	000002	COMMUNITY #1	F	14	05/04/02
PATIENT3, KRISTINA UP	000003	COMMUNITY #1	F	15	06/06/01
PATIENT4, RITA UP, AC	000004	COMMUNITY #1 EXAM: 05/06/16	F	15 Ex 34	10/24/01
PATIENT5, DIANE LOUISE UP	000005	COMMUNITY #1 EXAM: 02/24/16	F	15 Ex 34	11/18/01
PATIENT6, ALICE LILA UP, AC	000006	COMMUNITY #1	F	15	12/27/01

Figure 2-59: Sample Patient List, Intimate Partner (Domestic) Violence Screening

## 2.7.4 Depression Screening

### GPRAMA Measure Description

During GPRA Year 2016, achieve the target rate of 67.2% for the proportion of adults ages 18 and older who receive annual screening for depression.

#### Denominators

*Active Clinical patients* ages 18 and older. Broken down by gender. (GPRAMA Denominator)

- a. *Active Clinical patients ages 65 and older.* Broken down by gender.

*User Population patients* ages 18 and older. Broken down by gender.

- b. *User Population patients ages 65 and older.* Broken down by gender.

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, *and* at least two visits during the Report Period, *and* two DM-related visits ever. Broken down by gender.

*Active CHD patients*, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, *and* at least two visits during the Report Period, *and* two CHD-related visits ever. Broken down by gender.

## Numerators

Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note:** This numerator does not include refusals. (GPRAMA Numerator)

- a. Patients screened for depression during the Report Period.
- b. Patients with a diagnosis of a mood disorder during the Report Period.
- c. Patients who were screened in a Behavioral Health clinic.

Patients with depression-related education in past year.

**Note:** Depression-related patient education does not count toward the GPRAMA numerator and is included as a separate numerator only.

## Logic Description

Age is calculated at beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	ICD and Other Codes
Diabetes	<b>POV:</b> ICD-9: 250.00–250.93; ICD-10: E10.*-E13.*
Coronary Heart Disease	<i>Any of the following:</i> <b>1) POV:</b> ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0–I22.8, I24.0–I25.83, I25.89, I25.9, Z95.5 <b>2) One or more CABG or PCI procedures</b>
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1 <b>CPT:</b> 33510–33514, 33516–33519, 33521–33523, 33530, 33533–33536, 33572, 35500, 35600, S2205–S2209 <b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*

Subject Defined	ICD and Other Codes
PCI	<b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61 <b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290 <b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**
Depression Screening	<b>Exam:</b> Exam Code 36 <b>POV:</b> ICD-9: V79.0 <b>CPT:</b> 1220F, 3725F, G0444 <b>BHS Problem Code:</b> 14.1 (Screening for Depression) <b>Measurement in PCC or BHS:</b> PHQ2 or PHQ9
Mood Disorders	<b>At least 2 visits in PCC or BHS for:</b> Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS. <b>POV:</b> ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39 <b>BHS POV:</b> 14, 15
Depression-related Patient Education (does not count toward GPRA numerator)	<i>Documented education of any of the following during the Report Period:</i> <b>Patient education codes:</b> Containing "DEP-" (depression), 296.2* or 296.3*, "BH-" (behavioral and social health), 290319, 995.5*, or 995.80–995.85, "SB-" (suicidal behavior) or 300.9, or "PDEP-" (postpartum depression) or 648.44, or SNOMED codes 14183003, 15193003, 15639000, 18818009, 191610000, 191611001, 191613003, 191616006, 191659001, 192080009, 19527009, 19694002, 20250007, 231504006, 231542000, 2506003, 25922000, 2618002, 268621008, 28475009, 3109008, 319768000, 320751009, 33078009, 35489007, 36170009, 36474008, 36923009, 370143000, 38451003, 38694004, 39809009, 40379007, 40568001, 42925002, 430852001, 442057004, 48589009, 63778009, 66344007, 67711008, 69392006, 71336009, 73867007, 75084000, 75837004, 76441001, 77486005, 77911002, 78667006, 79298009, 81319007, 83176005, 832007, 84760002, 85080004, 87512008.

### Recommended Brief Screening Tool

A sample of a Patient Health Questionnaire (PHQ-2 Scaled Version) appears below.

Over the past 2 weeks, how often have you been bothered by any of the following problems?

1. Little interest or pleasure in doing things

- Not at all Value: 0
  - Several days Value: 1
  - More than half the days Value: 2
  - Nearly every day Value: 3
2. Feeling down, depressed, or hopeless
- Not at all Value: 0
  - Several days Value: 1
  - More than half the days Value: 2
  - Nearly every day Value: 3

Total Possible PHQ-2 Score: Range: 0–6

0–2: Negative

3–6: Positive; further evaluation indicated

Provider should note the screening tool used was the PHQ-2 Scaled in the COMMENT section of the Exam Code.

### Key Logic Changes from CRS Version 15.1

1. Added ICD-10 POV code Z95.5 to CHD definition.
2. Added CPT codes 33530, 33572, 35500, 35600 to CABG definition.
3. Added SNOMED codes to Patient Education for Depression-related patient education.

### Patient List Description

List of patients with documented depression screening/diagnosed with mood disorder, if any.

### Measure Source

USPSTF (US Preventive Services Task Force), HP 2010 developmental indicator 18 through 6.

### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2015 Performance	67.4%
IHS FY 2014 Performance	66.0%

Performance	Percent
IHS FY 2013 Performance	65.1%
IHS FY 2012 Performance	61.9%
IHS FY 2011 Performance	56.5%
IHS FY 2010 Performance	52.0%
IHS FY 2009 Performance	44.0%
IHS FY 2008 Performance	35.0%
IHS FY 2007 Performance	24.0%
IHS FY 2006 Performance	15.0%

DU	November 25, 2016						Page 130	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Depression Screening (con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts => 18 (GPRAMA)	1,191		815			668		
# w/Depression screening or Mood Disorder DX-No Refusals (GPRAMA)	82	6.9	42	5.2	+1.7	17	2.5	+4.3
A. # screened for depression	40	3.4	0	0.0	+3.4	0	0.0	+3.4
B. # w/mood disorder DX	43	3.6	42	5.2	-1.5	17	2.5	+1.1
# w/depression education	13	1.1	3	0.4	+0.7	0	0.0	+1.1
Male Active Clinical Pts >=18	480		316			250		
# w/ Depression screening or Mood Disorder DX-No Refusals	26	5.4	7	2.2	+3.2	1	0.4	+5.0
A. # screened for depression	15	3.1	0	0.0	+3.1	0	0.0	+3.1
B. # w/Mood Disorder DX	11	2.3	7	2.2	+0.1	1	0.4	+1.9
# w/depression education	3	0.6	1	0.3	+0.3	0	0.0	+0.6
Female Active Clinical Pts >=18	711		499			418		
# w/ Depression screening or Mood Disorder DX-No Refusals	56	7.9	35	7.0	+0.9	16	3.8	+4.0

A. # screened for depression	25	3.5	0	0.0	+3.5	0	0.0	+3.5
B. # w/Mood Disorder DX	32	4.5	35	7.0	-2.5	16	3.8	+0.7
# w/depression education	10	1.4	2	0.4	+1.0	0	0.0	+1.4
A. Active Clinical Pts => 65	122		71			65		
# w/ Depression screening or Mood Disorder DX-No Refusals	9	7.4	6	8.5	-1.1	2	3.1	+4.3
A. # screened for depression	3	2.5	0	0.0	+2.5	0	0.0	+2.5
B. # w/mood disorder DX	6	4.9	6	8.5	-3.5	2	3.1	+1.8
# w/depression education	2	1.6	2	2.8	-1.2	0	0.0	+1.6

Figure 2-60: Sample Report, Depression Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Depression Screening: List of patients with documented depression screening/diagnosed with mood disorder, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT55, LORETTA LYNN UP	000055	COMMUNITY #1	F	78	09/05/38
PATIENT56, TINA MARIE UP, AC, AD, CHD	000056	COMMUNITY #1	F	78	10/11/38
PATIENT57, DANIELLE UP, AC	000057	COMMUNITY #1	F	79	05/06/37
PATIENT58, LESLIE ANN UP, AC	000058	COMMUNITY #1	F	80	08/30/36
PATIENT59, DONNA SUE UP, AC	000059	COMMUNITY #1	F	86	03/22/30
PATIENT60, TAYLOR OLIVIA UP, AC	000060	COMMUNITY #1	F	87	09/08/29
PATIENT61, DENNIS GERALD UP	000061	COMMUNITY #1	M	18	01/24/98
PATIENT62, JOSHUA DALE UP, AC	000062	COMMUNITY #1	M	18	06/22/98

Figure 2-61: Sample Patient List, Depression Screening

## 2.7.5 Antidepressant Medication Management

### Denominators

As of the 120th day of the Report Period, *Active Clinical Plus BH patients* 18 years of age and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

As of the 120th day of the Report Period, *User Population patients* 18 years of age and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

### Numerators

*Effective Acute Phase Treatment:* Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication for continuous treatment of at least 84 days (12 weeks).

*Effective Continuation Phase Treatment:* Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication treatment to provide continuous treatment for at least 180 days (6 months).

### Logic Description

Age is calculated at the beginning of the report period. To be included in the denominator, patient must have filled a prescription for an antidepressant medication (see list of medications below) within the 121st day of the year prior to the Report period to the 120th day of the Report period. For example, if Report period is July 1, 2015 - June 30, 2016, patient must have filled a prescription during 11/1/2014 - 10/29/2015. In V Medication, Date Discontinued must not be equal to the prescription (i.e. visit) date. The Index Prescription Start Date (IPSD) is the date of the earliest prescription for antidepressant medication filled during that time period.

#### *Denominator Exclusions*

Patients who did not have a diagnosis of major depression in an inpatient, outpatient, ED, intensive outpatient or partial hospitalization setting during the 60 days prior to the IPSD (inclusive) through 60 days after the IPSD (inclusive).

Major depression defined as POV ICD-9: 296.20-296.25, 296.30-296.35, 298.0, 311; ICD-10: F32.0-F32.4, F32.8-F33.3, F33.41, F33.9.

Patients who had a new or refill prescription for antidepressant medication (see list of medications below) within 105 days prior to the Index Prescription Start Date are excluded as they do not represent new treatment episodes.



*Effective Acute Phase Treatment Numerator*

For all antidepressant medication prescriptions filled (see list of medications below) within 114 days of the Index Prescription Date, from V Medication CRS counts the days prescribed (i.e., treatment days) from the Index Prescription Date until a total of 84 treatment days has been established. If the patient had a total gap exceeding 30 days or if the patient does not have 84 treatment days within the 114-day time frame, the patient is not included in the numerator.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

**Example of Patient Included in Numerator:**

- First RX is Index Rx Date: 11/1/2015, # Days Prescribed=30
- Rx covers patient through 12/1/2015
- Second RX: 12/15/2015, # Days Prescribed=30
- Gap #1 = (12/15/2015-12/1/2015) = 14 days
- Rx covers patient through 1/14/2016
- Third RX: 1/10/2016, # Days Prescribed=30
- No gap days
- Rx covers patient through 2/13/2016
- Index Rx Date 11/1/2015 + 114 days = 2/23/2016
- Patient's 84th treatment day occurs on 2/7/2016, which is less than or equal to ( $\leq$ ) 2/23/2016 and # gap days of 14 is less than 30

**Example of Patient Not Included in Numerator:**

- First Rx is Index Rx Date: 11/1/2015, # Days Prescribed=30
- Rx covers patient through 12/1/2015
- Second Rx: 12/15/2015, # Days Prescribed=30
- Gap #1 = (12/15/2015-12/1/2015) = 14 days
- Rx covers patient through 1/14/2016
- Third Rx: 2/01/2016, # Days Prescribed=30

- Gap #2 = (2/01/2016 through 1/14/2016) = 18, total # gap days = 32, so patient is not included in the numerator

### *Effective Continuation Phase Treatment Numerator*

For all antidepressant medication prescriptions (see list of medications below) filled within 231 days of the Index Prescription Date, CRS counts the days prescribed (i.e., treatment days) (from V Medication) from the Index Prescription Date until a total of 180 treatment days has been established. If the patient had a total gap exceeding 51 days or if the patient does not have 180 treatment days within the 231 day time frame, the patient is not included in the numerator.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

*Antidepressant medications* defined with medication taxonomy BGP HEDIS ANTIDEPRESSANT MEDS. (Medications are: Tricyclic antidepressants (TCA) and other cyclic antidepressants, Selective serotonin reuptake inhibitors (SSRI), Monoamine oxidase inhibitors (MAOI), Serotonin-norepinephrine reuptake inhibitors (SNRI), and other antidepressants.) Medications must not have a comment of RETURNED TO STOCK.

### **Key Logic Changes from CRS Version 15.1**

None.

### **Patient List Description**

List of patients with new depression DX and acute phase treatment (APT) and continuation phase treatment (CONPT), if any.

### **Measure Source**

HEDIS, HP 2010 18–9b

### **Measure Past Performance and Long-Term Targets**

None

DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Antidepressant Medication Management (con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
AC+BH Pts =>18 w/new depression DX and antidepressant meds	17		6			2		
# w/12 week treatment meds	9	52.9	4	66.7	-13.7	0	0.0	+52.9
# w/180 day treatment meds	4	23.5	3	50.0	-26.5	0	0.0	+23.5
User Pop Pts =>18 w/new depression DX and antidepressant meds	18		7			3		
# w/12 week treatment meds	9	50.0	4	57.1	-7.1	0	0.0	+50.0
# w/180 day treatment meds	4	22.2	3	42.9	-20.6	0	0.0	+22.2

Figure 2-62: Sample Report, Antidepressant Medication Management

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Antidepressant Medication Management: List of patients with new depression DX and acute phase treatment (APT) and continuation phase treatment (CONPT), if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, MICHELLE D UP, AC+BH	000001	COMMUNITY #1	F	22	02/22/94
DAYS=60, GAP=1		IESD: 06/06/15; NOT APT: DAYS=60, GAP=1; NOT CONPT:			
PATIENT2, PAULA KAY UP, AC+BH	000002	COMMUNITY #1	F	34	01/14/82
PATIENT3, RHONDA SUE UP	000003	COMMUNITY #1	F	35	10/15/81
DAYS=74, GAP=0		IESD: 04/21/16; NOT APT: DAYS=74, GAP=0; NOT CONPT:			
PATIENT4, KATHLEEN UP, AC+BH	000004	COMMUNITY #1	F	38	08/03/78
		IESD: 11/15/15; APT; CONPT			

Figure 2-63: Sample Patient List, Antidepressant Medication Management

## 2.8 Cardiovascular Disease Related Measure Topics

## 2.8.1 Obesity Assessment

### Denominators

*Active Clinical patients* ages 2 through 74. Broken down by gender and age groups (2 through 5, 6 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74).

All *User Population patients* ages 2 through 74. Broken down by gender.

### Numerators

Patients for whom a Body Mass Index (BMI) could be calculated.

**Note:** This numerator does *not* include refusals.

1. For those with a BMI calculated, those considered overweight but not obese using BMI and standard tables
2. For those with a BMI calculated, those considered obese using BMI and standard tables
3. Total of overweight and obese

Patients with documented refusal in past year.

### Logic Description

Age is calculated at beginning of the Report Period.

*BMI calculation definition:* CRS calculates BMI at the time the report is run, using NHANES II. For age 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults 19 and older. Obese is defined as BMI of 30 or more for adults 19 and older. For ages 2-18, definitions are based on standard tables. Refusals include REF, NMI, and UAS (unable to screen) and must be documented during the past year. For ages 18 and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 and older, the height and weight must be refused during the past year and are not required to be on the same visit.

Patients whose BMI either is greater or less than the Data Check Limit range shown in the BMI Standard Reference Data Table in PCC will not be included in the report counts for Overweight or Obese.

## Key Logic Changes from CRS Version 15.1

None.

## Patient List Description

List of patients with current BMI, if any.

## Measure Source

HP 2020: NWS-9 Obesity in Adults 20+, NWS-10.1 (Obesity in Children 2-5), NWS-10.2 Overweight or Obesity in Children 6-11, NWS-10.3 Overweight or Obesity in Adolescents 12-19, NWS-10.4 Overweight or Obesity in Children 2-19

## Measure Past Performance and Long-Term Targets

Performance	Percent
Assessed as Obese—IHS FY 2012 Performance	47.1%
Assessed as Obese—IHS FY 2011 Performance	46.9%
Assessed as Obese—IHS FY 2010 Performance	47.0%
Assessed as Obese—IHS FY 2009 Performance	47.0%
Assessed as Obese—IHS FY 2008 Performance	46.0%
BMI Measured—IHS FY 2012 Performance	81.6%
BMI Measured—IHS FY 2011 Performance	78.0%
BMI Measured—IHS FY 2010 Performance	76.0%
BMI Measured—IHS FY 2009 Performance	75.0%
BMI Measured—IHS FY 2008 Performance	74.0%
BMI Measured— FY 2005 Performance	64.0%
BMI Measured—IHS FY 2004 Performance	60.0%
<i>HP 2020 Goal: Obesity in Adults 20+ (NWS-9)</i>	30.6%
<i>HP 2020 Goal: Overweight or Obesity in Children 2–5 (NWS-10.1)</i>	9.6%
<i>HP 2020 Goal: Overweight or Obesity in Children 6–11 (NWS-10.2)</i>	15.7%
<i>HP 2020 Goal: Overweight or Obesity in Adolescents 12–19 (NWS-10.3)</i>	16.1%
<i>HP 2020 Goal: Overweight or Obesity in Children 2–19 (NWS-10.4)</i>	14.6%

## Performance Improvement Tips

1. A Body Mass Index report can be run from your PCC Management Reports menu. This report can be run for all patients or for a specific template of patients that has been pre-defined with a QMan search. The BMI report will provide you with patient height, weight, date weight taken, BMI and NHANES percentile.

2. Recent guidelines indicate that height for adults must be taken at least once every 5 years, rather than once after age 18. Your BMI rates may be lower than anticipated because of height data that is over 5 years old.
3. If height and weight measurements are being recorded as cm/kg vs. in/lbs ensure providers are *noting* they are cm/kg *and* that data entry is entering the measurements correctly in PCC, as shown below.
  - Use mnemonics of CHT and KWT (vs. HT and WT), or
  - Add “c” after height value and “k” after weight value (e.g. 100c, 50k)

DU		November 25, 2016				Page 143			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Obesity Assessment (con't)									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts ages 2-74	1,400		1,096			982			
# w/BMI calculated									
-No Refusals	880	62.9	824	75.2	-12.3	712	72.5	-9.6	
A. # Overweight w/ % of Total BMI	242	27.5	237	28.8	-1.3	191	26.8	+0.7	
B. # Obese w/ % of Total BMI	372	42.3	339	41.1	+1.1	267	37.5	+4.8	
C. # Overweight/Obese w/ % of Total BMI	614	69.8	576	69.9	-0.1	458	64.3	+5.4	
# w/BMI refusal (No BMI)	4	0.3	0	0.0	+0.3	0	0.0	+0.3	
Male Active Clinical Pts 2-74	595		465			410			
# w/BMI calculated									
-No Refusals	341	57.3	331	71.2	-13.9	283	69.0	-11.7	
A. # Overweight w/ % of Total BMI	103	30.2	98	29.6	+0.6	73	25.8	+4.4	
B. # Obese w/ % of Total BMI	155	45.5	141	42.6	+2.9	117	41.3	+4.1	
C. #Overweight/Obese w/ % of Total BMI	258	75.7	239	72.2	+3.5	190	67.1	+8.5	
# w/BMI refusal (no BMI)	2	0.3	0	0.0	+0.3	0	0.0	+0.3	
Female Active Clinical Pts 2-74	805		631			572			

# w/BMI calculated								
-No Refusals	539	67.0	493	78.1	-11.2	429	75.0	-8.0
A. # Overweight w/ % of Total BMI	139	25.8	139	28.2	-2.4	118	27.5	-1.7
B. # Obese w/ % of Total BMI	217	40.3	198	40.2	+0.1	150	35.0	+5.3
C. #Overweight/Obese w/ % of Total BMI	356	66.0	337	68.4	-2.3	268	62.5	+3.6
# w/BMI refusal (No BMI)	2	0.2	0	0.0	+0.2	0	0.0	+0.2

Figure 2-64: Sample Report, Obesity Assessment

Obesity Assessment (con't)	TOTAL ACTIVE CLINICAL POPULATION							
	Age Distribution							
	2-5	6-11	12-19	20-24	25-34	35-44	45-54	55-74
CURRENT REPORT PERIOD								
Total # Active Clin	109	112	157	133	233	215	216	225
# w/BMI calculated								
-No Refusals	52	44	89	117	183	146	128	121
% w/BMI calculated								
-No Refusals	47.7	39.3	56.7	88.0	78.5	67.9	59.3	53.8
# A. Overweight	9	10	21	33	44	39	38	48
% A. Overweight w/ % Total BMI	17.3	22.7	23.6	28.2	24.0	26.7	29.7	39.7
# B. Obese	7	13	28	39	86	86	61	52
% B. Obese w/ % of Total BMI	13.5	29.5	31.5	33.3	47.0	58.9	47.7	43.0
# C. Overweight or Obese	16	23	49	72	130	125	99	100
% C. Overweight or Obese w/ % Total BMI	30.8	52.3	55.1	61.5	71.0	85.6	77.3	82.6
# w/BMI refusal (No BMI)	1	0	0	0	0	1	1	1
% w/BMI refusal (No BMI)	1.9	0.0	0.0	0.0	0.0	0.7	0.8	0.8
PREVIOUS YEAR PERIOD								
Total # Active Clin	111	120	137	128	172	151	140	137
# w/BMI calculated								
-No Refusals	49	56	88	114	155	129	113	120
% w/BMI calculated								
-No Refusals	44.1	46.7	64.2	89.1	90.1	85.4	80.7	87.6
# A. Overweight	7	11	20	38	47	33	36	45
% A. Overweight w/ % Total BMI	14.3	19.6	22.7	33.3	30.3	25.6	31.9	37.5
# B. Obese	14	14	26	35	65	77	56	52
% B. Obese w/ % of Total BMI								

% of Total BMI	28.6	25.0	29.5	30.7	41.9	59.7	49.6	43.3
# C. Overweight or Obese	21	25	46	73	112	110	92	97
% C. Overweight or Obese w/ % Total BMI	42.9	44.6	52.3	64.0	72.3	85.3	81.4	80.8
# w/BMI refusal (No BMI)	0	0	0	0	0	0	0	0
% w/BMI refusal (No BMI)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CHANGE FROM PREV YR % w/BMI calculated								
-No Refusals	+3.6	-7.4	-7.5	-1.1	-11.6	-17.5	-21.5	-33.8
A. Overweight	+3.0	+3.1	+0.9	-5.1	-6.3	+1.1	-2.2	+2.2
B. Obese	-15.1	+4.5	+1.9	+2.6	+5.1	-0.8	-1.9	-0.4
C. Overweight or Obese	-12.1	+7.6	+2.8	-2.5	-1.2	+0.3	-4.1	+1.8
w/BMI refusal (No BMI)	+1.9	+0.0	+0.0	+0.0	+0.0	+0.7	+0.8	+0.8

Figure 2-65: Sample Report, Age Breakout, Obesity Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Obesity Assessment: List of patients with current BMI, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, PAMELA UP, AC	000001	COMMUNITY #1 16.03	F	3	05/22/13
PATIENT2, GLENDA UP, AC	000002	COMMUNITY #1 17.49	F	3	05/30/13
PATIENT3, SHIRLEY UP	000003	COMMUNITY #1	F	5	09/21/11
PATIENT4, MARY ANNE UP, AC	000004	COMMUNITY #1 Refused	F	5	11/05/11
PATIENT5, JACKIE UP	000005	COMMUNITY #1	F	9	05/19/07
PATIENT6, ZINNIA UP	000006	COMMUNITY #1 29.41 [OVERWEIGHT]	F	15	09/01/01
PATIENT7, MARY RYAN UP, AC	000007	COMMUNITY #1 33.69 [OBESE]	F	15	12/12/01

Figure 2-66: Sample Patient List, Obesity Assessment



## 2.8.2 Childhood Weight Control

### GPRA Measure Description

During GPRA Year 2016, achieve the long-term target rate of 22.8% for the proportion of children with a BMI of 95% or higher.

#### Denominators

*Active Clinical patients* aged 2 through 5 for whom a BMI could be calculated. Broken down by gender and age groups (2, 3, 4, 5). (GPRA Denominator)

*User Population patients* aged 2 through 5 for whom a BMI could be calculated.

#### Numerators

Patients with BMI in the 85th to 94th percentile.

Patients with a BMI at or above the 95th percentile. (GPRA Numerator)

Patients with a BMI at or above the 85th percentile.

#### Logic Description

*BMI calculation definition:* All patients for whom a BMI could be calculated and who are between the ages of 2 and 5 at the beginning of the Report Period and who do not turn age 6 during the Report Period are included in this measure. Age in the age groups is calculated based on the date of the most current BMI found. For example, a patient may be 2 years of age at the beginning of the time period, but is 3 years old at the time of the most current BMI found. That patient will fall into the age 3 group. CRS looks for the most recent BMI in the Report Period. CRS calculates BMI at the time the report is run using NHANES II. A height and weight must be taken on the same day any time during the Report Period. The BMI values for this measure are reported differently than in Obesity Assessment since this age group is children ages 2 through 5, whose BMI values are age-dependent. The BMI values are categorized as Overweight for patients with a BMI in the 85th to 94th percentile and Obese for patients with a BMI at or above the 95th percentile.

Patients whose BMI either is greater or less than the Data Check Limit range shown below will not be included in the report counts for Overweight or Obese.

#### BMI Standard Reference Data

Low-High Ages	Sex	BMI >= (OVERWT)	BMI >= (OBESE)	Data Check Limits BMI >	Data Check Limits BMI <
2-2	MALE	17.7	18.7	36.8	7.2

Low-High Ages	Sex	BMI >= (OVERWT)	BMI >= (OBESE)	Data Check Limits BMI>	Data Check Limits BMI <
2-2	FEMALE	17.5	18.6	37.0	7.1
3-3	MALE	17.1	18.0	35.6	7.1
3-3	FEMALE	17.0	18.1	35.4	6.8
4-4	MALE	16.8	17.8	36.2	7.0
4-4	FEMALE	16.7	18.1	36.0	6.9
5-5	MALE	16.9	18.1	36.0	6.9
5-5	FEMALE	16.9	18.5	39.2	6.8

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients ages 2 through 5, with current BMI.

### Measure Source

CDC, National Center for Health Statistics, HP 2020 NWS-10.1

### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2015 Performance	21.8%
IHS FY 2014 Performance	22.8%
IHS FY 2013 Performance	22.8%
IHS FY 2012 Performance	24.0%
IHS FY 2011 Performance	24.1%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	25.0%
IHS FY 2008 Performance	24.0%
IHS FY 2007 Performance	24.0%
IHS FY 2006 Performance	24.0%
<i>HP 2020 Goal</i>	<i>9.6%</i>

DU

November 25, 2016

Page 156

\*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2016 to Dec 31, 2016

Previous Year Period: Jan 01, 2015 to Dec 31, 2015

Baseline Period: Jan 01, 2010 to Dec 31, 2010

-----

Childhood Weight Control (con't)									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts									
2-5 w/BMI	44		39			40			
# w/BMI 85-94%	7	15.9	5	12.8	+3.1	10	25.0	-9.1	
# w/BMI =>95%	5	11.4	9	23.1	-11.7	5	12.5	-1.1	
# w/BMI =>85%	12	27.3	14	35.9	-8.6	15	37.5	-10.2	
Active Clinical Pts									
Age 2	2		8			5			
# w/BMI 85-94%	1	50.0	0	0.0	+50.0	1	20.0	+30.0	
# w/BMI =>95%	0	0.0	2	25.0	-25.0	0	0.0	+0.0	
# w/BMI =>85%	1	50.0	2	25.0	+25.0	1	20.0	+30.0	
Active Clinical Pts									
Age 3	23		15			8			
# w/BMI 85-94%	2	8.7	2	13.3	-4.6	3	37.5	-28.8	
# w/BMI =>95%	3	13.0	3	20.0	-7.0	2	25.0	-12.0	
# w/BMI =>85%	5	21.7	5	33.3	-11.6	5	62.5	-40.8	
Active Clinical Pts									
Age 4	12		10			17			
# w/BMI 85-94%	1	8.3	2	20.0	-11.7	3	17.6	-9.3	
# w/BMI =>95%	1	8.3	2	20.0	-11.7	2	11.8	-3.4	
# w/BMI =>85%	2	16.7	4	40.0	-23.3	5	29.4	-12.7	
Active Clinical Pts									
Age 5	7		6			10			
# w/BMI 85-94%	3	42.9	1	16.7	+26.2	3	30.0	+12.9	
# w/BMI =>95%	1	14.3	2	33.3	-19.0	1	10.0	+4.3	
# w/BMI =>85%	4	57.1	3	50.0	+7.1	4	40.0	+17.1	

Figure 2-67: Sample Report, Childhood Weight Control

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Childhood Weight Control: List of patients ages 2-5, with current BMI.

PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB
DENOMINATOR		NUMERATOR			
PATIENT1,MELISSA ANN	000001	COMMUNITY #1	F	4	11/12/12
AC		Age at BMI: 4;		08/20/16	16.03
PATIENT2,RANDY	000002	COMMUNITY #1	M	2	03/02/14
AC		Age at BMI: 2;		05/06/16	17.96 [OVERWEIGHT]
PATIENT3,PAUL BARRY	000003	COMMUNITY #1	M	2	04/13/14
AC		Age at BMI: 2;		08/05/16	19.87 [OBESE]

PATIENT4, TYLER	000004	COMMUNITY #1	M	4	04/27/12
AC		Age at BMI: 4;	02/19/16	15.67	
PATIENT5, SAMUEL III	000005	COMMUNITY #1	M	5	05/22/11
AC		Age at BMI: 5;	11/24/16	19.07 [OBESE]	
PATIENT21, JOSEPHINE	000021	COMMUNITY #2	F	4	10/10/12
AC		Age at BMI: 4;	05/30/16	15.71	

Figure 2-68: Sample Patient List, Childhood Weight Control

## 2.8.3 Weight Assessment and Counseling for Nutrition and Physical Activity

### Denominators

*Active Clinical patients* ages 3 and older. Broken down by gender and age groups (3 through 11, 12 through 17, 18 and older).

### Numerators

Patients with comprehensive assessment, defined as having BMI documented, counseling for nutrition, and counseling for physical activity during the Report Period.

Patients with BMI documented during the Report Period.

Patients with counseling for nutrition during the Report Period.

Patients with counseling for physical activity during the Report Period.

### Logic Description

Age is calculated at the end of the Report Period.

CRS uses any of the following codes to define the numerators.

Subject Defined	CPT Codes	ICD and Other Codes
BMI Documented		<p><b>BMI:</b> CRS calculates BMI at the time the report is run, using NHANES II. For age 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.</p> <p><b>POV:</b> ICD-9: V85*; ICD-10: Z68.20-Z68.54</p>

Subject Defined	CPT Codes	ICD and Other Codes
Counseling for Nutrition	97802-97804, G0270, G0271, G0447, S9449, S9452, S9470	<b>POV:</b> ICD-9: V65.3; ICD-10: Z71.3 <b>Patient education codes:</b> ending “-N” (nutrition), “-MNT” (medical nutrition therapy), (or old code “-DT” (diet)) or containing V65.3, 97802-97804, G0270, G0271, G0447, S9449, S9452, or S9470.
Counseling for Physical Activity	G0447, S9451	<b>POV:</b> ICD-9: V65.41 <b>Patient education codes:</b> ending “-EX” (exercise) or containing V65.41, G0447, or S9451.

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of patients ages 3 plus (+) with assessments, if any.

**Measure Source**

HEDIS

**Measure Past Performance and Long-Term Targets**

Performance	Percent
N/A	

DU	November 25, 2016						Page 143		
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Weight Assessment and Counseling for Nutrition and Physical Activity									
(Con't)									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %	
Active Clinical Pts									
Age 3+	1,583		1,151			1,009			
# w/ comprehensive									
assessment	57	3.6	37	3.2	+0.4	52	5.2	-1.6	
# w/BMI									
documented	930	58.7	848	73.7	-14.9	733	72.6	-13.9	

# w/ nutrition counseling	128	8.1	99	8.6	-0.5	108	10.7	-2.6
# w/ physical activity counseling	87	5.5	46	4.0	+1.5	61	6.0	-0.5
Male Active Clinical Pts Age 3+	664		486			423		
# w/ comprehensive assessment	23	3.5	14	2.9	+0.6	22	5.2	-1.7
# w/BMI documented	360	54.2	342	70.4	-16.2	294	69.5	-15.3
# w/ nutrition counseling	45	6.8	37	7.6	-0.8	39	9.2	-2.4
# w/ physical activity counseling	33	5.0	20	4.1	+0.9	25	5.9	-0.9
Female Active Clinical Pts Age 3+	919		665			586		
# w/ comprehensive assessment	34	3.7	23	3.5	+0.2	30	5.1	-1.4
# w/BMI documented	570	62.0	506	76.1	-14.1	439	74.9	-12.9
# w/ nutrition counseling	83	9.0	62	9.3	-0.3	69	11.8	-2.7
# w/ physical activity counseling	54	5.9	26	3.9	+2.0	36	6.1	-0.3

Figure 2-69: Sample Report, Weight Assessment and Counseling for Nutrition and Physical Activity

Weight Assessment and Counseling for Nutrition and Physical Activity (con't)			
	Active Clinical Pts =>3		
	3 - 11	12 - 17	18+
CURRENT REPORT PERIOD			
Active Clinical Pts =>3	216	121	1,246
# w/comprehensive assessment	6	4	47
% w/comprehensive assessment	2.8	3.3	3.8
# w/BMI documented	94	58	778
% w/BMI documented	43.5	47.9	62.4
% w/nutrition counseling	8	11	109
% w/nutrition counseling	3.7	9.1	0.0
# w/physical activity counseling	9	7	71
% w/physical activity counseling	4.2	5.8	5.7
PREVIOUS REPORT PERIOD			
Active Clinical Pts =>3	214	107	830
# w/comprehensive assessment	0	0	37

% w/comprehensive assessment	0.0	0.0	4.5
# w/BMI documented	98	53	697
% w/BMI documented	45.8	49.5	84.0
% w/nutrition counseling	2	3	94
% w/nutrition counseling	0.9	2.8	0.0
# w/physical activity counseling	0	0	46
% w/physical activity counseling	0.0	0.0	5.5
CHANGE FROM PREVIOUS YR %			
# w/comprehensive assessment	+2.8	+3.3	-0.7
# w/BMI documented	+43.5	+47.9	+58.0
# w/nutrition counseling	+3.7	+9.1	-4.5
# w/physical activity counseling	+4.2	+5.8	+1.2

Figure 2-70: Sample Report, Age Breakout, Weight Assessment and Counseling for Nutrition and Physical Activity

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Weight Assessment and Counseling for Nutrition and Physical Activity: List of patients ages 3+ with assessments, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,PAMELA AC	000001	COMMUNITY #1	F	4	10/15/12
PATIENT2,GLENDA AC	000002	COMMUNITY #1 BMI: 16.03	F	4	12/02/12
PATIENT3,SHIRLEY AC	000003	COMMUNITY #1	F	5	02/03/11
PATIENT4,MARY ANNE AC	000004	COMMUNITY #1 COMP ASSESS; BMI: V85.53; NUTR: 03/03/16 CPT 97804; PHY: 03/03/16 DX V65.41	F	5	02/18/11
PATIENT5,JACKIE AC	000005	COMMUNITY #1 PHY: 08/08/16 OBS-EX	F	9	03/16/07
PATIENT6,ZINNIA AC	000006	COMMUNITY #1	F	15	07/21/01
PATIENT7,MARY RYAN AC	000007	COMMUNITY #1 BMI: 35.04; PHY: 03/03/16 DX V65.41	F	15	09/22/01

Figure 2-71: Sample Patient List, Weight Assessment and Counseling for Nutrition and Physical Activity

## 2.8.4 Nutrition and Exercise Education for At Risk Patients

### Denominators

*Active Clinical patients* ages 6 and older considered overweight (including obese). Broken down by gender.

- a. Active Clinical patients ages 6 and older *considered obese*. Broken down by gender and age groups (6 through 11, 12 through 19, 20 through 39, 40 through 59, 60 years plus).

*Active Diabetic patients*, defined as all Active Clinical patients diagnosed with diabetes at least 1 year prior to the end of the Report Period, *and* at least two visits in the past year, *and* two diabetes-related visits ever.

### Numerators

Patients provided with medical nutrition therapy during the Report Period.

Patients provided specific nutrition education during the Report Period.

Patients provided specific exercise education during the Report Period.

Patients provided with other related exercise and nutrition (lifestyle) education.

### Logic Description

Age of the patient is calculated at beginning of Report Period.

*Diabetes*: First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Overweight*: Ages 19 and older, BMI greater than or equal to ( $\Rightarrow$ ) 25. Overweight is defined as including both obese and overweight categories calculated by BMI.

*Obese*: Ages 19 and older, BMI greater than or equal to ( $\Rightarrow$ ) 30. For ages 18 and under, the definition is based on standard tables. CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time in the year prior to the end of the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years; not required to be recorded on same day.

CRS uses any of the following codes to define the numerators.



Subject Defined	CPT Codes	ICD and Other Codes
Medical nutrition therapy	97802-97804, G0270, G0271	<b>Primary or secondary provider codes:</b> 07, 29 <b>Clinic codes:</b> 67 (dietary) or 36 (WIC)
Nutrition education		<b>POV:</b> ICD-9: V65.3 dietary surveillance and counseling; ICD-10: Z71.3 <b>Patient education codes:</b> ending “-N” (nutrition), “-MNT” (medical nutrition therapy), (or old code “-DT” (diet)) or containing V65.3, 97802-97804, G0270, or G0271.
Exercise education		<b>POV:</b> ICD-9: V65.41 exercise counseling <b>Patient education codes:</b> ending “-EX” (exercise) or containing V65.41.
Related exercise and nutrition education	S9449, S9451, S9452, S9470	<b>Patient education codes:</b> ending “-LA” (lifestyle adaptation) or containing “OBS-” (obesity) or 278.00 or 278.01, S9449, S9451, S9452, S9470, or SNOMED codes 111036000, 162863004, 162863004, 162864005, 162864005, 170798000, 190965006, 190966007, 238131007, 238132000, 238133005, 238134004, 238136002, 248311001, 248312008, 270486005, 275947003, 276792008, 290439001, 292464007, 293481008, 294493008, 295509007, 296526005, 297500005, 298464002, 360566006, 363247006, 408512008, 413487000, 414438005, 414916001, 414917005, 414918000, 414919008, 414920002, 415530009, 444862003, 444862003, 44772007, 450451007, 48499001, 5036006, 53146006, 62999006, 703316004, 705131003, 80660001, 82793005.

### Key Logic Changes from CRS Version 15.1

1. Added SNOMED codes to Patient Education for Related exercise and nutrition education.

### Patient List Description

A list of at risk patients with education, if any.

### Measure Source

HP 2010 19–17

### Measure Past Performance and Long-Term Targets for Diabetic Education

Performance	Percent
HP 1997 data	42.0%

DU November 25, 2016 Page 160  
 \*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*  
 DEMO INDIAN HOSPITAL  
 Report Period: Jan 01, 2016 to Dec 31, 2016  
 Previous Year Period: Jan 01, 2015 to Dec 31, 2015  
 Baseline Period: Jan 01, 2010 to Dec 31, 2010

---

Nutrition and Exercise Education for At Risk Patient

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# Overweight Active Clinical patients =>6	598		555			442		
# w/medical nutrition therapy	44	7.4	23	4.1	+3.2	27	6.1	+1.2
# specific nutrition education provided	83	13.9	79	14.2	-0.4	78	17.6	-3.8
# w/exercise educ	34	5.7	28	5.0	+0.6	35	7.9	-2.2
# w/ other exec or nutrition educ	75	12.5	59	10.6	+1.9	24	5.4	+7.1
# Male Overweight Active Clinical pts =>6	251		230			182		
# w/medical nutrition therapy	18	7.2	8	3.5	+3.7	10	5.5	+1.7
# specific nutrition education provided	36	14.3	32	13.9	+0.4	28	15.4	-1.0
# w/exercise educ	16	6.4	12	5.2	+1.2	16	8.8	-2.4
# w/ other exec or nutrition educ	41	16.3	22	9.6	+6.8	11	6.0	+10.3
# Female Overweight Active Clinical pts =>6	347		325			260		
# w/medical nutrition therapy	26	7.5	15	4.6	+2.9	17	6.5	+1.0
# specific nutrition education provided	47	13.5	47	14.5	-0.9	50	19.2	-5.7
# w/exercise educ	18	5.2	16	4.9	+0.3	19	7.3	-2.1
# w/ other exec or nutrition educ	34	9.8	37	11.4	-1.6	13	5.0	+4.8

Figure 2-72: Sample Report, Nutrition and Exercise Education for At Risk Patients

Nutrition and Exercise Education for At Risk Patient (con't)					
	TOTAL OBESE ACTIVE CLINICAL POPULATION				
	Age Distribution				
# Obese Active Clinical	6-11	12-19	20-39	40-59	=>60
CURRENT REPORT PERIOD					
# Obese Active Clinical	13	28	167	125	32
# w/medical nutrition therapy	0	2	15	10	3
% w/medical nutrition therapy	0.0	7.1	9.0	8.0	9.4
# # w/specific nutrition education provided	0	3	22	28	7
% # w/specific nutrition education provided	0.0	10.7	13.2	22.4	21.9
# w/exercise educ	0	1	8	14	5
% w/exercise educ	0.0	3.6	4.8	11.2	15.6
# w/other exec or nutrition educ	0	3	18	16	7
% w/other exec or nutrition educ	0.0	10.7	10.8	12.8	21.9
PREVIOUS YEAR PERIOD					
# Obese Active Clinical	14	26	137	116	32
# w/medical nutrition therapy	0	3	8	3	2
% w/medical nutrition therapy	0.0	11.5	5.8	2.6	6.3
# # w/specific nutrition education provided	0	2	19	22	7
% # w/specific nutrition education provided	0.0	7.7	13.9	19.0	21.9
# w/exercise educ	0	0	4	14	4
% w/exercise educ	0.0	0.0	2.9	12.1	12.5
# w/other exec or nutrition educ	0	2	13	23	3
% w/other exec or nutrition educ	0.0	7.7	9.5	19.8	9.4
CHANGE FROM PREV YR %					
medical nutrition therapy	+0.0	-4.4	+3.1	+5.4	+3.1
Spec nutr ed	+0.0	+3.0	-0.7	+3.4	+0.0
w/exercise educ	+0.0	+3.6	+1.9	-0.9	+3.1
w/other exec or nutrition educ	+0.0	+3.0	+1.3	-7.0	+12.5

Figure 2-73: Sample Age Breakout Report, Nutrition and Exercise Education for At Risk Patients

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;

HR=High Risk Patient

Nutrition and Exercise Education for At Risk Patients: List of at risk patients, with education if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, SANDRA KAY AC-OW, AC-OB	000001	COMMUNITY #1 LIFE: 05/15/16	F	21	07/09/95
PATIENT2, CAITLYN AC-OW	000002	COMMUNITY #1 NUTR: 03/15/16	F	22	10/07/94
PATIENT3, BRITNEY AC-OW, AC-OB	000003	COMMUNITY #1 MNT: 03/04/16	F	22	11/12/94
PATIENT4, LORETTA AC-OW, AC-OB	000004	COMMUNITY #1 NUTR: 05/07/16	F	22	11/22/94
PATIENT5, HALEY AC-OW, AC-OB	000005	COMMUNITY #1	F	25	02/19/91
PATIENT6, BRITTANY AC-OW, AC-OB	000006	COMMUNITY #1 EXER ED: 01/15/16	F	25	06/02/91

Figure 2-74: Sample Patient List, Nutrition, and Exercise Education for At Risk Patients

## 2.8.5 Physical Activity Assessment

### Denominators

*Active Clinical patients* ages 5 and older. Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)75).

Numerator 1 (Active Clinical Patients assessed for physical activity during the Report Period). Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)75).

*User Population patients* ages 5 and older. Broken down by gender.

Numerator 1 (User Population Patients assessed for physical activity during the Report Period). Broken down by gender.

### Numerators

Patients assessed for physical activity during the Report Period.

Patients from Numerator 1 who have received exercise education following their physical activity assessment.

Patients from Numerator 1 who have set at least one exercise goal following their physical activity assessment.

### Logic Description

Age of the patient is calculated at beginning of Report Period.

CRS uses any of the following codes to define the numerators.

Subject Defined	ICD and Other Codes
Physical Activity Assessment	<b>Health Factors:</b> Any health factor for category Activity Level documented during the Report Period.
Exercise education	<b>POV:</b> V65.41 exercise counseling <b>Patient education codes:</b> ending "-EX" (exercise) or containing V65.41.
Exercise goal	<b>Patient Goal:</b> Goal Type of "Physical Activity" and Goal Status of "Goal Set"

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients with physical activity assessment and any exercise education or goals.

DU	November 25, 2016						Page 171	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Physical Activity Assessment								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts 5 and older	1,357		1,031			911		
# w/ physical activity assessment	19	1.4	0	0.0	+1.4	0	0.0	+1.4
# w/ exercise educ w/ % of physical activity assessment	4	21.1	0	0.0	+21.1	0	0.0	+21.1
Male Active Clinical =>5	570		430			374		
# w/ physical activity assessment	7	1.2	0	0.0	+1.2	0	0.0	+1.2
# w/ exercise educ w/ % of physical activity assessment	1	14.3	0	0.0	+14.3	0	0.0	+14.3

Female Active Clinical =>5	787		601			537		
# w/ physical activity assessment	12	1.5	0	0.0	+1.5	0	0.0	+1.5
# w/ exercise educ w/ % of physical activity assessment	3	25.0	0	0.0	+25.0	0	0.0	+25.0
User Pop ages 5 and older	2,592		2,142			2,025		
# w/ physical activity assessment	19	0.7	0	0.0	+0.7	0	0.0	+0.7
# w/ exercise educ w/ % of physical activity assessment	4	21.1	0	0.0	+21.1	0	0.0	+21.1
Male User Pop Pts =>5	1,211		988			945		
# w/ physical activity assessment	7	0.6	0	0.0	+0.6	0	0.0	+0.6
# w/ exercise educ w/ % of physical activity assessment	1	14.3	0	0.0	+14.3	0	0.0	+14.3
Female User Pop Pts =>5	1,381		1,154			1,080		
# w/ physical activity assessment	12	0.9	0	0.0	+0.9	0	0.0	+0.9
# w/ exercise educ w/ % of physical activity assessment	3	25.0	0	0.0	+25.0	0	0.0	+25.0

Figure 2-75: Sample Report, Physical Activity Assessment

Physical Activity Assessment (con't)								
	TOTAL ACTIVE CLINICAL5 AND OLDER							
	Age Distribution							
	5-11	12-19	20-24	25-34	35-44	45-54	55-74	>74 yrs
CURRENT REPORT PERIOD								
Total # AC Pts =>5	132	157	133	233	215	216	225	46
# w/ physical activity assessment	2	6	3	1	2	0	3	2
% w/ physical activity assessment	1.5	3.8	2.3	0.4	0.9	0.0	1.3	4.3
# w/ exercise educ w/ % of physical activity assessment	1	2	1	0	0	0	0	0
% w/ exercise educ w/ % of physical activity assessment	50.0	33.3	33.3	0.0	0.0	0.0	0.0	0.0

PREVIOUS YEAR PERIOD								
Total # AC Pts =>5	141	137	128	172	151	140	137	25
# w/ physical activity assessment	0	0	0	0	0	0	0	0
% w/ physical activity assessment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
# w/ exercise educ w/ % of physical activity assessment	0	0	0	0	0	0	0	0
% w/ exercise educ w/ % of physical activity assessment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CHANGE FROM PREV YR %								
# w/ physical activity assessment	+1.5	+3.8	+2.3	+0.4	+0.9	+0.0	+1.3	+4.3
w/ exercise educ w/ % of physical activity assessment	+50.0	+33.3	+33.3	+0.0	+0.0	+0.0	+0.0	+0.0

Figure 2-76: Sample Age Breakout Report, Physical Activity Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Physical Activity Assessment: List of patients with physical activity assessment and any exercise education.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB	
PATIENT1,MISTY DAWN UP,AC	000001	COMMUNITY #1 PHYS ACT: 08/08/16	F	5	03/13/11	VERY ACTIVE; EXER ED: 08/08/16 OBS-EX
PATIENT2,RITA ANN UP,AC	000002	COMMUNITY #1 PHYS ACT: 03/06/16	F	15	06/12/01	SOME ACTIVITY; EXER ED: 03/06/16 TO-EX
PATIENT3,RHONDA SUE UP,AC	000003	COMMUNITY #1 PHYS ACT: 04/02/16	F	22	06/07/94	ACTIVE; EXER ED: 04/02/16 V65.41
PATIENT4,MARY UP,AC	000004	COMMUNITY #1 PHYS ACT: 11/12/16	F	28	01/16/88	SOME ACTIVITY;
PATIENT5,JOSEPH HENRY UP,AC	000005	COMMUNITY #1 PHYS ACT: 08/02/16	M	12	10/10/04	SOME ACTIVITY;
PATIENT6,BOB UP,AC	000006	COMMUNITY #1 PHYS ACT: 05/05/16	M	17	11/19/99	INACTIVE; EXER ED: 05/05/16 OBS-EX

Figure 2-77: Sample Patient List, Physical Activity Assessment

## 2.8.6 Comprehensive Health Screening

### Denominators

*Active Clinical patients ages 2 and older.*

*Active Clinical patients ages 12 to 75.*

*Active Clinical patients ages 18 and older.*

*Female Active Clinical patients ages 14 through 46.*

*Active Clinical patients ages 5 and older.*

*Active Clinical patients ages 2 through 74.*

*Active Clinical patients ages 20 and over.*

*Active Clinical patients ages 5 and older.*

### **Numerators**

ALL Comprehensive Health Screening: Patients with Comprehensive Health Screening for which they are eligible, defined as having alcohol, depression, and Intimate Partner Violence/Domestic Violence (IPV/DV) screening, BMI calculated, and tobacco use, BP, and physical activity assessed.

**Note:** This does *not* include refusals.

Comprehensive Health Screening: Patients with Comprehensive Health Screening minus physical activity assessment for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use and BP assessed.

**Note:** This does *not* include physical activity assessment and does *not* include refusals.

Alcohol Screening: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.

**Note:** This numerator does *not* include refusals or alcohol-related patient education.

Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note:** This numerator does *not* include refusals.

IPV/DV Screening: Patients screened for IPV/DV at any time during the Report Period.



**Note:** This numerator does *not* include refusals.

Tobacco Use Assessed: Patients who have been screened for tobacco use during the Report period.

BMI Available: Patients for whom a BMI could be calculated.

**Note:** This numerator does *not* include refusals.

BP Assessed: Patients with BP value documented at least twice in prior 2 years.

Physical Activity Assessed: Patients assessed for physical activity during the Report Period.

### Logic Description

Age of the patient is calculated at beginning of Report Period.

*Alcohol screening definition:* Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

Subject Defined	ICD and Other Codes
Alcohol Screening	<p><b>Exam Code:</b> 35</p> <p><b>CPT code:</b> 99408, 99409, G0396, G0397, H0049, H0050, 3016F</p> <p><b>Any CAGE Health Factor</b></p> <p><b>POV:</b> ICD-9: V11.3 (history of alcoholism), V79.1 (screening for alcoholism)</p> <p><b>BHS Problem Code:</b> 29.1 (Screening for Alcoholism)</p> <p><b>Measurement in PCC or BHS:</b> AUDT, AUDC, or CRFT</p>
Alcohol-related Diagnosis	<p><b>POV, Current PCC or BHS Problem List:</b> ICD-9: 303.*, 305.0*, 291.*, 357.5*; ICD-10: F10.1*, F10.20, F10.220-F10.29, F10.920-F10.982, F10.99, G62.1</p> <p><b>BHS POV:</b> 10, 27, 29</p>
Alcohol-related Procedure	<p><b>Procedure:</b> ICD-9: 94.46, 94.53, 94.61-94.63, 94.67-94.69</p>

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

*Depression screening definition:* CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
Depression Screening	<b>Exam:</b> Exam Code 36 <b>POV:</b> ICD-9: V79.0 <b>CPT:</b> 1220F, 3725F, G0444 <b>BHS Problem Code:</b> 14.1 (Screening for Depression) <b>Measurement in PCC or BHS:</b> PHQ2 or PHQ9
Mood Disorders	<b>At least two visits in PCC or BHS for:</b> Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS. <b>POV:</b> ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39 <b>BHS POV:</b> 14, 15

*IPV/DV screening definition:* CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
IPV/DV Screening	<b>Exam:</b> Code 34 <b>BHS Exam:</b> IPV/DV
IPV/DV Diagnosis	<b>POV or current PCC or BHS Problem List:</b> ICD-9: 995.80-995.83, 995.85, V15.41, V15.42, V15.49; ICD-10: T74.11XA, T74.21XA, T74.31XA, T74.91XA, T76.11XA, T76.21XA, T76.31XA, T76.91XA, Z91.410 <b>BHS POV:</b> 43.*, 44.*
IPV/DV Education	<b>Patient education codes:</b> Containing "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, V15.49, or SNOMED 3027571011, 3027627017, 371772001, 406138006, 412732008, 429746005, 431027007, 432527004
IPV/DV Counseling	<b>POV:</b> ICD-9: V61.11; ICD-10: Z69.11

*Tobacco screening definition:* CRS uses the following codes to define the numerator.

Subject Defined	CPT Codes	ICD and Other Codes
Screened for Tobacco Use	D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8455-G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed)	<p><b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z72.0, Z87.891</p> <p><b>Patient Education codes:</b> Containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, or SNOMED codes 160603005, 160604004, 160605003, 160606002, 160619003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005</p> <p><b>Dental code:</b> 1320</p> <p><b>Health Factor categories:</b> Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE)</p>

*BMI calculation definition:* CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.

*Blood pressure definition:* Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses mean of last 3 Blood Pressures documented in the past 2 years. If 3 BPs are not available, use the mean of last 2 BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

*Physical Activity Assessment definition:* CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
Physical Activity Assessment	<b>Health Factors:</b> Any health factor for category Activity Level documented during the Report Period.

### Key Logic Changes from CRS Version 15.1

1. Updated age range to 14-46 for IPV/DV measure.
2. Added SNOMED codes to Patient Education for IPV/DV Patient Education.
3. Added SNOMED codes to Patient Education for Tobacco Screening.

### Patient List Description

List of patients with assessments received, if any.

DU	November 25, 2016	Page 181
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		
Baseline Period: Jan 01, 2010 to Dec 31, 2010		
-----		
Comprehensive Health Screening		
REPORT	%	PREV YR % CHG from BASE % CHG from

	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
Active Clinical ages 2 and older	1,446		1,121			1,007		
# w/ Comprehensive Health Screening-No Refusals	56	3.9	39	3.5	+0.4	40	4.0	-0.1
# w/ Comprehensive Health Screening-No Refusals or Phys Activity	67	4.6	46	4.1	+0.5	53	5.3	-0.6
Active Clinical ages 12-75	1,180		867			753		
# w/ alcohol screening/ Dx/Proc/-No Refusals or Pt Ed	95	8.1	12	1.4	+6.7	3	0.4	+7.7
Active Clinical => 18	1,112		793			666		
# w/ Depression screening or Mood Disorder Dx- No Refusals	81	7.3	42	5.3	+2.0	17	2.6	+4.7
# Female Active Clinical ages 15-40	380		311			267		
# w/IPV/DV screening- No Refusals	11	2.9	1	0.3	+2.6	0	0.0	+2.9
# Active Clinical Pts =>5	1,357		1,031			911		
# w/Tobacco Screening	624	46.0	426	41.3	+4.7	328	36.0	+10.0
Active Clinical Pts 2-74	1,400		1,096			982		
# w/BMI calculated- No Refusals	880	62.9	824	75.2	-12.3	712	72.5	-9.6
Active Clinical Patients ages 20 and older	1,068		753			640		
# w/ BPs documented w/in 2 yrs	643	60.2	557	74.0	-13.8	478	74.7	-14.5
Active Clinical Pts 5 and older	1,357		1,031			911		
# w/ physical activity assessment	19	1.4	0	0.0	+1.4	0	0.0	+1.4

Figure 2-78: Sample Report, Comprehensive Health Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Comprehensive Health Screening: List of patients with assessments received, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,SANDRA KAY AC	000001	COMMUNITY #1 ALL COMP HEALTH:	F	15	08/18/01
03/06/16 Ex 34; ACTIVITY		NEVER SMOKED;			
PATIENT2,CAITLYN AC	000002	COMMUNITY #1	F	16	03/19/00
PATIENT3,BRITNEY AC	000003	COMMUNITY #1 TOB: 10/26/16	F	16	07/24/00
PATIENT4,LORETTA AC	000004	COMMUNITY #1 ALC: 10/14/16	F	17	05/12/99
PATIENT5,HALEY AC	000005	COMMUNITY #1 BMI: 19.79; BP: 125/67	F	18	07/22/98
PATIENT6,BRITTANY AC	000006	COMMUNITY #1 ALC: 10/30/16	F	19	12/16/97
		CPT G0397; TOB: 08/11/16			
		STATUS UNKNOWN; BMI: 21.01			

Figure 2-79: Sample Patient List, Comprehensive Health Screening

## 2.8.7 Cardiovascular Disease and Blood Pressure Control

### Denominators

All *Active Clinical patients* ages 18 and over. Broken down by gender.

All *User Population patients* ages 18 and older. Broken down by gender.

*Active CHD patients*, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, *and* at least two visits during the Report Period, *and* two CHD-related visits ever. Broken down by gender.

### Numerators

Patients with Blood Pressure value documented during the Report Period.

### Logic Description

Age of the patient is calculated at beginning of the Report Period.

CRS uses the following codes to define the CHD denominator.

Subject Defined	ICD and Other Codes
Coronary Heart Disease	<i>Any of the following:</i>

Subject Defined	ICD and Other Codes
	<p><b>1) POV:</b> ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0–I22.8, I24.0–I25.83, I25.89, I25.9, Z95.5</p> <p><b>2) One or more CABG or PCI procedures</b></p>
CABG	<p><b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1</p> <p><b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33530, 33533-33536, 33572, 35500, 35600, S2205-S2209</p> <p><b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*</p>
PCI	<p><b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61</p> <p><b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290</p> <p><b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**</p>

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

*Blood pressure definition:* CRS uses mean of last 3 Blood Pressures documented during the Report Period. If 3 BPs are not available, uses mean of last 2 BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

### Key Logic Changes from CRS Version 15.1

1. Added ICD-10 POV code Z95.5 to CHD definition.
2. Added CPT codes 33530, 33572, 35500, 35600 to CABG definition.

## Patient List Description

List of Patients greater than or equal to (=>) 18 or who have CHD with BP value, if any.

## Measure Source

HP 2020 HDS-5

## Measure Past Performance and Long-Term Targets

Measure	Percent
HP 2020 goal for adults with high blood pressure (140/90)	26.9%

DU									
November 25, 2016									
Page 196									
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Cardiovascular Disease and Blood Pressure Control									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %	
Active Clinical Patients									
ages 20 and older	1,068		753			640			
# w/ BPs documented									
w/in 2 yrs	643	60.2	557	74.0	-13.8	478	74.7	-14.5	
A. # w/Normal BP w/ %									
of Total Screened	128	19.9	134	24.1	-4.2	121	25.3	-5.4	
B. # w/Pre HTN I BP w/ %									
of Total Screened	107	16.6	115	20.6	-4.0	83	17.4	-0.7	
C. # w/Pre HTN II BP w/ %									
of Total Screened	148	23.0	114	20.5	+2.6	105	22.0	+1.1	
D. # w/Stage 1 HTN BP w/ %									
of Total Screened	173	26.9	150	26.9	+0.0	130	27.2	-0.3	
E. # w/Stage 2 HTN BP w/ %									
of Total Screened	37	5.8	39	7.0	-1.2	39	8.2	-2.4	
Male Active Clinical Patients									
ages 20 and older	432		293			241			
# w/ BPs documented									
w/in 2 yrs	231	53.5	203	69.3	-15.8	177	73.4	-20.0	
A. # w/Normal BP w/ %									
of Total Screened	8	3.5	23	11.3	-7.9	22	12.4	-9.0	
B. # w/Pre HTN I BP w/ %									
of Total Screened	27	11.7	37	18.2	-6.5	22	12.4	-0.7	
C. # w/Pre HTN II BP w/ %									
of Total Screened	64	27.7	46	22.7	+5.0	45	25.4	+2.3	



D. # w/Stage 1 HTN BP w/ % of Total Screened	89	38.5	79	38.9	-0.4	63	35.6	+2.9
E. # w/Stage 2 HTN BP w/ of Total Screened	16	6.9	17	8.4	-1.4	25	14.1	-7.2
Female Active Clinical Patients ages 20 and older								
	636		460			399		
# w/ BPs documented w/in 2 yrs	412	64.8	354	77.0	-12.2	301	75.4	-10.7
A. # w/Normal BP w/ % of Total Screened	120	29.1	111	31.4	-2.2	99	32.9	-3.8
B. # w/Pre HTN I BP w/ % of Total Screened	80	19.4	78	22.0	-2.6	61	20.3	-0.8
C. # w/Pre HTN II BP w/ % of Total Screened	84	20.4	68	19.2	+1.2	60	19.9	+0.5
D. # w/Stage 1 HTN BP w/ % of Total Screened	84	20.4	71	20.1	+0.3	67	22.3	-1.9
E. # w/Stage 2 HTN BP w/ % of Total Screened	21	5.1	22	6.2	-1.1	14	4.7	+0.4

Figure 2-80: Sample Report, CVD and Blood Pressure Control

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Cardiovascular Disease and Blood Pressure Control: List of Patients => 20 or  
 who have CHD with BP value, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,SANDRA KAY UP,AC	000001	COMMUNITY #1	F	21	03/12/95
PATIENT2,EVELYN UP	000002	COMMUNITY #1 /3080F	F	21	05/19/95
PATIENT3,MICHELLE UP,AC	000003	COMMUNITY #1 125/67	F	22	02/15/94
PATIENT4,CAITLYN UP,AC,IHD	000004	COMMUNITY #1 131/67	F	22	08/12/94
PATIENT5,BRITNEY JANE UP,AC	000005	COMMUNITY #1 102/56	F	22	10/01/94
PATIENT6,KATHRYN ANNE UP,AC	000006	COMMUNITY #1 161/90	F	22	10/16/94
PATIENT7,RHONDA UP,AC	000007	COMMUNITY #1 153/85	F	22	11/23/94

Figure 2-81: Sample Patient List, CVD and Blood Pressure Control

## 2.8.8 Controlling High Blood Pressure

### Denominator

*Active Clinical patients* ages 18 through 85 diagnosed with hypertension and no documented history of ESRD. Broken down by gender and age groups (18 through 45 and 46 through 85).

### Numerators

Number of patients with Blood Pressure value documented during the Report Period.

### Logic Description

Age of the patient is calculated at beginning of the Report Period.

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

*Blood pressure definition:* CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, use the mean of last 2 BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

CRS uses the following codes to define ESRD and hypertension.

Subject Defined	CPT Codes	ICD and Other Codes
ESRD	36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339	<b>POV:</b> ICD-9: 585.6, V42.0, V45.1, (old code), V45.11, V45.12, V56.*; ICD-10: N18.6, Z48.22, Z49.*, Z91.15, Z94.0, Z99.2 <b>Procedure:</b> ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6*
Hypertension		<b>POV or Problem List entry where the status is not Inactive or Deleted Prior to the Report Period and at Least One Hypertension POV during Report Period:</b> ICD-9: 401.*; ICD-10: I10

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients with hypertension and BP value, if any.

### Measure Source

HP 2020 HDS-5, HDS-12

### Measure Past Performance and Long-Term Targets

Measure	Percent
<i>HP 2020 goal for adults with high blood pressure (140/90)</i>	26.9%
<i>HP 2020 goal for adults with high blood pressure and whose blood pressure is controlled</i>	61.2%

DU	November 25, 2016	Page 200
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		

Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Controlling High Blood Pressure									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %	
Active Clinical Pts									
18-85 w/HTN dx	108		101			91			
# w/ BPs									
documented	96	88.9	92	91.1	-2.2	85	93.4	-4.5	
A. # w/Normal BP w/ %									
of Total Screened	5	5.2	6	6.5	-1.3	3	3.5	+1.7	
B. # w/Pre HTN I BP w/ %									
of Total Screened	8	8.3	13	14.1	-5.8	8	9.4	-1.1	
C. # w/Pre HTN II BP w/ %									
of Total Screened	23	24.0	17	18.5	+5.5	19	22.4	+1.6	
D. # w/Stage 1 HTN BP w/ %									
of Total Screened	36	37.5	41	44.6	-7.1	42	49.4	-11.9	
E. # w/Stage 2 HTN BP w/ %									
of Total Screened	10	10.4	15	16.3	-5.9	13	15.3	-4.9	
A. Active Clinical Pts									
18-45 w/HTN dx	23		19			13			
# w/ BPs									
documented	17	73.9	16	84.2	-10.3	11	84.6	-10.7	
A. # w/Normal BP w/ %									
of Total Screened	2	11.8	2	12.5	-0.7	0	0.0	+11.8	
B. # w/Pre HTN I BP w/ %									
of Total Screened	1	5.9	1	6.3	-0.4	1	9.1	-3.2	
C. # w/Pre HTN II BP w/ %									
of Total Screened	3	17.6	2	12.5	+5.1	2	18.2	-0.5	
D. # w/Stage 1 HTN BP w/ %									
of Total Screened	7	41.2	6	37.5	+3.7	7	63.6	-22.5	
E. # w/Stage 2 HTN BP w/ %									
of Total Screened	2	11.8	5	31.3	-19.5	1	9.1	+2.7	
B. Active Clinical Pts									
46-85 w/HTN dx	85		82			78			
# w/ BPs									
documented	79	92.9	76	92.7	+0.3	74	94.9	-1.9	
A. # w/Normal BP w/ %									
of Total Screened	3	3.8	4	5.3	-1.5	3	4.1	-0.3	
B. # w/Pre HTN I BP w/ %									
of Total Screened	7	8.9	12	15.8	-6.9	7	9.5	-0.6	
C. # w/Pre HTN II BP w/ %									
of Total Screened	20	25.3	15	19.7	+5.6	17	23.0	+2.3	
D. # w/Stage 1 HTN BP w/ %									
of Total Screened	29	36.7	35	46.1	-9.3	35	47.3	-10.6	
E. # w/Stage 2 HTN BP w/ %									
of Total Screened	8	10.1	10	13.2	-3.0	12	16.2	-6.1	

Figure 2-82: Sample Report, Controlling High Blood Pressure

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Controlling High Blood Pressure: List of patients with hypertension and BP value, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,STELLA LYNN HTN PT	000001	COMMUNITY #1 156/82	F	46	06/12/70
PATIENT2,TARA HTN PT	000002	COMMUNITY #1 201/87	F	51	03/18/65
PATIENT3,BOBBIE HTN PT	000003	COMMUNITY #1 3074F/	F	52	05/16/64
PATIENT4,DARLENE HTN PT	000004	COMMUNITY #1 139/73	F	54	04/12/62
PATIENT5,NADINE HTN PT	000005	COMMUNITY #1 159/86	F	61	10/18/55

Figure 2-83: Sample Patient List, Controlling High Blood Pressure

## 2.8.9 Controlling High Blood Pressure (Million Hearts)

### **GPRA Measure Description**

During GPRA Year 2016, achieve the target rate of 60.6% for the proportion of patients with BP less than (<) 140/90.

### **Denominator**

User Population patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD or current diagnosis of pregnancy. Broken down by age groups 18 through 59 and 60 through 85 (Million Hearts (NQF 0018)).

### **Numerators**

Patients with BP less than (<) 140/90, i.e., the systolic value is less than (<) 140 AND the diastolic value is less than (<) 90 (Million Hearts (NQF 0018)).

Patients with BP less than (<) 150/90 (i.e., the systolic value is less than (<) 150 AND the diastolic value is less than (<) 90).

### **Logic Description**

Age of the patient is calculated at the end of the Report Period.

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses the last Blood Pressure documented during the Report Period.

CRS uses the following codes to define ESRD, hypertension, and pregnancy.

Subject Defined	CPT Codes	ICD and Other Codes
ESRD	36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339	<b>POV:</b> ICD-9: 585.6, V42.0, V45.1, (old code), V45.11, V45.12, V56.*; ICD-10: N18.6, Z48.22, Z49.*, Z91.15, Z94.0, Z99.2 <b>Procedure:</b> ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6*
Hypertension		<b>POV or Problem List entry where the status is not Inactive or Deleted ever through the first 6 months of the Report Period, and at least one hypertension POV during Report Period:</b> ICD-9: 401.*; ICD-10: I10

Subject Defined	CPT Codes	ICD and Other Codes
<p>Pregnancy - At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following codes. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.</p>	<p><b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828</p>	<p><b>POV or Problem diagnosis:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36</p> <p><b>Procedure:</b> ICD-9: 72.*, 73.*, 74.*</p>
Miscarriage	59812, 59820, 59821, 59830	<p><b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9</p>
Abortion	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267	<p><b>POV:</b> ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2</p> <p><b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z</p>

### Key Logic Changes from CRS Version 15.1

1. Added two new measures: 18-59 with BP < 140/90 and 60-85 with BP < 150/90.
2. Removed POV codes 674.\*3, 675.\*3, and 676.\*3 from pregnancy definition.
3. Added POV codes V24.\* and V27.\* to pregnancy definition.
4. Added Procedure codes 72.\*, 73.\*, and 74.\* to pregnancy definition.
5. Added CPT codes 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, and 76801-76828 to pregnancy definition.

### Patient List Description

List of patients with hypertension and BP value, if any.

### Measure Source

Not Available

### Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2015 Performance	58.5%
IHS FY 2014 Performance	59.5%

DU		November 25, 2016		Page 200				
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Controlling High Blood Pressure - Million Hearts								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %
User Pop Pts 18-85 w/HTN dx (Million Hearts) (GPRA)	302		403			380		
# w/ BP <140/90 (Million Hearts) (GPRA)	145	48.0	218	54.1	-6.1	211	55.5	-7.5
User Pop Pts 18-59 w/HTN dx	208		292			274		
# w/ BP <140/90								



(Million Hearts)	95	45.7	156	53.4	-7.8	144	52.6	-6.9
User Pop Pts 60-85 w/HTN dx	93		110			104		
# w/ BP <150/90	64	68.8	83	75.5	-6.6	73	70.2	-1.4

Figure 2-84: Sample Report, Controlling High Blood Pressure (Million Hearts)

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Controlling High Blood Pressure - Million Hearts: List of patients with hypertension and BP value, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,STELLA LYNN HTN PT	000001	COMMUNITY #1 156/82	F	46	06/15/70
PATIENT2,TARA HTN PT	000002	COMMUNITY #1 201/87	F	51	02/01/65
PATIENT3,BOBBIE HTN PT	000003	COMMUNITY #1 3074F/	F	52	03/28/64
PATIENT4,DARLENE HTN PT	000004	COMMUNITY #1 139/73	F	54	10/19/62
PATIENT5,NADINE HTN PT	000005	COMMUNITY #1 159/86	F	61	01/16/55

Figure 2-85: Sample Patient List, Controlling High Blood Pressure (Million Hearts)

## 2.8.10 Comprehensive CVD-Related Assessment

### GPRAMA Measure Description

During GPRA Year 2016, achieve the target rate of 53.3% for the proportion of at-risk patients who have a comprehensive assessment.

#### Denominators

*Active CHD patients* ages 22 and older, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, *and* at least two visits during the Report Period, *and* two CHD-related visits ever. (GPRAMA Denominator)

- a. *Active CHD patients* ages 22 and older who are not Active Diabetic
- b. *Active CHD patients* ages 22 and older who are Active Diabetic

*User Pop CHD patients* ages 22 and older, defined as all User Population patients diagnosed with coronary heart disease (CHD) prior to the Report Period, *and* at least two visits during the Report Period, *and* two CHD-related visits ever.

## Numerators

*BP Assessed:* Patients with Blood Pressure value documented at least twice in prior 2 years.

*Tobacco Use Assessed:* Patients who have been screened for tobacco use during the Current Report period.

*BMI Available:* Patients for whom a BMI could be calculated.

**Note:** This numerator does *not* include refusals.

*Lifestyle Counseling:* Patients who have received any lifestyle adaptation counseling, including medical nutrition therapy, or nutrition, exercise or other lifestyle education or patient goals during the Report Period.

Patients with *comprehensive CVD assessment*, defined as having BP and tobacco use assessed, BMI calculated, and lifestyle counseling. (GPRAMA Numerator)

**Note:** This does *not* include depression screening and *does not* include refusals of BMI.

*Depression Screening:* Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note:** This numerator does *not* include refusals.

## Logic Description

Age of the patient is calculated at beginning of the Report Period.

*Diabetes defined as:* Diagnosed with diabetes (first POV in V POV with ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\*) prior to the Current Report Period, *and* at least two visits during the Current Report Period, *and* two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

CRS uses the following codes and taxonomies to define the denominators.

Subject Defined	ICD and Other Codes
Coronary Heart Disease	<i>Any of the following:</i> <b>1) POV:</b> ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0–I22.8, I24.0–I25.83, I25.89, I25.9, Z95.5 <b>2) One or more CABG or PCI procedures</b>
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1

Subject Defined	ICD and Other Codes
	<b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33530, 33533-33536, 33572, 35500, 35600, S2205-S2209 <b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	<b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61 <b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290 <b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**

*Blood pressure definition:* Having a minimum of 2 BPs documented in past 2 years. If CRS does not find 2 BPs, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the past 2 years. The following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

*BMI definition:* CRS calculates when the report is run, using NHANES II. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years; not required to be recorded on same day.

CRS uses the following codes and taxonomies to define the numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Tobacco Screening	D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code) or G8453 (old code), G9275, G9276	<p><b>Any health factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE) (see table on next page)</b></p> <p><b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z72.0, Z87.891</p> <p><b>Patient education codes:</b> containing “TO-”, “-TO”, “-SHS”, 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code) or G8453 (old code), G9275, G9276, or SNOMED codes 160603005, 160604004, 160605003, 160606002, 160619003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005</p> <p><b>Dental code:</b> 1320</p>		
Medical Nutrition Therapy	97802-97804, G0270, G0271	<p><b>Primary or secondary provider codes:</b> 07, 29</p> <p><b>Clinic codes:</b> 67 (dietary) or 36 (WIC)</p>		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Nutrition Education		<p><b>POV:</b> ICD-9: V65.3 dietary surveillance and counseling; ICD-10: Z71.3</p> <p><b>Patient education codes:</b> ending “-N” (nutrition) or “-MNT” (medical nutrition therapy) (or old code “-DT” (diet)) or containing V65.3; or Patient Goal with Goal Type of "Nutrition" and Goal Status of "Goal Set", "Goal Met", "Maintaining Goal", or "No Change" during the Report Period</p>		
Exercise Education		<p><b>POV:</b> ICD-9: V65.41 exercise counseling</p> <p><b>Patient education codes:</b> ending “-EX” (exercise) or containing V65.41; or Patient Goal with Goal Type of "Physical Activity" and Goal Status of "Goal Set", "Goal Met", "Maintaining Goal", or "No Change" during the Report Period</p>		
Related Exercise and Nutrition Education		<p><b>Patient education codes:</b> ending “-LA” (lifestyle adaptation) or containing “OBS-“ (obesity) or 278.00 or 278.01, or SNOMED codes 111036000, 162863004, 162863004, 162864005, 162864005, 170798000, 190965006, 190966007, 238131007, 238132000, 238133005, 238134004, 238136002, 248311001, 248312008, 270486005, 275947003, 276792008, 290439001, 292464007, 293481008, 294493008, 295509007, 296526005, 297500005, 298464002, 360566006, 363247006, 408512008, 413487000, 414438005, 414916001, 414917005, 414918000, 414919008, 414920002, 415530009, 444862003, 444862003, 44772007, 450451007, 48499001, 5036006, 53146006, 62999006, 703316004, 705131003, 80660001, 82793005.</p>		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Depression Screening		<b>Exam:</b> Exam Code 36 <b>POV:</b> ICD-9: V79.0 <b>CPT:</b> 1220F, 3725F, G0444 <b>BHS Problem Code:</b> 14.1 (Screening for Depression) <b>Measurement in PCC or BH:</b> PHQ2 or PHQ9		
Mood Disorders		<b>At least 2 visits in PCC or BHS for:</b> Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS (see codes below). <b>POV:</b> ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39 <b>BHS POV:</b> 14, 15		
Suicide Ideation		<b>POV:</b> ICD-9: V62.84; ICD-10: R45.851 <b>BHS POV:</b> 39		

All existing national Tobacco Health Factors listed below are counted as tobacco screening.

Health Factor
Ceremonial
Cessation-Smokeless
Cessation-Smoker
Current Smokeless
Current Smoker
Current Smoker, status unknown
Current smoker, every day

<b>Health Factor</b>
Current smoker, some day
Non-Tobacco User
Previous Smokeless
Previous (Former) Smokeless
Previous Smoker
Previous (Former) Smoker
Smoke Free Home
Smoker In Home
Current Smoker & Smokeless
Exposure To Environmental Tobacco Smoke

### **Key Logic Changes from CRS Version 15.1**

1. Removed LDL measure from topic and comprehensive measure.
2. Added ICD-10 POV code Z95.5 to CHD definition.
3. Added CPT codes 33530, 33572, 35500, and 35600 to CABG definition.
4. Added SNOMED codes to Patient Education for related exercise and nutrition education.
5. Added SNOMED codes to Patient Education for tobacco screening.

### **Patient List Description**

List of patients with assessments received, if any.

### **Measure Source**

Not Available

### **Measure Past Performance Long-Term Targets**

<b>Performance</b>	<b>Percent</b>
IHS FY 2015 Performance (Comprehensive CVD Assessment)	55.0%
IHS FY 2014 Performance (Comprehensive CVD Assessment)	52.3%
IHS FY 2013 Performance (Comprehensive CVD Assessment)	46.7%
IHS FY 2012 Performance (Comprehensive CVD Assessment)	37.5%
IHS FY 2011 Performance (Comprehensive CVD Assessment)	32.2%
<i>Former definitions:</i>	
IHS FY 2012 Performance (Comprehensive CVD Assessment)	45.4%

Performance	Percent
IHS FY 2011 Performance (Comprehensive CVD Assessment)	39.8%
IHS FY 2010 Performance (Comprehensive CVD Assessment)	35.0%
IHS FY 2009 Performance (Comprehensive CVD Assessment)	32.0%
IHS FY 2008 Performance (Comprehensive CVD Assessment)	30.0%
IHS FY 2007 Performance (Comprehensive CVD Assessment)	30.0%
IHS FY 2011 Performance (BP Assessed)	97.2%
IHS FY 2010 Performance (BP Assessed)	98.0%
IHS FY 2009 Performance (BP Assessed)	97.0%
IHS FY 2008 Performance (BP Assessed)	98.0%
IHS FY 2011 Performance (LDL Assessed)	92.9%
IHS FY 2010 Performance (LDL Assessed)	92.0%
IHS FY 2009 Performance (LDL Assessed)	91.0%
IHS FY 2008 Performance (LDL Assessed)	90.0%
IHS FY 2011 Performance (Tobacco Assessed)	84.2%
IHS FY 2010 Performance (Tobacco Assessed)	84.0%
IHS FY 2009 Performance (Tobacco Assessed)	83.0%
IHS FY 2008 Performance (Tobacco Assessed)	79.0%
IHS FY 2011 Performance (BMI Assessed)	97.2%
IHS FY 2010 Performance (BMI Assessed)	98.0%
IHS FY 2008 Performance (BMI Assessed or Refused)	85.0%
IHS FY 2011 Performance (Lifestyle Counseling)	45.3%
IHS FY 2010 Performance (Lifestyle Counseling)	41.0%
IHS FY 2009 Performance (Lifestyle Counseling)	39.0%
IHS FY 2008 Performance (Lifestyle Counseling)	38.0%
IHS FY 2011 Performance (Depression Screen)	75.7%
IHS FY 2010 Performance (Depression Screen)	72.0%
IHS FY 2009 Performance (Depression Screen)	62.0%
IHS FY 2008 Performance (Depression Screen)	53.0%

DU	November 25, 2016	Page 207						
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Comprehensive CVD-Related Assessment								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active CHD Pts 22+ (GPRAMA)	73		40			31		



# w/ BPs documented								
w/in 2 yrs	54	74.0	38	95.0	-21.0	31	100.0	-26.0
# w/Tobacco Screening								
w/in 1 yr	57	78.1	32	80.0	-1.9	23	74.2	+3.9
# w/BMI calculated								
-No Refusals	58	79.5	38	95.0	-15.5	31	100.0	-20.5
# w/ lifestyle								
educ w/in 1 yr	40	54.8	21	52.5	+2.3	20	64.5	-9.7
# w/ BP, tobacco, BMI and								
life counseling-No Refusals or Dep								
(GRPAMA)	19	26.0	15	37.5	-11.5	6	19.4	+6.7
# w/ Depression screening, or mood								
disorder or suicide ideation								
DX-No Refusals	22	30.1	3	7.5	+22.6	1	3.2	+26.9
A. Active CHD Pts 22+								
and are NOT Active								
Diabetic								
	40		19			13		
# w/ BPs documented								
w/in 2 yrs	25	62.5	18	94.7	-32.2	13	100.0	-37.5
# w/Tobacco Screening								
w/in 1 yr	27	67.5	13	68.4	-0.9	10	76.9	-9.4
# w/BMI calculated								
-No Refusals	29	72.5	18	94.7	-22.2	13	100.0	-27.5
# w/ lifestyle								
educ w/in 1 yr	21	52.5	7	36.8	+15.7	5	38.5	+14.0
# w/ BP, tobacco, BMI and								
life counseling-No Refusals or Dep								
Screen (GPRA Dev.)	9	22.5	6	31.6	-9.1	2	15.4	+7.1
# w/ Depression screening, or mood								
disorder or suicide ideation								
DX-No Refusals	14	35.0	1	5.3	+29.7	1	7.7	+27.3

Figure 2-86: Sample Report, Comprehensive CVD-Related Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Comprehensive CVD-Related Assessment: List of patients with assessments received, if any.

PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB
DENOMINATOR		NUMERATOR			
PATIENT1,CAITLYN	000001	COMMUNITY #1	F	22	03/08/94
IHD		ALL: BP: 131/67; TOB: 07/25/16 NEVER SMOKED; BMI: 25.4; LIFE: 08/15/16 UTI-N SN; DEP: 05/03/16 Meas PHQ9			
PATIENT2,CARLA	000002	COMMUNITY #1	F	40	06/07/76
IHD		BP: 112/66; TOB: 08/26/16 NEVER SMOKED; BMI: 33.7			
PATIENT3,JENNY	000003	COMMUNITY #1	F	47	06/12/69
IHD		BP: 3074F//; TOB: 11/01/16 D1320; BMI: 39.5; LIFE: 03/03/16 Prv 97; DEP: 11/01/16 CPT 1220F			
PATIENT4,SHERRY	000004	COMMUNITY #1	F	68	09/09/48
IHD,AD		ALL: BP: 150/82; TOB: 10/30/16 NEVER SMOKED; BMI: 26.8; LIFE: 10/19/16 PM-LA			

PATIENT5, PAULINE	000005	COMMUNITY #1	F	70	12/12/46
IHD, AD		BP: 149/72;	TOB: 10/24/16	CURRENT	SMOKER, STATUS
UNKNOWN;	BMI: 37.5				
PATIENT6, TINA MARIE	000006	COMMUNITY #1	F	78	11/03/38
IHD, AD		BP: 3077F/;	TOB: 01/27/16	G8402;	BMI: 43.4; DEP:
09/11/16 Meas	PHQ2				

Figure 2-87: Sample Patient List: Comprehensive CVD-Related Assessment

## 2.8.11 Appropriate Medication Therapy after a Heart Attack

### Denominator

*Active Clinical patients* aged 35 and older discharged for an AMI during the first 51 weeks of the Report Period and were not readmitted for any diagnosis within 7 days of discharge. Broken down by gender.

### Numerators

Patients with active prescription for or who have a contraindication/previous adverse reaction to *beta-blockers*.

**Note:** This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/previous adverse reaction to *ASA (aspirin) or other anti-platelet agent*.

**Note:** This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *ACEIs/ARBs*.

**Note:** This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *statins*.

**Note:** This numerator does *not* include refusals.

Also included for the numerators above are sub-numerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with active prescriptions for *all post-AMI medications* (i.e., beta-blocker, ASA/anti-platelet, ACEI/ARB, and statin), and/or who have a contraindication/previous adverse reaction.

**Note:** This numerator does *not* include refusals.

### Logic Description

Age is calculated at the beginning of the Report Period.

*Acute Myocardial Infarction (AMI) definition:* POV ICD-9: 410.\*1; ICD-10: I21.\*, I22.\* (i.e., first eligible episode of an AMI) with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the Report Period, CRS will include only the first discharge.

#### *Denominator Exclusions*

Patients meeting any of the following conditions will be excluded from the denominator.

1. Patients with Discharge Type of Irregular (AMA), Transferred, or contains "Death."
2. Patients readmitted for any diagnosis within 7 days of discharge.
3. Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).
4. Patients with a Provider Narrative beginning with "Consider"; "Doubtful"; "Maybe"; "Possible"; "Perhaps"; "Rule Out"; "R/O"; "Probable"; "Resolved"; "Suspect"; "Suspicious"; or "Status Post."

#### *Numerator Logic*

In the logic below, "ever" is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the two conditions below:

1. An active prescription (not discontinued as of [discharge date plus (+) 7 days] and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within 7 days after discharge. "Active" prescription defined as: Days Prescribed greater than (>) ((Discharge Date plus (+) 7 days) - Order Date); *or*
2. Have a contraindication/previous adverse reaction to the indicated medication.

Contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy will be counted in sub-numerator B.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

### Beta-Blocker Numerator Logic

*Beta-blocker medication codes* defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. (Medications are: Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.)

CRS uses the following codes to define contraindications to beta-blockers.

Contraindication to Beta-Blockers (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Asthma		<b>POV:</b> 2 diagnoses of ICD-9: 493*; ICD-10: J45.* on different visit dates
Hypotension		<b>POV:</b> 1 diagnosis of ICD-9: 458*; ICD-10: I95.*
Heart Block greater than (>)1 Degree		<b>POV:</b> 1 diagnosis of ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: I44.1, I44.2, I45.2, I45.3, I45.6
Sinus Bradycardia		<b>POV:</b> 1 diagnosis of ICD-9: 427.81; ICD-10: I49.5, R00.1
COPD		<b>POV:</b> 2 diagnoses on different visit dates of ICD-9: 491.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496

NMI Refusal	G8011 (old code), G9190 (Documentation of medical reason(s) for not prescribing beta-blocker therapy (e.g., allergy, intolerance, other medical reasons)) at least once during hospital stay through 7 days after discharge date	<b>Refusal:</b> NMI (not medically indicated) refusal for any beta-blocker at least once during hospital stay through 7 days after discharge date
-------------	--	---

CRS uses the following codes to define adverse drug reactions/documentated allergies to beta-blockers.

### Adverse Drug Reaction/Allergy to Beta-Blockers

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.0
<b>Entry in ART (Patient Allergies File):</b> "beta block*"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "beta block*", "bblock*" or "b block*"

### ASA (aspirin)/Other Anti-Platelet Numerator Logic

*ASA medication codes* defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

*Other anti-platelet medication codes* defined with medication taxonomy site-populated DM AUDIT ANTI-PLATELET DRUGS taxonomy.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

<b>Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Active prescription for Warfarin/Coumadin at time of arrival or prescribed at discharge		<b>Site-Populated Drug Taxonomy:</b> BGP CMS WARFARIN MEDS
Hemorrhage		<b>POV:</b> ICD-9: 459.0; ICD-10: R58

<b>Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
NMI Refusal	G8008 (old code) at least once during hospital stay through 7 days after discharge date	<b>Refusal:</b> NMI (not medically indicated) refusal for any aspirin at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documentated allergies to ASA/other anti-platelets.

### **Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets**

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E935.3; ICD-10: T39.015* or T39.095*
<b>Entry in ART (Patient Allergies File):</b> "aspirin"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "ASA" or "aspirin"

### **ACEI/ARB Numerator Logic**

*Ace Inhibitor (ACEI) medication codes* defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

CRS uses the following codes to define contraindications to ACE inhibitors.

<b>Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)</b>	<b>ICD and Other Codes</b>
Pregnancy	See below for definition

<b>Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)</b>	<b>ICD and Other Codes</b>
Breastfeeding	<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Moderate or Severe Aortic Stenosis	<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal	<b>Refusal:</b> NMI (not medically indicated) refusal for any ACE inhibitor at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documentated allergies to ACE inhibitors.

### **Adverse Drug Reaction/ Allergy to ACE Inhibitors**

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
<b>Entry in ART (Patient Allergies File):</b> "ace inhibitor" or "ACEI"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "ace i*" or "ACEI"

*ARB (Angiotensin Receptor Blocker) medication codes* defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Amlodipine-valsartan, Azilsartan-chlorthalidone, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

CRS uses the following codes to define contraindications to ARBs.

<b>Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)</b>	<b>ICD and Other Codes</b>
Pregnancy	See below for definition
Breastfeeding	<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Moderate or Severe Aortic Stenosis	<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal	<b>Refusal:</b> NMI refusal for any ARB at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documentated allergies to ARBs.

### **Adverse Drug Reaction/Allergy to ARBs**

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6
<b>Entry in ART (Patient Allergies File):</b> "Angiotensin Receptor Blocker" or "ARB"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "Angiotensin Receptor Blocker" or "ARB"

### **Statins Numerator Logic**

*Statin medication codes* defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altacor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

CRS uses the following codes to define contraindications to statins.



<b>Contraindication to Statins (any of the codes occurring ever unless otherwise noted)</b>	<b>ICD and Other Codes</b>
Pregnancy	See below for definition
Breastfeeding	<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Acute Alcoholic Hepatitis	<b>POV:</b> ICD-9: 571.1; ICD-10: K70.10, K70.11 during the Report Period
NMI Refusal	<b>Refusal:</b> NMI refusal for any statin at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documentated allergies to statins.

### **Adverse Drug Reaction/Allergy to Statins**

<b>ICD and Other Codes</b>
<b>Site-Populated Lab Taxonomy or LOINC Taxonomy:</b> DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period
<b>Site-Populated Lab Taxonomy or LOINC Taxonomy:</b> BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period
<b>POV:</b> Myopathy/Myalgia, defined as any of the following during the Report Period: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.9
<b>Entry in ART (Patient Allergies File):</b> "statin" or "statins"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "Statin" or "Statins"

Subject Defined	ICD and CPT Codes
<p><b>Pregnancy</b> - At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following codes. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.</p>	<p><b>POV or Problem List:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.* , V27.* , V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.* , O60.0*, O61.*-O66.* , O68, O69.* , O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.* , O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.* , Z36.</p> <p><b>Procedure:</b> ICD-9: 72.* , 73.* , 74.*</p> <p><b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828</p>
<p><b>Abortion</b></p>	<p><b>CPT:</b> 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267</p> <p><b>POV:</b> ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.* , Z33.2</p> <p><b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z</p>
<p><b>Miscarriage</b></p>	<p><b>CPT:</b> 59812, 59820, 59821, 59830</p> <p><b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9</p>

### All Medications Numerator Logic

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

### Key Logic Changes from CRS Version 15.1

1. Removed POV codes 674.\*3, 675.\*3, 676.\*3 from pregnancy definition.

2. Added POV codes V24.\*, V27.\* to pregnancy definition.
3. Added Procedure codes 72.\*, 73.\*, 74.\* to pregnancy definition.
4. Added CPT codes 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 to pregnancy definition.
5. Added SNOMED codes to Patient Education for breastfeeding.
6. Updated BGP PQA STATIN MEDS medication taxonomy.

**Patient List Description**

List of patients with AMI, with appropriate medication therapy, if any.

**Measure Source**

American Heart Association/American College of Cardiology Guidelines for the Treatment of AMI.

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016						Page 216	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Appropriate Medication Therapy after a Heart Attack								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts 35+ hospitalized for AMI	71		0			0		
# w/beta-blocker								
Rx/contra/ADR								
-No Refusals	27	38.0	0	0.0	+38.0	0	0.0	+38.0
A. # w/beta-blocker								
Rx w/ % of Total	5	18.5	0	0.0	+18.5	0	0.0	+18.5
B. # w/contra/ADR								
w/ % of Total	22	81.5	0	0.0	+81.5	0	0.0	+81.5
# w/ASA Rx/contra/ADR								
-No Refusals	9	12.7	0	0.0	+12.7	0	0.0	+12.7
A. # w/ASA								
Rx w/% of Total	3	33.3	0	0.0	+33.3	0	0.0	+33.3
B. # w/contra/ADR								

w/ % of Total	6	66.7	0	0.0	+66.7	0	0.0	+66.7
# w/ACEI/ARB Rx/contra/ADR -No Refusals	19	26.8	0	0.0	+26.8	0	0.0	+26.8
A. # w/ACEI/ARB Rx w/% of Total	4	21.1	0	0.0	+21.1	0	0.0	+21.1
B. # w/contra/ADR w/ % of Total	15	78.9	0	0.0	+78.9	0	0.0	+78.9
# w/statin Rx/contra/ADR -No Refusals	17	23.9	0	0.0	+23.9	0	0.0	+23.9
A. # w/statin Rx w/% of Total	5	29.4	0	0.0	+29.4	0	0.0	+29.4
B. # w/contra/ADR w/ % of Total	12	70.6	0	0.0	+70.6	0	0.0	+70.6
# w/Rx/contra/ADR of ALL meds-No Refusals	4	5.6	0	0.0	+5.6	0	0.0	+5.6

Figure 2-88: Sample Report, Appropriate Medication Therapy after a Heart Attack

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Appropriate Medication Therapy after a Heart Attack: List of patients with AMI,  
 with appropriate medication therapy, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,CECELIA AC	000001	COMMUNITY #1	F	37	08/18/79
BETA: 06/30/16 Contra 2/3 heart block POV 426.3					
PATIENT2,KATHLEEN AC	000002	COMMUNITY #1	F	38	12/15/78
ACEI/ARB: Contra pregnant; STATIN: Contra pregnant					
PATIENT3,KIMBERLY A AC	000003	COMMUNITY #1	F	49	02/27/67
ASA: 11/16/16 CLOPIDOGREL BISULFATE 75MG TAB; ACEI/ARB: 01/14/16 Contra BF-HC; STATIN: 01/14/16 Contra BF-HC					
PATIENT4,TIMOTHY JOHN AC	000004	COMMUNITY #1	M	57	04/30/59
ACEI/ARB: 06/01/16 Contra NMI CAPTOPRIL 25MG TABS					
PATIENT5,FELIPE AC	000005	COMMUNITY #1	M	57	09/12/59
PATIENT6,JAMES DALTON AC	000006	COMMUNITY #1	M	77	06/14/39
ALL MEDS: BETA: 07/23/16 Contra CPT G8011; ASA: 07/23/16 Contra CPT G8008; ACEI/ARB: 07/27/13 Contra POV 396.0; STATIN: 06/05/16 SIMVASTATIN 40MG TAB					

Figure 2-89: Sample Patient List: Appropriate Medication Therapy after a Heart Attack

## 2.8.12 Persistence of Appropriate Medication Therapy after a Heart Attack

### Denominator

*Active Clinical patients* 35 and older diagnosed with an AMI 6 months prior to the Report Period through the first 6 months of the Report Period. Broken down by gender.

### Numerators

Patients with a *135-day course of treatment with beta-blockers*, or who have a contraindication/previous adverse reaction to beta-blocker therapy.

**Note:** This numerator does *not* include refusals.

Patients with a *135-day course of treatment with ASA (aspirin) or other anti-platelet agent* or who have a contraindication/previous adverse reaction to ASA/anti-platelet therapy.

**Note:** This numerator does *not* include refusals.

Patients with a *135-day course of treatment with ACEIs/ARBs* or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

**Note:** This numerator does *not* include refusals.

Patients with a *135-day course of treatment with statins* or who have a contraindication/previous adverse reaction to statin therapy.

**Note:** This numerator does *not* include refusals.

Also included for the numerators above are sub-numerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with a *135-day course of treatment for all post-AMI medications* (i.e., beta-blocker, ASA/anti-platelet, ACEI/ARB, and statin) following first discharge date or visit date, including previous active prescriptions; and/or who have a contraindication/previous adverse reaction.

**Note:** This numerator does *not* include refusals.

## Logic Description

Age is calculated at the beginning of the Report Period.

*Acute Myocardial Infarction (AMI) definition:* POV ICD-9: 410.0\* through 410.9\*, 412; ICD-10: I21.\*, I22.\*. AMI diagnosis may be made at an inpatient or outpatient visit but must occur between 6 months prior to beginning of Report Period through first 6 months of the Report Period. Inpatient visit defined as Service Category of H (Hospitalization). If patient has more than one episode of AMI during the timeframe, CRS will include only the first hospital discharge or ambulatory visit.

## Denominator Exclusions

Patients meeting any of the following conditions will be excluded from the denominator.

- If inpatient visit, patients with Discharge Type of Irregular (AMA), Transferred, or contains “Death.”
- Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).
- Patients with a Provider Narrative beginning with “Consider,” “Doubtful,” “Maybe,” “Possible,” “Perhaps,” “Rule Out,” “R/O,” “Probable,” “Resolved,” “Suspect,” “Suspicious,” or “Status Post.”

## Numerator Logic

In the logic below, “ever” is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the two conditions below.

1. A total days’ supply greater than or equal to ( $\geq$ ) 135 days in the 180 days following discharge date for inpatient visits or visit date for ambulatory visits. Medications must not have a comment of RETURNED TO STOCK. Prior active prescriptions can be included if the treatment days fall within the 180 days following discharge/visit date. Prior active prescription defined as most recent prescription (see codes below) prior to admission/visit date with the number of days supply greater than or equal to the discharge/visit date minus the prescription date; *or*
2. Have a contraindication/previous adverse reaction to the indicated medication.
3. Contraindications/previous ADR/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy will be counted in sub-numerator B.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

Example of patient included in the beta-blocker numerator who has prior active prescription:

- Admission Date: 2/1/2016, Discharge Date: 2/15/2016
- Must have 135 days prescribed by 8/13/2016 (Discharge Date+180)
- Prior Beta-Blocker Rx Date: 1/15/2016
- # Days Prescribed: 60 (treats patient through 3/15/2016)
- Discharge Date minus Rx Date: 2/15/2016 through 1/15/2016 = 31, 60 is greater than or equal to ( $\geq$ ) 31, prescription is considered Prior Active Rx
- 3/15/2016 is between 2/15 and 8/13/2016, thus remainder of Prior Active Rx can be counted toward 180-day treatment period
- # Remaining Days Prescribed from Prior Active Rx:
- $(60 - (\text{Discharge Date} - \text{Prior Rx Date})) = 60 - (2/15/2016 - 1/15/2016) = 60 - 31 = 29$
- Rx #2: 4/1/2016, # Days Prescribed: 90
- Rx #3: 7/10/2016, #Days Prescribed: 90
- Total Days Supply Prescribed between 2/15 and 8/13/2016:  $29 + 90 + 90 = 209$

### **Beta-Blocker Numerator Logic**

*Beta-blocker medication codes* defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. (Medications are: Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol and Hydrochlorothiazide-propranolol.)

CRS uses the following codes to define contraindications to beta-blockers.

<b>Contraindication to Beta-Blockers (any of the codes occurring ever, unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Asthma		<b>POV:</b> 2 diagnoses of ICD-9: 493*; ICD-10: J45.* on different visit dates
Hypotension		<b>POV:</b> 1 diagnosis of ICD-9: 458*; ICD-10: I95.*
Heart Block greater than (>)1 Degree		<b>POV:</b> 1 diagnosis of ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: I44.1, I44.2, I45.2, I45.3, I45.6
Sinus Bradycardia		<b>POV:</b> 1 diagnosis of ICD-9: 427.81; ICD-10: I49.5, R00.1
COPD		<b>POV:</b> 2 diagnoses on different visit dates of ICD-9: 491.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
NMI Refusal	G8011 (old code), G9190 (Documentation of medical reason(s) for not prescribing beta-blocker therapy (e.g., allergy, intolerance, other medical reasons)) at least once during the period admission/visit date through the 180 days after discharge/visit date	<b>Refusal:</b> NMI refusal for any beta-blocker at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documentated allergies to beta-blockers.

### **Adverse Drug Reaction/Allergy to Beta-Blockers**

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.0
<b>Entry in ART (Patient Allergies File):</b> "beta block*"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "beta block*", "bblock*" or "b block*"



### ASA (Aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

<b>Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever, unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Active prescription for Warfarin/Coumadin during the period admission/visit date through the 180 days after discharge/visit date		<b>Site-Populated Drug Taxonomy:</b> BGP CMS WARFARIN MEDS
Hemorrhage		<b>POV:</b> ICD-9: 459.0; ICD-10: R58
NMI Refusal	G8008 (old code) at least once during the period admission/visit date through the 180 days after discharge/visit date	<b>Refusal:</b> NMI (not medically indicated) refusal for any aspirin/other anti-platelet at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documentated allergies to ASA/other anti-platelets.

**Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets**

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E935.3; ICD-10: T39.015* or T39.095*
<b>Entry in ART (Patient Allergies File):</b> "aspirin"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "ASA" or "aspirin"

**ACEI/ARB Numerator Logic**

*Ace Inhibitor (ACEI) medication codes* defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

CRS uses the following codes to define contraindications to ACE inhibitors.

<b>Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the period admission/visit date through the 180 days after discharge/visit date <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the period admission/visit date through the 180 days after discharge/visit date
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
NMI Refusal		<b>Refusal:</b> NMI refusal for any ACE inhibitor at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documentated allergies to ACE inhibitors.

### Adverse Drug Reaction/Allergy to ACE Inhibitors

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
<b>Entry in ART (Patient Allergies File):</b> "ace inhibitor" or "ACEI"
<b>Contained within or Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "ace i*" or "ACEI"

*ARB (Angiotensin Receptor Blocker) medication codes* defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications are: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.).

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Amlodipine-valsartan, Azilsartan-chlorthalidone, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

CRS uses the following codes to define contraindications to ARBs.

Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the period admission/visit date through the 180 days after discharge/visit date <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the period admission/visit date through the 180 days after discharge/visit date
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22

<b>Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
NMI Refusal		<b>Refusal:</b> NMI refusal for any ARB at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documentated allergies to ARBs.

### Adverse Drug Reaction/Allergy to ARBs

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6
<b>Entry in ART (Patient Allergies File):</b> "Angiotensin Receptor Blocker" or "ARB"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "Angiotensin Receptor Blocker" or "ARB"

### Statins Numerator Logic

*Statin medication codes* defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altacor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

CRS uses the following codes to define contraindications to statins.

<b>Contraindication to Statins (any of the codes occurring ever, unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the period admission/visit date through the 180 days after discharge/visit date <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the period admission/visit date through the 180 days after discharge/visit date

<b>Contraindication to Statins (any of the codes occurring ever, unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Acute Alcoholic Hepatitis		<b>POV:</b> ICD-9: 571.1; ICD-10: K70.10, K70.11 during the period admission/visit date through the 180 days after discharge/visit date
NMI Refusal		<b>Refusal:</b> NMI refusal for any statin at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documentated allergies to statins.

### Adverse Drug Reaction/Allergy to Statins

<b>ICD and Other Codes</b>
<b>Site-Populated Lab Taxonomy or LOINC Taxonomy:</b> DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the period admission/visit date through the 180 days after discharge/visit date
<b>Site-Populated Lab Taxonomy or LOINC Taxonomy:</b> BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the period admission/visit date through the 180 days after discharge/visit date
<b>POV:</b> Myopathy/Myalgia, defined as any of the following during the period admission/visit date through the 180 days after discharge/visit date: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1
<b>POV:</b> ICD-9: 995.0–995.3 AND E942.9
<b>Entry in ART (Patient Allergies File):</b> “statin” or “statins”
<b>Entry in Problem List or in Provider Narrative for any ICD-9: POV 995.0–995.3, V14.8; ICD-10: Z88.8:</b> “Statin” or “Statins”

Subject Defined	ICD and CPT Codes
<p><b>Pregnancy - At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following codes. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.</b></p>	<p><b>POV or Problem List:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.* , V27.* , V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.* , O60.0* , O61.*-O66.* , O68, O69.* , O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.* , O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7* , Z32.01, Z33.1, Z34.* , Z36.</p> <p><b>Procedure:</b> ICD-9: 72.* , 73.* , 74.*</p> <p><b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828</p>
<p><b>Abortion</b></p>	<p><b>CPT:</b> 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267</p> <p><b>POV:</b> ICD-9: 635* , 636* , 637* ; ICD-10: O00.* through O03.89, O04.* , Z33.2</p> <p><b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z</p>
<p><b>Miscarriage</b></p>	<p><b>CPT:</b> 59812, 59820, 59821, 59830</p> <p><b>POV:</b> ICD-9: 630, 631, 632, 633* , 634* ; ICD-10: O03.9</p>

### All Medications Numerator Logic

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

### Key Logic Changes from CRS Version 15.1

1. Removed POV codes 674.\*3, 675.\*3, 676.\*3 from pregnancy definition.

2. Added POV codes V24.\*, V27.\* to pregnancy definition.
3. Added Procedure codes 72.\*, 73.\*, 74.\* to pregnancy definition.
4. Added CPT codes 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 to pregnancy definition.
5. Added SNOMED codes to Patient Education for breastfeeding.
6. Updated BGP PQA STATIN MEDS medication taxonomy.

### Patient List Description

List of patients with AMI, with persistent medication therapy, if any.

### Measure Source

American Heart Association/American College of Cardiology Guidelines for the Treatment of AMI.

### Measure Past Performance and Long-Term Targets

None

REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR	BASE % PERIOD	%	CHG from BASE %
DU November 25, 2016 Page 228							
*** IHS 2016 Selected Measures with Community Specified Report ***							
DEMO INDIAN HOSPITAL							
Report Period: Jan 01, 2016 to Dec 31, 2016							
Previous Year Period: Jan 01, 2015 to Dec 31, 2015							
Baseline Period: Jan 01, 2010 to Dec 31, 2010							
-----							
Persistence of Appropriate Medication Therapy after a Heart Attack							
Active Clinical Pts 35+ w/ AMI DX	61	4			4		
# w/135-day beta-blocker Rx/contra/ADR							
-No Refusals	23 37.7	2 50.0		-12.3	3 75.0		-37.3
A. # w/135-day beta blocker Rx w/ % of Total	3 13.0	2 100.0		-87.0	2 66.7		-53.6
B. # w/contra/ADR w/ % of Total	20 87.0	0 0.0		+87.0	1 33.3		+53.6
# w/135-day ASA Rx/contra/ADR							
-No Refusals	5 8.2	0 0.0		+8.2	2 50.0		-41.8
A. # w/135-day ASA Rx w/% of Total	1 20.0	0 0.0		+20.0	2 100.0		-80.0

B. # w/contra/ADR w/ % of Total	4	80.0	0	0.0	+80.0	0	0.0	+80.0
# w/135-day ACEI/ARB Rx/contra/ADR -No Refusals	13	21.3	1	25.0	-3.7	1	25.0	-3.7
A. # w/135-day ACEI/ARB Rx w/% of Total	1	7.7	1	100.0	-92.3	1	100.0	-92.3
B. # w/contra/ADR w/ % of Total	12	92.3	0	0.0	+92.3	0	0.0	+92.3
# w/135-day statin Rx/contra/ADR -No Refusals	6	9.8	2	50.0	-40.2	2	50.0	-40.2
A. # w/135-day statin Rx w/% of Total	2	33.3	2	100.0	-66.7	2	100.0	-66.7
B. # w/contra/ADR w/ % of Total	4	66.7	0	0.0	+66.7	0	0.0	+66.7
# w/Rx/contra/ADR of ALL meds-No Refusals	2	3.3	0	0.0	+3.3	1	25.0	-21.7

Figure 2-90: Sample Report, Persistence of Appropriate Medication Therapy after a Heart Attack

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Persistence of Appropriate Medication Therapy after a Heart Attack: List of patients with AMI, with persistent medication therapy, if any

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,RHONDA AC	000001	COMMUNITY #1	F	35	07/12/80
ALL MEDS: BETA: 03/07/14 03/13/14 Contra 2 POV asthma; ASA: 05/23/16 Contra NMI ASPIRIN 325MG CAP; ACEI/ARB: 07/01/16 ADR Problem List 995.0 ACEI; STATIN: 07/01/16 ADR creat kinase of 5000					
PATIENT2,KATHLEEN AC	000002	COMMUNITY #1	F	38	10/14/77
BETA: 06/02/16 ADR POV V14.8					
PATIENT3,KIMBERLY A AC	000003	COMMUNITY #1	F	49	03/22/66
BETA: 03/01/16 Contra 2/3 heart block POV 426.12; ACEI/ARB: 05/02/16 Contra pregnant; STATIN: 05/02/16 Contra pregnant					
PATIENT4,TIMOTHY AC	000004	COMMUNITY #1	M	57	06/06/58
ACEI/ARB: 06/15/16 Contra POV V24.1; STATIN: 06/15/16 Contra POV V24.1					
PATIENT5,JOSHUA AC	000005	COMMUNITY #1	M	63	11/02/52
ACEI/ARB: 02/03/16 Contra Aortic POV 395.0					

Figure 2-91: Sample Patient List: Persistence of Appropriate Medication Therapy after a Heart Attack



## 2.8.13 Appropriate Medication Therapy in High Risk Patients

### Denominators

*Active CHD patients* ages 22 and older; defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, *and* at least two visits during the Report Period, *and* two CHD-related visits ever.

- *Active CHD patients* ages 22 and older who are not Active Diabetic.
- *Active CHD patients* ages 22 and older who are Active Diabetic

### Numerators

Patients with a 180-day course of treatment with *beta-blockers* during the Report Period, or who have a contraindication/previous adverse reaction to beta-blocker therapy.

**Note:** This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *ASA (aspirin) or other anti-platelet agent* during the Report Period, or who have a contraindication/previous adverse reaction to ASA/anti-platelet therapy.

**Note:** This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *ACEIs/ARBs* during the Report Period, or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

**Note:** This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *statins* during the Report Period, or who have a contraindication/previous adverse reaction to statin therapy.

**Note:** This numerator does *not* include refusals.

Also included for the numerators above are sub-numerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with a 180-day course of treatment for *all medications* (i.e., beta-blocker, aspirin/anti-platelet, ACEI/ARB, *and* statin) during the Report Period, and/or who have a contraindication/previous adverse reaction.

<b>Note:</b> This numerator does <i>not</i> include refusals.
---

### Logic Description

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominators.

Subject Defined	ICD and Other Codes
Coronary Heart Disease	<p><i>Any of the following:</i></p> <p><b>1) POV:</b> ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0–I22.8, I24.0–I25.83, I25.89, I25.9, Z95.5</p> <p><b>2) One or more CABG or PCI procedures</b></p>
CABG	<p><b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1</p> <p><b>CPT:</b> 33510–33514, 33516–33519, 33521–33523, 33530, 33533–33536, 33572, 35500, 35600, S2205–S2209</p> <p><b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*</p>
PCI	<p><b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61</p> <p><b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290</p> <p><b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06–36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**</p>

*Diabetes* defined as: Diagnosed with diabetes (first POV in V POV with ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\*) prior to the Current Report Period, *and* at least two visits during the Current Report period, *and* two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

#### *Numerator Logic*

In the logic below, “ever” is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the two conditions below:

1. Prescription(s) for the indicated medication with a total days supply of 180 days or more during the Report Period. Medications must not have a comment of RETURNED TO STOCK; *or*
2. Have a contraindication/previous adverse reaction to the indicated medication

Contraindications/prior ADR/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/ allergy will be counted in sub-numerator B.

For prescriptions, the days supply requirement may be met with a single prescription or from a combination of prescriptions for the indicated medication that were filled during the Report Period and prescriptions filled prior to the Report Period but which are still active (i.e., prior active prescription). Prior active prescriptions can be included if the treatment days fall within the Report Period. Prior active prescription defined as most recent prescription for the indicated medication (see codes below) prior to Report Period Start Date with the number of days supply greater than or equal to the Report Period Start Date minus the prescription date.

**Note:** If a prescription for a medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

Example of patient included in the beta-blocker numerator with prior active prescription:

- Report Period: 07/01/2015 through 06/30/2016
- Must have 180 days supply of indicated medication 6/30/2016 (end of Report Period)
- Prior Beta-Blocker Rx Date: 06/01/2015
- # Days Prescribed: 60 (treats patient through 07/31/2015)
- Report Period Start Date minus Rx Date: 07/01/2015-06/01/2015 = 30; 60 (#Days Prescribed) is greater than or equal to ( $\geq$ ) 30, prescription is considered Prior Active Rx
- 07/31/2015 is between the Report Period of 07/01/2015 and 06/30/2016, thus remainder of Prior Active Rx can be counted toward 180-days supply
- # Remaining Days Prescribed from Prior Active Rx:
- (# Days Prescribed-(Report Period Start Date-Prior Rx Date) = 60-(07/01/2015-06/01/2015) = 60-30 = 30
- Rx #2: 08/05/2015, # Days Prescribed: 90
- Rx #3: 11/10/2015, #Days Prescribed: 90

- Total Days Supply Prescribed between 07/01/2015 and 06/30/2016, including prior active prescription: 30+90+90=210

### Beta-Blocker Numerator Logic

*Beta-blocker medication codes* defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. Medications are: Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.

CRS uses the following codes to define contraindications to beta-blockers.

Contraindication to Beta-Blockers (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
Asthma		<b>POV:</b> 2 diagnoses of ICD-9: 493*; ICD-10: J45.* on different visit dates
Hypotension		<b>POV:</b> 1 diagnosis of ICD-9: 458*; ICD-10: I95.*
Heart Block greater than (>)1 Degree		<b>POV:</b> 1 diagnosis of ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: I44.1, I44.2, I45.2, I45.3, I45.6
Sinus Bradycardia		<b>POV:</b> 1 diagnosis of ICD-9: 427.81; ICD-10: I49.5, R00.1
COPD		<b>POV:</b> 2 diagnoses on different visit dates of ICD-9: 491.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
NMI Refusal	G8011 (old code), G9190 (Documentation of medical reason(s) for not prescribing beta-blocker therapy (e.g., allergy, intolerance, other medical reasons)) at least once during the Report Period	<b>Refusal:</b> NMI refusal for any beta-blocker at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documentated allergies to beta-blockers.

### Adverse Drug Reaction/Allergy to Beta-Blockers

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.0
<b>Entry in ART (Patient Allergies File):</b> “beta block*”
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> “beta block*”, “bblock*” or “b block*”

### ASA (aspirin)/Other Anti-Platelet Numerator Logic

*ASA medication codes* defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
180-day course of treatment for Warfarin/Coumadin during the Report Period		<b>Site-Populated Drug Taxonomy:</b> BGP CMS WARFARIN MEDS
Hemorrhage		<b>POV:</b> ICD-9: 459.0; ICD-10: R58
NMI Refusal	G8008 (old code) at least once during the Report Period	<b>Refusal:</b> NMI (not medically indicated) refusal for any aspirin at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documentated allergies to ASA/other anti-platelets.

### Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E935.3; ICD-10: T39.015* or T39.095*
<b>Entry in ART (Patient Allergies File):</b> “aspirin”

**Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ASA" or "aspirin"**

### ACEI/ARB Numerator Logic

*Ace Inhibitor (ACEI) medication codes* defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril.)

Antihypertensive Combinations: (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil.)

CRS uses the following codes to define contraindications to ACE inhibitors.

<b>Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		<b>Refusal:</b> NMI refusal for any ACE inhibitor at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documentated allergies to ACE inhibitors.

**Adverse Drug Reaction/Allergy to ACE Inhibitors**

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
<b>Entry in ART (Patient Allergies File):</b> “ace inhibitor” or “ACEI”
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> “ace i*” or “ACEI”

*ARB (Angiotensin Receptor Blocker) medication codes* defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications are: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Amlodipine-valsartan, Azilsartan-chlorthalidone, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

CRS uses the following codes to define contraindications to ARBs.

<b>Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		<b>Refusal:</b> NMI (not medically indicated) refusal for any ARB at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documentated allergies to ARBs.

### Adverse Drug Reaction/Allergy to ARBs

<b>ICD and Other Codes</b>
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6
<b>Entry in ART (Patient Allergies File):</b> “Angiotensin Receptor Blocker” or “ARB”
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> “Angiotensin Receptor Blocker” or “ARB”

### Statins Numerator Logic

*Statin medication codes* defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications are: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altacor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

*Statin Combination Products:* Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

CRS uses the following codes to define contraindications to statins.

<b>Contraindication to ACE Inhibitors (any of the codes occurring ever, unless otherwise noted)</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period <b>Patient Education:</b> BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED 169745008, 200430001, 405029003, 406213009, 413711008, 413712001 during the Report Period
Acute Alcoholic Hepatitis		<b>POV:</b> ICD-9: 571.1; ICD-10: K70.10, K70.11 during the Report Period
NMI Refusal		<b>Refusal:</b> NMI refusal for any statin at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documentated allergies to statins.



**Adverse Drug Reaction/Allergy to Statins**

<b>ICD and Other Codes</b>
<b>Site-Populated Lab Taxonomy or LOINC</b> <b>Taxonomy:</b> DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period
<b>Site-Populated Lab Taxonomy or LOINC</b> <b>Taxonomy:</b> BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period
<b>POV:</b> Myopathy/Myalgia, defined as any of the following during the Report Period: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.9
<b>Entry in ART (Patient Allergies File):</b> "statin" or "statins"
<b>Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8:</b> "Statin" or "Statins"

Subject Defined	ICD and CPT Codes
<p><b>Pregnancy - At least two visits during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following codes. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.</b></p>	<p><b>POV or Problem List:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.* , V27.* , V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.* , O60.0*, O61.*-O66.* , O68, O69.* , O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.* , O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.* , Z36.</p> <p><b>Procedure:</b> ICD-9: 72.* , 73.* , 74.*</p> <p><b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828</p>
<p><b>Abortion</b></p>	<p><b>CPT:</b> 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267</p> <p><b>POV:</b> ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.* , Z33.2</p> <p><b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z</p>
<p><b>Miscarriage</b></p>	<p><b>CPT:</b> 59812, 59820, 59821, 59830</p> <p><b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9</p>

### All Medications Numerator Logic

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

### Key Logic Changes from CRS Version 15.1

1. Removed POV codes 674.\*3, 675.\*3, 676.\*3 from pregnancy definition.

2. Added POV codes V24.\*, V27.\* to pregnancy definition.
3. Added Procedure codes 72.\*, 73.\*, 74.\* to pregnancy definition.
4. Added CPT codes 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 to pregnancy definition.
5. Added ICD-10 POV code Z95.5 to CHD definition.
6. Added CPT codes 33530, 33572, 35500, 35600 to CABG definition.
7. Added SNOMED codes to Patient Education for breastfeeding.
8. Updated BGP PQA STATIN MEDS medication taxonomy.

### Patient List Description

List of CHD patients 22 plus (+) with 180-day medication therapy during the Report Period, if any.

### Measure Source

American Heart Association/American College of Cardiology Guidelines

### Measure Past Performance and Long-Term Targets

None

DU		November 25, 2016				Page 241			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Appropriate Medication Therapy in High Risk Patients									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active CHD pts 22+	59		38			30			
# w/180 day beta-blocker Rx/contra/ADR									
-No Refusals	32	54.2	22	57.9	-3.7	14	46.7	+7.6	
A. # w/180 day beta-blocker Rx w/% of Total	18	56.3	14	63.6	-7.4	11	78.6	-22.3	
B: # w/contra/ADR w/ % of Total	14	43.8	8	36.4	+7.4	3	21.4	+22.3	
# w/180 day ASA									

Rx/contra/ADR								
-No Refusals	22	37.3	21	55.3	-18.0	23	76.7	-39.4
A. # w/180 day ASA								
Rx w/% of Total	17	77.3	18	85.7	-8.4	18	78.3	-1.0
B. # w/contra/ADR								
w/ % of Total	5	22.7	3	14.3	+8.4	5	21.7	+1.0
# w/180 day ACEI/ARB								
Rx/contra/ADR								
-No Refusals	29	49.2	15	39.5	+9.7	18	60.0	-10.8
A. # w/180 day ACEI/ARB								
Rx w/% of Total	26	89.7	14	93.3	-3.7	17	94.4	-4.8
B. # w/contra/ADR								
w/ % of Total	3	10.3	1	6.7	+3.7	1	5.6	+4.8
# w/180 day statin								
Rx/contra/ADR								
-No Refusals	30	50.8	22	57.9	-7.0	14	46.7	+4.2
A. # w/180 day statin								
Rx w/% of Total	26	86.7	20	90.9	-4.2	14	100.0	-13.3
B. # w/contra/ADR								
w/ % of Total	4	13.3	2	9.1	+4.2	0	0.0	+13.3
# w/180 day Rx/contra/ADR/ of ALL meds								
-No Refusals	16	27.1	8	21.1	+6.1	6	20.0	+7.1

Figure 2-92: Sample Report, Appropriate Medication Therapy in High Risk Patients

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Appropriate Medication Therapy in High Risk Patients: List of CHD patients 22+  
 with 180-day medication therapy during the Report Period, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,CAITLYN CHD	000001	COMMUNITY #1	F	22	06/12/94
PATIENT2,CARLA CHD	000002	COMMUNITY #1	F	40	06/24/76
PATIENT3,GENEVA JACKSON,SHERRY LADAWN	000003 100939	COMMUNITY #1 BRAGGS	F F	47 68	09/08/69 01/16/48
CHD,AD		ACEI/ARB: (268 TOTAL DAYS); STATIN: (319 TOTAL DAYS)			
PATIENT4,SHERRY LISA CHD	000004	COMMUNITY #1	F	68	10/12/48
		BETA: 09/12/16 Contra hypotension POV 458.9; ASA: aspirin Contra total days WARFARIN: 372; STATIN: (328 TOTAL DAYS)			
PATIENT5,PAULINE CHD,AD	000005	COMMUNITY #1	F	70	04/12/46
		ALL MEDS; BETA: (305 TOTAL DAYS); ASA: (291 TOTAL DAYS); ACEI/ARB: (405 TOTAL DAYS); STATIN: (305 TOTAL DAYS)			

Figure 2-93: Sample Patient List: Appropriate Medication Therapy in High Risk Patients

## 2.8.14 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

### Denominator

Number of visits for *User Population patients* ages 18 and older who were hospitalized during the Report Period with ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation.

### Numerators

Number of visits where patients received a prescription for anticoagulant at discharge

Number of visits where patients did not receive anticoagulation therapy

### Logic Description

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes to define ischemic stroke or transient ischemic attack with atrial fibrillation.

Subject Defined	ICD and Other Codes
<p>Ischemic Stroke or TIA with Atrial Fibrillation (Non-PRC inpatient visit - Type not equal to C and Service Category=H)</p> <p>The patient must be admitted to the hospital during the report period with a condition described here but the discharge may occur after the report period.</p>	<p><b>POV:</b> ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9; ICD-10: G45.0-G45.2, G45.8, G45.9, G46.0-G46.2, I63.* AND ICD-9: 427.31; ICD-10: I48.0-I48.2, I48.91 (atrial fibrillation)</p>

*Anticoagulant Therapy:* Patient must meet one of the conditions below to be counted as receiving anticoagulant therapy. For all prescriptions, medications must not have a comment of RETURNED TO STOCK.

- Active prescription for Warfarin, aspirin, or other anti-platelet as of discharge date. "Active" prescription defined as:
  - Rx Days Supply greater than or equal to ( $\geq$ ) (Discharge Date - Prescription Date), where the prescription has not been discontinued as of the discharge date.
- Prescription for Warfarin, aspirin, or other anti-platelet on discharge date.

*Warfarin Medication:* Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.

*Aspirin Medication:* Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy.

*Other Anti-Platelet/Anticoagulant Medication:* Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

*No Anticoagulant Therapy:* Patients who did not have an active prescription for anticoagulant therapy at time of discharge.

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016				Page 248			
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# Stroke/TIA w/ Atrial Fib Visits for User Pop Pts 18+	17		0			0		
# Visits w/ Anticoagulant Rx	5	29.4	0	0.0	+29.4	0	0.0	+29.4

# Visits w/ No Anticoagulant Therapy	12	70.6	0	0.0	+70.6	0	0.0	+70.6
--------------------------------------	----	------	---	-----	-------	---	-----	-------

Figure 2-94: Sample Report, Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge: List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB	
PATIENT1,SHERRY UP NOT MET: NO THERAPY	000001	COMMUNITY #1	F	38	05/14/78	Visit: 1) 04/01/16 POV 433.81 + POV 427.31 THERAPY:
PATIENT2,CODY JACK UP 05/01/16 MET: WARF; 2) 09/01/16 THERAPY; 3) 10/16/16 MET: ASA	000002	COMMUNITY #1	M	31	04/28/85	Visit: 1) 05/01/16 POV 433.81 + POV 427.31 THERAPY: NOT MET: NO THERAPY; 2) 09/01/16 POV 433.21 + POV 427.31 THERAPY: 10/16/16 MET: ASA
PATIENT3,TIMOTHY ALLEN UP NOT MET: NO THERAPY	000003	COMMUNITY #1	M	33	04/13/83	Visit: 1) 04/01/16 POV 433.21 + POV 427.31 THERAPY:
PATIENT4,TRACE UP NOT MET: NO THERAPY	000004	COMMUNITY #1	M	37	05/16/79	Visit: 1) 06/01/16 POV 434.01 + POV 427.31 THERAPY:

Figure 2-95: Sample Patient List: Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

## 2.8.15 Heart Failure and Evaluation of LVS Function

### Denominator

Active Clinical patients ages 18 or older discharged with heart failure during the Report Period.

### Numerators

Patients whose LVS function was evaluated before arrival, during hospitalization, or is planned for after discharge.

### Logic Description

Age of the patient is calculated as of the hospital admission date.

*Denominator exclusions are defined as any of the following:*

1. Patients receiving comfort measures only (i.e., patients who received palliative care and usual interventions were not received because a medical decision was made to limit care).
2. Patients with a Discharge Type of Transferred or Irregular or containing “Death.”
3. Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospitalization.

CRS uses the following codes to define the denominator and numerators.

### **Denominator Exclusions**

<b>Subject Defined</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Comfort Measures		<b>POV:</b> ICD-9: V66.7 (Encounter for palliative care); ICD-10: Z51.5 documented during hospital stay
LVAD/Heart Transplant		<b>Procedure:</b> ICD-9: 33.6, 37.41, 37.51–37.54, 37.61–37.66, 37.68; ICD-10: 02HA**Z, 02PA*RZ, 02RK0JZ, 02RL0JZ, 02UA4JZ, 02WA0JZ, 02WA0QZ, 02WA0RZ, 02WA3QZ, 02WA3RZ, 02WA4QZ, 02WA4RZ, 02YA0Z*, 5A02*10, 5A02*16, 5A02*1D documented during hospital stay

### **Denominator Definition**

<b>Subject Defined</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Heart Failure		<b>POV (Primary Diagnosis only):</b> ICD-9: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9, 429.1, 997.1; ICD-10: I11.0, I13.0, I13.2, I50.* <i>and</i> with Service Category H (hospitalization). <b>NOTE:</b> If a patient has multiple admissions matching these criteria during the Report Period, the earliest admission will be used.



***Numerator Definition (Evaluation of LVS Function): Any of the codes listed below***

<b>Subject Defined</b>	<b>CPT Codes</b>	<b>ICD and Other Codes</b>
Ejection Fraction (ordered or documented anytime one year prior to discharge date)	78414, 78468, 78472, 78473, 78480, 78481, 78483, 78494, 93303, 93304, 93307, 93308, 93312, 93314–93318, 93350, 93543, 93555	<b>Measurement:</b> "CEF" <b>Procedure:</b> ICD-9: 88.53, 88.54; ICD-10: B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ
RCIS Order for Cardiovascular Disorders Referral (ordered during the hospital stay but no later than the hospital discharge date)		<b>ICD Diagnostic Category:</b> "Cardiovascular Disorders" <b>AND</b> one of the following: <b>CPT Categories:</b> "Evaluation and/or Management," "Non-surgical Procedures" or "Diagnostic Imaging"
Other Procedures (documented anytime one year prior to discharge date)		<b>Echocardiogram:</b> Procedure ICD-9: 88.72, 37.28, 00.24; ICD-10: B245YZZ, B245ZZ4, B245ZZZ, B246YZZ, B246ZZ4, B246ZZZ, B24BYZZ, B24BZZ4, B24BZZZ <b>Nuclear Medicine Test:</b> Procedure ICD-9: 92.2*; <b>Cardiac Catheterization with a Left Ventriculogram:</b> Procedure ICD-9: 37.22, 37.23, 88.53, 88.54; ICD-10: 4A02*N7, 4A02*N8, B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of Active Clinical heart failure patients 18 plus (+) who received evaluation of LVS function, if any.

**Measure Source**

CMS HF-2

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016	Page 255
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		

Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Heart Failure and Evaluation of LVS Function								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR	BASE % PERIOD	%	CHG from BASE %
AC 18+ w/Heart Failure Dx	44		2			1		
Patients w/Eval of LVS Function	14	31.8	0	0.0	+31.8	0	0.0	+31.8

Figure 2-96: Sample Report, Heart Failure and Evaluation of LVS Function

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Heart Failure and Evaluation of LVS Function: List of Active Clinical heart failure patients 18+ who received evaluation of LVS function, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,JOAN AC	000164	COMMUNITY #1	F	36	08/12/80
					Admission: 06/01/16 LVS: NOT DOCUMENTED
PATIENT2,SARAH AC	000127	COMMUNITY #1	F	35	10/09/81
					Admission: 06/01/16 LVS: 06/03/16 Proc 88.72
PATIENT3,JOHN AC	000151	COMMUNITY #1	M	36	12/16/80
					Admission: 05/01/16 LVS: 05/01/16 Meas CEF 40
PATIENT4,ROGER AC	000125	COMMUNITY #1	M	47	08/01/69
					Admission: 06/01/16 LVS: NOT DOCUMENTED
PATIENT5,DANIEL AC	000129	COMMUNITY #1	M	57	07/12/59
					Admission: 06/01/16 LVS: 06/01/16 CPT 78468

Figure 2-97: Sample Patient List: Heart Failure and Evaluation of LVS Function

## 2.9 STD-Related Measure Topics

### 2.9.1 HIV Screening

#### **GPRA Measure Description**

During GPRA Year 2016, establish a baseline for the proportion of patients who have ever been screened for HIV.

#### **Denominators**

*All pregnant Active Clinical female patients* with no documented miscarriage or abortion and with no recorded HIV diagnosis ever.

*User Population patients* ages 13 through 64 with no recorded HIV diagnosis prior to the Report Period. (GPRA Denominator).

### **Numerators**

Patients who were screened for HIV during the past 20 months.

**Note:** This numerator does *not* include refusals.

Patients who were screened for HIV during the Report Period. (GPRA Developmental Numerator)

**Note:** This numerator does *not* include refusals.

Patients who were screened for HIV at any time before the end of the Report Period. (GPRA Numerator)

**Note:** This numerator does *not* include refusals.

No denominator. This measure is a total count only, not a percentage. Number of HIV screens provided to User Population patients during the report period, where the patient was not diagnosed with HIV any time prior to the screen. (GPRA Developmental Numerator)

**Note:** This numerator does not include refusals.

### **Logic Description**

Age of the patient is calculated at the beginning of the Report period.

*Pregnancy definition:* At least two visits during the past 20 months from the end of the Report Period, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period. The time period is extended to include patients who were pregnant during the Report Period but whose initial diagnosis (and HIV test) were documented prior to Report Period.

*HIV Screening definition:* For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted.

**Notes:** The time frame for screening for the pregnant patients denominator is anytime during the past 20 months and for User Population patients 13–64 is anytime during the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Pregnancy (at least 2 visits in past 20 months with 1 during the Report Period)	<b>CPT:</b> 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828	<b>POV:</b> ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 678.*3, 679.*3, V22.0-V23.9, V24.*, V27.*, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82, O98.911-O98.92, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36 <b>Procedure:</b> ICD-9: 72.*, 73.*, 74.*		
Miscarriage (after second pregnancy POV in past 20 months)	59812, 59820, 59821, 59830	<b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Abortion (after second pregnancy POV in past 20 months)	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267	<b>POV:</b> ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 <b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z		
HIV Diagnosis (documented anytime prior to the end of the Report Period)		<b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 042, 042.0–044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711–O98.73		
HIV Screening	86689, 86701–86703, 87390, 87391, 87534–87539		Yes	BGP HIV TEST TAX

### Key Logic Changes from CRS Version 15.1

1. Changed GPRA measure to those with HIV Screening Ever.
2. Removed measure for pregnant User Population patients.
3. Removed refusal measures and corresponding logic.
4. Removed POV codes 674.\*3, 675.\*3, and 676.\*3 from pregnancy definition.
5. Added POV codes V24.\* and V27.\* to pregnancy definition.
6. Added Procedure codes 72.\*, 73.\*, and 74.\* to pregnancy definition.
7. Added CPT codes 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, and 76801-76828 to pregnancy definition.

### Patient List Description

List of pregnant patients (any age) or User Population patients 13-64 with documented HIV test, if any.

### Measure Source

HP 2020 HIV-14.3

**Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2015 Performance	86.6%
IHS FY 2014 Performance	88.0%
IHS FY 2013 Performance	87.7%
IHS FY 2012 Performance	85.8%
IHS FY 2011 Performance	80.0%
IHS FY 2010 Performance	78.0%
IHS FY 2009 Performance	76.0%
IHS FY 2008 Performance	75.0%
IHS FY 2007 Performance	74.0%
IHS FY 2006 Performance	65.0%
IHS FY 2005 Performance	54.0%
<i>HP 2020 Goal</i>	<i>74.1%</i>

DU	November 25, 2016				Page 256			
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
HIV Screening								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
Pregnant AC Pts w/ no HIV ever	39		61			64		
# w/HIV screening -No Refusals	21	53.8	46	75.4	-21.6	42	65.6	-11.8
User Pop Pts 13-64 w/ no HIV (GPRA)	1,617		1,667			1,680		
# w/HIV screening -No Refusals (GPRA Dev.)	41	2.5	107	6.4	-3.9	90	5.4	-2.8
# w/HIV screening ever- No Refusals (GPRA)	431	26.7	419	25.1	+1.5	339	20.2	+6.5
# HIV screens for User Pop Pts w/ no prior HIV-No Refusals (GPRA Dev.)	44		121		-77	104		-60

Figure 2-98: Sample Report, HIV Screening

```

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

HIV Screening: List of pregnant patients or User Population patients with
documented HIV test or refusal, if any.

PATIENT NAME          HRN      COMMUNITY      SEX AGE  DOB
DENOMINATOR          NUMERATOR
-----
PATIENT1,HELEN MARY   000001  COMMUNITY #1   F  12   09/08/04
UP                   03/31/16 Lab; Screen Count: 1
PATIENT2,CECELIA     000002  COMMUNITY #1   F  19   10/10/97
UP
PATIENT15,BRENDA G   000015  COMMUNITY #2   F  30   12/03/86
UP                   03/14/16 CPT 87534; 02/14/16 CPT 86689; Screen Count:
2
PATIENT16,ALYSHA     000016  COMMUNITY #2   F  33   06/09/83
UP,AC PREG          08/25/16 Lab; Screen Count: 1

```

Figure 2-99: Sample Patient List, HIV Screening

## 2.9.2 HIV Quality of Care

### Denominator

All *User Population patients* ages 13 and older with at least two direct care visits (i.e., not Contract/PRC) with HIV diagnosis during the Report Period, including one HIV diagnosis in last 6 months.

### Numerators

Patients who received CD4 test only (without HIV viral load) during the Report Period

Patients who received HIV viral load only (without CD4) during the Report Period

Patients who received both CD4 and HIV viral load during the Report Period

Total patients receiving any test

Patients who received at least one prescription for an Antiretroviral medication.

### Logic Description

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.



Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
HIV		<b>POV:</b> ICD-9: 042, 042.0-044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711-O98.73		
CD4	86359, 86360 86361, G9214		Yes	BGP CD4 TAX
HIV Viral Load	87536, 87539, G9242, G9243		Yes	BGP HIV VIRAL LOAD TAX
Antiretroviral medication				BGP PQA ANTIRETROVIRAL MEDS - Medications must not have a comment of RETURNED TO STOCK.

**Key Logic Changes from CRS Version 15.1**

1. Updated BGP PQA ANTIRETROVIRAL MEDS medication taxonomy.

**Patient List Description**

List of patients 13 and older diagnosed with HIV, with CD4 test, if any.

**Measure Source**

HP 2010 developmental measure 13–13a Viral Load Testing

**Measure Past Performance and Long-Term Targets**

Performance	Percent
<i>IHS 2020 goal for viral load testing</i>	<i>Nearly 100%</i>
<i>IHS 2020 baseline for CD4 testing</i>	<i>Nearly 100%</i>

DU	November 25, 2016	Page 258						
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
HIV Quality of Care								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR	%	PERIOD	BASE
								%
User Pop Pts >13 w/								

HIV Dx	7		2			2		
# w/CD4 only	2	28.6	0	0.0	+28.6	0	0.0	+28.6
# w/viral load only	0	0.0	0	0.0	+0.0	0	0.0	+0.0
# w/both	1	14.3	1	50.0	-35.7	2	100.0	-85.7
TOTAL # w/ any tests	3	42.9	1	50.0	-7.1	2	100.0	-57.1
# w/ART Rx	1	14.3	0	0.0	+14.3	1	50.0	-35.7

Figure 2-100: Sample Report HIV Quality of Care

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

HIV Quality of Care: List of patients 13 and older diagnosed with HIV, with CD4 test, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, MARY UP	000001	COMMUNITY #1	F	19	08/02/97
		CD4: 02/01/16		86359	
PATIENT2, TANYA UP	000002	COMMUNITY #1	F	37	01/10/79
PATIENT15, JOHN UP	000015	COMMUNITY #2	M	18	09/22/98
		Viral Load: 05/01/16		87539	
PATIENT16, HAROLD UP	000016	COMMUNITY #2	M	20	10/16/96
		CD4: 03/01/16		86360; Viral Load: 03/01/16	87536

Figure 2-101: Sample Patient List, HIV Quality of Care

### 2.9.3 Hepatitis C Screening

#### Denominator

*User Population patients* born between 1945 and 1965 with no recorded Hep C diagnosis. Broken down by gender.

*User Population patients* with documented Hep C diagnosis ever. Broken down by gender.

*User Population patients* born between 1945-1965 with documented Hep C diagnosis ever. Broken down by gender.

#### Numerators

Patients screened for Hepatitis C ever.

Patients who were given a Hepatitis C confirmation test.

- a. Patients with a positive result.
- b. Patients with a negative result.
- c. Patients with no result.

**Logic Description**

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Hepatitis C diagnosis (documented any time prior to the end of the Report Period)		<b>POV or Problem List entry where the status is not Inactive or Deleted:</b> ICD-9: 070.41, 070.44, 070.51, 070.54, 070.70-070.71, V02.62; ICD-10: B17.10, B17.11, B18.2, B19.20, B19.21		
Hepatitis C Screening	86803		Yes	BGP HEP C TEST TAX
Hepatitis C Confirmation Test (documented any time prior to the end of the Report Period)  If patient has more than one confirmatory test, CRS will use the first test that has a result recorded, if any. If there is no test with a result, CRS will use the first test documented.	86804, 87520, 87521, 87522, G9203, G9207, G9209		Yes	BGP HEP C CONF TEST TAX

Positive confirmation test result defined as a number greater than zero.

Negative confirmation test result defined as result containing "<15 IU/mL" or "<1.18 LogIU/mL" or comment containing "Not Detected".

No result defined as any confirmation test that does not have a positive or negative result.

**Key Logic Changes from CRS Version 15.1**

1. Added new confirmatory measures for all User Population patients.
2. Added LOINC codes 24011-9, 39008-8, 42506-6, 5011-2, 51657-5 to BGP HEP C TEST LOINC CODES taxonomy.

**Patient List Description**

List of patients with documented Hepatitis C screening or confirmatory test ever, if any.

DU		November 25, 2016				Page 258			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Hepatitis C Screening									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
User Pop Pts w/ no Hep C	790		628			551			
# w/Hep C Screening	48	6.1	33	5.3	+0.8	22	4.0	+2.1	
Male User Pop Pts w/no Hep C	371		292			253			
# w/Hep C Screening	24	6.5	17	5.8	+0.6	11	4.3	+2.1	
Female User Pop Pts w/ no Hep C	419		336			298			
# w/Hep C screening	24	5.7	16	4.8	+1.0	11	3.7	+2.0	
User Pop Pts w/ Hep C	32		33			36			
# w/confirmation test	20	62.5	17	51.5	+11.0	13	36.1	+26.4	

A. # w/ positive result w/ % of Total Screened	8	40.0	7	41.2	-1.2	8	61.5	-21.5
B. # w/ negative result w/ % of Total Screened	6	30.0	5	29.4	+0.6	3	23.1	+6.9
C. # w/ no result w/ % of Total Screened	6	30.0	5	29.4	+0.6	2	15.4	+14.6
User Pop Pts born 1945-1965 w/ Hep C	18		19			21		
# w/confirmation test	12	66.7	9	47.4	+19.3	7	33.3	+33.3
A. # w/ positive result w/ % of Total Screened	4	33.3	3	33.3	+0.0	5	71.4	-38.1
B. # w/ negative result w/ % of Total Screened	3	25.0	2	22.2	+2.8	0	0.0	+25.0
C. # w/ no result result w/ % of Total Screened	5	41.7	4	44.4	-2.8	2	28.6	+13.1

Figure 2-102: Sample Report Hepatitis C Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Hepatitis C Screening: List of patients with documented Hepatitis C screening ever, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, MARY UP	000001	COMMUNITY #1	F	50	05/15/66
		Screen: 08/17/02			Lab Test
PATIENT2, TANYA UP, HEP	000002	COMMUNITY #1	F	52	08/07/64
		Conf 09/09/10			Lab result=POS
PATIENT15, JOHN UP	000015	COMMUNITY #2	M	65	02/03/51
		Screen: 02/03/15			CPT 86803
PATIENT16, HAROLD UP	000016	COMMUNITY #2	M	66	01/15/50
		Screen: 08/20/12			Lab Test

Figure 2-103: Sample Patient List, Hepatitis C Screening

## 2.9.4 Chlamydia Screening

### Denominators

*Female Active Clinical patients ages 16 through 25.*

- a. Female Active Clinical 16 through 20.

- b. Female Active Clinical 21 through 25.

*Female User Population patients ages 16 through 25.*

- a. Female User Population 16 through 20.
- b. Female User Population 21 through 25.

### Numerator

Patients tested for Chlamydia during the Report Period.

### Logic Description

Age is calculated at beginning of the Report Period. The following codes are used to determine a test for Chlamydia.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Chlamydia Test	86631, 86632, 87110, 87270, 87320, 87490-92, 87810, 3511F, G9228	POV: ICD-9: V73.88, V73.98	Yes	BGP CHLAMYDIA TESTS TAX

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients with documented Chlamydia screening, if any.

### Measure Source

HP 2020 STD-4, annual screening for genital Chlamydia–females enrolled in commercial MCOs (aged 25 years and under); STD-3, annual screening for genital Chlamydia–females enrolled in Medicaid MCOs (aged 25 years and under).

### Measure Past Performance and Long-Term Targets

Performance	Percent
<i>HP 2020 goal for Females 16 through 20 with Medicaid (STD-3.1)</i>	57.9%
<i>HP 2020 goal for Females 21 through 24 with Medicaid (STD-3.2)</i>	65.3%
<i>HP 2020 goal for Females 16 through 20 with Commercial Health Insurance (STD-4.1)</i>	44.1%

Performance	Percent
HP 2020 goal for Females 21 through 24 with Commercial Health Insurance (STD-4.2)	47.9%

DU November 25, 2016 Page 260  
 \*\*\* IHS 2016 Selected Measures with Community Specified Report \*\*\*  
 DEMO INDIAN HOSPITAL  
 Report Period: Jan 01, 2016 to Dec 31, 2016  
 Previous Year Period: Jan 01, 2015 to Dec 31, 2015  
 Baseline Period: Jan 01, 2010 to Dec 31, 2010

---

Chlamydia Testing

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Female Active Clinical 16-25	166		143			128		
# w/Chlamydia Screen	53	31.9	49	34.3	-2.3	43	33.6	-1.7
A. Female Active Clinical 16-20	70		55			57		
# w/Chlamydia Screen	24	34.3	16	29.1	+5.2	23	40.4	-6.1
B. Female Active Clinical 21-25	96		88			71		
# w/Chlamydia Screen	29	30.2	33	37.5	-7.3	20	28.2	+2.0
Female User Population 16-25	287		255			239		
# w/Chlamydia Screen	69	24.0	58	22.7	+1.3	51	21.3	+2.7
A. Female User Population 16-20	139		118			119		
# w/Chlamydia Screen	32	23.0	19	16.1	+6.9	25	21.0	+2.0
B. Female User Population 21-25	148		137			120		
# w/Chlamydia Screen	37	25.0	39	28.5	-3.5	26	21.7	+3.3

Figure 2-104: Sample Report Chlamydia Testing

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Chlamydia Testing: List of patients with documented Chlamydia screening, if any.

PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB
--------------	-----	-----------	-----	-----	-----

DENOMINATOR	NUMERATOR
PATIENT1,MELISSA ANNE UP,AC	000001 COMMUNITY #1 F 16 08/12/00
PATIENT2,LISA MARIE UP,AC	000002 COMMUNITY #1 F 16 10/18/00 04/04/16 Lab test
PATIENT3,CRYSTAL LEE UP,AC	000003 COMMUNITY #1 F 17 01/16/99 07/25/16 Lab test
PATIENT4,DANIELLE UP,AC	000004 COMMUNITY #1 F 18 03/22/98 06/01/16 CPT 87490
PATIENT5,KELLYE UP,AC	000005 COMMUNITY #1 F 19 09/12/97

Figure 2-105: Sample Patient List, Chlamydia Testing

## 2.9.5 Sexually Transmitted Infection Screening

### Denominators

*HIV/AIDS screenings* needed for key STI incidents for *Active Clinical patients* that occurred during the defined period. Broken down by gender.

### Numerators

No denominator; count only. The total count of *Active Clinical patients* who were diagnosed with one or more key STIs during the period 60 days prior to the Report Period through the first 300 days of the Report Period. Broken down by gender.

No denominator; count only. The total count of separate *key STI incidents for Active Clinical patients* during the defined period.

*Number of needed HIV/AIDS screenings* performed from one month prior to the date of first STI diagnosis of each incident through 2 months after.

**Note:** This numerator does *not* include refusals.

### Logic Description

Key STIs are Chlamydia, Gonorrhea, HIV/AIDS, and Syphilis. Key STI diagnoses are defined with the following codes.

STI	ICD and Other Codes
Chlamydia	<b>POV:</b> ICD-9: 079.88, 079.98, 099.41, 099.50-099.59; ICD-10: A56.*, A74.81-A74.9
Gonorrhea	<b>POV:</b> ICD-9: 098.0-098.89; ICD-10: A54.*, O98.2*
HIV/AIDS	<b>POV:</b> ICD-9: 042, 042.0-044.9, 079.53, 795.71, V08; ICD-10: B20, B97.35, R75, Z21, O98.711-O98.73



STI	ICD and Other Codes
Syphilis	POV: ICD-9: 090.0-093.9, 094.1-097.9; ICD-10: A51.*-A53.*

*Logic for Identifying Patients Diagnosed with Key STI:*

Any patient with one or more diagnoses of any of the key STIs defined above during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period.

*Logic for Identifying Separate Incidents of Key STIs:*

One patient may have one or multiple occurrences of one or multiple STIs during the year, except for HIV. An occurrence of HIV is only counted if it is the initial HIV diagnosis for the patient ever. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see definition above) occurring between 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. A second incident of the same STI (other than HIV) is counted if another diagnosis with the same STI occurs 2 months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day time period as the first STI counts as a separate incident.

*Example of Patient with Multiple Incidents of Single STI:*

Visit	Total Incidents
08/01/15: Patient screened for Chlamydia	0
08/08/15: Patient diagnosed with Chlamydia	1
10/15/15: Patient diagnosed with Chlamydia	2
10/25/15: Follow-up for Chlamydia	2
11/15/15: Patient diagnosed with Chlamydia	2
03/01/16: Patient diagnosed with Chlamydia	3

*Denominator Logic for Needed Screenings:*

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed HIV screening tests denominator, the count will be derived from the number of separate non-HIV STI incidents. HIV screening tests are recommended for the following key STIs: Chlamydia, Gonorrhea, Syphilis.

“Needed” screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).

1. Only one screening for HIV is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening is needed for HIV/AIDS.
2. A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.

*Numerator Logic:*

To be counted in the numerator, each needed screening in the denominator must have a corresponding laboratory test or test refusal documented in the period from one month prior to the relevant STI diagnosis date through 2 months after the STI incident.

Key STI screenings are defined with the following codes.

STI	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
HIV/AIDS	86689, 86701–86703, 87390–87391, 87534–87539		Yes	BGP HIV TEST TAX

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients diagnosed with one or more STIs during the defined time period with related screenings.

### Measure Source

None

### Measure Past Performance and Long-Term Targets

None

DU	November 25, 2016	Page 266
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		
Baseline Period: Jan 01, 2010 to Dec 31, 2010		

-----									
Sexually Transmitted Infection (STI) Screening (con't)									
	REPORT PERIOD		PREV YR PERIOD	CHG from PREV YR	BASE PERIOD	CHG from BASE			
Active Clinical Pts w/ Key STI Dx	41		13	+28	10	+31			
Male Active Clinical Pts w/ Key STI Dx	10		7	+3	8	+2			
Female Active Clinical Pts w/ Key STI Dx	31		6	+25	2	+29			
Total # Key STI Incidents for Active Clinical Pts	44		13	+31	10	+34			
# HIV/AIDS Screens Needed for Key STIs-AC Pts (GPRA Dev.)	8		25		29				
# Needed HIV/AIDS Screens Performed-No Refusals (GPRA Dev.)	4	50.0	9	36.0	+14.0	5	17.2	+32.8	
# HIV/AIDS Screens Needed for Key STIs-Male AC Pts	2		7		12				
# Needed HIV/AIDS Screens Performed-No Refusals	1	50.0	3	42.9	+7.1	0	0.0	+50.0	
# HIV/AIDS Screens Needed for Key STIs-Female AC Pts	6		18		17				
# Needed HIV/AIDS Screens Performed-No Refusals	3	50.0	6	33.3	+16.7	5	29.4	+20.6	

Figure 2-106: Sample Report Sexually Transmitted Infection (STI) Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Sexually Transmitted Infection (STI) Screening: List of patients diagnosed with one or more STIs during the defined time period with related screenings.

PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB
DENOMINATOR		NUMERATOR			
PATIENT1,DIANE	000001	COMMUNITY #1	F	15	02/12/01
UP;AC Visit 1) 02/12/16		POV: HIV 042. 1) N/A			
PATIENT2,LEIGHANN	000002	COMMUNITY #1	F	18	06/18/98

UP;AC Visit 1) 11/02/16	POV: GC 098.89	1) HIV-Y 12/02/16	CPT [87390]
PATIENT3,WHITNEY	000003	COMMUNITY #1	F 25 12/15/91
UP;AC Visit 1) 06/17/16	POV: CHL 078.89	1) HIV-N	
PATIENT4, NANCY	000004	COMMUNITY #1	F 29 08/28/87
UP;AC Visit 1) 03/01/16	POV: CHL 079.88	1) HIV-Contraind Prior DX 04/11/08	POV: HIV [079.53]
PATIENT5,JOHN	000005	COMMUNITY #1	M 40 10/22/76
UP;AC Visit 1) 06/15/16	POV: GC 098.89; 2) 07/15/16	POV: HIV 042. 1) HIV-N; 2) N/A	
PATIENT6,NORMAN	000006	COMMUNITY #1	M 42 07/29/74
UP;AC Visit 1) 10/11/16	POV: CHL 079.98, 10/11/16	POV: GC 098.891)	HIV-N

Figure 2-107: Sample Patient List, Sexually Transmitted Infection (STI) Screening

## 2.10 Other Clinical Measures Topics

### 2.10.1 Osteoporosis Management

#### Denominators

*Female Active Clinical patients* ages 67 through 85 who had a new fracture occurring 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period with no osteoporosis screening or treatment in the two years prior to the fracture.

*Female User Population patients* ages 67 through 85 who had a new fracture occurring 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period with no osteoporosis screening or treatment in the two years prior to the fracture.

#### Numerator

Patients treated or tested for osteoporosis after the fracture.

#### Logic Description

Age is calculated at the beginning of the Report Period. Fractures do not include fractures of finger, toe, face, or skull. CRS will search for the first (i.e., earliest) fracture during the period 6 months (182) days prior to the beginning of the Report Period and the first 6 months of the Report Period. If multiple fractures are present, only the first fracture will be used.

*Index Episode Start Date definition:* The Index Episode Start Date is the date the fracture was diagnosed. If the fracture was diagnosed at an outpatient visit (Service Category A, S, or O), the Index Episode Start Date is equal to the Visit Date. If diagnosed at an inpatient visit (Service Category H), the Index Episode Start Date is equal to the Discharge Date.

*Denominator Exclusions*

1. Patients receiving osteoporosis screening or treatment in the year (365 days) prior to the Index Episode Start Date. Osteoporosis screening or treatment is defined as a Bone Mineral Density (BMD) test (see below for codes) or receiving any osteoporosis therapy medication (see below for codes).
2. Patients with a fracture diagnosed at an outpatient visit, which also had a fracture within 60 days prior to the Index Episode Start Date.
3. Patients with a fracture diagnosed at an inpatient visit, which also had a fracture within 60 days prior to the ADMISSION DATE.

*Osteoporosis Treatment and Testing definition:* (1) For fractures diagnosed at an outpatient visit: a nondiscontinued prescription within 6 months (182 days) of the Index Episode Start Date (i.e., visit date) or B) a BMD test within 6 months of the Index Episode Start Date. (2) For fractures diagnosed at an inpatient visit, a BMD test performed during the inpatient stay.

CRS uses the following codes to define fracture and BMD test.

Subject Defined	CPT Codes	ICD and Other Codes
<b>Fracture Codes</b>	21800 through 21825, 22305 through 22314, 22316 through 22324, 22520, 22521, 22523, 22524, 23500 through 23515, 23570 through 23630, 23665 through 23680, 24500 through 24585, 24620, 24635, 24650 through 24685, 25500–25609, 25611 (old code), 25620 (old code), 25622–25652, 25680, 25685, 27193 through 27248, 27254, 27500 through 27514, 27520 through 27540, 27750 through 27828, S2360, S2362	<p><b>POV:</b> ICD-9: 805*–806*, 807.0*–807.4, 808*–815*, 818*–825*, 827*, 828*; ICD-10: M48.5*XA, M80.**A, M84.40xA-M84.443A (ending in A only), M84.451A-M84.476A (ending in A only), M84.48xA, S22.0*0A, S22.0*0B, S32.0*0A, S32.0*0B, S52.001A-S52.236C (ending in A, B, or C only), S52.251A-S52.279C (ending in A, B, or C only), S52.291A-S52.336C (ending in A, B, or C only), S52.351A-S52.366C (ending in A, B, or C only), S52.391A-S52.92xC (ending in A, B, or C only), S62.001A-S62.186B (ending in A or B only), S72.001A-S72.019C (ending in A, B, or C only), S72.031A-S72.92xC (ending in A, B, or C only), S82.001A-S82.856C (ending in A, B, or C only), S82.891A-S82.92XC (ending in A, B, or C only)</p> <p><b>Procedure:</b> ICD-9: 79.01–79.03, 79.05–79.07, 79.11–79.13, 79.15–79.17, 79.21–79.23, 79.25–79.27, 79.31–79.33, 79.35–79.37, 79.61–79.63, 79.65–79.67, 81.65–81.66; ICD-10: 0PSC***, 0PSD***, 0PSF***, 0PSG***, 0PSH***, 0PSJ***, 0PSK***, 0PSL***, 0PU337Z, 0PU33JZ, 0PU347Z, 0PU34JZ, 0PU437Z, 0PU43JZ, 0PU447Z, 0PU44JZ, 0QS6***, 0QS7***, 0QS8***, 0QS9***, 0QSB***, 0QSC***, 0QSG***, 0QSH***, 0QSJ***, 0QSK***, 0QU037Z, 0QU03JZ, 0QU047Z, 0QU04JZ, 0QU137Z, 0QU13JZ, 0QU147Z, 0QU14JZ</p>
<b>BMD Test Codes</b>	77078, 76070 (old code), 77079 (old code), 76071 (old code), 77080, 76075 (old code), 77081, 76076 (old code), 77083 (old code), 76078 (old code), 76977, G0130	<p><b>POV:</b> ICD-9: V82.81; ICD-10: Z13.820</p> <p><b>Procedure:</b> ICD-9: 88.98</p>

*Treatment medication codes* are defined with medication taxonomy BGP HEDIS OSTEOPOROSIS MEDS. (Medications are: Alendronate, Alendronate-Cholecalciferol (Fosomax Plus D), Ibandronate (Boniva), Risedronate, Zoledronic acid, Calcitonin, Denosumab, Raloxifene, and Teriparatide.) Medications must not have a comment of RETURNED TO STOCK.

### Key Logic Changes from CRS Version 15.1

None.

**Patient List Description**

List of female patients with new fracture who have had osteoporosis treatment or testing, if any.

**Measure Source**

HEDIS

**Measure Past Performance and Long-Term Targets**

None

DU		November 25, 2016				Page 277			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Osteoporosis Management									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Female Active Clinical Pts									
67 and older									
w/fracture	8		0			0			
# w/osteoporosis treatment or testing	3	37.5	0	0.0	+37.5	0	0.0	+37.5	
Female User Pop Pts									
67 and older									
w/fracture	9		0			0			
# w/osteoporosis treatment or testing	4	44.4	0	0.0	+44.4	0	0.0	+44.4	

Figure 2-108: Sample Report Osteoporosis Management

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic					
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;					
HR=High Risk Patient					
Osteoporosis Management: List of female patients with new fracture who have had osteoporosis treatment or testing, if any.					
PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB
DENOMINATOR	NUMERATOR				
-----					
PATIENT1,ALWENA	000001	COMMUNITY #1	F	68	03/31/48
UP,AC	FX: 01/01/16		CPT 22524		

PATIENT2, SYBIL	000002	COMMUNITY #1	F	69	08/17/47
UP, AC					FX: 02/10/16 CPT 22524 TX: 02/10/16 CPT G0130
PATIENT3, ELIZABETH	000003	COMMUNITY #1	F	78	10/18/38
UP, AC					FX: 02/16/16 CPT S2362
PATIENT4, KATIE	000004	COMMUNITY #1	F	80	02/16/36
UP, AC					FX: 02/05/16 PROC 81.66
PATIENT5, LINDSAY	000005	COMMUNITY #1	F	81	09/22/35
UP					FX: 02/01/16 DX 733.13 TX: 02/15/16 CPT 77081
PATIENT6, ELIZABETH	000006	COMMUNITY #1	F	86	05/16/30
UP, AC					FX: 01/15/16 DX 733.13 TX: 01/31/16 CPT 77081

Figure 2-109: Sample Patient List, Osteoporosis Management

## 2.10.2 Osteoporosis Screening in Women

### Denominators

*Female Active Clinical patients* ages 65 and older without a documented history of osteoporosis.

*Female User Population patients* ages 65 and older without a documented history of osteoporosis.

### Numerators

Patients who had osteoporosis screening documented after the age of 65.

**Note:** This numerator does *not* include refusals.

### Logic Description

Age is calculated at the beginning of the Report Period.

*Osteoporosis definition:* No osteoporosis diagnosis ever (POV ICD-9: 733.\*; ICD-10: M80.\*\*A, M81\*, M84.4\*\*A, M84.6\*\*A).

CRS uses the following codes to define osteoporosis screening.



Subject Defined	V Radiology or CPT Codes	ICD and Other Codes
Osteoporosis Screening (any test documented after age 65)	<b>Central DEXA:</b> 77080, 76075 (old code) <b>Peripheral DEXA:</b> 77081, 76076 (old code) <b>SEXA:</b> G0130 <b>Central CT:</b> 77078, 76070 (old code) <b>Peripheral CT:</b> 77079, 76071 (old code) <b>US Bone Density:</b> 76977	<b>Procedure:</b> ICD-9: 88.98 (Quantitative CT) <b>POV:</b> ICD-9: V82.81 Special screening for other conditions, Osteoporosis; ICD-10: Z13.820

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of female patients ages 65 and older with osteoporosis screening after age 65, if any.

**Measure Source**

None.

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016						Page 279	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Osteoporosis Screening in Women								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Female Active Clinical Pts =>65	57		31			29		
# w/osteoporosis screening after age 65								
-No Refusals	13	22.8	1	3.2	+19.6	0	0.0	+22.8
Female User Pop Pts =>65	112		85			81		

# w/osteoporosis screening after age 65								
-No Refusals	13	11.6	3	3.5	+8.1	1	1.2	+10.4

Figure 2-110: Sample Report, Osteoporosis Screening in Women

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Osteoporosis Screening in Women: List of female patients ages 65 and older with osteoporosis screening after age 65, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, SHERRY UP, AC	000001	COMMUNITY #1 05/15/13 Proc 88.98	F	68	05/14/48
PATIENT2, APRIL UP, AC	000002	COMMUNITY #1 04/01/14 CPT G0130	F	68	07/11/48
PATIENT3, JACKIE UP, AC	000003	COMMUNITY #1 08/21/12 RAD CT, BONE MIN DENSITY, 1/+, APPEND	F	69	03/28/47
PATIENT4, PAULINE UP, AC	000004	COMMUNITY #1	F	70	06/28/46
PATIENT5, SHANNON UP, AC	000005	COMMUNITY #1	F	72	04/14/44
PATIENT6, TINA MARIE UP, AC	000006	COMMUNITY #1 04/15/11 CPT 77081	F	78	02/02/38

Figure 2-111: Sample Patient List, Osteoporosis Screening in Women

### 2.10.3 Rheumatoid Arthritis Medication Monitoring

#### Denominator

Active Clinical patients ages 16 and older diagnosed with *rheumatoid arthritis (RA)* prior to the Report Period and with at least two RA-related visits any time during the Report Period who were prescribed maintenance therapy medication chronically during the Report Period.

#### Numerator

Patients who received appropriate monitoring of chronic medication during the Report Period.

#### Logic Description

Age is calculated at the beginning of the Report Period.

RA defined as diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 714.\*; ICD-10: M05.\*through M06.\*, M08.0\*, M08.2 through M08.99, M12.0\* prior to the Report Period, and at least two RA POVs during the Report Period.

For all maintenance therapy medications *except* intramuscular gold, each medication must be prescribed within the past 465 days of the end of the Report Period (i.e., the Medication Period) and the sum of the days supply greater than or equal to ( $\geq$ )348. This means the patient must have been on the medication at least 75% of the Medication Period. Two examples are shown below to illustrate this logic. *All* medications must not have a comment of RETURNED TO STOCK.

*Example of Patient Not on Chronic Medication (not included in Denominator):*

Report Period: January 1 through December 31, 2016

Medication Period: 465 days from end of Report Period (December 31, 2016):  
September 22, 2015 through December 31, 2016

Medication Prescribed:

Diclofenac: 1st Rx: Oct 15, 2015, Days Supply=90; 2nd Rx: Jan 01, 2016:  
Days Supply=90; 3rd Rx: Mar 15, 2016: Days Supply=90.

Total Days Supply=270. 270 is not greater than ( $>$ ) 348. Patient is not considered on chronic medication and is not included in the denominator.

*Example of Patient on Chronic Medication (included in Denominator):*

Report Period: January 1 through December 31, 2016

Medication Period: 465 days from end of Report Period (December 31, 2016):  
September 22, 2015 through December 31, 2016

Medications Prescribed:

Sulfasalazine: 1st Rx: Sep 30, 2015, Days Supply=90; 2nd Rx: December 30,  
2015, Days Supply=90; 3rd Rx: March 15, 2016 Days Supply=180.

Total Days Supply=360. 360 is greater than ( $>$ ) 348. Patient is considered on chronic medication and is included in denominator.

The days' supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the Medication Period. However, for all medications, there must be at least one prescription filled during the Report period.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

For intramuscular gold, the patient must have 12 or more prescriptions during the Report Period.

Appropriate monitoring of rheumatoid arthritis medications is defined with lab tests and varies by medication, as shown in the table below. If patient is prescribed two or more types of medications, patient must meet criteria for all of the medications.

*Maintenance Therapy Medications Definition*

- **Medications shown in table below.** *Except* for Gold, Intramuscular, all medications requiring more than one of each type of test during the Report Period, there must be a minimum of ten days between tests. For example, if a Sulfasalazine test was performed on March 1, March 7, and March 21, 2015, the March 7 test will not be counted since it was performed only 6 days after the March 1 test.

Medication	Required Monitoring Tests
Gold, Intramuscular	CBC and urine Protein on same day as each injection during Report Period
Azathioprine or Sulfasalazine	4 CBCs during the Report Period
Leflunomide or Methotrexate	6 each of CBC, Serum Creatinine, and Liver Function Tests during the Report Period
Cyclosporin	CBC, Liver Function Tests, and Potassium within past 180 days from Report Period end date 12 Serum Creatinine tests during the Report Period
Gold, Oral or Penicillamine	4 each of CBC and Urine Protein during the Report Period
Mycophenolate	CBC within past 180 days from Report Period end date

The medications in the above table are defined with medication taxonomies: BGP RA IM GOLD MEDS, BGP RA AZATHIOPRINE MEDS, BGP RA LEFLUNOMIDE MEDS, BGP RA METHOTREXATE MEDS, BGP RA CYCLOSPORINE MEDS, BGP RA ORAL GOLD MEDS, BGP RA MYCOPHENOLATE MEDS, BGP RA PENICILLAMINE MEDS, BGP RA SULFASALAZINE MEDS.

1. **NSAID Medications:** All of the following medications must have Creatinine, Liver Function Tests, and CBC during the Report Period: Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefanamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celocoxib. All of these medications *except* aspirin are defined with medication taxonomy BGP RA OA NSAID MEDS. Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.
2. **Glucocorticoid Medications:** Dexamethasone, Methylprednisolone, Prednisone, Hydrocortisone, Betamethasone, Prednisolone, Triamcinolone. These medications defined with medication taxonomy BGP RA GLUCOCORTICOIDS MEDS. Glucocorticoids must have a glucose test, which must be performed during the Report Period.

*Example of Patient Not Included in Numerator:*

Medications Prescribed and Required Monitoring:

- Gold, Oral, last Rx June 15, 2015. Requires CBC and Urine Protein within past 90 days of Report Period end date.
- CBC performed on December 1, 2015, which is within past 90 days of Report Period end date of December 31, 2015. No Urine Protein performed during that period. Patient is not in numerator.

*Example of Patient Included in Numerator:*

Medications Prescribed and Required Monitoring:

- Diclofenac, last Rx Sep 1, 2015. Requires LFT and CBC during Report Period.
- Mycophenolate, last Rx March 10, 2015. Requires CBC within past 180 days from Report Period end date.
- LFT and CBC performed during Report Period. CBC performed November 1, 2015, which is within past 180 days of Report Period end date of December 31, 2015. Patient is in numerator.

Monitoring Test	CPT Codes	LOINC Codes	Taxonomy
CBC	85025, 85027	Yes	BGP CBC TESTS
Urine Protein		Yes	DM AUDIT URINE PROTEIN TAX
Serum Creatinine	82540, 82565-75	Yes	DM AUDIT CREATININE TAX
Liver Function Tests-ALT	84460	Yes	DM AUDIT ALT TAX
Liver Function Tests-AST	84450	Yes	DM AUDIT AST TAX
Liver Function	80076	Yes	BGP LIVER FUNCTION TESTS

Monitoring Test	CPT Codes	LOINC Codes	Taxonomy
Glucose	82947, 82948, 82950, 82951, 82952, 82962	Yes	DM AUDIT GLUCOSE TESTS TAX
Potassium	84132	Yes	BGP POTASSIUM TESTS

**Key Logic Changes from CRS Version 15.1**

1. Added LOINC codes 53553-4 and 75405-1 and removed codes 10968-6, 1491-0, 1532-1, 1541-2, 16906-0, 16907-8, 16908-6, 16909-4, 16910-2, 16911-0, 16912-8, 16913-6, 26538-9, 26540-5, 26548-8, 26549-6, 26552-0, 42604-9, 42609-8, 42615-5, 42629-6, 42631-2, 45204-5, 45205-2, 45206-0, 46222-6, 46223-4, 6753-8, 6754-6, 6755-3, 6759-5, 6764-5 from BGP GLUCOSE LOINC taxonomy.

**Patient List Description**

List of RA patients age 16 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with YES and patients who did not meet the measure are prefixed with NO The chronic medications and all laboratory tests the patient *did* have are displayed.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016	Page 284						
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Rheumatoid Arthritis Medication Monitoring								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %
Active Clinical Pts =>16								
w/RA DX and maintenance								
therapy RX	3		0			0		
# w/RA chronic med								

monitoring	2	66.7	0	0.0	+66.7	0	0.0	+66.7
------------	---	------	---	-----	-------	---	-----	-------

Figure 2-112: Sample Report, Rheumatoid Arthritis Medication Monitoring

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Rheumatoid Arthritis Medication Monitoring: List of RA patients 16 and older prescribed maintenance therapy medication with monitoring lab tests, if any. The numerator values for patients who meet the measure are prefixed with "YES:" and patients who did not meet the measure are prefixed with "NO:". The chronic medications and all lab tests the patient DID have are displayed.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, RUTH AC	000001	COMMUNITY #1 YES: NSAID: 10/21/16 CREAT, 09/22/16 CBC, 05/21/16 LFT	F	64	05/14/52
PATIENT2, SHANNON AC	000002	COMMUNITY #1 YES: Glucocorticoids: 11/02/16 Glucose	F	72	08/18/44
PATIENT34, CATHERINE AC	000034	COMMUNITY #3 NO: Glucocorticoids: does not have Glucose	F	50	06/03/66

Figure 2-113: Sample Patient List, Rheumatoid Arthritis Medication Monitoring

## 2.10.4 Osteoarthritis Medication Monitoring

### Denominator

Active Clinical patients ages 40 and older diagnosed with *osteoarthritis (OA)* prior to the Report Period and with at least two OA-related visits any time during the Report Period and prescribed maintenance therapy medication chronically during the Report Period.

### Numerator

Patients who received appropriate monitoring of chronic medication during the Report Period.

### Logic Description

Age is calculated at the beginning of the Report Period.

OA defined as diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 715.\*; ICD-10: M15.\* through M19.\* prior to the Report period, and at least two OA POVs during the Report Period.

For all maintenance therapy medications, each medication must be prescribed within the past 465 days of the end of the Report Period (i.e., the Medication Period) and the sum of the days supply greater than or equal to ( $\geq$ ) 348. This means the patient must have been on the medication at least 75% of the Medication Period. Two examples are shown below to illustrate this logic. Medications must not have a comment of RETURNED TO STOCK.

*Example of Patient Not on Chronic Medication (not included in Denominator):*

- Report Period: January 1 through December 31, 2016
- Medication Period: 465 days from end of Report Period (December 31, 2016): September 22, 2015 through December 31, 2016
- Medication Prescribed:
  - Diclofenac: 1st Rx: October 15, 2015, Days Supply=90; 2nd Rx: January 1, 2016: Days Supply=90; 3rd Rx: March 15, 2016: Days Supply=90.
  - Total Days Supply=270. 270 is not greater than ( $>$ ) 348. Patient is not considered on chronic medication and is not included in the denominator.

*Example of Patient on Chronic Medication (included in Denominator):*

- Report Period: January 1 through December 31, 2016
- Medication Period: 465 days from end of Report Period (December 31, 2016): September 22, 2015 through December 31, 2016
- Medication Prescribed:
  - Etodolac: 1st Rx: September 30, 2015, Days Supply=90; 2nd Rx: December 30, 2015, Days Supply=90; 3rd Rx: March 15, 2016: Days Supply =180.
  - Total Days Supply=360. 360 is greater than ( $>$ ) 348. Patient is considered on chronic medication and is included in denominator.

The days supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the Medication Period. However, for all medications, there must be at least one prescription filled during the Report Period.



**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

Appropriate monitoring of OA medications is defined with laboratory tests and varies by medication, as shown below.

*Maintenance Therapy Medications Defined with the Following NSAID Medications:*

Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefanamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celcoxib. All of these medications, *except* aspirin, are defined with medication taxonomy BGP RA OA NSAID MEDS. Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

All NSAID medications must have Creatinine, Liver Function Tests and CBC during the Report Period.

*Example of Patient Not Included in Numerator:*

- Medication Prescribed and Required Monitoring:
  - Diclofenac, last Rx June 15, 2016. Requires Creatinine, LFT and CBC during Report Period. Only the LFT was performed during Report Period. Patient is not in numerator.

*Example of Patient Included in Numerator:*

- Medications Prescribed and Required Monitoring:
  - Diclofenac, last Rx September 1, 2016. Requires Creatinine, LFT and CBC during Report Period. Creatinine, LFT, and CBC performed during Report Period. Patient is in numerator.

CRS uses the following codes to define the monitoring tests.

Monitoring Test	CPT Codes	LOINC Codes	Taxonomy
Serum Creatinine	82540, 82565-82575	Yes	DM AUDIT CREATININE TAX
CBC	85025, 85027	Yes	BGP CBC TESTS
Liver Function Tests-ALT	84460	Yes	DM AUDIT ALT TAX
Liver Function Tests-AST	84450	Yes	DM AUDIT AST TAX
Liver Function	80076	Yes	BGP LIVER FUNCTION TESTS

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of OA patients 40 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with YES and patients who did not meet the measure are prefixed with NO. All laboratory tests the patient did have are displayed.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016		Page 287				
*** IHS 2016 Selected Measures with Community Specified Report ***							
DEMO INDIAN HOSPITAL							
Report Period: Jan 01, 2016 to Dec 31, 2016							
Previous Year Period: Jan 01, 2015 to Dec 31, 2015							
Baseline Period: Jan 01, 2010 to Dec 31, 2010							
-----							
Osteoarthritis Medication Monitoring							
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from BASE PREV YR % PERIOD	%	CHG from BASE %
Active Clinical Pts =>40 w/OA DX and maintenance therapy RX	3		6		4		
# w/OA chronic med monitoring	2	66.7	3	50.0	+16.7	2	50.0 +16.7

Figure 2-114: Sample Report, Osteoarthritis Medication Monitoring

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient
Osteoarthritis Medication Monitoring: List of OA patients 40 and older prescribed maintenance therapy medication with monitoring lab tests, if any. The numerator values for patients who meet the measure are prefixed with "YES:" and patients who did not meet the measure are prefixed with "NO:". All lab tests the patient DID have are displayed.
PATIENT NAME                      HRN            COMMUNITY            SEX AGE    DOB

DENOMINATOR	NUMERATOR
PATIENT1,RUTH AC 451 days of NSAID	000001 COMMUNITY #1 F 64 05/14/52 YES: 10/21/16 CREAT, 09/22/16 CBC, 05/21/16 LFT
PATIENT2,JACKIE AC 472 days of NSAID	000002 COMMUNITY #1 F 69 06/09/47 YES: 10/30/16 CREAT, 08/06/16 CBC, 10/30/16 LFT
PATIENT15,RAYMOND AC 804 days of NSAID	000015 COMMUNITY #2 M 84 11/07/32 NO: 09/12/16 CREAT

Figure 2-115: Sample Patient List, Osteoarthritis Medication Monitoring

## 2.10.5 Asthma

### Denominators

All *Active Clinical patients*. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

*Patients who have had two asthma-related visits* during the Report Period or with persistent asthma. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

### Numerators

Patients who have had two asthma-related visits during the Report Period or with persistent asthma.

Patients from Numerator 1 who have been hospitalized at any hospital for asthma during the Report Period.

Patients from Numerator 1 who have visited the ER or Urgent Care for asthma during the Report Period.

Patients from Numerator 1 who have a Severity of 1.

Patients from Numerator 1 who have a Severity of 2.

Patients from Numerator 1 who have a Severity of 3.

Patients from Numerator 1 who have a Severity of 4.

Patients from Numerator 1 who have no documented Severity.

### Logic Description

Age is calculated at beginning of Report Period.

*Asthma visits definition:* Diagnosis (POV) ICD-9: 493.\*; ICD-10: J45.\*.

*Persistent asthma definition:* Any of the following:

- Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at *any* time before the end of the Report Period, *or*
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented *any* time before the end of the Report Period.

*Severity definition:* Severity of 1, 2, 3 or 4 in an active entry in the PCC Problem List for ICD-9: 493.\*; ICD-10: J45.\* or in V Asthma.

*Hospitalizations definition:* Service Category H with primary POV ICD-9: 493.\*; ICD-10: J45.\*.

*ER and Urgent Care definition:* Clinic codes 30 or 80 with primary POV ICD-9: 493.\*; ICD-10: J45.\*.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients diagnosed with asthma and any asthma-related hospitalizations.

### Measure Source

HP 2020 RD-2

### Measure Past Performance and Long-Term Targets

Measure	Target
<b>HP1998 baseline for hospitalizations for asthma:</b>	
Under 5	45.6 per 10,000
5-64	12.5 per 10,000
65 and older	17.7 per 10,000
<b>HP 2020 goal for hospitalizations for asthma:</b>	
Under 5	18.1 per 10,000
5-64	8.6 per 10,000
65 and older	20.3 per 10,000

DU	November 25, 2016	Page 289
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		

Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Asthma (con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Total Active Clinical Patients								
	1,646		1,224			1,101		
# w/asthma	58	3.5	42	3.4	+0.1	25	2.3	+1.3
A. Under 15	28	48.3	22	52.4	-4.1	17	68.0	-19.7
B. 15-34	7	12.1	7	16.7	-4.6	3	12.0	+0.1
C. 35-64	15	25.9	8	19.0	+6.8	3	12.0	+13.9
D. 65 and older	8	13.8	5	11.9	+1.9	2	8.0	+5.8
# w/asthma	58		42			25		
# w/asthma hospitalization	2	3.4	2	4.8	-1.3	2	8.0	-4.6
A. Under 15	1	50.0	0	0.0	+50.0	1	50.0	+0.0
B. 15-34	0	0.0	1	50.0	-50.0	0	0.0	+0.0
C. 35-64	0	0.0	0	0.0	+0.0	1	50.0	-50.0
D. 65 and older	1	50.0	1	50.0	+0.0	0	0.0	+50.0
# w/ ER/UC visit	6	10.3	6	14.3	-3.9	9	36.0	-25.7
A. Under 15	2	33.3	3	50.0	-16.7	7	77.8	-44.4
B. 15-34	0	0.0	2	33.3	-33.3	1	11.1	-11.1
C. 35-64	2	33.3	0	0.0	+33.3	1	11.1	+22.2
D. 65 and older	2	33.3	1	16.7	+16.7	0	0.0	+33.3
# w/ Severity 1	3	5.2	0	0.0	+5.2	0	0.0	+5.2
# w/ Severity 2	7	12.1	3	7.1	+4.9	0	0.0	+12.1
# w/ Severity 3	4	6.9	0	0.0	+6.9	0	0.0	+6.9
# w/ Severity 4	6	10.3	2	4.8	+5.6	0	0.0	+10.3
# w/ No Severity	38	65.5	37	88.1	-22.6	25	100.0	-34.5

Figure 2-116: Sample Report, Asthma

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Asthma: List of patients diagnosed with asthma and any asthma-related hospitalizations/ER/Urgent Care visits.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,GENEVA AC	000001	COMMUNITY #1	F	47	05/19/69
Severity: 4		Severity 4 on visit			02/02/16; ER/UC: 11/02/16;
PATIENT2,JACKIE AC	000002	COMMUNITY #1	F	69	06/07/47
Severity: 2		Severity 2 on PL;			Severity: 2
PATIENT3,PAULINE AC	000003	COMMUNITY #1	F	70	08/11/46
Severity: 1		2 Dx PCC:			03/01/16, 03/03/16; ER/UC: 10/01/16;
PATIENT4,WILLIAM R	000004	COMMUNITY #1	M	7	06/05/09

AC	2 Dx PCC: 05/05/16, 06/06/16; Hospital: 05/05/16;
ER/UC: 06/06/16	
PATIENT5,ZACHARY	000005 COMMUNITY #1 M 11 02/06/05
AC	2 Dx PCC: 03/20/16, 08/08/16
PATIENT42,JOSEPHINE	000042 COMMUNITY #2 F 4 06/11/12
AC	2 Dx PCC: 07/01/16, 09/19/16; Severity: 2

Figure 2-117: Sample Patient List, Asthma

## 2.10.6 Asthma Assessments

### Denominators

*Active Clinical patients* ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

### Numerator

Patients with asthma management plan during the Report Period.

Patients with severity documented at any time before the end of the Report Period.

Patients with control documented during the Report Period.

Patients who were assessed for number of symptom free days during the Report Period.

Patients with number of symptom free days score of 0 through 5.

Patients with number of symptom free days score of 6 through 12.

Patients with number of symptom free days score of 13 through 14.

Patients who were assessed for number of school/work days missed during the Report Period.

Patients with number of school/work days missed score of 0 through 2.

Patients with number of school/work days missed score of 3 through 7.

Patients with number of school/work days missed score of 8 through 14.

### Logic Description

Age of the patient is calculated at the beginning of the Report Period.

*Emphysema definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 492.\*, 506.4, 518.1, 518.2; ICD-10: J43.\*, J68.4, J68.8, J98.2, J98.3.

*COPD definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8.

*Persistent asthma definition:*

1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)
  - b. At least one acute inpatient discharge with primary diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
  - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* *and* at least two asthma medication dispensing events (see definition below)
  - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
  - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

*Dispensing event definition:* One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events ( $100/30 = 3.33$ , rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

*Asthma medication codes for denominator* defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

*Asthma management plan definition:* Patient Education code ASM-SMP.

*Severity documented definition:*

Meeting any of the following criteria below:

1. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at ANY time before the end of the Report Period or
2. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented ANY time before the end of the Report Period.

*Control documented definition:* POV ICD-9: 493.\*; ICD-10: J45.\* with Asthma Control recorded in the V Asthma file.

*Number of symptom free days definition:* The most recent V Measurement documented during the Report Period.

*Number of school/work days missed definition:* The most recent V Measurement documented during the Report Period.

### **Key Logic Changes from CRS Version 15.1**

None.



**Patient List Description**

List of asthmatic patients with assessments, if any.

**Measure Source**

None

**Measure Past Performance and Long-term Targets**

None

DU	November 25, 2016						Page 295	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Asthma Assessments								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
Active Clinical								
Pts =>5 w/ persistent								
asthma	29		11			5		
# w/management plan	1	3.4	0	0.0	+3.4	0	0.0	+3.4
# w/severity								
documented	17	58.6	5	45.5	+13.2	1	20.0	+38.6
# w/control								
documented	3	10.3	0	0.0	+10.3	0	0.0	+10.3
# w/# symptom free								
days	3	10.3	0	0.0	+10.3	0	0.0	+10.3
# w/# symptom free								
days 0-5	1	3.4	0	0.0	+3.4	0	0.0	+3.4
# w/# symptom free								
days 6-12	1	3.4	0	0.0	+3.4	0	0.0	+3.4
# w/# symptom free								
days 13-14	1	3.4	0	0.0	+3.4	0	0.0	+3.4
# w/# school/work								
days missed	3	10.3	0	0.0	+10.3	0	0.0	+10.3
# w/# school/work								
days missed 0-2	1	3.4	0	0.0	+3.4	0	0.0	+3.4
# w/# school/work								
days missed 3-7	1	3.4	0	0.0	+3.4	0	0.0	+3.4
# w/# school/work								
days missed 8-14	1	3.4	0	0.0	+3.4	0	0.0	+3.4

Figure 2-118: Sample Report, Asthma Assessments

DU	November 25, 2016						Page 95	
*** IHS 2016 Selected Measures with Community Specified Report ***								

DEMO INDIAN HOSPITAL				
Report Period: Jan 01, 2016 to Dec 31, 2016				
Previous Year Period: Jan 01, 2015 to Dec 31, 2015				
Baseline Period: Jan 01, 2010 to Dec 31, 2010				
-----				
Asthma Assessments (con't)				
	Active Clinical Pts =>5 w/Persistent Asthma			
	5-14	15-34	35-64	65+
CURRENT REPORT PERIOD				
Active Clinical Pts =>5				
w/persistent asthma	11	6	6	6
# w/management plan	1	0	0	0
% w/management plan	9.1	0.0	0.0	0.0
# w/severity documented	7	3	6	1
% w/severity documented	63.6	50.0	100.0	16.7
% w/control documented	0	1	1	1
% w/control documented	0.0	16.7	16.7	16.7
# w/# symptom free days	1	0	0	2
% w/# symptom free days	9.1	0.0	0.0	33.3
# w/# symptom free days 0-5	0	0	0	1
% w/# symptom free days 0-5	0.0	0.0	0.0	16.7
# w/# symptom free days 6-12	1	0	0	0
% w/# symptom free days 6-12	9.1	0.0	0.0	0.0
# w/# symptom free days 13-14	0	0	0	1
% w/# symptom free days 13-14	0.0	0.0	0.0	16.7
# w/# school/work days missed	1	0	0	2
% w/# school/work days missed	9.1	0.0	0.0	33.3
# w/# school/work days missed 0-2	1	0	0	0
% w/# school/work days missed 0-2	9.1	0.0	0.0	0.0
# w/# school/work days missed 3-7	0	0	0	1
% w/# school/work days missed 3-7	0.0	0.0	0.0	16.7
# w/# school/work days missed 8-14	0	0	0	1
% w/# school/work days missed 8-14	0.0	0.0	0.0	16.7

Figure 2-119: Sample Age Breakdown Report, Asthma Assessments

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;

HR=High Risk Patient

Asthma Assessments: List of asthmatic patients with assessments, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,GENEVA	000001	COMMUNITY #1	F	47	06/15/69
UP,AC Severity 4 in V Asthma 02/02/16 Severity: 4; Symptom Free Days: 03/01/16 [12]; Days Missed: 03/01/16 [0]					
PATIENT2,JACKIE	000002	COMMUNITY #1	F	69	02/25/47
UP,AC Severity >1 on PL for 493.00 Severity: 2					
PATIENT3,PAULINE	000003	COMMUNITY #1	F	70	06/22/46
UP,AC Severity >1 on PL for 493.00 Mgmt Plan: 06/01/16; Severity: 3					
PATIENT4,WILLIAM R	000004	COMMUNITY #1	M	7	04/11/09
UP,AC 4 meds					
PATIENT5,ZACHARY	000005	COMMUNITY #1	M	11	06/18/05
AC Severity 4 in V Asthma 04/04/16 Severity: 4; Control: 05/06/16					
PATIENT42,JOSEPHINE	000042	COMMUNITY #2	F	4	07/24/12
AC DX ON HOSP/OR ER ON 05/05/16 DX ON HOSP/OR ER ON 06/03/16 Control: 10/03/16; Symptom Free Days: 07/01/16 [3]; Days Missed: 07/01/16 [3]					

Figure 2-120: Sample Patient List, Asthma Assessments

## 2.10.7 Asthma Quality of Care

### Denominators

*Active Clinical patients* ages 5 through 56 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 9, 10 through 17, and 18 through 56).

*User Population patients* ages 5 through 56 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema and chronic COPD. Broken down by age groups (5 through 9, 10 through 17, and 18 through 56).

### Numerator

Patients who had at least one dispensed prescription for preferred asthma therapy medication during the Report Period.

### Logic Description

Age of the patient is calculated at the beginning of the Report Period.

*Emphysema definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 492.\*, 518.1, 518.2; ICD-10: J43.\*, J98.2, J98.3.

*COPD definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8.

*Persistent asthma definition:*

1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)
  - b. At least one acute inpatient discharge with Primary Diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
  - c. At least four outpatient visits on different dates of service, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* *and* at least two asthma medication dispensing events (see definition below)
  - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
  - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

*Dispensing event definition:* One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events ( $100/30 = 3.33$ , rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

*Asthma medication codes for denominator* defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

*To be included in the numerator*, patient must have a non-discontinued prescription for preferred asthma therapy (see list of medications below) during the Report Period.

*Preferred asthma therapy medication codes for numerator* defined with medication taxonomy: BGP HEDIS PRIMARY ASTHMA MEDS Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline). Medications must not have a comment of RETURNED TO STOCK.

### **Key Logic Changes from CRS Version 15.1**

None.

### **Patient List Description**

List of asthmatic patients with preferred asthma therapy medications, if any.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU		November 25, 2016				Page 292			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Asthma Quality of Care (con't)									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts 5-56 w/persistent asthma	21		10			5			
# w/ preferred asthma control med	7	33.3	5	50.0	-16.7	3	60.0	-26.7	
A. Active Clinical ages 5-9	11		3			1			
# w/ preferred asthma control med	3	27.3	1	33.3	-6.1	1	100.0	-72.7	
B. Active Clinical ages 10-17	2		2			1			
# w/ preferred asthma control med	2	100.0	2	100.0	+0.0	0	0.0	+100.0	
C. Active Clinical ages 18-56	8		5			3			
# w/ preferred asthma control med	2	25.0	2	40.0	-15.0	2	66.7	-41.7	
User Pop Pts 5-56 w/persistent asthma	21		11			6			
# w/ preferred asthma control med	7	33.3	5	45.5	-12.1	3	50.0	-16.7	
A. User Pop ages 5-9	11		4			1			

# w/ preferred asthma control med	3	27.3	1	25.0	+2.3	1	100.0	-72.7
B. User Pop ages 10-17	2		2			1		
# w/ preferred asthma control med	2	100.0	2	100.0	+0.0	0	0.0	+100.0
C. User Pop ages 18-56	8		5			4		
# w/ preferred asthma control med	2	25.0	2	40.0	-15.0	2	50.0	-25.0

Figure 2-121: Sample Report, Asthma Quality of Care

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Asthma Quality of Care: List of asthmatic patients with preferred asthma therapy medications, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,ZACHARY	000011	COMMUNITY	F	5	12/18/11
UP,AC,Severity 4 in V Asthma 02/02/16					
PATIENT12,TINA DANIELLE	000012	COMMUNITY	F	6	06/17/10
UP,AC,Severity >1 on PL for 493.00,NUM: 06/01/16, MOMETASONE/FORMOTEROL 100/5MCG INH					
PATIENT13,THERESA LYNN	000013	COMMUNITY	M	47	02/11/69
UP,AC,Severity 2 in V Asthma 03/03/16,NUM: 06/01/16, FLUTICASONE PROPIONATE 110MCG INHALER					
PATIENT36,NATHAN BRADLEY	000014	COMMUNITY	M	16	06/12/00
UP,AC,DX ON HOSP/OR ER ON 09/26/16,4 POVS AND 2 MEDSNUM: 09/19/16, FLUTICASONE PROPIONATE 110MCG INHALER					
PATIENT37,JANELLE MARIE	000015	COMMUNITY	F	50	08/14/66
UP,AC,Severity 2 in V Asthma 09/04/16					
PATIENT38,THOMAS ELLIS	000016	COMMUNITY	M	6	07/24/10
UP,AC,4 meds					

Figure 2-122: Sample Patient List, Asthma Quality of Care

## 2.10.8 Medication Therapy for Persons with Asthma

### Denominators

*Active Clinical patients* ages 5-50 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD).

*Active Clinical patients* ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

*Active Clinical patients* ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD) who had two or more prescriptions for a LABA during the Report Period. Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

### **Numerators**

Suboptimal Control: Patients who were dispensed more than three canisters of a short-acting beta2 agonist inhaler during the same 90-day period during the Report Period.

Absence of Controller Therapy: Patients who were dispensed more than three canisters of short acting beta2 agonist inhalers over a 90-day period and who did not receive controller therapy during the same 90-day period.

Patients who were prescribed two or more controller therapy medications during the Report Period.

Patients who were prescribed two or more inhaled corticosteroid medications during the Report Period.

Patients who were not prescribed two or more inhaled corticosteroid medications during the Report Period.

### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

*Emphysema definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 492.\*, 506.4, 518.1, 518.2; ICD-10: J43.\*, J68.4, J68.8, J98.2, J98.3.

*COPD definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8.

*Persistent asthma definition:*



1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)
  - b. At least one acute inpatient discharge with Primary Diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
  - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* *and* at least two asthma medication dispensing events (see definition below)
  - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
  - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

*Dispensing event definition:* One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events ( $100/30 = 3.33$ , rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

*Asthma medication codes for denominator* defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Beclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

*To be included in the Suboptimal Control and Absence of Controller Therapy numerators*, patient must have one or more non-discontinued prescriptions for short acting Beta2 Agonist inhalers totaling at least four canisters in one 90-day period. Short acting Beta2 Agonist inhaler medications defined with medication taxonomy BGP PQA SABA MEDS. (Medications are: Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

*Controller Therapy definition:*

At least one non-discontinued prescription of controller therapy medications during the same 90 day period.

*Controller therapy medications* defined with medication taxonomy BGP PQA CONTROLLER MEDS. (Medications are: Beclomethasone, Budesonide, Budesonide-Formoterol, Ciclesonide, Flunisolide, Fluticasone, Fluticasone-Salmeterol, Formoterol, Mometasone, Mometasone-Formoterol, Montelukast, Salmeterol, Theophylline, Zafirlukast, Zileuton). Medications must not have a comment of RETURNED TO STOCK.

*Inhaled corticosteroid medications* defined with medication taxonomy BGP PQA ASTHMA INHALED STEROIDS. (Medications are: Beclomethasone, Budesonide, Ciclesonide, Fluticasone, Flunisolide, Fluticasone-salmeterol, Mometasone, Triamcinolone, Budesonide-formoterol, Mometasone-formoterol.) Medications must not have a comment of RETURNED TO STOCK.

*Long-Acting Beta-2 Agonist (LABA) medications* defined with medication taxonomy BGP ASTHMA LABA MEDS. (Medications are: Formoterol, Salmeterol, Fluticasone-salmeterol, Budesonide-formoterol, Mometasone-formoterol) Medications must not have a comment of RETURNED TO STOCK.

### Key Logic Changes from CRS Version 15.1

- Updated the following medication taxonomies: BGP PQA SABA MEDS, BGP PQA CONTROLLER MEDS, BGP PQA ASTHMA INHALED STEROIDS, and BGP ASTHMA LABA MEDS (removed Aformoterol and added Fluticasone-salmeterol, Budesonide-formoterol, and Mometasone-formoterol).

### Patient List Description

List of patients with asthma with suboptimal control and controller therapy, if any.

### Measure Source

PQA (Pharmacy Quality Alliance)

### Measure Past Performance and Long-term Targets

None

DU		November 25, 2016		Page 299			
*** IHS 2016 Selected Measures with Community Specified Report ***							
DEMO INDIAN HOSPITAL							
Report Period: Jan 01, 2016 to Dec 31, 2016							
Previous Year Period: Jan 01, 2015 to Dec 31, 2015							
Baseline Period: Jan 01, 2010 to Dec 31, 2010							
-----							
Medication Therapy for Persons with Asthma							
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from BASE PREV YR % PERIOD	%	CHG from BASE %
Active Clinical ages 5-50 w/ asthma	19		8		5		
# w/ Suboptimal Control	1	5.3	0	0.0	+5.3	0	0.0
# w/ Absence of Controller Therapy	1	100.0	0	0.0	+100.0	0	0.0
Active Clinical Pts =>5 w/persistent asthma	29		11		5		
# w/ 2 or more controller Rx	10	34.5	5	45.5	-11.0	3	60.0
# w/ 2 or more inhaled steroid Rx	3	10.3	3	27.3	-16.9	0	0.0

Active Clinical =>5 w/persistent asthma and LABA Rx	4		0		0			
# w/o 2 or more inhaled steroid Rx	3	75.0	0	0.0	+75.0	0	0.0	+75.0

Figure 2-123: Sample Report, Medication Therapy for Persons with Asthma

DU	November 25, 2016				Page 95
*** IHS 2016 Selected Measures with Community Specified Report ***					
DEMO INDIAN HOSPITAL					
Report Period: Jan 01, 2016 to Dec 31, 2016					
Previous Year Period: Jan 01, 2015 to Dec 31, 2015					
Baseline Period: Jan 01, 2010 to Dec 31, 2010					
-----					
Medication Therapy for Persons with Asthma (con't)					
	Active Clinical Pts =>5 w/persistent asthma				
	5-14	15-34	35-64	65+	
CURRENT REPORT PERIOD					
Active Clinical Pts =>5 w/persistent asthma	11	6	6	6	
# w/ 2 or more controller Rx	6	2	1	1	
% w/ 2 or more controller Rx	54.5	33.3	16.7	16.7	
# w/ 2 or more inhaled steroid Rx	3	0	0	0	
% w/ 2 or more inhaled steroid Rx	27.3	0.0	0.0	0.0	
PREVIOUS REPORT PERIOD					
Active Clinical Pts =>5 w/persistent asthma	4	2	3	1	
# w/ 2 or more controller Rx	2	1	1	0	
% w/ 2 or more controller Rx	50.0	50.0	33.3	0.0	
# w/ 2 or more inhaled steroid Rx	1	1	1	0	
% w/ 2 or more inhaled steroid Rx	25.0	50.0	33.3	0.0	
CHANGE FROM PREVIOUS YR %					
# w/ 2 or more controller Rx	+4.5	-16.7	-16.7	+16.7	
# w/ 2 or more inhaled steroid Rx	-22.7	-50.0	-33.3	+0.0	
BASELINE REPORT PERIOD					
Active Clinical Pts =>5 w/persistent asthma	2	2	1	0	
# w/ 2 or more controller Rx	1	1	1	0	
% w/ 2 or more controller Rx	50.0	50.0	100.0	0.0	

# w/ 2 or more inhaled steroid Rx	0	0	0	0
% w/ 2 or more inhaled steroid Rx	0.0	0.0	0.0	0.0
CHANGE FROM BASELINE YR %				
# w/ 2 or more controller Rx	+4.5	-16.7	-83.3	+16.7
# w/ 2 or more inhaled steroid Rx	-22.7	-50.0	-100.0	+0.0

Figure 2-124: Sample Age Breakdown Report, Medication Therapy for Persons with Asthma

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Medication Therapy for Persons with Asthma: List of patients with asthma with asthma medications, if any.

PATIENT NAME DENOMINATOR	HRN NUMERATOR	COMMUNITY	SEX	AGE	DOB
PATIENT1,GWEN AC,Severity 4 in V Asthma	02/02/16	000001 COMMUNITY #1	F	5	10/10/11
PATIENT2,ALICE AC,Severity >1 on PL for	493.00	000002 COMMUNITY #1	F	6	06/17/10
PATIENT3,GENEVA AC,Severity 2 in V Asthma	03/03/16	000003 COMMUNITY #1	F	47	05/05/69
PATIENT22,MELANIE AC,Severity >1 on PL for	493.00	000022 COMMUNITY #1	F	47	10/02/69
PATIENT27,RANDALL AC,Severity >1 on PL for	493.00	000027 COMMUNITY #1	M	6	04/17/10

-----  
 SABA: 06/15/16 ALBUTEROL 90MCG/INHALATION MDI(4)  
 CONT: 06/01/16 FLUTICASONE PROPIONATE 110MCG INHALER, 10/15/16 FLUTICASONE PROPIONATE 110MCG INHALER; 2+ STEROID: 06/01/16 FLUTICASONE PROPIONATE 110MCG INHALER, 10/15/16 FLUTICASONE PROPIONATE 110MCG INHALER  
 LABA2+ CONT: 03/03/16 MOMETASONE/FORMOTEROL 100/5MCG INH, 05/01/16 MOMETASONE/FORMOTEROL 100/5MCG INH; 2+ STEROID: 03/03/16 MOMETASONE/FORMOTEROL 100/5MCG INH, 05/01/16 MOMETASONE/FORMOTEROL 100/5MCG INH

Figure 2-125: Sample Patient List, Medication Therapy for Persons with Asthma

## 2.10.9 Chronic Kidney Disease Assessment

### Denominators

*Active Clinical patients* ages 18 and older with serum creatinine test during the Report Period.

*User Population patients* ages 18 and older with serum creatinine test during the Report Period.

## Numerators

Patients with Estimated GFR.

- a. Patients with GFR less than (<) 60.
- b. Patients with normal GFR (i.e., greater than or equal to (>=) 60).

## Logic Description

Age is calculated at beginning of the Report Period.

For the GFR less than (<) 60 numerator, CRS will include GFR results containing a numeric value less than 60 or with a text value of “less than (<) 60”. For the normal GFR (greater than or equal to (>=) 60) numerator, CRS will include GFR results containing a numeric value greater than or equal to 60 or with a text value of “60”

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Creatinine test	82540, 82565-75		Yes	DM AUDIT CREATININE TAX
Estimated GFR test			Yes	BGP GPRA ESTIMATED GFR TAX

## Key Logic Changes from CRS Version 15.1

1. Removed LOINC code 48643-1 from BGP ESTIMATED GFR LOINC taxonomy.

## Patient List Description

List of patients with Creatinine test, with GFR and value, if any.

## Measure Source

None

## Measure Past Performance and Long-Term Targets

None

DU	November 25, 2016	Page 303
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		

Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Chronic Kidney Disease Assessment (con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts => 18 with Serum Creatinine test								
	271		258			221		
w/Est GFR	189	69.7	33	12.8	+57.0	16	7.2	+62.5
A. # w/ GFR <60	52	19.2	30	11.6	+7.6	15	6.8	+12.4
B. # w/Normal GFR (>=60)	137	50.6	2	0.8	+49.8	0	0.0	+50.6
User Pop Pts =>18 with Serum Creatinine								
	331		311			262		
# w/ Est GFR	221	66.8	33	10.6	+56.2	16	6.1	+60.7
A. # w/GFR <60	55	16.6	30	9.6	+7.0	15	5.7	+10.9
B. # w/Normal GFR (>=60)	165	49.8	2	0.6	+49.2	0	0.0	+49.8

Figure 2-126: Sample Report, Chronic Kidney Disease Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Chronic Kidney Disease Assessment: List of patients with Creatinine test, with GFR and value, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, SHERISA UP, AC	000001	COMMUNITY #1 08/16/16 GFR: 78	F	18	08/22/98
PATIENT2, CAITLYN UP, AC	000002	COMMUNITY #1	F	22	10/02/94
PATIENT3, HALEY DEBRA UP, AC	000003	COMMUNITY #1 07/09/16 GFR: >60	F	25	04/11/91
PATIENT4, HELENE MARIE UP, AC	000004	COMMUNITY #1 11/20/16 GFR: 114	F	29	03/22/87
PATIENT5, MARTHA UP	000005	COMMUNITY #1	F	30	07/07/86

Figure 2-127: Sample Patient List, Chronic Kidney Disease Assessment

## 2.10.10 Proportion of Days Covered by Medication Therapy

### Denominators

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *beta-blockers* during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *RAS Antagonists* and no documented history of ESRD during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *calcium channel blockers (CCB)* during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *biguanides* and no documented history of ESRD during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *sulfonylureas* and no documented history of ESRD during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *thiazolidinediones* and no documented history of ESRD during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *DiPeptidyl Peptidase (DPP)-IV Inhibitors* and no documented history of ESRD during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *Diabetes All Class medications* and no documented history of ESRD during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *statins* during the Report Period

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *non-warfarin oral anticoagulants* during the Report Period.

*Active Clinical patients* ages 18 and older who had two or more prescriptions for *antiretroviral agents* during the Report Period.

### Numerators

Patients with proportion of days covered (PDC) greater than or equal to ( $\geq$ )80% during the Report Period.

Patients with a gap in medication therapy greater than or equal to ( $\geq$ )30 days.



Patients with proportion of days covered (PDC) greater than or equal to ( $\geq$ )90% during the Report Period.

### Logic Description

Age is calculated at the beginning of the report period.

To be included in the denominator, patients must have at least two prescriptions for that particular type of medication on two unique dates of service at any time during the Report Period. Medications must not have a comment of RETURNED TO STOCK.

For the Non-warfarin anticoagulants measures, the two unique dates of service must be at least 180 days apart and the patient must have received greater than 60 days supply of the medication during the Report Period. Patients who received one or more prescriptions for warfarin, low molecular weight heparin (LMWH), heparin or an SC Factor Xa inhibitor (defined by medication taxonomy BGP PQA WARFARIN) will be excluded from the denominator.

*The Index Prescription Start Date* is the date when the medication was first dispensed within the Report Period. For all measures except Non-warfarin anticoagulants, this date must be greater than 90 days from the end of the Report Period to be counted in the denominator.

*The medications in the measures* are defined with medication taxonomies:

- BGP PQA BETA BLOCKER MEDS: Beta-blocker medications (Acebutolol HCL, Atenolol, Betaxolol HCL, Bisoprolol fumarate, Carvedilol, Labetalol HCL, Metoprolol succinate, Metoprolol tartrate, Nadolol, Nebivolol HCL, Penbutolol sulfate, Pindolol, Propranolol HCL, Timolol maleate); Beta-blocker combination products (Atenolol-chlorthalidone, Bisoprolol-HCTZ, Nadolol-bendroflumethiazide, Metoprolol-HCTZ, Propranolol-HCTZ)

- BGP PQA RASA MEDS: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril); Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-HCTZ, Captopril-HCTZ, Enalapril-HCTZ, Fosinopril-HCTZ, Lisinopril-HCTZ, Moexipril-HCTZ, Quinapril-HCTZ, Trandolapril-verapamil); Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan); Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Amlodipine-olmesartan, Azilsartan-Chlorthalidone, Candesartan-HCTZ, Eprosartan-HCTZ, Irbesartan-HCTZ, Losartan-HCTZ, Olmesartan-amlodipine-HCTZ, Olmesartan-HCTZ, Telmisartan-amlodipine, Telmisartan-HCTZ, Valsartan-HCTZ); Direct Renin Inhibitors (Aliskiren); Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-HCTZ, Aliskiren-HCTZ, Aliskiren-valsartan)
- BGP PQA CCB MEDS: Calcium-Channel Blocker medications (Amlodipine besylate, Diltiazem HCL, Felodipine, Isradipine, Nicardipine HCL, Nifedipine (long acting only), Verapamil HCL, Nisoldipine); CCB Combination Products (Amlodipine besylate-benazepril HCL, Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Aliskiren-amlodipine, Aliskiren-amlodipine-HCTZ, Telmisartan-amlodipine, Amlodipine-olmesartan, Trandolapril-verapamil HCL, Amlodipine-atorvastatin, Olmesartan-amlodipine-HCTZ)
- BGP PQA BIGUANIDE MEDS: Biguanides (Metformin); Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-metformin, Pioglitazone-metformin, Repaglinide-metformin, Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Linagliptin-metformin, Alogliptin-metformin, Dapagliflozin-Metformin, Canagliflozin-Metformin)
- BGP PQA SULFONYLUREA MEDS: Sulfonylureas (Chlorpropamide, Glimepiride, Glipizide, Glyburide, Tolazamide, Tolbutamide); Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride)
- BGP PQA THIAZOLIDINEDIONE MEDS: Thiazolidinediones (Pioglitazone, Rosiglitazone); Combination Products (Rosiglitazone-metformin, Pioglitazone-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride, Alogliptin-pioglitazone)
- BGP PQA DPP IV MEDS: DPP-IV Inhibitors (Sitagliptin, Linagliptin, Saxagliptin, Alogliptin); Combination Products (Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Sitagliptin-simvastatin, Linagliptin-metformin, Alogliptin-metformin, Alogliptin-pioglitazone, Linagliptin-empagliflozin)

- BGP PQA DIABETES ALL CLASS: Biguanide medications (see list above); Sulfonylurea medications (see list above); Thiazolidinedione medications (see list above); DPP-IV Inhibitor medications (see list above); Incretin Mimetic Agents (Albiglutide, Exenatide, Liraglutide, Dulaglutide); Meglitinides (Nateglinide, Repaglinide, Repaglinide-metformin); Sodium glucose co-transporter2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Dapagliflozin-Metformin, Linagliptin-empagliflozin, Canagliflozin-Metformin)
- BGP PQA STATIN MEDS: Statins (Lovastatin, Rosuvastatin, Fluvastatin, Atorvastatin, Pravastatin, Pitavastatin); Combination Products (Niacin-lovastatin, Atorvastatin-amlodipine, Niacin-simvastatin, Sitagliptin-simvastatin, Ezetimibe-simvastatin, Ezetimibe-atorvastatin)
- BGP PQA NON-WARFARIN ANTICOAG: (Apixaban, Dabigatran, Rivaroxaban, Edoxaban)
- BGP PQA WARFARIN: (Warfarin, Dalteparin, Fondaparinux, Enoxaparin, Heparin, Tinzaparin)
- BGP PQA ANTIRETROVIRAL MEDS: Single Agents (Enfuvirtide, Maraviroc, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Dolutegravir, Raltegravir, Delavirdine, Efavirenz, Etravirine, Nevirapine, Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine, Rilpivirine, Elvitegravir); Combination Agents (Lopinavir-Ritonavir, Lamivudine-zidovudine, Darunavir-Cobicistat, Atazanavir-Cobicistat, Abacavir-Lamivudine-Zidovudine, Efavirenz-emtricitabine-Tenofovir, Emtricitabine-tenofovir, Abacavir-lamivudine, Emtricitabine-rilpivirine-Tenofovir, Elvitegravir-cobicistat-emtricitabine-tenofovir, Abacavir-dolutegravir-lamivudine)

*ESRD diagnosis/treatment definition:* Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

*For each PDC numerator:*

Proportion of days covered = # of days the patient was covered by at least one drug in the class / # of days in the patient's measurement period.

*Measurement Period definition:*

The patient's measurement period is defined as the number of days between the Index Prescription Start Date and the end of the Report Period. When calculating the number of days the patient was covered by at least one drug in the class, if prescriptions for the same drug overlap, the prescription start date for the second prescription will be adjusted to be the day after the previous fill has ended.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4.

**Example of Proportion of Days Covered:**

- Report Period: January 1 through December 31, 2016
- 1st Rx is Index Rx Start Date: 3/1/16, Days Supply=90
- Rx covers patient through 5/29/16
- 2nd Rx: 5/26/16, Days Supply=90
- Rx covers patient through 8/27/16
- 3rd Rx: 9/11/16, Days Supply=180
- Gap = (9/11/16 - 8/27/16) = 15 days
- Rx covers patient through 3/8/17
- Patient's measurement period: 3/1/16 through 12/31/16 = 306 Days
- Days patient was covered: 3/1/16 through 8/27/16 + 9/11/16 through 12/31/16 = 292 Days
- PDC =  $292 / 306 = 95\%$

*For each Gap numerator:*

CRS will calculate whether a gap in medication therapy of 30 or more days has occurred between each consecutive medication dispensing event during the Report Period. A gap is calculated as the days not covered by the days supply between consecutive medication fills.

**Example of Medication Gap greater than or equal to ( $\geq$ ) 30 Days:**

- Report Period: January 1 through December 31, 2016

- 1st Rx: 4/1/16, Days Supply=30
- Rx covers patient through 4/30/16
- 2nd Rx: 7/1/16, Days Supply=90
- Gap #1 = (7/1/16 - 4/30/16) = 61 days
- Rx covers patient through 9/28/16
- 3rd Rx: 10/1/16, Days Supply=90
- Gap #2 = (10/1/16 - 9/28/16) = 2 days
- Rx covers patient through 12/29/16
- Gap #1 greater than or equal to ( $\geq$ ) 30 days, therefore patient will be included in the numerator for that medication.

### Key Logic Changes from CRS Version 15.1

1. Added denominator exclusion of ESRD for Biguanides, Sulfonylureas, thiazolidinediones, and DPP-IV measures.
2. Updated the following medication taxonomies: BGP PQA BETA BLOCKER MEDS, BGP PQA RASA MEDS, BGP PQA CCB MEDS, BGP PQA BIGUANIDE MEDS, BGP PQA SULFONYLUREA MEDS, BGP PQA THIAZOLIDINEDIONE MEDS, BGP PQA DPP IV MEDS, BGP PQA DIABETES ALL CLASS, BGP PQA STATIN MEDS, BGP PQA NON-WARFARIN ANTICOAG, BGP PQA WARFARIN, and BGP PQA ANTIRETROVIRAL MEDS.

### Patient List Description

List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

### Measure Source

PQA (Pharmacy Quality Alliance)

### Measure Past Performance and Long-Term Targets

None

DU	November 25, 2016	Page 314
*** IHS 2016 Selected Measures with Community Specified Report ***		
DEMO INDIAN HOSPITAL		
Report Period: Jan 01, 2016 to Dec 31, 2016		
Previous Year Period: Jan 01, 2015 to Dec 31, 2015		
Baseline Period: Jan 01, 2010 to Dec 31, 2010		

-----									
Proportion of Days Covered by Medication Therapy									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %	
Active Clinical Pts w/beta-blockers	53		44			37			
# w/ PDC >=80%	31	58.5	24	54.5	+3.9	22	59.5	-1.0	
# w/ gap >=30 days	27	50.9	23	52.3	-1.3	15	40.5	+10.4	
Active Clinical Pts w/ RAS Antagonists	97		80			74			
# w/ PDC >=80%	60	61.9	55	68.8	-6.9	39	52.7	+9.2	
# w/ gap >=30 days	45	46.4	32	40.0	+6.4	42	56.8	-10.4	
Active Clinical Pts w/ CCBs	56		48			55			
# w/ PDC >=80%	34	60.7	30	62.5	-1.8	37	67.3	-6.6	
# w/ gap >=30 days	30	53.6	20	41.7	+11.9	22	40.0	+13.6	
Active Clinical Pts w/ biguanides	30		26			11			
# w/ PDC >=80%	12	40.0	18	69.2	-29.2	3	27.3	+12.7	
# w/ gap >=30 days	19	63.3	10	38.5	+24.9	8	72.7	-9.4	
Active Clinical Pts w/ sulfonylureas	7		6			7			
# w/ PDC >=80%	3	42.9	1	16.7	+26.2	4	57.1	-14.3	
# w/ gap >=30 days	5	71.4	5	83.3	-11.9	3	42.9	+28.6	
Active Clinical Pts w/ thiazolidinediones	20		15			4			
# w/ PDC >=80%	13	65.0	10	66.7	-1.7	2	50.0	+15.0	
# w/ gap >=30 days	8	40.0	7	46.7	-6.7	1	25.0	+15.0	
Active Clinical Pts w/ DPP-IV Inhibitors	2		0			0			
# w/PDC >=80%	1	50.0	0	0.0	+50.0	0	0.0	+50.0	
# w/ gap >=30 days	1	50.0	0	0.0	+50.0	0	0.0	+50.0	
Active Clinical Pts w/ Diabetes All Class	36		30			13			
# w/ PDC >=80%	17	47.2	18	60.0	-12.8	6	46.2	+1.1	
# w/ gap >=30 days	20	55.6	14	46.7	+8.9	7	53.8	+1.7	
Active Clinical Pts w/ statins	60		49			37			

# w/ PDC >=80%	43	71.7	33	67.3	+4.3	25	67.6	+4.1
# w/ gap >=30 days	24	40.0	19	38.8	+1.2	16	43.2	-3.2
Active Clinical Pts w/ antiretrovial agents	2		0			1		
# w/ PDC >=90%	1	50.0	0	0.0	+50.0	0	0.0	+50.0

Figure 2-128: Sample Report, Proportion of Days Covered by Medication Therapy

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Proportion of Days Covered by Medication Therapy: List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
Patient75,PAULA KAY AC	000075	COMMUNITY #1 CCB: IXRD: 03/24/16 [282]	F	34	11/12/82
Patient76,CRSCT AC	000076	COMMUNITY #1 CCB: IXRD: 06/01/16 [213]	F	36	01/16/80
Patient77,CRSAC AC	000077	COMMUNITY #1 RASA: IXRD: 06/05/16 [209]	F	44	03/03/72
Patient78,DEBORA ELLEN AC	000078	COMMUNITY #1 BB: IXRD: 07/23/16 [161]	F	45	05/05/71
Patient79,STELLA LYNN AC	000079	COMMUNITY #1 BB: IXRD: 01/21/16 [344]	F	46	06/22/70
Patient80,TARA MARIE AC	000080	COMMUNITY #1 BB: IXRD: 08/25/16 [128]	F	51	11/08/65
Patient81,CRSNK AC	000081	COMMUNITY #1 SULF: IXRD: 09/01/16 [121]	F	51	11/23/65

Figure 2-129: Sample Patient List, Proportion of Days Covered by Medication Therapy

### 2.10.11 Primary Medication Non-adherence

#### Denominator

Number of e-prescriptions for newly initiated drug therapy for chronic medications for *Active Clinical patients* ages 18 and older.

#### Numerator

Number of medications returned to stock within 30 days.

## Logic Description

Age is calculated at beginning of the Report Period.

To be included in the denominator, the e-prescription must be for a chronic medication during the Report Period.

### *Denominator Exclusions*

1. Any prescription where there is a prescription dispensing record in the preceding 180 days for the same drug.
2. Any duplicate medications, defined as any medication that has been e-prescribed twice in a 30-day period with no prescription fill in between the e-prescriptions.
3. Any prescription sent to an outside pharmacy, as it is not possible to know if the medication was returned to stock.

*Chronic medications* are defined with medication taxonomies:

- BGP PQA ASTHMA INHALED STEROIDS: (Beclomethasone, Budesonide, Ciclesonide, Fluticasone, Flunisolide, Fluticasone-salmeterol, Mometasone, Budesonide-formoterol, Mometasone-formoterol)
- BGP PQA COPD: (Tiotropium, Indacaterol, Olodaterol, Umeclidinium, Ipratropium-albuterol, Roflumilast, Fluticasone-vilanterol, Ipratropium, Aclidinium, Umeclidinium-vilanterol, Tiotropium-olodaterol)



- BGP PQA DIABETES ALL CLASS: Biguanides (Metformin); Biguanide Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-metformin, Pioglitazone-metformin, Repaglinide-metformin, Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Linagliptin-metformin, Alogliptin-metformin, Dapagliflozin-Metformin, Canagliflozin-Metformin); Sulfonylureas (Chlorpropamide, Glimepiride, Glipizide, Glyburide, Tolazamide, Tolbutamide); Sulfonylurea Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride); Thiazolidinediones (Pioglitazone, Rosiglitazone); Thiazolidinedione Combination Products (Rosiglitazone-metformin, Pioglitazone-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride, Alogliptin-pioglitazone); DPP-IV Inhibitors (Sitagliptin, Linagliptin, Saxagliptin, Alogliptin); DPP-IV Inhibitor Combination Products (Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Sitagliptin-simvastatin, Linagliptin-metformin, Alogliptin-metformin, Alogliptin-pioglitazone, Linagliptin-empagliflozin); Incretin Mimetic Agents (Albiglutide, Exenatide, Liraglutide, Dulaglutide); Meglitinides (Nateglinide, Repaglinide, Repaglinide-metformin); Sodium glucose co-transporter2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Dapagliflozin-Metformin, Linagliptin-empagliflozin, Canagliflozin-Metformin)
- BGP PQA RASA MEDS: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril); Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-HCTZ, Captopril-HCTZ, Enalapril-HCTZ, Fosinopril-HCTZ, Lisinopril-HCTZ, Moexipril-HCTZ, Quinapril-HCTZ, Trandolapril-verapamil); Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan); Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Amlodipine-olmesartan, Azilsartan-Chlorthalidone, Candesartan-HCTZ, Eprosartan-HCTZ, Irbesartan-HCTZ, Losartan-HCTZ, Olmesartan-amlodipine-HCTZ, Olmesartan-HCTZ, Telmisartan-amlodipine, Telmisartan-HCTZ, Valsartan-HCTZ); Direct Renin Inhibitors (Aliskiren); Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-HCTZ, Aliskiren-HCTZ, Aliskiren-valsartan)
- BGP PQA STATIN MEDS: Statins (Lovastatin, Rosuvastatin, Fluvastatin, Atorvastatin, Pravastatin, Pitavastatin); Combination Products (Niacin-lovastatin, Atorvastatin-amlodipine, Niacin-simvastatin, Sitagliptin-simvastatin, Ezetimibe-simvastatin, Ezetimibe-atorvastatin)

To be included in the numerator, the e-prescription medication must have a comment of RETURNED TO STOCK within 30 days of the prescription date (i.e., visit date).

### Key Logic Changes from CRS Version 15.1

- Updated the following medication taxonomies: BGP PQA ASTHMA INHALED STEROIDS, BGP PQA COPD, BGP PQA DIABETES ALL CLASS, BGP PQA RASA MEDS, and BGP PQA STATIN MEDS.

### Patient List Description

List of patients 18 and older with an e-prescription for chronic medications, with returned to stock, if any.

### Measure Source

PQA (Pharmacy Quality Alliance)

### Measure Past Performance and Long-Term Targets

None

DU	November 25, 2016						Page 316	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Primary Medication Non-adherence (con't)								
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
# e-prescriptions for AC => 18	500		0			0		
# med returned to stock	200	40.0	0	0.0	+40.0	0	0.0	+40.0

Figure 2-130: Sample Report, Primary Medication Non-adherence

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Primary Medication Non-adherence: List of patients 18 and older with an e-prescription for chronic medications, with returned to stock, if any.

PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB
DENOMINATOR	NUMERATOR				
-----					
PATIENT1,ANDREA MARY	000001	COMMUNITY #1	F	33	08/02/83
AC 1) 03/25/16 IPRATROPRIMUM BR / ALBUTEROL SO4 INH1) 03/25/16 IPRATROPRIMUM BR / ALBUTEROL SO4 INH-RTS					
PATIENT2,VIRGINIA A	000002	COMMUNITY #1	F	34	06/29/82

AC 1)	03/25/16	ROSIGLITAZONE 4MG TAB					
PATIENT3,	MICHAELA	000003	COMMUNITY #1	F	37	04/15/79	
AC 1)	03/25/16	CAPTROPRIIL 50MG TABS					
PATIENT4,	DIANE LOUISE	000006	COMMUNITY #1	F	41	01/09/75	
AC 1)	04/09/16	IPRATROPRIUM BR / ALBUTEROL SO4 INH;	2)	04/09/16	CAPTROPRIIL 50MG		
TABS1)	04/09/16	IPRATROPRIUM BR / ALBUTEROL SO4 INH-RTS					
PATIENT5,	ALYSHA	000008	COMMUNITY #1	F	55	09/28/61	
AC 1)	08/14/16	ROSIGLITAZONE 4MG TAB					
PATIENT6,	SHELLY	000009	COMMUNITY #1	F	62	04/19/54	
AC 1)	06/25/16	CAPTROPRIIL 50MG TABS					

Figure 2-131: Sample Patient List, Primary Medication Non-adherence

## 2.10.12 Medications Education

### Denominators

*Active Clinical patients* with medications dispensed at their facility during the Report Period.

*All User Population patients* with medications dispensed at their facility during the Report Period.

### Numerator

Patients who were provided patient education about their medications in any location.

### Logic Description

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility. The purpose of this definition is to ensure that sites are not being held responsible for educating patients about medications received elsewhere that may be recorded in RPMS. CRS assumes that the appropriate facility is the one the user has logged onto to run the report.

**Note:** If a site's system identifier, i.e., ASUFAC code, has changed during the period between the Baseline start date and the Current Year end date, due to compacting/contracting or other reasons, your report may display zeros (0s) or very low counts for some time periods.

CRS uses the following patient education codes to define the numerator:

Medication Education	Any Patient Education code containing "M-" or "-M" (medication) or DMC-IN (Diabetes Medicine–Insulin) FP-DPO (Family Planning–Depot Medroxyprogesterone Injections) FP-OC (Family Planning–Oral Contraceptives) FP-TD (Family Planning–Transdermal (Patch)) *-NEB (*Nebulizer) *-MDI (*Metered Dose Inhalers)
----------------------	--

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of patients receiving medications with medication education, if any.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

Measure	Target
IHS 2020 Goal	75.0%

DU	November 25, 2016						Page 316		
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Medications Education (con't)									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts receiving medications	757		631			592			
# receiving medication educ	490	64.7	268	42.5	+22.3	81	13.7	+51.0	
User Pop Pts receiving medications	981		800			753			
# receiving medication educ	599	61.1	306	38.3	+22.8	87	11.6	+49.5	

Figure 2-132: Sample Report, Medications Education

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Medications Education: List of patients receiving medications with med education or refusal, if any

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, ANDREA MARY UP, AC	000001	COMMUNITY #1	F	0	05/15/16
PATIENT2, VIRGINIA A UP	000002	COMMUNITY #1 08/06/16 HTN-M	F	0	05/23/16
PATIENT3, MICHAELA UP	000003	COMMUNITY #1 03/10/16 M-I	F	0	10/22/16
PATIENT4, MISTY UP, AC	000004	COMMUNITY #1 05/16/16 M-DI	F	5	04/18/11
PATIENT5, RITA ANN UP, AC	000005	COMMUNITY #1 07/05/16 M-I	F	15	06/14/01
PATIENT6, DIANE LOUISE UP	000006	COMMUNITY #1 08/21/16 M-I	F	15	06/23/01
PATIENT7, ALICIA UP, AC	000007	COMMUNITY #1	F	15	08/15/01
PATIENT8, ALYSHA UP, AC	000008	COMMUNITY #1	F	16	05/07/00
PATIENT9, SHELLY UP, AC	000009	COMMUNITY #1 03/12/16 PP-M	F	18	09/17/98

Figure 2-133: Sample Patient List, Medications Education

### 2.10.13 Medication Therapy Management Services

#### Denominators

*Active Clinical patients greater than or equal to (=>)18 with medications dispensed at their facility during the Report Period.*

#### Numerator

Patients who received medication therapy management (MTM) during the Report Period.

#### Logic Description

Age is calculated at the beginning of the report period.

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility.

*Medication Therapy Management (MTM) definition:* 1) CPT 99605 through 99607 or 2) Clinic codes: D1, D2, D5.

**Key Logic Changes from CRS Version 15.1**

None.

**Patient List Description**

List of patients greater than or equal to (>=) 18 receiving medications with medication therapy management, if any.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016						Page 316	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Medications Therapy Management Services (con't)								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %
Active Clinical Pts =>18 receiving medications	594		472			424		
# w/MTM	5	0.8	0	0.0	+0.8	0	0.0	+0.8

Figure 2-134: Sample Report, Medications Therapy Management Services

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient						
Medications Education: List of patients receiving medications with med education or refusal, if any (con't)						
PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB	
DENOMINATOR		NUMERATOR				
-----						
PATIENT5,RITA ANN	000005	COMMUNITY #1	F	18	09/07/98	
AC		06/01/16 CPT 99607				

PATIENT6,DIANE LOUISE	000006	COMMUNITY #1	F	20	05/28/96
AC		07/28/16 CPT 99606			
PATIENT7,ALICIA	000007	COMMUNITY #1	F	21	04/01/95
AC					
PATIENT8,ALYSHA	000008	COMMUNITY #1	F	25	03/28/91
AC		04/01/16 C1 D1			
PATIENT9,SHELLY	000009	COMMUNITY #1	F	52	10/19/64
AC		07/01/16 C1 D2			

Figure 2-135: Sample Patient List, Medications Therapy Management Services

## 2.10.14 Self Management (Confidence)

### Denominators

*Active Clinical patients* assessed for confidence in managing their health problems during the Report Period.

### Numerator

Patients who are very confident in managing their health problems during the Report Period.

### Logic Description

*Confidence in managing health problems definition:* Any health factor for category CONFIDENCE IN MANAGING HEALTH PROBLEMS.

*Very confident definition:* The most recent health factor in the CONFIDENCE IN MANAGING HEALTH PROBLEMS category of VERY SURE.

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients who are confident in managing their health problems.

### Measure Source

None

### Measure Past Performance and Long-Term Targets

Measure	Target
<i>IHS 2020 Goal</i>	<i>75.0%</i>

```

DU                               November 25, 2016                               Page 316
*** IHS 2016 Selected Measures with Community Specified Report ***
                                DEMO INDIAN HOSPITAL
                                Report Period: Jan 01, 2016 to Dec 31, 2016
                                Previous Year Period: Jan 01, 2015 to Dec 31, 2015
                                Baseline Period: Jan 01, 2010 to Dec 31, 2010
-----
Self Management (Confidence) (con't)

```

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %
Active Clinical Pts assessed for confidence	8		1			0		
# very confident	4	50.0	0	0.0	+50.0	0	0.0	+50.0

Figure 2-136: Sample Report, Medications Education

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
HR=High Risk Patient

Self Management (Confidence): List of patients who are confident in managing their health problems.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT5,RITA ANN AC	000005	COMMUNITY #1 06/01/16	F	18	09/08/98
PATIENT6,DIANE LOUISE AC	000006	COMMUNITY #1 07/28/16	F	20	10/22/96
PATIENT7,ALICIA AC	000007	COMMUNITY #1	F	21	04/08/95
PATIENT8,ALYSHA AC	000008	COMMUNITY #1	F	25	05/11/91

Figure 2-137: Sample Patient List, Medications Education

## 2.10.15 Public Health Nursing

### Patient-Related Measures

#### Denominator

*All User Population patients.*

#### Numerators

*For User Population only, the number of patients in the denominator served by Public Health Nurses (PHNs) in any setting, including Home.*



*For User Population only*, the number of patients in the denominator served by a PHN driver/interpreter in any setting.

*For User Population only*, the number of patients in the denominator served by PHNs in a HOME setting.

*For User Population only*, the number of patients in the denominator served by a PHN driver/interpreter in a HOME Setting.

## **Visit-Related Measures**

### **Denominators**

*Number of visits to User Population patients* by PHNs in any setting, including Home

- Number of visits to patients ages 0 to 28 days (Neonate) in any setting.
- Number of visits to patients ages 29 days to 12 months (infants) in any setting.
- Number of visits to patients ages 1 through 64 years in any setting
- Number of visits to patients ages 65 and older (Elders) in any setting
- Number of PHN driver/interpreter (Provider Code 91) visits

*Number of visits to User Population patients* by PHNs in Home setting

- Number of Home visits to patients age 0 to 28 days (Neonate)
- Number of Home visits to patients age 29 days to 12 months (Infants)
- Number of Home visits to patients ages 1 through 64 years
- Number of Home visits to patients aged 65 and over (Elders).
- Number of PHN driver/interpreter (Provider Code 91) visits in a HOME setting.

### **Numerator**

No numerator: count of visits only

### **Logic Description**

PHN visit is defined as any visit with primary or Secondary Provider Code 13 or 91. Home visit defined as: (1) Clinic 11 and a primary or Secondary Provider Code 13 or 91 or (2) Location Home (as defined in Site Parameters) and a primary or Secondary Provider Code 13 or 91.

### **Key Logic Changes from CRS Version 15.1**

None.

## Patient List Description

List of patients with PHN visits documented.

Numerator codes in patient list: All PHN = Number of PHN visits in any setting;  
Home = Number of PHN visits in home setting; Driver All = Number of PHN  
driver/interpreter visits in any setting; Driver Home = Number of PHN  
driver/interpreter visits in home setting.

## Measure Source

None

## Measure Past Performance and Long-Term Targets

Performance	All PHN visits	PHN Home Visits
IHS FY 2005 Performance	438,376	Not Reported
IHS FY 2004 Performance	423,379	192,121
IHS FY 2003 Performance	359,089	160,650
IHS FY 2002 Performance	343,874	156,263

DU									
November 25, 2016									
Page 317									
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Public Health Nursing (con't)									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %	
All User Population patients	2,896		2,456			2,346			
# served by PHNs in any Setting	13	0.4	13	0.5	-0.1	13	0.6	-0.1	
# served by PHN drivers/interpreter - in any Setting	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
# served by PHNs in a Home Setting	1	0.0	1	0.0	+0.0	0	0.0	+0.0	
# served by PHN drivers/interpreters in Home Setting	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
Total # PHN Visits - Any Setting	18		16		+2	19		-1	
A. Ages 0-28 days	0		0		+0	0		+0	

B. Ages 29 days - 12 months	1	3	-2	0	+1
C. Ages 1-64 years	16	13	+3	19	-3
D. Ages 65+	1	0	+1	0	+1
E. Driver/Interpreter visits - any setting	0	0	+0	0	+0
Total # PHN Visits - Home Setting	3	1	+2	0	+3
A. Ages 0-28 days	0	0	+0	0	+0
B. Ages 29 days- 12 months	0	1	-1	0	+0
C. Ages 1-64 years	3	0	+3	0	+3
D. Ages 65+	0	0	+0	0	+0
E. Driver/interpreter visits - Home Setting	0	0	+0	0	+0

Figure 2-138: Sample Report, Public Health Nursing

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Public Health Nursing: List of patients with PHN visits documented

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,HELENE MARIE UP	000001	COMMUNITY #1	F	29	08/07/87
		2 all PHN; 0 home; 0 driver all; 0 driver home			
PATIENT2,KATHLEEN UP	000002	COMMUNITY #1	F	38	10/12/78
		3 all PHN; 3 home; 0 driver all; 0 driver home			
PATIENT40,ERIKA SUE UP	000040	COMMUNITY #2	F	37	04/05/79
		1 all PHN; 0 home; 0 driver all; 0 driver home			
PATIENT41,DANIEL RAY UP	000041	COMMUNITY #2	M	0	01/06/16
		1 all PHN; 0 home; 0 driver all; 0 driver home			

Figure 2-139: Sample Patient List, Public Health Nursing

## 2.10.16 Breastfeeding Rates

### **GPRA Measure Description**

During GPRA Year 2016, achieve the target rate of 35.8% for the proportion of 2-month olds who are mostly or exclusively breastfeeding.

### **Denominators**

*Active Clinical patients* who are 30 to 394 days old

*Active Clinical patients* who are 30 to 394 days old who were screened for infant feeding choice at the age of *2 months* (45 to 89 days) (GPRA Denominator)

*Active Clinical patients* who are 30 to 394 days old who were screened for infant feeding choice at the age of *6 months* (165 to 209 days)

*Active Clinical patients* who are 30 to 394 days old who were screened for infant feeding choice at the age of *9 months* (255 to 299 days)

*Active Clinical patients* who are 30 to 394 days old who were screened for infant feeding choice at the age of *1 year* (350 to 394 days)

*User Population patients* who are 30 to 394 days old who were screened for infant feeding choice at the age of *2 months* (45 to 89 days)

### **Numerators**

Patients who were screened for infant feeding choice *at least once*

Patients who were screened for infant feeding choice at the age of *2 months* (45 to 89 days)

Patients who were screened for infant feeding choice at the age of *6 months* (165 to 209 days)

Patients who were screened for infant feeding choice at the age of *9 months* (255 to 299 days)

Patients who were screened for infant feeding choice at the age of *1 year* (350 to 394 days)

Patients who, at the age of *2 months* (45 to 89 days), were either exclusively or mostly breastfed (GPRA Numerator)

Patients who, at the age of *6 months* (165 to 209 days), were either exclusively or mostly breastfed

Patients who, at the age of *9 months* (255–299 days), were either exclusively or mostly breastfed

Patients who, at the age of *1 year* (350 to 394 days), were either exclusively or mostly breastfed

### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period. Therefore, this measure may include patients up to 25 months old if they were within the eligible age range on the first day of the report period, and will not include any patients that were born after the first day of the report period. Patients born after the first day of the report period will be included in the following report period.

*Infant feeding choice definition:* The documented feeding choice from the file V Infant Feeding Choice that is closest to the exact age that is being assessed will be used. For example, if a patient was assessed at 45 days old as half breastfed and half formula and assessed again at 65 days old as mostly breastfed, the mostly breastfed value will be used since it is closer to the exact age of 2 months (i.e., 60 days). Another example is a patient who was assessed at 67 days as mostly breastfed and again at 80 days as mostly formula. In this case, the 67 days value of mostly breastfed will be used. The other exact ages are 180 days for 6 months, 270 days for 9 months, and 365 days for 1 year.

In order to be included in the age-specific screening numerators, the patient must have been screened at the specific age range. For example, if a patient was screened at 6 months and was exclusively breastfeeding but was not screened at 2 months, then the patient will only be counted in the 6 months numerator.

### **Key Logic Changes from CRS Version 15.1**

None.

### **Patient List Description**

List of patients 30 to 394 days old, with infant feeding choice value, if any.

**Note:** “DO” represents “Days Old.”

**Measure Source**

HP 2020, MICH-21.4 Exclusive breastfeeding-through 3 months, MICH-21.5 Exclusive breastfeeding-through 6 months.

**Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2015 Performance	35.7%
IHS FY 2014 Performance	35.1%
IHS FY 2013 Performance	29.0%
IHS FY 2012 Performance	30.3%
IHS FY 2011 Performance	26.7%
IHS FY 2010 Performance	33%
IHS FY 2008 Performance	28%
<i>HP 2020 goal for breastfeeding through 3 months of age</i>	<i>44.3%</i>
<i>HP 2020 goal for breastfeeding through 6 months of age</i>	<i>23.7%</i>

DU		November 25, 2016				Page 321			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Breastfeeding Rates									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts 30-394 days	46		30			34			
# w/infant feeding choice screening	11	23.9	0	0.0	+23.9	1	2.9	+21.0	
# w/screening @ 2 mos	4	8.7	0	0.0	+8.7	1	2.9	+5.8	
# w/screening @ 6 mos	3	6.5	0	0.0	+6.5	0	0.0	+6.5	
# w/screening @ 9 mos	4	8.7	0	0.0	+8.7	0	0.0	+8.7	
# w/screening @ 1 yr	3	6.5	0	0.0	+6.5	0	0.0	+6.5	
AC Pts 30-394 days screened @ 2 mos (GPRA)	4		0			1			
# @ 2 mos exclusive/ mostly breastfed (GPRA)	4	100.0	0	0.0	+100.0	1	100.0	+0.0	

AC Pts 30-394 days screened @ 6 mos	3	0	0					
# @ 6 mos exclusive/mostly breastfed	2	66.7	0	0.0	+66.7	0	0.0	+66.7
AC Pts 30-394 days screened at 9 mos	4	0	0					
# @ 9 mos exclusive/mostly breastfed	3	75.0	0	0.0	+75.0	0	0.0	+75.0
AC Pts 30-394 days screened @ 1 yr	3	0	0					
# @ 1 year exclusive/mostly breastfed	2	66.7	0	0.0	+66.7	0	0.0	+66.7

Figure 2-140: Sample Report, Breastfeeding Rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Breastfeeding Rates: List of patients 30-394 days old, with infant feeding  
 choice value, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,AMANDA DEBRA AC	000001	COMMUNITY #1 Scrn: 33 DO,	F	0	01/07/16
PATIENT2,LEROY JAMES AC	000002	COMMUNITY #1 Scrn: 2 MOS: 48 DO,	M	1	12/03/15
PATIENT3,TERRY SCOTT AC	000003	COMMUNITY #1 Scrn: 6 MOS: 187 DO,	M	0	11/15/16
PATIENT4,ROBERT AC	000004	COMMUNITY #1 Scrn: 2 MOS: 60 DO,	M	0	02/05/16
PATIENT11,STEVEN CODY AC	000011	COMMUNITY #2 Scrn: 2 MOS: 60 DO,	M	0	09/04/16

Figure 2-141: Sample Patient List, Breastfeeding Rates

## 2.10.17 Use of High-Risk Medications in the Elderly

### Denominators

*Active Clinical patients* ages 65 and older. Broken down by gender and age groups (65 through 74, 75 through 84, greater than (>) 85).

*User Population patients* ages 65 and older. Broken down by gender.

### **Numerators**

Patients who received at least one high-risk medication for the elderly during the Report Period.

Patients who received at least two different high-risk medications for the elderly during the Report Period.

### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

**Note:** The logic below is a deviation from the logic written by PQA, as PQA requires at least two prescriptions fills for the same high-risk medication during the Report Period, while the logic below only requires one prescription fill.

For nitrofurantoin, a patient must have received a cumulative days supply for any nitrofurantoin product greater than 90 days during the Report Period.

For nonbenzodiazepine hypnotics, a patient must have received a cumulative days supply for any nonbenzodiazepine hypnotic products greater than 90 days during the Report Period.

*Medication definitions:* High-risk medications for the elderly defined with medication taxonomies:

- BGP HEDIS ANTICHOLINERGIC MEDS: First-generation antihistamines (Includes combination drugs) (Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyproheptadine, Dexbrompheniramine, Dexchlorpheniramine, Diphenhydramine (oral), Doxylamine, Hydroxyzine, Promethazine, Triprolidine); Antiparkinson agents (Benztropine (oral), Trihexyphenidyl)
- BGP HEDIS ANTITHROMBOTIC MEDS: (Ticlopidine, Dipyridamole, oral short-acting)
- BGP HEDIS ANTI-INFECTIVE MEDS: (Nitrofurantoin)
- BGP HEDIS CARDIOVASCULAR MEDS: Alpha blockers, central (Guanfacine, Methyldopa, Reserpine); Cardiovascular, other (Disopyramide, Digoxin, Nifedipine, immediate release)



- BGP HEDIS CENTRAL NERVOUS MEDS: Tertiary TCAs (Includes combination drugs) (Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine); Antipsychotics, first-generation (conventional) (ThioridazineBarbiturates (Amobarbital, Butabarbital, Butalbital, Pentobarbital, Phenobarbital, Secobarbital); Central Nervous System, other (Chloral hydrate, Meprobamate); Nonbenzodiazepine hypnotics (Eszopiclone, Zolpidem, Zaleplon); Vasodilators (Ergoloid mesylates, Isoxsuprine)
- BGP HEDIS ENDOCRINE MEDS: Endocrine (Desiccated thyroid, Estrogens with or without progesterone (oral and topical patch products only), Megestrol); Sulfonylureas, long-duration (Chlorpropamide, Glyburide)
- BGP HEDIS GASTROINTESTINAL MEDS: (Trimethobenzamide)
- BGP HEDIS PAIN MEDS: Other (Meperidine, Pentazocine); Non-COX-selective NSAIDs (Indomethacin, Ketorolac)
- BGP HEDIS SKL MUSCLE RELAX MED (Includes combination drugs) (Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine)

**Note:** For each medication, the days supply must be greater than (>) 0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

### Key Logic Changes from CRS Version 15.1

1. Updated the following medication taxonomies: BGP HEDIS NONBENZODIAZ MEDS, BGP HEDIS ANTICHOLINERGIC MEDS, BGP HEDIS ANTITHROMBOTIC MEDS, BGP HEDIS ANTI-INFECTIVE MEDS, BGP HEDIS CARDIOVASCULAR MEDS, BGP HEDIS CENTRAL NERVOUS MEDS, BGP HEDIS ENDOCRINE MEDS, BGP HEDIS GASTROINTESTINAL MED, BGP HEDIS PAIN MEDS, and BGP HEDIS SKL MUSCLE RELAX MED.

### Patient List Description

List of patients 65 and older with at least one high-risk medication.

### Measure Source

HEDIS

## Measure Past Performance and Long-Term Targets

None

DU									
November 25, 2016									
Page 324									
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Use of High-Risk Medications in the Elderly									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %	
Active Clinical Pts =>65	122		71					65	
# w/exposure to at least 1 high-risk med	48	39.3	15	21.1	+18.2		25	38.5	+0.9
# w/exposure to multiple high-risk meds	17	13.9	5	7.0	+6.9		9	13.8	+0.1
Male Active Clinical =>65	56		33					27	
# w/exposure to at least 1 high-risk med	34	60.7	6	18.2	+42.5		11	40.7	+20.0
# w/exposure to multiple high-risk meds	9	16.1	3	9.1	+7.0		3	11.1	+5.0
Female Active Clinical =>65	66		38					38	
# w/exposure to at least 1 high-risk med	14	21.2	9	23.7	-2.5		14	36.8	-15.6
# w/exposure to multiple high-risk meds	8	12.1	2	5.3	+6.9		6	15.8	-3.7
User Pop Pts =>65	225		164					144	
# w/exposure to at least 1 high-risk med	49	21.8	16	9.8	+12.0		26	18.1	+3.7
# w/exposure to multiple high-risk meds	17	7.6	5	3.0	+4.5		9	6.3	+1.3
Male User Pop =>65	99		68					54	

# w/exposure to at least 1 high-risk med	35	35.4	6	8.8	+26.5	11	20.4	+15.0
# w/exposure to multiple high-risk meds	9	9.1	3	4.4	+4.7	3	5.6	+3.5

Figure 2-142: Sample Report, Use of High-Risk Medications in the Elderly

DU	November 25, 2016			Page 326
*** IHS 2016 Selected Measures with Community Specified Report ***				
DEMO INDIAN HOSPITAL				
Report Period: Jan 01, 2016 to Dec 31, 2016				
Previous Year Period: Jan 01, 2015 to Dec 31, 2015				
Baseline Period: Jan 01, 2010 to Dec 31, 2010				
-----				
Use of High-Risk Medications in the Elderly (con't)				
ACTIVE CLINICAL PATIENTS 65+				
Age Distribution				
	65-74	75-84	85+	
CURRENT REPORT PERIOD				
AC Patients 65+	70	36	10	
# w/exposure to at least 1 high-risk med	15	6	2	
% w/exposure to at least 1 high-risk med	21.4	16.7	20.0	
# w/exposure to multiple high-risk meds	8	2	1	
% w/exposure to multiple high-risk meds	11.4	5.6	10.0	
PREVIOUS YEAR PERIOD				
AC Patients 65+	39	19	6	
# w/exposure to at least 1 high risk med	7	4	1	
% w/exposure to at least 1 high-risk med	17.9	21.1	16.7	
# w/exposure to multiple high-risk meds	1	0	0	
% w/exposure to multiple high-risk meds	2.6	0.0	0.0	
CHANGE FROM PREV YR %				
w/exposure to at least 1 high risk med	+3.5	-4.4	+3.3	
w/exposure to multiple high-risk meds	+8.9	+5.6	+10.0	

Figure 2-143: Sample Report, Use of High-Risk Medications in the Elderly

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Use of High Risk Medications in the Elderly: List of patients 65 and older with at least one high-risk medication.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, JONELLE	000001	COMMUNITY #1	F	69	06/08/47
UP, AC	2 drugs:	08/04/16	ESTERIFIED ESTROGENS	0.625MG	TAB (ORAL ESTROGEN);
	08/04/16	PROPOXYPHENE-N	100MG/APAP	650MG	TAB (NARCOTIC)
PATIENT2, PAULINE	000002	COMMUNITY #1	F	70	04/12/46
UP, AC	1 drug:	11/02/16	PROPOXYPHENE-N	100MG/APAP	650MG
					TAB (NARCOTIC)
PATIENT3, NADINE	000003	COMMUNITY #1	F	82	02/16/34
UP, AC	2 drugs:	09/25/16	DIAZEPAM	5MG	TAB (BENZODIAZEPINE);
		09/25/16	PROPOXYPHENE-N	100MG/APAP	650MG
					TAB (NARCOTIC)
PATIENT4, JESSE NATHAN	000004	COMMUNITY #1	M	77	10/16/39
UP, AC	1 drug:	08/27/16	CYCLOBENZAPRINE HCL	10MG	TAB (SKL MUSCLE)

Figure 2-144: Sample Patient List, Use of High-Risk Medications in the Elderly

## 2.10.18 Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

### Denominators

*Active Clinical patients* ages 65 and older.

*User Population patients* ages 65 and older.

### Numerators

Patients who received at least two prescription fills for any benzodiazepine sedative hypnotic medications for more than 90 days.

### Logic Description

Age of the patient is calculated at the beginning of the Report Period.

The patient must have received a cumulative days supply for any benzodiazepine sedative hypnotic products greater than 90 days during the Report Period.

*Medication definitions:* Benzodiazepine sedative hypnotic medications defined with medication taxonomy BGP PQA BENZODIAZ MEDS (Etaxolam, Flurazepam, Quazepam, Temazepam, Triazolam).

**Note:** For each medication, the days supply must be greater than (>) 0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2016, Discontinued Date=11/19/2016, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

## Key Logic Changes from CRS Version 15.1

1. Updated BGP PQA BENZODIAZ MEDS medication taxonomy.

## Patient List Description

List of patients 65 and older with two or more prescriptions for benzodiazepine sedative hypnotic medications.

## Measure Source

PQA

## Measure Past Performance and Long-Term Targets

None

DU		November 25, 2016				Page 324			
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Use of High-Risk Medications in the Elderly									
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %	
Active Clinical Pts =>65	124		118			109			
# w/ 2+ benzodiazepine sedative hypnotic meds	10	8.0	0	0.0	+8.0	0	0.0	+8.0	
User Pop Pts =>65	146		139			129			
# w/ 2+ benzodiazepine sedative hypnotic									

meds	15	10.2	0	0.0	+10.2	0	0.0	+10.2
------	----	------	---	-----	-------	---	-----	-------

Figure 2-145: Sample Report, Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly: List of patients 65 and older with two or more prescriptions for benzodiazepine sedative hypnotic medications.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, JONELLE UP, AC	000001	COMMUNITY #1	F	69	02/19/47
PATIENT2, PAULINE UP, AC	000002	COMMUNITY #1	F	70	03/14/46
PATIENT3, NADINE UP, AC	000003	COMMUNITY #1	F	82	03/02/34
PATIENT4, JESSE NATHAN UP, AC	000004	COMMUNITY #1	M	77	04/13/39

Figure 2-146: Sample Patient List, Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

## 2.10.19 Functional Status Assessment in Elders

### Denominator

*Active Clinical patients* ages 55 and older. Broken down by gender.

### Numerator

Patients screened for functional status at any time during the Report Period.

### Logic Description

Age is calculated at the beginning of the Report Period.

*Functional status screening definition:* Any non-null values in V Elder Care for (1) at least one of the following ADL fields: toileting, bathing, dressing, transfers, feeding, or continence *and* (2) at least one of the following IADL fields: finances, cooking, shopping, housework/chores, medications or transportation during the Report Period.

### Key Logic Changes from CRS Version 15.1

None.

**Patient List Description**

List of patients greater than or equal to (=>) 55 with functional status codes, if any. The following are the abbreviations used in the Numerator column:

- TLT–Toileting
- BATH–Bathing
- DRES–Dressing
- XFER–Transfers
- FEED–Feeding
- CONT–Continence
- FIN–Finances
- COOK–Cooking
- SHOP–Shopping
- HSWK–Housework/Chores
- MEDS–Medications
- TRNS–Transportation

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016						Page 328	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Functional Status Assessment in Elders								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
Active Clinical Pts								
=>55	271		162			127		
# w/functional status								
screening	2	0.7	0	0.0	+0.7	0	0.0	+0.7
Male Active Clinical								

=>55	135		77			60		
# w/functional status screening	1	0.7	0	0.0	+0.7	0	0.0	+0.7
Female Active Clinical =>55	136		85			67		
# w/functional status screening	1	0.7	0	0.0	+0.7	0	0.0	+0.7

Figure 2-147: Sample Report, Functional Status Assessment in Elders

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Functional Status Assessment in Elders: List of patients => 55 with functional status codes, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, GLENDA JOYCE AC	000001	COMMUNITY #1	F	57	11/12/59
PATIENT2, NADINE AC	000002	COMMUNITY #1	F	61	09/22/55
PATIENT3, CHARLOTTE MAE AC	000003	COMMUNITY #1	F	64	10/18/52
		YES: 02/24/16	BATH, CONT, COOK, DRES, FEED, FIN, HSWK, MEDS, SHOP, TLT, TRNS, XFER		
PATIENT4, KATHERINE ANN AC	000004	COMMUNITY #1	F	66	10/29/50
		YES: 07/11/16	BATH, FIN		
PATIENT5, ANNA MARIE AC	000005	COMMUNITY #1	F	66	12/01/50
PATIENT6, DIANA AC	000006	COMMUNITY #1	F	67	08/14/49
PATIENT7, PEGGY ANN AC	000007	COMMUNITY #1	F	70	05/12/46
		NO: 05/20/16	FIN		

Figure 2-148: Sample Patient List, Functional Status Assessment in Elders

## 2.10.20 Fall Risk Assessment in Elders

### Denominators

*Active Clinical patients* ages 65 and older. Broken down by gender.

*User Population patients* ages 65 and older. Broken down by gender.

### Numerators

Patients who have been screened for fall risk or with a fall-related diagnosis in the past year.



**Note:** This numerator does *not* include refusals.

- a. Patients who have been screened for fall risk in the past year
- b. Patients with a documented history of falling in the past year
- c. Patients with a fall-related injury diagnosis in the past year
- d. Patients with abnormality of gait/balance or mobility diagnosis in the past year

Patients with a documented refusal of fall risk screening exam in the past year

### Logic Description

Age of the patient is calculated at the beginning of the Report Period.

Fall risk screening/fall related diagnosis is defined as any of the codes in the table below.

Subject Defined	ICD and Other Codes	Exam Code	E Codes (Injury)
Fall Risk Exam	<b>CPT:</b> 1100F, 1101F, 3288F	<b>Exam:</b> 37 (Fall Risk)	
History of Falling	<b>POV:</b> ICD-9: V15.88 (Personal History of Fall); ICD-10: Z91.81		
Fall-related Injury			<b>POV (Cause Codes #1-3):</b> ICD-9: E880.*, E881.*, E883.*, E884.*, E885.*, E886.*, E888.*; ICD-10: (All codes ending in A or D only) W01.*, W06.*-W08.*, W10.*, W18.*, W19.*
Abnormality of Gait/Balance or Mobility	<b>POV:</b> ICD-9: 781.2, 781.3, 719.7, 719.70 (old code), 719.75–719.77 (old codes), 438.84, 333.99, 443.9; ICD-10: G25.7*, G25.89, G25.9, G26, I69.*93, I73.9, R26.*, R27.*		
Refusal		<b>Exam:</b> 37 (Fall Risk)	

### Key Logic Changes from CRS Version 15.1

None.

### Patient List Description

List of patients 65 years or older with fall risk assessment, if any.

**Measure Source**

HP 2010 15–28 Reduce hip fractures among older adults.

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016						Page 331		
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Fall Risk Assessment in Elders (con't)									
Active Clinical Pts									
65+	116		64			65			
# w/ fall risk screen/ Dx-No Refusals	14	12.1	8	12.5	-0.4	8	12.3	-0.2	
A. # w/ fall risk screen	5	4.3	0	0.0	+4.3	0	0.0	+4.3	
B. # w/ history of fall	1	0.9	0	0.0	+0.9	0	0.0	+0.9	
C. # w/ fall injury	2	1.7	1	1.6	+0.2	3	4.6	-2.9	
D. # w/ abnormal gait	6	5.2	7	10.9	-5.8	5	7.7	-2.5	
# w/ refusal	3	2.6	0	0.0	+2.6	0	0.0	+2.6	
Male Active Clinical									
65+	53		28			27			
# w/ fall risk screen/ Dx-No Refusals	6	11.3	3	10.7	+0.6	2	7.4	+3.9	
A. # w/ fall risk screen	2	3.8	0	0.0	+3.8	0	0.0	+3.8	
B. # w/ history of fall	1	1.9	0	0.0	+1.9	0	0.0	+1.9	
C. # w/ fall injury	0	0.0	0	0.0	+0.0	1	3.7	-3.7	
D. # w/ abnormal gait	3	5.7	3	10.7	-5.1	1	3.7	+2.0	
# w/ refusal	1	1.9	0	0.0	+1.9	0	0.0	+1.9	
Female Active Clinical									
65+	63		36			38			
# w/ fall risk screen/ Dx-No Refusals	8	12.7	5	13.9	-1.2	6	15.8	-3.1	
A. # w/ fall risk screen	3	4.8	0	0.0	+4.8	0	0.0	+4.8	
B. # w/ history of fall	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
C. # w/ fall injury	2	3.2	1	2.8	+0.4	2	5.3	-2.1	
D. # w/ abnormal gait									

gait	3	4.8	4	11.1	-6.3	4	10.5	-5.8
# w/ refusal	2	3.2	0	0.0	+3.2	0	0.0	+3.2

Figure 2-149: Sample Report, Fall Risk Assessment in Elders

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Fall Risk Assessment in Elders: List of patients 65 years or older with fall risk assessment, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1, SHERRY UP, AC	000001	COMMUNITY #1	F	68	06/12/48
PATIENT2, LORETTA LYNN UP, AC	000002	COMMUNITY #1 Refused 03/03/16 Ex 37	F	78	04/11/38
PATIENT17, NICOLE UP, AC	000017	COMMUNITY #2 Abnormal Gait: 11/24/16 POV 443.9	F	71	09/12/45
PATIENT18, VERONICA UP	000018	COMMUNITY #2 Screen: 03/03/16 CPT 1100F	F	72	10/15/44
PATIENT19, STEPHANIE UP, AC	000019	COMMUNITY #2 Fall Injury: 11/10/16 E-CODE E883.9	F	76	08/17/40

Figure 2-150: Sample Patient List, Fall Risk Assessment in Elders

## 2.10.21 Palliative Care

### Denominators

No denominator; count only.

### Numerators

No denominator; count only. The total number of *Active Clinical patients* with at least one palliative care visit during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

No denominator; count only. The total number of palliative care visits for *Active Clinical patients* during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

### Logic Description

Age is calculated at the beginning of the Report Period.

*Palliative care visit definition:* POV ICD-9: V66.7; ICD-10: Z51.5.

**Patient List Description**

List of patients with a palliative care visit.

**Key Logic Changes from CRS Version 15.1**

None.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016				Page 334
*** IHS 2016 Selected Measures with Community Specified Report ***					
DEMO INDIAN HOSPITAL					
Report Period: Jan 01, 2016 to Dec 31, 2016					
Previous Year Period: Jan 01, 2015 to Dec 31, 2015					
Baseline Period: Jan 01, 2010 to Dec 31, 2010					
-----					
Palliative Care					
	REPORT PERIOD	PREV YR PERIOD	CHG from PREV YR	BASE PERIOD	CHG from BASE
Total # of Patients w/At Least 1 Palliative Care Visit	40	0	+40	0	+40
A. Total # of Patients <18 w/At Least 1 Palliative Care Visit	1	0	+1	0	+1
B. Total # of Patients 18-54 w/At Least 1 Palliative Care Visit	25	0	+25	0	+25
C. Total # of Patients 55+ w/At Least 1 Palliative Care Visit	14	0	+14	0	+14
Total # of Palliative Care Visits	62	0	+62	0	+62
A. Total # of Palliative Care Visits-Pts <18	2	0	+2	0	+2
B. Total # of Palliative					

Care Visits-Pts 18-54	38	0	+38	0	+38
C. Total # of Palliative Care Visits-Pts 55+	22	0	+22	0	+22
Active Clinical Pts 18+ w/ 2+ types of cancer	28	3		3	
# w/ 2+ Palliative Care Visits	14	50.0	0	0.0	+50.0
				0	0.0
					+50.0

Figure 2-151: Sample Report, Palliative Care

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Palliative Care: List of patients with a palliative care visit, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
PATIENT1,JOHN AC	000012	Community #1 1 visit: 05/01/16	M	57	12/12/59
PATIENT2,ROBERT AC	000013	Community #1 2 visits: 01/25/16, 05/10/16	M	59	06/19/57
PATIENT3,JAMES AC	000014	Community #2 0 visits:	M	67	01/12/49
PATIENT4,TONYA AC	000015	Community #3 1 visit: 06/01/16	F	78	03/28/38
PATIENT5,RITA ANN AC	000016	Community #3 2 visits: 06/01/16; 06/07/16	F	96	08/17/20
PATIENT6,Clifford AC	000017	Community #3 3 visits: 01/25/16, 05/10/16, 08/01/16	M	24	11/14/92

Figure 2-152: Sample Patient List, Palliative Care

## 2.10.22 Annual Wellness Visit

### Denominators

Active Clinical patients ages 65 and older. Broken down by gender.

### Numerators

Patients with at least one Annual Wellness Exam in the past 15 months.

### Logic Description

Age is calculated at the beginning of the Report Period.

*Annual Wellness Exam: CPT G0438, G0439, G0402.*

**Patient List Description**

List of patients with an annual wellness visit in the past 15 months.

**Key Logic Changes from CRS Version 15.1**

None.

**Measure Source**

None

**Measure Past Performance and Long-Term Targets**

None

DU	November 25, 2016								Page 337
*** IHS 2016 Selected Measures with Community Specified Report ***									
DEMO INDIAN HOSPITAL									
Report Period: Jan 01, 2016 to Dec 31, 2016									
Previous Year Period: Jan 01, 2015 to Dec 31, 2015									
Baseline Period: Jan 01, 2010 to Dec 31, 2010									
-----									
Annual Wellness Visit									
	REPORT		PREV YR		CHG from	BASE		CHG from	
	PERIOD		PERIOD		PREV YR	PERIOD		BASE	
Active Clinical Pts									
65+	116		64			65			
# w/ Annual Wellness Exam	2	1.7	0	0.0	+1.7	0	0.0	+1.7	
Male Active Clinical Pts 65+	53		28			27			
# w/ Annual Wellness Exam	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
Female Active Clinical Pts 65+	63		36			38			
# w/ Annual Wellness Exam	2	3.2	0	0.0	+3.2	0	0.0	+3.2	

Figure 2-153: Sample Report, Annual Wellness Visit

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;

HR=High Risk Patient

Annual Wellness Visit: List of patients with an annual wellness visit in the past 15 months, if any.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
Patient1,DENISE AC	000001	Community #1 12/31/15 G0402	F	65	05/12/51
Patient2,MELISSA GAYLE AC	000002	Community #1	F	66	07/14/50
Patient3,JESSICA DAWN AC	000003	Community #1 02/22/16 G0438	F	67	11/12/49
Patient4,RUTH ALICE AC	000004	Community #1	F	69	01/19/47
Patient5,BRYSON DEWAY AC	000005	Community #1	F	72	05/02/44
Patient6,BRITTNEY ANN AC	000006	Community #1 05/31/16 G0439	F	73	07/14/43
Patient7,MARK AC	000007	Community #1	M	67	11/19/49
Patient8,HOWIE AC	000008	Community #1 10/01/16 G0402	M	72	12/08/44

Figure 2-154: Sample Patient List, Annual Wellness Visit

## 2.10.23 Optometry

### Denominators

*Active Clinical patients* ages 18 and older with a diagnosis of primary open-angle glaucoma during the Report Period. (GPRA Developmental Denominator (NQF 0086))

### Numerators

Patients with an optic nerve head evaluation during the Report Period. (GPRA Developmental Denominator (NQF 0086))

### Logic Description

Age is calculated at the beginning of the Report Period.

*Primary open-angle glaucoma:* POV ICD-9: 365.10-365.12, 365.15; ICD-10: H40.10\* - H40.12\*, H40.15\*.

*Optic nerve head evaluation:* CPT 2027F.

### Patient List Description

List of patients >=18 with primary open-angle glaucoma and optic nerve head evaluation, if any.

### Key Logic Changes from CRS Version 15.1

None.

### Measure Source

NQF 0086

### Measure Past Performance and Long-Term Targets

None

DU	November 25, 2016						Page 337	
*** IHS 2016 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL								
Report Period: Jan 01, 2016 to Dec 31, 2016								
Previous Year Period: Jan 01, 2015 to Dec 31, 2015								
Baseline Period: Jan 01, 2010 to Dec 31, 2010								
-----								
Optometry								
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR	% PERIOD		BASE %
AC Pts => 18								
w/ primary open-angle								
glaucoma	5		13			8		
# w/ optic nerve								
head eval	1	20.0	0	0.0	+20.0	0	0.0	+20.0

Figure 2-155: Sample Report, Optometry

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic					
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;					
HR=High Risk Patient					
Annual Wellness Visit: List of patients with an annual wellness visit in					
the past 15 months, if any.					
PATIENT NAME	HRN	COMMUNITY	SEX	AGE	DOB
DENOMINATOR	NUMERATOR				
-----					
Patient1,DENISE	000001	Community #1	F	20	06/06/96
AC					
Patient2,MELISSA GAYLE	000002	Community #1	F	76	08/15/40



AC	Patient3,JESSICA DAWN	000003	Community #1	F	47	07/14/69
AC	Patient4,RUTH ALICE	000004	Community #1	M	35	05/08/81
AC	Patient5,BRYSON DEWAY	000005	Community #1	M	38	09/09/78
AC			04/04/16	2027F		

Figure 2-156: Sample Patient List, Optometry

## 2.10.24 Goal Setting

### Denominators

*User Population patients.*

Number of goal topics set during the Report Period.

Number of goal topics met during the Report Period.

### Numerators

Number of patients who set at least one goal during the Report Period.

Number of goals set for ALCOHOL OR OTHER DRUGS.

Number of goals set for DIABETES CURRICULUM.

Number of goals set for MEDICATIONS.

Number of goals set for MONITORING.

Number of goals set for NUTRITION.

Number of goals set for OTHER.

Number of goals set for PHYSICAL ACTIVITY.

Number of goals set for STRESS AND COPING.

Number of goals set for TOBACCO.

Number of goals set for WELLNESS AND SAFETY.

Number of patients who met at least one goal during the Report Period.

Number of goals met for ALCOHOL OR OTHER DRUGS.

Number of goals met for DIABETES CURRICULUM.

Number of goals met for MEDICATIONS.

Number of goals met for MONITORING.

Number of goals met for NUTRITION.

Number of goals met for OTHER.

Number of goals met for PHYSICAL ACTIVITY.

Number of goals met for STRESS AND COPING.

Number of goals met for TOBACCO.

Number of goals met for WELLNESS AND SAFETY.

### **Logic Description**

*Patient education codes* must be the standard national patient education codes, which are included in the Patient and Family Education Protocols and Codes (PEPC) manual published each year. If codes are found that are not in the table, they will not be reported on (i.e., locally-developed codes).

*Numerator Logic:*

*For Goal Set*, the Goal Setting value must be "Goal Set" and the Goal Start Date must be during the Report Period..

*For Goal Met*, the Goal Status value must be "Goal Met" and the Date/Time Last Modified must be during the Report Period. The patient is not required to have set a goal during the Report Period.

### **Patient List Description**

List of User Population patients with goal setting information during the Report Period.

### **Key Logic Changes from CRS Version 15.1**

None.

### **Measure Source**

None

### Measure Past Performance and Long-Term Targets

None

DU	November 25, 2016				Page 338
*** IHS 2016 Selected Measures with Community Specified Report ***					
DEMO INDIAN HOSPITAL					
Report Period: Jan 01, 2016 to Dec 31, 2016					
Previous Year Period: Jan 01, 2015 to Dec 31, 2015					
Baseline Period: Jan 01, 2010 to Dec 31, 2010					
-----					
Goal Setting					
	REPORT PERIOD	PREV YR PERIOD	CHG from PREV YR	BASE PERIOD	CHG from BASE
# User Pop w/ Pat Ed	1,024	858		644	
# w/ goal set	8	0.8	0 0.0	+0.8	0 0.0 +0.8
# w/ goal met	6	0.6	0 0.0	+0.6	0 0.0 +0.6

Figure 2-157: Sample Report, Goal Setting

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic  
 PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;  
 HR=High Risk Patient

Goal Setting: List of User Population patients who received patient education during the Report Period with goal setting information.

PATIENT NAME DENOMINATOR	HRN	COMMUNITY NUMERATOR	SEX	AGE	DOB
Patient1,Paula UP	000001	Community #1	F	34	11/14/82
		GS: 11/17/16			
Patient2,PENNY UP	000002	Community #1	F	43	08/01/73
Patient3,RITA UP	000003	Community #1	F	64	07/02/52
		GS: 04/15/16, GM: 06/15/16			
Patient4,HARRY UP	000004	Community #1	M	50	05/01/66
		GM: 10/30/16			
Patient5,ROSS UP	000005	Community #1	M	55	06/05/61
Patient6,FELIPE UP	000006	Community #1	M	57	06/01/59
		GS: 09/10/16			
Patient7,MARK UP	000007	Community #1	M	67	05/08/49
Patient8,CATHERINE UP	000008	Community #2	F	72	04/08/44
		GM: 07/30/16			

Figure 2-158: Sample Patient List, Goal Setting

## Contact Information

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

**Phone:** (888) 830-7280 (toll free)

**Web:** <http://www.ihs.gov/helpdesk/>

**Email:** [support@ihs.gov](mailto:support@ihs.gov)